

1,3-Substituted Cyclobutyl Derivatives and Uses thereof

Field of the Disclosure

The present disclosure relates to 1,3-substituted cyclobutyl compounds and pharmaceutical compositions and their use in antagonizing TRPV1 activity, and in the treatment of ocular diseases or disorders (e.g., ocular surface disorder) such as dry eye disease.

Background of the Disclosure

Transient receptor potential cation channel, subfamily V, member 1 (TRPV1), also known as capsaicin receptor and vanilloid receptor 1 (VR1), is an ion channel belonging to the transient receptor potential (TRP) family. TRPV1 is a non-selective cation channel that can be activated by heat, protons, and vanilloid compounds (e.g., capsaicin). Activation of TRPV1 leads to the release of neurotransmitters, and results in pain and inflammation. TRPV1 antagonists, which can alleviate inflammation and pain caused by TRPV1 activation, fall into two major categories, those that inhibit both capsaicin and proton activation, and those that inhibit capsaicin but not proton activation. Several such TRPV1 antagonists are known, as described by Roberts and Connor (2006, Recent Patents on CNS Drug Discovery 1:65-76). As discussed herein, TRPV1 antagonists can effectively reduce ocular pain and reduce symptoms of dry eye without causing anesthesia effects on the ocular surface.

The role of TRPV1 has been well established in pain models. TRPV1 has also been implicated in other diseases where symptoms are potentially driven wholly or in part by neuronal hypersensitivity or hyperactivity, because of its role in sensory signalling in peripheral nerves. Such diseases include asthma, rhinitis, cough, overactive bladder, reflux oesophagitis, irritable bowel syndrome and migraine. TRPV1 has been implicated to have a role in the afferent sensory loop of the cough reflex and the heightened cough sensitivity seen in disease (Grace, Dubuis, Birrell, Belvisi (2012), TRP Channel Antagonists as Potential Antitussives, Lung 190: 11-15, and Gu and Lee (2011), Airway irritation and cough evoked by acid: from human to ion channel, Current Opinion in Pharmacology 11: 238-247). TRPV1 has been implicated in inflammatory responses occurring in dry eye syndrome (Pan, Wang, Yang, Zhang & Reinach (2010), TRPV1 Activation is Required for Hypertonicity Stimulated Inflammatory Cytokine Release in Human Corneal Epithelial Cells, Manuscript IOVS, 10-5801). TRPV1 is also implicated to play a role in metabolic diseases such as diabetes and obesity (Mottet A L & Ahern G P (2008) FEBS Letters 582, 2257-2262; Suri & Szallasi A (2007), The emerging role of TRPV1 in diabetes and obesity, Trends in Pharm Sci, Rasavi et al (2006) Cell 127, 1123-1135).

The ocular surface, particularly the cornea, is densely innervated by sensory nerves. The activity of corneal nerves can be modified by inflammation caused by a number of factors, such as osmotic stress and tissue damage, as well as nerve injuries of the ocular surface. Ocular surface symptoms are the alarm system to indicate an imbalanced ocular surface homeostasis

resulting in chronic ocular surface pain due to continuous stimuli causing stress and sensitization of the ocular surface.

Patients suffering from ocular surface pain, particularly chronic ocular surface pain have a significant decline in quality of life. In utility studies to date, the burden of severe chronic ocular surface pain has been likened to moderate to severe angina, dialysis, or disabling hip fracture. Severe chronic ocular surface pain has also been associated with depression and suicidal ideation. In many patients, the ocular surface pain remains unresolved despite treatment of the underlying pathology (e.g., recent trauma or surgery, infection, or inflammation). Moreover, treatments that are used for short term management of ocular pain (e.g., nonsteroidal anti-inflammatory drugs, steroids,) cannot be used for long term therapy. Thus, there is a long-felt and unmet need for safe, effective treatments for the treatment of ocular surface pain, particularly chronic ocular surface pain, when there are no other options to improve patients' quality of life, or to supplement current treatments.


Other approaches to treating ocular pain, such as local topical ocular application of anesthetics, NSAIDS, or topical corticosteroids are undesirable due to side effects upon chronic administration. Ocular pain manifests in a number of conditions including Dry eye disease, Sjogren's Syndrome, lacrimal gland dysfunction due autoimmune diseases such as Sjögren's syndrome or Systemic Lupus Erythymatus, organ transplantation such as graft versus host disease, or simply as a result of aging, corneal neuropathies (including LASIK induced corneal neuropathies), corneal dystrophies (including recurrent corneal dystrophies), epithelial basement membrane dystrophy, corneal erosions or abrasions (including recurrent corneal erosions or abrasions), ocular surface diseases, blepharitis, , meibomitis, meibomian gland dysfunction, glaucoma, conjunctivochalasis, keratopathies, corneal infections etc. In such patients, there is a need for more effective therapies to address the ocular pain.

The present disclosure provides compounds for treating or alleviating pain in general, and ocular surface pain, in particular.

Summary of the Disclosure

The disclosure relates to compounds effective as TRPV1 antagonists, pharmaceutically acceptable salts thereof, compositions thereof, and their use in therapies for the conditions and purposes detailed herein.

The disclosure provides, in a first aspect, a compound of Formula (I), or a pharmaceutically acceptable salt thereof,



(I)

wherein:

W is C(=O) or absent;

5 X is N or N oxide;

Y is N or CH;

Z is NH, O or S;

A is CH₂ or absent;

L is selected from 5- to 10-membered heteroaryl having 1-3 heteroatoms independently
 10 selected from N, O, and S, C₆-C₁₀aryl and 6- to 10-membered partially saturated heterocycl
 having 1-3 heteroatoms independently selected from N, O, and S;

R^A is at each occurrence independently selected from halo, -CN, C₁-C₆haloalkyl, C₁-
 C₆alkyl, SF₅, C₃-C₆cycloalkyl, C₁-C₆alkoxyl, C₁-C₆haloalkoxyl, 4- to 6-membered heterocycl
 having 1-2 heteroatoms independently selected from N, O, and S, -(CH₂)_p-NR³R⁴ and -C(=O)-
 15 O-(C₁-C₆alkyl),

wherein the C₃-C₆cycloalkyl and 4- to 6-membered heterocycl are each independently
 substituted with 0-4 R^{A1};

R^{A1} is at each occurrence independently selected from halo and C₁-C₆haloalkyl;

R¹ is at each occurrence independently selected from hydroxyl, C₁-C₆alkyl, C₁-C₆alkoxyl,
 20 halo, C₁-C₆haloalkyl and NR³R⁴,

wherein the C₁-C₆alkyl and C₁-C₆haloalkyl are each independently substituted with 0-4
 R^{1a};

R^{1a} is at each occurrence independently selected from hydroxyl, NR³R⁴ and -C(=O)-OH;

R² is selected from hydrogen and C₁-C₆alkyl;

25 R³ is at each occurrence independently selected from hydrogen and C₁-C₆alkyl;

R⁴ is at each occurrence independently selected from -SO₂R⁵, hydrogen, -C(=O)-(C₁-
 C₆alkyl) and C₁-C₆alkyl;

R⁵ is at each occurrence independently selected from NH₂ and C₁-C₆alkyl;

n is 0, 1, 2, 3 or 4;

30 m is 0, 1, 2, 3, 4 or 5;

p is 0, 1 or 2.

In a second aspect, there is provided a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

5 In a third aspect, there is provided a method of treating or preventing a disease or disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

In a further aspect, there is provided a method of treating or preventing a disease or disorder mediated by TRPV1 in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
10

In a further aspect, there is provided a method of treating an ocular disease or disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the ocular disease or disorder is mediated by TRPV1.

15 In a further aspect, there is provided a method of treating an ocular surface disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

In a further aspect, there is provided a method of treating ocular surface pain (e.g., corneal induced pain) in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
20

In a further aspect, there is provided a method of treating ocular hyperemia in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

25 In a further aspect, there is provided a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of ocular surface pain (e.g., corneal induced pain).

In a further aspect, there is provided a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of ocular hyperemia.

In a further aspect, there is provided a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of an ocular surface disorder.
30

In a further aspect, there is provided the use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating an ocular disease or disorder that is mediated by TRPV1.

In a further aspect, there is provided the use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in the treatment of an ocular disease or disorder that is mediated by TRPV1.
35

In a further aspect, there is provided a pharmaceutical combination comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and one or more additional therapeutic agent(s).

Detailed Description of the Disclosure

5 The compounds disclosed herein are effective as TRPV1 antagonists. Without wishing to be bound by any theory, it is believed that the disclosed compounds may treat disorders associated with TRPV1, including the treatment of pain or discomfort associated with such disorders. In particular examples, the pain is ocular surface pain, particularly corneal or ocular surface induced pain and chronic ocular surface pain.

Definitions

10 Unless specified otherwise, the terms "compounds of the present disclosure," "compounds of the disclosure," or "compound of the disclosure" refer to compounds of formulae (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (I-i), (I-ii), exemplified compounds, salts thereof, particularly pharmaceutically acceptable salts thereof, hydrates, solvates, prodrugs, as well as all
15 stereoisomers (including diastereoisomers and enantiomers), rotamers, tautomers, and isotopically labeled compounds (including deuterium substitutions), as well as inherently formed moieties.

20 In the groups, radicals, or moieties defined below, the number of carbon atoms is often specified preceding the group, for example, C₁-C₁₀alkyl means an alkyl group or radical having 1 to 10 carbon atoms. In general, for groups comprising two or more subgroups, the last named group is the radical attachment point, for example, "alkylaryl" means a monovalent radical of the formula alkyl-aryl-, while "arylalkyl" means a monovalent radical of the formula aryl-alkyl-.

25 Furthermore, the use of a term designating a monovalent radical where a divalent radical is appropriate shall be construed to designate the respective divalent radical and vice versa. Unless otherwise specified, conventional definitions of terms control and conventional stable atom valences are presumed and achieved in all formulas and groups. The articles "a" and "an" refer to one or more than one (e.g., to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.

 The term "and/or" means either "and" or "or" unless indicated otherwise.

30 The term "substituted" means that the specified group or moiety bears one or more suitable substituents wherein the substituents may connect to the specified group or moiety at one or more positions. For example, an aryl substituted with a cycloalkyl may indicate that the cycloalkyl connects to one atom of the aryl with a bond or by fusing with the aryl and sharing two or more common atoms.

35 As used herein the term "C₁-C₆alkyl" refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to six carbon atoms, and which is attached to the rest of the molecule by a single bond. The terms C₁-C₃alkyl and C₁-C₅alkyl are to be construed accordingly. Examples of C₁-C₆alkyl include,

but are not limited to, methyl, ethyl, *n*-propyl, 1-methylethyl (*iso*-propyl), *n*-butyl, 1-methylpropyl (*sec*-butyl), 2-methylpropyl (*iso*-butyl), 1,1-dimethylethyl (*t*-butyl), *n*-pentyl and *n*-hexyl.

As used herein, the term "C₁-C₆alkoxy" refers to a radical of the formula -OR_a where R_a is a C₁-C₆alkyl radical as generally defined above. Examples of C₁-C₆alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, *iso*-propoxy, butoxy, *iso*-butoxy, *tert*-butoxy, *sec*-butoxy, pentoxy, and hexoxy.

As used herein, the term "C₁-C₆haloalkyl" refers to C₁-C₆alkyl radical, as defined above, substituted by one or more halo radicals, as defined herein. Examples of C₁-C₆haloalkyl include, but are not limited to, trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, 1,1-difluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-fluoropropyl, 3,3-difluoropropyl and 1-fluoromethyl-2-fluoroethyl, 1,3-dibromopropan-2-yl, 3-bromo-2-fluoropropyl and 1,4,4-trifluorobutan-2-yl.

As used herein, the term "C₁-C₆haloalkoxy" means a C₁-C₆alkoxy group as defined herein substituted with one or more halo radicals. Examples of C₁-C₆haloalkoxy groups include, but are not limited to, trifluoromethoxy, difluoromethoxy, fluoromethoxy, trichloromethoxy, 1,1-difluoroethoxy, 2,2-difluoroethoxy, 2,2,2-trifluoroethoxy, 1-fluoromethyl-2-fluoroethoxy, pentafluoroethoxy, 2-fluoropropoxy, 3,3-difluoropropoxy and 3-dibromopropoxy. Preferably, the one or more halo radicals of C₁-C₆haloalkoxy is fluoro. Preferably, C₁-C₆haloalkoxy is selected from trifluoromethoxy, difluoromethoxy, fluoromethoxy, 1,1-difluoroethoxy, 2,2-difluoroethoxy, 2,2,2-trifluoroethoxy, 1-fluoromethyl-2-fluoroethoxy, and pentafluoroethoxy.

The term "halogen" or "halo" means fluorine, chlorine, bromine or iodine.

As used herein, the term "cycloalkyl" means a monocyclic or polycyclic saturated or partially unsaturated carbon ring containing 3-18 carbon atoms wherein there are no delocalized pi electrons (aromaticity) shared among the ring carbon. The term "C₃-C₆cycloalkyl" is to be construed accordingly. The term polycyclic encompasses bridged (e.g., norbornane), fused (e.g., decalin) and spirocyclic cycloalkyl. Preferably, cycloalkyl, e.g., C₃-C₆cycloalkyl, is a monocyclic or bridged hydrocarbon group of 3 to 6 carbon atoms.

Examples of cycloalkyl groups include, without limitations, cyclopropenyl, cyclopropyl, cyclobutyl, cyclobutenyl, cyclopentyl, cyclohexyl, cycloheptanyl, cyclooctanyl, norboranyl, norborenyl, bicyclo[2.2.2]octanyl, bicyclo[2.2.2]octenyl, bicyclo[1.1.1]pentanyl and derivatives thereof.

Examples of C₃-C₆cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl.

"Heterocyclyl" means a saturated or partially saturated monocyclic or polycyclic ring containing carbon and at least one heteroatom selected from oxygen, nitrogen, and sulfur (O, N, and S) and wherein there are no delocalized pi electrons (aromaticity) shared among the ring carbon or heteroatoms. The term "4- to 6-membered heterocyclyl" is to be construed accordingly. The heterocyclyl ring structure may be substituted by one or more substituents. The substituents

can themselves be optionally substituted. The heterocyclyl may be bonded via a carbon atom or heteroatom. The term polycyclic encompasses bridged, fused and spirocyclic heterocyclyl.

Examples of heterocyclyl rings include, but are not limited to, oxetanyl, azetidiny, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidiny, oxazoliny, isoxazoliny, oxazolidiny, thiazolidiny, pyranly, thiopyranly, tetrahydropyranyl, dioxaliny, piperidiny, morpholiny, thiomorpholiny, thiomorpholiny S-oxide, thiomorpholiny S-dioxide, piperaziny, azepiny, oxepiny, diazepiny, tropany, oxazolidinony, 1,4-dioxany, dihydrofurany, 1,3-dioxolany, imidazolidiny, dihydroisoxazoliny, pyrroliny, pyrazoliny, oxazepiny, dithiolany, homotropany, dihydropyrany (e.g., 3,6-dihydro-2H-pyrany), oxaspiroheptany (e.g., 2-oxaspiro[3.3]heptan-6-yl) and the like.

Examples of 4- to 6-membered heterocyclyl include, without limitations, azetidiny, pyrrolidiny, tetrahydrofurany, tetrahydrothieny, piperidiny, piperaziny, dihydroisoxazoliny, tetrahydropyrany, morpholiny, dihydropyrany (e.g., 3,6-dihydro-2H-pyrany) and oxaspiroheptany (e.g., 2-oxaspiro[3.3]heptan-6-yl).

As used herein, the term "aryl" as used herein means monocyclic, bicyclic or polycyclic carbocyclic aromatic rings. Examples of aryl include, but are not limited to, phenyl, naphthyl (e.g., naphth-1-yl, naphth-2-yl), anthryl (e.g., anthr-1-yl, anthr-9-yl), phenanthryl (e.g., phenanthr-1-yl, phenanthr-9-yl), and the like. Aryl is also intended to include monocyclic, bicyclic or polycyclic carbocyclic aromatic rings substituted with carbocyclic aromatic rings. Representative examples are biphenyl (e.g., biphenyl-2-yl, biphenyl-3-yl, biphenyl-4-yl), phenylnaphthyl (e.g., 1-phenylnaphth-2-yl, 2-phenylnaphth-1-yl), and the like. Aryl is also intended to include partially saturated bicyclic or polycyclic carbocyclic rings with at least one unsaturated moiety (e.g., a benzo moiety). Representative examples are, indanyl (e.g., indan-1-yl, indan-5-yl), indenyl (e.g., inden-1-yl, inden-5-yl), 1,2,3,4-tetrahydronaphthyl (e.g., 1,2,3,4-tetrahydronaphth-1-yl, 1,2,3,4-tetrahydronaphth-2-yl, 1,2,3,4-tetrahydronaphth-6-yl), 1,2-dihydronaphthyl (e.g., 1,2-dihydronaphth-1-yl, 1,2-dihydronaphth-4-yl, 1,2-dihydronaphth-6-yl), fluorenyl (e.g., fluoren-1-yl, fluoren-4-yl, fluoren-9-yl), and the like. Aryl is also intended to include partially saturated bicyclic or polycyclic carbocyclic aromatic rings containing one or two bridges. Representative examples are, benzonorbornyl (e.g., benzonorborn-3-yl, benzonorborn-6-yl), 1,4-ethano-1,2,3,4-tetrahydronaphthyl (e.g., 1,4-ethano-1,2,3,4-tetrahydronaphth-2-yl, 1,4-ethano-1,2,3,4-tetrahydronaphth-10-yl), and the like. The term "C₆-C₁₀aryl" is to be construed accordingly.

Examples of aryl include, but are not limited to, indenyl, (e.g., inden-1-yl, inden-5-yl) phenyl (C₆H₅), naphthyl (C₁₀H₇) (e.g., naphth-1-yl, naphth-2-yl), indanyl (e.g., indan-1-yl, indan-5-yl), and tetrahydronaphthalenyl (e.g., 1,2,3,4-tetrahydronaphthalenyl). The term C₆-C₁₀aryl is to be construed accordingly. Examples of C₆-C₁₀aryl include a monocyclic or bicyclic carbocyclic aromatic ring.

Examples of C₆-C₁₀aryl include, but are not limited to, phenyl and naphthyl. In an embodiment, C₆-C₁₀aryl is phenyl.

As used herein, the term "heteroaryl" is intended to include monocyclic heterocyclic aromatic rings containing one or more heteroatoms selected from oxygen, nitrogen, and sulfur (O, N, and S). Representative examples are pyrrolyl, furanyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isothiazolyl, isooxazolyl, triazolyl, (e.g., 1,2,4-triazolyl), oxadiazolyl, (e.g., 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl), thiadiazolyl (e.g., 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl), tetrazolyl, pyranyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, thiadiazinyl, azepinyl, azecinyl, and the like.

Heteroaryl is also intended to include bicyclic heterocyclic aromatic rings containing one or more heteroatoms selected from oxygen, nitrogen, and sulfur (O, N, and S). Representative examples are indolyl, isoindolyl, benzofuranyl, benzothiophenyl, indazolyl, benzopyranyl, benzimidazolyl, benzothiazolyl, benzisothiazolyl, benzoxazolyl, benzisoxazolyl, benzoxazinyl, benzotriazolyl, naphthyridinyl, phthalazinyl, pteridinyl, purinyl, quinazolinyl, cinnolinyl, quinolinyl, isoquinolinyl, quinoxalyl, oxazolopyridinyl, isooxazolopyridinyl, pyrrolopyridinyl, furopyridinyl, thienopyridinyl, imidazopyridinyl, imidazopyrimidinyl, pyrazolopyridinyl, pyrazolopyrimidinyl, pyrazolotriazinyl, thiazolopyridinyl, thiazolopyrimidinyl, imidazothiazolyl, triazolopyridinyl, triazolopyrimidinyl, and the like.

Heteroaryl is also intended to include polycyclic heterocyclic aromatic rings containing one or more heteroatoms selected from oxygen, nitrogen, and sulfur (O, N, and S). Representative examples are carbazolyl, phenoxazinyl, phenazinyl, acridinyl, phenothiazinyl, carbolinyl, phenanthrolinyl, and the like.

The heteroaryl ring structure may be substituted by one or more substituents. The substituents can themselves be optionally substituted. The heteroaryl ring may be bonded via a carbon atom or heteroatom.

The term "5-10 membered heteroaryl" is to be construed accordingly.

Examples of 5-10 membered heteroaryl include, but are not limited to, indolyl, imidazopyridyl, isoquinolinyl, benzooxazolonyl, pyridinyl, pyrimidinyl, pyridinonyl, benzotriazolyl, pyridazinyl, pyrazolotriazinyl, indazolyl, benzimidazolyl, quinolinyl, triazolyl, (e.g., 1,2,4-triazolyl), pyrazolyl, thiazolyl, oxazolyl, isooxazolyl, pyrrolyl, oxadiazolyl, (e.g., 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl), imidazolyl, pyrrolopyridinyl, tetrahydroindazolyl, quinoxalyl, thiadiazolyl (e.g., 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl), pyrazinyl, oxazolopyridinyl, pyrazolopyrimidinyl, benzoxazolyl, indolinyl, isooxazolopyridinyl, dihydropyridooxazinyl and tetrazolyl.

The term "partially saturated heterocyclyl" is intended to include partially saturated monocyclic, bicyclic or polycyclic heterocyclyls containing one or more heteroatoms selected oxygen, nitrogen, and sulfur (O, N, and S). Representative examples are imidazolinyl, indolinyl, dihydrobenzofuranyl, dihydrobenzothieryl, dihydrobenzopyranyl, dihydropyridooxazinyl, dihydrobenzodioxinyl (e.g., 2,3-dihydrobenzo[b][1,4]dioxinyl), benzodioxolyl (e.g.,

benzo[d][1,3]dioxole), dihydrobenzooxaziny (e.g., 3,4-dihydro-2H-benzo[b][1,4]oxazine), tetrahydroindazolyl, tetrahydrobenzimidazolyl, tetrahydroimidazo[4,5-c]pyridyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, tetrahydroquinoxalinyl, and the like.

5 The term "6- to 10-membered partially saturated heterocycl" is to be construed accordingly.

Examples of 6- to 10-membered partially saturated heterocycl include, but are not limited to, indolinyl, dihydrobenzofuranyl, dihydrobenzothieryl, dihydrobenzopyranyl, dihydropyridooxaziny, dihydrobenzodioxiny (e.g., 2,3-dihydrobenzo[b][1,4]dioxiny), benzodioxolyl (e.g., benzo[d][1,3]dioxole), dihydrobenzooxaziny (e.g., 3,4-dihydro-2H-
10 benzo[b][1,4]oxazine), tetrahydroindazolyl, tetrahydrobenzimidazolyl, tetrahydroimidazo[4,5-c]pyridyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl and tetrahydroquinoxalinyl.

"TRPV1 receptor" refers to the Transient Receptor Potential Vanilloid 1 that has been characterized through molecular cloning and pharmacology. See, e.g., Caterina MJ, et al., Nature 1997; 389:816–824. TRPV1 receptor activity is measured as described in WO2005/120510,
15 hereby incorporated by reference in its entirety.

The term "TRPV1 antagonist" and "TRPV1 inhibitor" includes any agent that can inhibit the activity of TRPV1 (e.g., block TRPV1-mediated signaling cascade).

The language "effective amount" of the compounds described herein, refers to that amount of a therapeutic compound necessary or sufficient to perform its intended function within
20 a mammal. An effective amount of the therapeutic compound can vary according to factors such as the amount of the causative agent already present in the mammal, the age, sex, and weight of the mammal, and the ability of the therapeutic compounds of the present disclosure to treat the conditions wherein TRPV1 plays a role.

The phrase "ophthalmically compatible" refers to formulations, polymers and other
25 materials and/or dosage forms which are suitable for use in contact with the ocular tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or As used herein, "ocular surface" refers to the outer surface of the eye, which anatomically comprises the cornea (with epithelium, bowman layer, stroma, descemet membrane, endothelium), conjunctiva, cul de sac, and the comeo-scleral junction, i.e., limbus.

30 As used herein, the term "treat", "treating" or "treatment" in connection to a disease or disorder refers in some embodiments, to ameliorating the disease or disorder (i.e., slowing or arresting or reducing the development of the disease or at least one of the clinical symptoms thereof). In another embodiment "treat", "treating" or "treatment" refers to alleviating or ameliorating at least one physical parameter including those, which may not be discernible by the
35 patient. In yet another embodiment, "treat", "treating" or "treatment" refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both. In yet another embodiment,

“treat”, “treating” or “treatment” refers to preventing or delaying the onset or development or progression of the disease or disorder or a symptom thereof.

As used herein, the term “subject” or “patient” refers to human and non-human mammals, including but, not limited to, primates, rabbits, pigs, horses, dogs, cats, sheep, and cows. In particular embodiments, a subject or patient is a human. In some embodiments, the term “patient” or “subject” refers to a human being who is diseased with the condition (*i.e.*, disease or disorder) described herein and who would benefit from the treatment. As used herein, a subject is “in need of” a treatment if such subject (patient) would benefit biologically, medically or in quality of life from such treatment. In particular embodiments, the subject is an adult human at least about 18 years of age. In particular embodiments, the subject is an adult human from about 18 to about 75 years of age. In some embodiments, the subject is a human child up to about 18 years of age.

As used herein, “ocular surface” refers to the outer surface of the eye, which anatomically comprises the cornea (with epithelium, bowman layer, stroma, descemet membrane, endothelium), conjunctiva, cul de sac, and the corneo-scleral junction, *i.e.*, limbus.

As used herein, ocular administration includes administration to all parts of the eye including all parts of the ocular surface such as the cornea, conjunctiva, the cul de sac and the corneo-scleral junction, *i.e.*, limbus.

As used herein, “pain” refers to constant or intermittent sensation of actual pain described as but not limited to stabbing, dull, sharp, or ache. Pain may also refer to similar related descriptors such as but not limited to discomfort, burning, stinging, grittiness, foreign body sensation, dryness, sandy, tired, itchy, irritated, sensitivity to light.

As used herein, “ocular surface pain” refers to pain on the surface of the eye, *e.g.*, cornea. Ocular pain may be nociceptive pain, which is generally caused by external physical or chemical damaging stimuli such as corneal surgery, inflammation, or other damage to the corneal surface. Ocular pain may also result from neuropathic pain, which may occur due to direct damage to the neurons of the body, resulting in messages of pain being sent to the central nervous system and brain regardless of the presence of noxious stimuli. As used herein “ocular surface pain” includes both nociceptive pain and neuropathic pain.

Ocular surface pain may be measured using different scales. For example, the “visual analog scale” (VAS) is a measure of pain intensity where a subject typically marks a place on a scale that aligns with their level of pain. The pain is marked in a range of “no pain” (score of 0) and “pain as bad as it could be” or “worst imaginable pain” (score of 100). See *e.g.*, Hawker, et al., *Arthritis Care & Research* 63(11), pp. S240-S252 (November 2011). There are several other well-designed pain scales that may be used to help assess the extent of pain. The numerical rating scale (NRS) is often used, in which subjects use numbers to rate pain. The number scale may be from 1-10, or 1-100. The Wong-Baker FACES Pain Scale combines pictures and numbers for pain ratings. It can be used in children over the age of 3 and in adults. Six faces depict different expressions, ranging from happy to extremely upset. Each is assigned a

numerical rating between 0 (smiling) and 10 (crying). The Verbal Pain Intensity Scale uses wordings on a scale to rate pain intensity: No Pain / Mild Pain / Moderate Pain / Severe Pain Very Severe Pain / Worst Possible Pain.

5 The Eye Sensation Scale is a specific pain scale was developed to measure ophthalmic pain severity. See Caudle L.E. et al., *Optom Vis Sci.* 2007 Aug; 84(8):752-62. In this scale, pain, discomfort or light sensitivity is typically measured by 5 category labels of "extreme," "severe," "moderate," "mild," or "none."

10 The Ocular Pain Assessment Survey (OPAS) is a quantitative, multidimensional questionnaire, specifically designed for assessment of corneal and ocular surface pain and Quality of Life (QoL) changes. The OPAS assesses pain intensity, frequency of eye and non-eye pain, QoL changes, aggravating factors, associated factors, and symptomatic relief quantitative, allowing for monitoring of treatment responses. See Qazi et al., *Ophthalmology* July 123(7):1458-1468 (2016).

15 As used herein, "ocular hyperemia" refers to redness of the ocular surface. Ocular hyperemia may be a clinical marker for inflammation and/or ocular irritation. Ocular hyperemia may be measured using a visual scale such as the McMonnies scale, at values from 0 to 5, based on standard photographs or using photographs taken under standardized lighting conditions that can be analyzed digitally in an semi- or fully automated fashion for an reading or any relevant method.

20 The term "ocular surface disease" or "ocular surface disorder" encompasses disease entities as well as related symptoms that result from a variety of abnormalities, including abnormal lid anatomy or function, abnormal or altered tear production or composition, and related subclinical or clinical signs. Many diseases can cause ocular surface disorders. Patients with ocular surface disorders may exhibit clinical signs common to several diseases, and include but
25 not limited to chronic punctate keratopathy, filamentary keratopathy, recurrent corneal erosion, bacterial conjunctivitis, culture-negative conjunctivitis, cicatrising (scarring) conjunctivitis, persistent epithelial defect, infectious keratitis, corneal melt and ocular surface failure. The most common ocular surface disorders stem from tear-film abnormalities and/or meibomian gland dysfunction or blepharitis.

30 As used herein, the term "about" refers to a range of values +/- 10% of a specified value.

As used herein, a pharmaceutical composition is a composition suitable for pharmaceutical use. A composition suitable for pharmaceutical use may be sterile, homogeneous and/or isotonic. Pharmaceutical compositions may be prepared in certain embodiments in an aqueous form, for example in a pre-filled syringe or other single- or multi-dose container. In
35 certain embodiments of the invention, the pharmaceutical composition is ophthalmically compatible and suitable for ophthalmic administration to a human subject by, for example, topical or other known methods of delivery. These methods include but are not limited to incorporating

the compounds disclosed herein into an ocular insert or ocular film that dissolves and releases the compounds over extended periods of time.


As used herein, the term "a," "an," "the" and similar terms used in the context of the disclosure (especially in the context of the claims) are to be construed to cover both the singular and plural unless otherwise indicated herein or clearly contradicted by the context.

Various enumerated embodiments of the disclosure are described herein. It will be recognized that features specified in each embodiment may be combined with other specified features to provide further embodiments of the disclosure.

As used herein, the term "pharmaceutically acceptable carrier" refers to a substance useful in the preparation or use of a pharmaceutical composition and includes, for example, suitable diluents, solvents, dispersion media, surfactants, antioxidants, preservatives, isotonic agents, buffering agents, emulsifiers, absorption delaying agents, salts, drug stabilizers, binders, excipients, disintegration agents, lubricants, wetting agents, sweetening agents, flavoring agents, dyes, and combinations thereof, as would be known to those skilled in the art (see, for example, Remington The Science and Practice of Pharmacy, 22nd Ed. Pharmaceutical Press, 2013, pp. 1049-1070).

Enumerated Embodiments

Embodiment 1. A compound of Formula (I), or a pharmaceutically acceptable salt thereof,



wherein:

W is C(=O) or absent;

X is N or N oxide;

Y is N or CH;

Z is NH, O or S;

A is CH₂ or absent;

L is selected from 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from N, O, and S, C₆-C₁₀aryl and 6- to 10-membered partially saturated heterocyclyl having 1-3 heteroatoms independently selected from N, O, and S;

R^A is at each occurrence independently selected from halo, $-\text{CN}$, $\text{C}_1\text{-C}_6\text{haloalkyl}$, $\text{C}_1\text{-C}_6\text{alkyl}$, SF_5 , $\text{C}_3\text{-C}_6\text{cycloalkyl}$, $\text{C}_1\text{-C}_6\text{alkoxyl}$, $\text{C}_1\text{-C}_6\text{haloalkoxyl}$, 4- to 6-membered heterocyclyl having 1-2 heteroatoms independently selected from N, O, and S, $-(\text{CH}_2)_p\text{-NR}^3\text{R}^4$ and $-\text{C}(=\text{O})\text{-O}(\text{C}_1\text{-C}_6\text{alkyl})$,

5 wherein the $\text{C}_3\text{-C}_6\text{cycloalkyl}$ and 4- to 6-membered heterocyclyl are each independently substituted with 0-4 R^{A1} ;

R^{A1} is at each occurrence independently selected from halo and $\text{C}_1\text{-C}_6\text{haloalkyl}$;

R^1 is at each occurrence independently selected from hydroxyl, $\text{C}_1\text{-C}_6\text{alkyl}$, $\text{C}_1\text{-C}_6\text{alkoxyl}$, halo, $\text{C}_1\text{-C}_6\text{haloalkyl}$ and NR^3R^4 ,

10 wherein the $\text{C}_1\text{-C}_6\text{alkyl}$ and $\text{C}_1\text{-C}_6\text{haloalkyl}$ are each independently substituted with 0-4 R^{1a} ;

R^{1a} is at each occurrence independently selected from hydroxyl, NR^3R^4 and $-\text{C}(=\text{O})\text{-OH}$;

R^2 is selected from hydrogen and $\text{C}_1\text{-C}_6\text{alkyl}$;

R^3 is at each occurrence independently selected from hydrogen and $\text{C}_1\text{-C}_6\text{alkyl}$;

15 R^4 is at each occurrence independently selected from $-\text{SO}_2\text{R}^5$, hydrogen, $-\text{C}(=\text{O})\text{-(C}_1\text{-C}_6\text{alkyl)}$ and $\text{C}_1\text{-C}_6\text{alkyl}$;

R^5 is at each occurrence independently selected from NH_2 and $\text{C}_1\text{-C}_6\text{alkyl}$;

n is 0, 1, 2, 3 or 4;

m is 0, 1, 2, 3, 4 or 5;

20 p is 0, 1 or 2.

Embodiment 2. The compound of Embodiment 1 or a pharmaceutically acceptable salt thereof,

wherein

W is $\text{C}(=\text{O})$ or absent;

25 X is N or N oxide;

Y is CH ;

Z is NH , O or S;

A is CH_2 or absent;

30 L is selected from 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from N, O, and S, $\text{C}_6\text{-C}_{10}\text{aryl}$ and 6- to 10-membered partially saturated heterocyclyl having 1-3 heteroatoms independently selected from N, O, and S;

R^A is at each occurrence independently selected from halo, $-\text{CN}$, $\text{C}_1\text{-C}_6\text{haloalkyl}$, $\text{C}_1\text{-C}_6\text{alkyl}$, SF_5 , $\text{C}_3\text{-C}_6\text{cycloalkyl}$, $\text{C}_1\text{-C}_6\text{alkoxyl}$, $\text{C}_1\text{-C}_6\text{haloalkoxyl}$, 4- to 6-membered heterocyclyl having 1-2 heteroatoms independently selected from N, O, and S and $-(\text{CH}_2)_p\text{-NR}^3\text{R}^4$,

35 wherein the $\text{C}_3\text{-C}_6\text{cycloalkyl}$ and 4- to 6-membered heterocyclyl are each independently substituted with 0-4 R^{A1} ;

R^{A1} is at each occurrence independently selected from halo and $\text{C}_1\text{-C}_6\text{haloalkyl}$;

- R¹ is at each occurrence independently selected from C₁-C₆alkyl, halo, C₁-C₆haloalkyl and NR³R⁴,
 wherein the C₁-C₆alkyl and C₁-C₆haloalkyl are each independently substituted with 0-4 R^{1a};
- 5 R^{1a} is at each occurrence independently selected from hydroxyl, NR³R⁴ and -C(=O)-OH;
 R² is selected from hydrogen and C₁-C₆alkyl;
 R³ is at each occurrence independently selected from hydrogen and C₁-C₆alkyl;
 R⁴ is at each occurrence independently selected from -SO₂R⁵, hydrogen, -C(=O)-(C₁-C₆alkyl) and C₁-C₆alkyl;
- 10 R⁵ is at each occurrence independently selected from NH₂ and C₁-C₆alkyl;
 n is 0, 1, 2, 3, 4;
 m is 0, 1, 2, 3, 4 or 5;
 p is 0, 1 or 2.
- Embodiment 3. The compound of Embodiment 1 or 2 or a pharmaceutically
 15 acceptable salt thereof,
 wherein
 W is C(=O) or absent;
 X is N or N oxide;
 Y is CH;
 20 Z is NH, O or S;
 A is CH₂ or absent;
 L is selected from 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from N, O, and S, C₆-C₁₀aryl and 6- to 10-membered partially saturated heterocyclyl having 1-3 heteroatoms independently selected from N, O, and S;
- 25 R^A is at each occurrence independently selected from halo, -CN, C₁-C₆haloalkyl, C₁-C₆alkyl, C₃-C₆cycloalkyl, C₁-C₆alkoxyl, C₁-C₆haloalkoxyl, 4- to 6-membered heterocyclyl having 1-2 heteroatoms independently selected from N, O, and S and -(CH₂)_p-NR³R⁴,
 wherein the C₃-C₆cycloalkyl and 4- to 6-membered heterocyclyl are each independently substituted with 0-4 R^{A1};
- 30 R^{A1} is at each occurrence independently selected from halo and C₁-C₆haloalkyl;
 R¹ is at each occurrence independently selected from C₁-C₆alkyl, halo, C₁-C₆haloalkyl and NH₂,
 wherein the C₁-C₆alkyl and C₁-C₆haloalkyl are each independently substituted with 0-4 R^{1a};
- 35 R^{1a} is at each occurrence independently selected from hydroxyl, NR³R⁴ and -C(=O)-OH;
 R² is selected from hydrogen and C₁-C₃alkyl;
 R³ is at each occurrence independently selected from hydrogen and C₁-C₆alkyl;

R⁴ is at each occurrence independently selected from –SO₂R⁵, hydrogen, –C(=O)–(C₁–C₆alkyl) and C₁–C₆alkyl;

R⁵ is at each occurrence independently selected from NH₂ and C₁–C₆alkyl;

n is 0, 1, 2 or 3;

5 m is 0, 1, 2, 3 or 4;

p is 0, 1 or 2.

Embodiment 4. The compound of any of the preceding Embodiments or a pharmaceutically acceptable salt thereof,

wherein

10 W is absent;

X is N;

Y is CH;

Z is NH, O or S;

A is absent;

15 L is selected from 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from N, O, and S, C₆–C₁₀aryl and 6- to 10-membered partially saturated heterocyclyl having 1-3 heteroatoms independently selected from N, O, and S;

R^A is at each occurrence independently selected from halo, –CN, C₁–C₆haloalkyl, C₁–C₆alkyl, C₃–C₆cycloalkyl, C₁–C₆haloalkoxyl, 4- to 6-membered heterocyclyl having 1-2
20 heteroatoms independently selected from N, O, and S and –(CH₂)_p–NR³R⁴,

wherein the C₃–C₆cycloalkyl and 4- to 6-membered heterocyclyl are each independently substituted with 0-4 R^{A1};

R^{A1} is at each occurrence independently selected from halo and C₁–C₆haloalkyl;

25 R¹ is at each occurrence independently selected from C₁–C₆alkyl, halo, C₁–C₆haloalkyl, wherein the C₁–C₆alkyl and C₁–C₆haloalkyl are each independently substituted with 0-4 R^{1a};

R^{1a} is at each occurrence independently selected from hydroxyl, NR³R⁴ and –C(=O)–OH;

R² is selected from hydrogen and C₁–C₃alkyl;

R³ is at each occurrence independently selected from hydrogen and C₁–C₆alkyl;

30 R⁴ is at each occurrence independently selected from –SO₂R⁵, hydrogen, –C(=O)–(C₁–C₆alkyl) and C₁–C₆alkyl;

R⁵ is at each occurrence independently selected from NH₂ and C₁–C₆alkyl;

n is 0, 1, 2 or 3;

m is 0, 1, 2, 3 or 4;

35 p is 0, 1 or 2.

Embodiment 5. The compound of any of the preceding Embodiments or a pharmaceutically acceptable salt thereof,

wherein R^A is selected from fluoro, $-\text{CN}$, $-\text{CF}_3$, $-\text{CHF}_2$, $-\text{CHFCH}_2\text{F}$, $-\text{CH}_2\text{F}$, $\text{C}_1\text{-C}_4$ alkyl, $\text{C}_3\text{-C}_6$ cycloalkyl, $-\text{OCF}_3$, $-\text{OCHF}_2$, $-\text{OCH}_2\text{F}$, $-\text{OCHFCH}_2\text{F}$ and 4-membered heterocyclyl having 1 oxygen atom

wherein the $\text{C}_3\text{-C}_6$ cycloalkyl and the 4-membered O containing heterocyclyl are each independently substituted with 0-2 R^{A1} , and wherein

R^{A1} is at each occurrence independently selected from fluoro and $\text{C}_1\text{-C}_6$ fluoroalkyl.

Embodiment 6. The compound of any of the preceding Embodiments or a pharmaceutically acceptable salt thereof,

wherein R^A is selected from fluoro, $-\text{CN}$, $-\text{CF}_3$, $-\text{CHF}_2$, $-\text{CHFCH}_2\text{F}$, $-\text{CH}_2\text{F}$, $\text{C}_1\text{-C}_4$ alkyl, $\text{C}_3\text{-C}_6$ cycloalkyl, $-\text{OCF}_3$, $-\text{OCHF}_2$, $-\text{OCH}_2\text{F}$, $-\text{OCHFCH}_2\text{F}$ and 4-membered heterocyclyl having 1 oxygen atom

wherein the $\text{C}_3\text{-C}_6$ cycloalkyl and the 4-membered O containing heterocyclyl are each independently substituted with 0-2 R^{A1} , and wherein


R^{A1} is at each occurrence independently selected from fluoro and $\text{C}_1\text{-C}_6$ fluoroalkyl.

Embodiment 7. The compound of any of the preceding Embodiments or a pharmaceutically acceptable salt thereof,

wherein R^A is selected from fluoro, $-\text{CN}$, $-\text{CF}_3$, $-\text{CHF}_2$, $-\text{CHFCH}_2\text{F}$ and $-\text{CH}_2\text{F}$.

Embodiment 8. The compound of any of the preceding Embodiments or a pharmaceutically acceptable salt thereof,


wherein L is selected from $\text{C}_6\text{-C}_{10}$ aryl, 6- to 10-membered partially saturated heterocyclyl having 1-3 heteroatoms independently selected from N, O, and S, and 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from N, O, and S selected from



wherein the $\text{C}_6\text{-C}_{10}$ aryl, 6- to 10-membered partially saturated heterocyclyl and 5- to 10-membered heteroaryl are each independently substituted with 0-4 R^A , and wherein R^A is defined according to any of the preceding Embodiments.

Embodiment 9. The compound of any of the preceding Embodiments or a pharmaceutically acceptable salt thereof,

wherein L is selected from $\text{C}_6\text{-C}_{10}$ aryl, 6- to 10-membered partially saturated heterocyclyl having 1-3 heteroatoms independently selected from N, O, and S, and 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from N, O, and S selected from




wherein the C₆-C₁₀aryl and 6- to 10-membered partially saturated heterocyclyl are each independently substituted with 0-2 R^A,

5 and wherein R^A is defined according to any of the preceding Embodiments.

Embodiment 10. The compound of any of the preceding Embodiments or a pharmaceutically acceptable salt thereof,

wherein L is selected from C₆-C₁₀aryl, 6- to 10-membered partially saturated heterocyclyl having 1-3 heteroatoms independently selected from N, O, and S, and 5- to 10-membered
10 heteroaryl having 1-3 heteroatoms independently selected from N, O, and S selected from



wherein the C₆-C₁₀aryl and 6- to 10-membered partially saturated heterocyclyl are each independently substituted with 0-2 R^A, and wherein R^A is defined according to any of the
15 preceding Embodiments.

Embodiment 11. The compound of any of Embodiments 1 to 7, or a pharmaceutically acceptable salt thereof,


wherein L is selected from 6- to 10-membered partially saturated heterocyclyl having 1-3 heteroatoms independently selected from N, O, and S, 5- to 10-membered heteroaryl having 1-3
20 heteroatoms independently selected from N, O, and S, and C₆-C₁₀aryl selected from phenyl and naphthyl,

wherein the 6- to 10-membered partially saturated heterocyclyl, 5- to 10-membered heteroaryl, phenyl and naphthyl are each independently substituted with 0-4 R^A, and wherein R^A is defined according to any of the preceding Embodiments.

Embodiment 12. The compound of any of Embodiments 1 to 7, 11, or a pharmaceutically acceptable salt thereof,

wherein L is selected from 6- to 10-membered partially saturated heterocyclyl having 1-3 heteroatoms independently selected from N, O, and S, 5- to 10-membered heteroaryl having 1-3


heteroatoms independently selected from N, O, and S, and C₆-C₁₀aryl selected from




membered partially saturated heterocyclyl and 5- to 10-membered heteroaryl are each
5 independently substituted with 0-3 R^A, and wherein R^A is defined according to any of the
preceding Embodiments.

Embodiment 13. The compound of any of Embodiments 1 to 7, 11, 12, or a pharmaceutically acceptable salt thereof,

wherein L is selected from 6- to 10-membered partially saturated heterocyclyl having 1-3
10 heteroatoms independently selected from N, O, and S, 5- to 10-membered heteroaryl having 1-3
heteroatoms independently selected from N, O, and S, and C₆-C₁₀aryl selected from






and wherein the 6- to 10-membered partially saturated heterocyclyl and 5- to 10-membered heteroaryl are each independently substituted with 0-3 R^A , and wherein R^A is defined according to any of the preceding Embodiments.

Embodiment 14. The compound of any of Embodiments 1 to 7, or a pharmaceutically acceptable salt thereof, wherein L is selected from 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from N, O, and S, C_6 - C_{10} aryl and 6- to 10-membered partially

saturated heterocyclyl selected from and , wherein the 5- to 10-membered heteroaryl, C_6 - C_{10} aryl and 6- to 10-membered partially saturated heterocyclyl are each independently substituted with 0-4 R^A , and wherein R^A is defined according to any of the preceding Embodiments.

Embodiment 15. The compound of any of Embodiments 1 to 7, 14, or a pharmaceutically acceptable salt thereof, wherein L is selected from 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from N, O, and S, C_6 - C_{10} aryl and 6- to


10-membered partially saturated heterocyclyl selected from and



, wherein the 5- to 10-membered heteroaryl and C_6 - C_{10} aryl are each independently substituted with 0-4 R^A , and wherein R^A is defined according to any of the preceding Embodiments.

Embodiment 16. The compound of any of Embodiments 1 to 7, 14, 15, or a pharmaceutically acceptable salt thereof, wherein L is selected from 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from N, O, and S, C_6 - C_{10} aryl and 6- to

10-membered partially saturated heterocyclyl selected from and



, wherein the 5- to 10-membered heteroaryl and C₆-C₁₀aryl are each independently substituted with 0-4 R^A, and wherein R^A is defined according to any of the preceding Embodiments.

Embodiment 17. The compound of any of the preceding Embodiments or a pharmaceutically acceptable salt thereof,

wherein R¹ is at each occurrence is independently selected from C₁-C₆alkyl, halo, C₁-C₆haloalkyl and NH₂,

wherein the C₁-C₆alkyl and C₁-C₆haloalkyl are each independently substituted with 0-4 R^{1a},

wherein R^{1a} is at each occurrence independently selected from hydroxyl and NR³R⁴.

Embodiment 18. The compound of any of the preceding Embodiments or a pharmaceutically acceptable salt thereof,

wherein R¹ is at each occurrence is independently selected from C₁-C₆alkyl, fluoro, NH₂, -N(C₁-C₆alkyl)₂ and chloro,

wherein the C₁-C₆alkyl is at each occurrence independently substituted with 0-4 hydroxyl.

Embodiment 19. The compound of any of the preceding Embodiments or a pharmaceutically acceptable salt thereof,

wherein R¹ is at each occurrence is independently selected from C₁-C₆alkyl and fluoro, wherein the C₁-C₆alkyl is each occurrence independently substituted with 0-4 hydroxyl.

Embodiment 20. The compound of any of the preceding Embodiments or a pharmaceutically acceptable salt thereof,

wherein n is 1, 2 or 3.

Embodiment 21. The compound of any of the preceding Embodiments or a pharmaceutically acceptable salt thereof,

wherein m is 1, 2 or 3.

Embodiment 22. The compound of any of the preceding Embodiments or a pharmaceutically acceptable salt thereof,

wherein R² is hydrogen.

Embodiment 23. The compound of any of the preceding Embodiments or a pharmaceutically acceptable salt thereof,

wherein Y is CH.

Embodiment 24. The compound of any of the preceding Embodiments or a pharmaceutically acceptable salt thereof,

wherein W is absent.

Embodiment 25. The compound of any of the preceding Embodiments or a pharmaceutically acceptable salt thereof,

wherein Z is O.

Embodiment 26. The compound of any of the preceding Embodiments or a pharmaceutically acceptable salt thereof,

wherein

5 W is absent;

X is N;

Y is CH;

Z is O;

A is absent;

10 L is C₆-C₁₀aryl;

R^A is at each occurrence independently selected from halo, -CN, C₁-C₆haloalkyl, C₁-C₆alkyl;

R¹ is at each occurrence independently selected from C₁-C₆alkyl, halo and C₁-C₆haloalkyl, wherein the C₁-C₆alkyl and C₁-C₆haloalkyl are each independently substituted with 0-4

15 R^{1a};

R^{1a} is at each occurrence independently selected from hydroxyl and NR³R⁴;

R² is selected from hydrogen and C₁-C₃alkyl;

R³ is at each occurrence independently selected from hydrogen and C₁-C₆alkyl;

R⁴ is at each occurrence independently selected from -SO₂R⁵, hydrogen and C₁-C₆alkyl;

20 R⁵ is at each occurrence independently selected from NH₂ and C₁-C₆alkyl;

n is 1, 2 or 3;

m is 0, 1, 2 or 3.

Embodiment 27. The compound of any of the preceding Embodiments or a pharmaceutically acceptable salt thereof,

25 wherein

W is absent;

X is N;

Y is CH;

Z is O;

30 A is absent;

L is C₆-C₁₀aryl;

R^A is at each occurrence independently selected from halo (*e.g.*, fluoro), C₁-C₆haloalkyl (*e.g.*, C₁-C₆fluoroalkyl) and C₁-C₆alkyl;


35 R¹ is at each occurrence independently selected from C₁-C₆alkyl and halo (*e.g.*, fluoro), wherein the C₁-C₆alkyl is substituted with 0-4 hydroxyl;

R² is hydrogen;


n is 1, 2 or 3;

m is 1, 2 or 3.


Embodiment 28. The compound of any of the preceding Embodiments or a pharmaceutically acceptable salt thereof, wherein R^1 is at each occurrence independently selected from



5 Embodiment 29. The compound of any of the preceding Embodiments or a pharmaceutically acceptable salt thereof, wherein R^1 is at each occurrence independently selected from




10 Embodiment 30. The compound of any of the preceding Embodiments or a pharmaceutically acceptable salt thereof, wherein R^1 is at each occurrence independently selected from



wherein R^{1b} is hydrogen or C₁-C₅alkyl,


15 wherein the C₁-C₅alkyl is substituted with 0-3 hydroxyl.

Embodiment 31. The compound of any of the preceding Embodiments or a pharmaceutically acceptable salt thereof, of Formula (Ia)



20 wherein W, L, R^1 , R^2 , R^A , n and m are defined according to any of the preceding Embodiments.


Embodiment 32. The compound of any of the preceding Embodiments or a pharmaceutically acceptable salt thereof, of Formula (Ib)



(Ib)

wherein W , L , R^1 , R^2 , R^A , n and m are defined according to any of the preceding Embodiments.


- 5 Embodiment 33. The compound of any of the preceding Embodiments or a pharmaceutically acceptable salt thereof, of Formula (Ig)



(Ig)

- 10 wherein W , L , R^1 , R^2 , R^A , n and m are defined according to any of the preceding Embodiments.


- Embodiment 34. The compound of any of the preceding Embodiments or a pharmaceutically acceptable salt thereof, of Formula (Ic)



(Ic)


- 15 wherein L , R^1 , R^2 , R^A , n and m are defined according to any of the preceding Embodiments.

- Embodiment 35. The compound of any of the preceding Embodiments or a pharmaceutically acceptable salt thereof, of Formula (Id)




wherein L, R¹, R², R^A, n and m are defined according to any of the preceding Embodiments.

- 5 Embodiment 36. The compound of any of the preceding Embodiments or a pharmaceutically acceptable salt thereof, of Formula (Ih)




- 10 wherein L, R¹, R², R^A, n and m are defined according to any of the preceding Embodiments.

- Embodiment 37. The compound of any of the preceding Embodiments or a pharmaceutically acceptable salt thereof, of Formula (Ie)




- 15 wherein L, R¹, R², R^A and m are defined according to any of the preceding Embodiments.

- Embodiment 38. The compound of any of the preceding Embodiments or a pharmaceutically acceptable salt thereof, of Formula (If)



wherein L, R¹, R², R^A and m are defined according to any of the preceding Embodiments.

Embodiment 39. The compound of any of the preceding Embodiments or a
5 pharmaceutically acceptable salt thereof, of Formula (li)












wherein L, R¹, R², R^A and m are defined according to any of the preceding Embodiments.











Embodiment 40. The compound of any of Embodiments 1 to 31, 34, 37 or a
10 pharmaceutically acceptable salt thereof, wherein the substituents at the 1- and 3-positions of the cyclobutyl ring have a *trans* configuration.









Embodiment 41. The compound of any of Embodiments 1 to 31, 34, 37 or a
pharmaceutically acceptable salt thereof, wherein the substituents at the 1- and 3-positions of the cyclobutyl ring have a *cis* configuration.











15 Embodiment 42. The compound of Embodiment 1 or a pharmaceutically acceptable salt thereof, selected from:





















 (1r,3r)-N-((6-fluoroisoquinolin-5-yl)methyl)-3-(3-(pentafluoro-λ⁶-sulfaneyl)phenoxy)cyclobutan-1-amine	 (1r,3r)-N-((6-fluoroisoquinolin-5-yl)methyl)-3-(3-(trifluoromethoxy)phenoxy)cyclobutan-1-amine
 (1r,3r)-3-(4-(2,2-difluorocyclopropyl)phenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine	 (1r,3r)-3-((3-fluoro-4-(trifluoromethyl)benzyl)oxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine
 (1r,3r)-N1-(4-fluoro-3-(trifluoromethyl)phenyl)-N3-((6-fluoroisoquinolin-5-yl)methyl)cyclobutane-1,3-diamine	 2-(6-fluoro-5-(((1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethan-1-ol
 (1r,3r)-3-(3,4-difluorophenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine	 (5-(((1r,3r)-3-(3,5-difluoro-4-methoxyphenoxy)cyclobutyl)amino)methyl)-6-fluoroisoquinolin-8-yl)methanol











 N-(2-(6-fluoro-5-(((1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)-2-hydroxyethyl) sulfuric diamide	 (1r,3r)-3-((4-fluoro-3-(trifluoromethyl)phenyl)thio)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine
 1-(6-fluoro-5-(((1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)propane-1,3-diol	 (1r,3r)-3-(4-(difluoromethoxy)phenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine
 (1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-N-((7-fluoroquinazolin-8-yl)methyl)cyclobutan-1-amine	 ethyl 4-(((1r,3r)-3-((6-fluoroisoquinolin-5-yl)methyl)amino)cyclobutoxy)benzoate
 (1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-N-(quinazolin-8-ylmethyl)cyclobutan-1-amine	 (1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-N-((6-methylisoquinolin-5-yl)methyl)cyclobutan-1-amine
 (1s,3s)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine	 (1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine











fluoroisoquinolin-5-yl)methyl)-1-methylcyclobutan-1-amine	(R)-1-(6-fluoro-5-((((1r,3R)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethane-1,2-diol
 (1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)-1-methylcyclobutan-1-amine	 (1r,3r)-N-((6-fluoroisoquinolin-5-yl)methyl)-3-(3-(trifluoromethyl)phenoxy)cyclobutan-1-amine
 2-(3-amino-6-fluoroisoquinolin-5-yl)-N-(((1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)acetamide	 5-((((1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-amine
 (S)-1-(3-amino-6-fluoro-5-((((1r,3S)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethane-1,2-diol	 (1r,3r)-3-((2,6-difluoropyridin-3-yl)oxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine
 N-(((1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)-2-(6-fluoro-8-(hydroxymethyl)isoquinolin-5-yl)acetamide	 (5-((((1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)methanol









 (3-amino-6-fluoro-5-(((1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)methanol	 (1r,3r)-N-(((6-fluoroisoquinolin-5-yl)methyl)-3-(4-(pentafluoro-λ⁶-sulfaneyl)phenoxy)cyclobutan-1-amine
 (1r,3r)-N-(((6-fluoroisoquinolin-5-yl)methyl)-3-(naphthalen-2-yloxy)cyclobutan-1-amine	 (1r,3r)-3-(4-(difluoromethyl)-3-fluorophenoxy)-N-(((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine
 (3-amino-6-fluoro-5-(((1r,3r)-3-((2-(trifluoromethyl)pyridin-4-yl)oxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)methanol	 ethyl 5-(((1r,3r)-3-(((6-fluoroisoquinolin-5-yl)methyl)amino)cyclobutoxy)-2-(trifluoromethyl)benzoate
 (1r,3r)-3-(3-fluoro-4-(trifluoromethoxy)phenoxy)-N-(((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine	 6-fluoro-5-(((1r,3r)-3-((2-(trifluoromethyl)pyridin-4-yl)oxy)cyclobutyl)amino)methyl)isoquinolin-3-amine
 (1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-N-((8-(trifluoromethyl)-5,6-dihydroisoquinolin-2-yl)methyl)cyclobutan-1-amine	 (1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-N-((8-(trifluoromethyl)-5,6-dihydroisoquinolin-2-yl)methyl)cyclobutan-1-amine









4-(((1 <i>r</i> ,3 <i>r</i>)-3-(((6-fluoroisoquinolin-5-yl)methyl)amino)cyclobutoxy)-2-(trifluoromethyl)benzonitrile	methylisoquinolin-5-yl)methyl)cyclobutan-1-amine
 (1<i>r</i>,3<i>r</i>)-3-(4-(difluoromethoxy)-3-fluorophenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine	 (<i>R</i>)-1-(3-amino-6-fluoro-5-(((1<i>r</i>,3<i>R</i>)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethane-1,2-diol
 (1<i>r</i>,3<i>r</i>)-3-(3,5-dimethylphenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine	 (5-(((1<i>r</i>,3<i>r</i>)-3-(4-(tert-butyl)-3,5-difluorophenoxy)cyclobutyl)amino)methyl)-6-fluoroisoquinolin-8-yl)methanol
 6-fluoro-5-(((1<i>r</i>,3<i>r</i>)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-3-amine	 ethyl 3-(((1<i>r</i>,3<i>r</i>)-3-(((6-fluoroisoquinolin-5-yl)methyl)amino)cyclobutoxy)benzoate
 N-(2-(6-fluoro-5-(((1<i>r</i>,3<i>r</i>)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)-2-hydroxyethyl)methanesulfonamide	 2-(6-fluoro-5-(((1<i>r</i>,3<i>r</i>)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)butane-1,4-diol









 3-fluoro-6-(((1r,3r)-3-(((6-fluoroisoquinolin-5-yl)methyl)amino)cyclobutoxy)-2-(trifluoromethyl)aniline	 5-((((1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-3-amine
 (1r,3r)-3-(benzo[d]thiazol-2-yloxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine	 (1r,3r)-3-(3-(difluoromethoxy)phenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine
 5-((((1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)-N,N-dimethylisoquinolin-6-amine	 (1r,3r)-N-((6-methylisoquinolin-5-yl)methyl)-3-((6-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutan-1-amine
 (1r,3r)-3-((4-fluoro-3-(trifluoromethyl)phenyl)thio)-N-(isoquinolin-5-ylmethyl)cyclobutan-1-amine	 (1r,3r)-N-((6-fluoroisoquinolin-5-yl)methyl)-3-((2,2,3,3-tetrafluoro-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)oxy)cyclobutan-1-amine
 5-((((1r,3r)-3-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)methyl)amino)methyl)-6-fluoroisoquinolin-3-amine	 6-fluoro-5-((((1r,3r)-3-((6-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutyl)amino)methyl)isoquinolin-3-amine










yl)oxy)cyclobutyl)amino)methyl)-6-fluoroisoquinolin-8-yl)methanol	
 6-fluoro-5-(((1r,3r)-3-(((6-fluoroisoquinolin-5-yl)methyl)amino)cyclobutoxy)picolinonitrile	 (1r,3r)-N-((6-fluoroisoquinolin-5-yl)methyl)-3-((6-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutan-1-amine
 (1r,3r)-3-(3-(3,5-difluoro-4-methylphenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine	 5-(((1r,3r)-3-(3-(3,5-difluoro-4-methylphenoxy)cyclobutyl)amino)methyl)-6-fluoroisoquinolin-8-yl)methanol
 (1r,3r)-3-(3-(3,5-difluorophenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine	 (1r,3r)-3-((6-chloro-5-(trifluoromethyl)pyridin-3-yl)oxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine
 (1r,3r)-3-(3-(cyclopropylphenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine	 2-(6-fluoro-5-(((1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)-2-hydroxyacetic acid
 (1r,3r)-3-((2-fluoro-6-(trifluoromethyl)pyridin-3-yl)oxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine	 1-(6-fluoro-5-(((1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethan-1-ol

 (1r,3r)-N-((6-fluoroisoquinolin-5-yl)methyl)-3-(3-(2-(trifluoromethyl)oxetan-2-yl)phenoxy)cyclobutan-1-amine	 (3-amino-5-(((1r,3r)-3-(2,4-difluorophenoxy)cyclobutyl)amino)methyl)-6-fluoroisoquinolin-8-yl)methanol
 (1r,3r)-3-(3,5-difluoro-4-methoxyphenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine	 (1r,3r)-N-((6-fluoroisoquinolin-5-yl)methyl)-3-((6-methoxy-5-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutan-1-amine
 (1r,3r)-3-(2,3-difluorophenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine	 (1r,3r)-3-(4-fluoro-3-(trifluoromethoxy)phenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine
 (1r,3r)-N-((3-chloroisoquinolin-5-yl)methyl)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine	 (1r,3r)-3-((3,4-difluorobenzyl)oxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine
 (1r,3r)-3-(2,4-difluorophenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine	 (1r,3r)-3-(2,4-difluorophenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine

	1-(6-fluoro-5-((((1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethane-1,2-diol
 (6-fluoro-5-((((1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)methanol	 (1r,3r)-3-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)oxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine
 (1r,3r)-N-((6-fluoroisoquinolin-5-yl)methyl)-3-((5-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutan-1-amine	 (1r,3r)-3-(3-(difluoromethoxy)-4-fluorophenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine
 (1r,3r)-3-(4-cyclopropylphenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine	 (1r,3r)-3-(3,4-difluoro-5-methylphenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine
 6-fluoro-5-((((1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinoline 2-oxide	 (1r,3r)-N-((6-ethylisoquinolin-5-yl)methyl)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine

 (1r,3r)-3-(3-(1,2-difluoroethyl)-4-fluorophenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine	 (1r,3r)-N-((6-fluoroisoquinolin-5-yl)methyl)-3-(4-(trifluoromethoxy)phenoxy)cyclobutan-1-amine
 (1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-N-(isoquinolin-5-ylmethyl)cyclobutan-1-amine	 (1r,3r)-3-(3,4-dimethylphenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine
 N-(2-(6-fluoro-5-(((1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)-2-hydroxyethyl)acetamide	 (1r,3r)-3-(4-fluoro-3-isopropylphenoxy)-N-(isoquinolin-5-ylmethyl)cyclobutan-1-amine
 (1r,3r)-3-(3-chloro-4-fluorophenoxy)-N-(isoquinolin-5-ylmethyl)cyclobutan-1-amine	 3,3,3-trifluoro-1-(6-fluoro-5-(((1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)propan-1-ol

 5-(((1r,3r)-3-(2,4-difluorophenoxy)cyclobutyl)amino)methyl)-6-fluoroisoquinolin-3-amine	 1-(6-fluoro-5-(((1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)propane-1,3-diol
 5-(((1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-ol	 (1r,3r)-3-((5,6-difluoropyridin-3-yl)oxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine
 (1r,3r)-N-((6-fluoroisoquinolin-5-yl)methyl)-3-((7-fluoronaphthalen-2-yl)oxy)cyclobutan-1-amine	 (1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine
 5-((1r,3r)-3-(((6-fluoroisoquinolin-5-yl)methyl)amino)cyclobutoxy)-2-(trifluoromethyl)benzonitrile	 N-((1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)-2-(isoquinolin-5-yl)acetamide

 (1r,3r)-3-(3-(difluoromethyl)-4-fluorophenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine	 (1r,3r)-N-((6-fluoroisoquinolin-5-yl)methyl)-3-(4-(trifluoromethyl)phenoxy)cyclobutan-1-amine
 2-(((1r,3r)-3-((6-fluoroisoquinolin-5-yl)methyl)amino)cyclobutoxy)-6-(trifluoromethyl)benzonitrile	 (1r,3r)-N-((6-fluoroisoquinolin-5-yl)methyl)-3-((2-(trifluoromethyl)pyridin-4-yl)oxy)cyclobutan-1-amine
 5-(((1r,3r)-3-((6-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutyl)amino)methyl)isoquinolin-3-amine	 (6-fluoro-5-(((1r,3r)-3-((2-(trifluoromethyl)pyridin-4-yl)oxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)methanol
 6-fluoro-5-(((1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-amine	 (6-fluoro-5-(((1s,3s)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)methanol
 (1r,3r)-3-(4-fluoro-3-(fluoromethyl)phenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine	

Embodiment 43. The compound of any of the preceding Embodiments, or a pharmaceutically acceptable salt thereof, wherein the pharmaceutically acceptable salt is an acid addition salt.

Embodiment 44. A pharmaceutical composition comprising a therapeutically effective amount of a compound of any one of Embodiments 1 to 43, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

Embodiment 45. A method of treating or preventing a disease or disorder in a subject
5 in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of any one of Embodiments 1 to 43, or a pharmaceutically acceptable salt thereof.

Embodiment 46. A method of treating or preventing a disease or disorder mediated by TRPV1 in a subject in need thereof, the method comprising administering to the subject a
10 therapeutically effective amount of a compound of any one of Embodiments 1 to 43, or a pharmaceutically acceptable salt thereof.

Embodiment 47. A method of treating or preventing pain in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of any one of Embodiments 1 to 43, or a pharmaceutically acceptable salt thereof.
15 The pain may be acute, such as pain caused after injury or surgery, or chronic. Examples of pain include, in particular, pain, e.g., bone and joint pain (osteoarthritis), cancer pain, myofascial pain (muscular injury, fibromyalgia) and perioperative pain (general surgery, gynecologic surgery). Other examples include chronic pain, especially inflammatory, e.g., chronic inflammatory pain. Additional examples of pain include pain in which TRPV1 activation plays a role or is implicated,
20 and therefore susceptible to treatment by the compounds disclosed herein. Such conditions include chronic pain with an inflammatory component such as rheumatoid arthritis; bone and joint pain (osteoarthritis); post-surgical pain; musculo-skeletal pain such as fibromyalgia; myofascial pain syndromes; headache, including migraine, acute or chronic tension headache, cluster headache, temporomandibular pain, and maxillary sinus pain; ear pain; episiotomy pain; burns,
25 and especially primary hyperalgesia associated therewith; deep and visceral pain, such as heart pain, muscle pain, eye pain, orofacial pain, migraine, abdominal pain, gynaecological pain, such as dysmenorrhoea, and labour pain; pain associated with the urogenital tract such as cystitis and vulvodynia; inflammatory skin disorders, for example psoriasis and eczema, or itch of non-specific origin; chronic pain associated with nerve injury and/or diseases affecting the nervous system,
30 such as neuropathic pain associated with post-herpetic neuralgia, diabetic neuropathy, chemotherapy-induced neuropathy, amputations ("phantom limb pain"), nerve entrapment and brachial plexus avulsions, low back pain, sciatica and ankylosing spondylitis, reflex sympathetic dystrophy and other chronic nerve injuries; complex regional pain syndromes; central nervous system pain, such as pain due to spinal cord or brain stem damage, or stroke; gout; scar pain;
35 pain associated with carcinoma, often referred to as cancer pain.

Embodiment 48. A method of treating or preventing inflammatory diseases in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of any one of Embodiments 1 to 43, or a pharmaceutically

acceptable salt thereof. Exemplary inflammatory diseases include inflammatory airways disease, e.g., chronic obstructive pulmonary disease (COPD), or asthma; cough; urinary incontinence; migraine; visceral disorders, e.g., inflammatory bowel disease; rhinitis; cystitis, e.g. interstitial cystitis; pancreatitis; uveitis; inflammatory skin disorders such as eczema and psoriasis;
5 rheumatoid arthritis; inflammatory disorders of the gut, e.g., irritable bowel syndrome; Crohn's disease; ulcerative colitis; and cystitis, e.g., interstitial cystitis, nephritis and uveitis.

Embodiment 49. A method of relaxing smooth muscle in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of any one of Embodiments 1 to 43, or a pharmaceutically acceptable salt thereof.
10 Examples of diseases or conditions requiring smooth muscle relaxants include, e.g., treatment of spasm of the gastrointestinal tract or uterus, e.g., in the therapy of Crohn's disease, ulcerative colitis or pancreatitis.

Embodiment 50. A method of treating or preventing airway hyperreactivity or treating or preventing inflammatory events associated with airways disease, the method comprising
15 administering to the subject a therapeutically effective amount of a compound of any one of Embodiments 1 to 43, or a pharmaceutically acceptable salt thereof. Exemplary conditions include asthma, restriction or reversal of airways hyperreactivity in asthma. Other conditions include both intrinsic and, especially, extrinsic asthma, such as allergic asthma, as well as, e.g., exercise induced asthma, occupational asthma, asthma induced following bacterial infection,
20 other non-allergic asthmas and "wheezy-infant syndrome". Efficacy in the treatment of asthma will be evidenced by reduced frequency or severity of symptomatic attack, e.g., of acute asthmatic or bronchoconstrictor attack and by reduced requirement for other, symptomatic therapy, e.g., anti-inflammatory, e.g., corticosteroid; or bronchodilator, e.g., β_2 adrenergic, therapy. Other inflammatory or obstructive airways diseases include pneumoconiosis (an inflammatory,
25 commonly occupational, disease of the lungs, frequently accompanied by repeated inhalation of dusts) of whatever type or genesis including, e.g., aluminosis, anthracosis, asbestosis, chalicosis, ptilosis, siderosis, silicosis, tabacosis and, in particular, byssinosis. Further inflammatory or obstructive airways diseases and conditions include adult respiratory distress syndrome (ARDS), chronic obstructive pulmonary or airways disease (COPD or COAD), and bronchitis, allergic and
30 vasomotor rhinitis.

Embodiment 51. A method of treating or preventing septic shock in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of any one of Embodiments 1 to 43, or a pharmaceutically acceptable salt thereof. Exemplary conditions include septic shock, e.g., as anti-hypovolaemic and/or anti-hypotensive
35 agents; in the treatment of inflammatory bowel disease; cerebral oedema; headache;

Embodiment 52. A method of treating an ocular disease or disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective

amount of a compound of any one of Embodiments 1 to 43, or a pharmaceutically acceptable salt thereof.

Embodiment 53. A method of treating an ocular surface disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of
5 a compound of any one of Embodiments 1 to 43, or a pharmaceutically acceptable salt thereof.

Embodiment 54. The method of Embodiment 53, wherein the ocular surface disorder is selected from chronic ocular surface pain (COSP), dry eye disease, Sjogren's Syndrome, conjunctivitis (including keratoconjunctivitis, vernal keratoconjunctivitis, allergic conjunctivitis), Map-Dot-Fingerprint Dystrophy, acanthamoeba, fibromyalgia, Meibomian gland dysfunction,
10 thyroid eye disease, rosacea, ptosis, keratoconus, ocular pain syndrome, Steven-Johnson's syndrome, corneal epitheliopathies, corneal neuropathies (including LASIK induced corneal neuropathies), corneal dystrophies (including recurrent corneal dystrophies), epithelial basement membrane dystrophy, corneal erosions or abrasions (including recurrent corneal erosions or abrasions), ocular surface diseases, blepharitis, graft vs host disease, meibomitis, glaucoma,
15 conjunctivochalasis, keratopathies (including herpetic keratopathy, filamentary keratopathy, band or bullous keratopathy, exposure keratopathy), keratitis (including herpes simplex virus keratitis), iritis, episcleritis, corneal surgery, multiple sclerosis, trichiasis, pterygium, neuralgia, xerophthalmia, and patients recovering from neurotrophic keratitis.

Embodiment 55. The method of Embodiment 54, wherein the ocular surface disorder
20 is dry eye disease.

Embodiment 56. A method of treating or reducing ocular surface pain (e.g., corneal induced pain) in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of any one of Embodiments 1 to 43, or a pharmaceutically acceptable salt thereof.

Embodiment 57. The method of Embodiment 56, wherein the administration of a
25 compound of any one of Embodiments 1 to 43, or a pharmaceutically acceptable salt thereof results in a reduction in the subject's ocular pain, compared to a placebo. In some embodiments, the reduction in the subjects ocular pain is at least about 10%, at least about 15%, at least about 20%, or at least about 25%, compared to a placebo, when measured on a pain scale, for example,
30 the VAS or the OPAS.

Embodiment 58. A method of treating or reducing corneal induced pain in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of any one of Embodiments 1 to 43, or a pharmaceutically acceptable salt thereof.

Embodiment 59. The method of Embodiment 58, wherein the administration of a
35 compound of any one of Embodiments 1 to 43, or a pharmaceutically acceptable salt thereof results in a reduction in the subject's ocular pain, compared to a placebo. In some embodiments, the reduction in the subjects ocular pain is at least about 10%, at least about 15%, at least about

20%, or at least about 25%, compared to a placebo, when measured on a pain scale, for example, the VAS or the OPAS.

Embodiment 60. The method of Embodiments 56 to 59, wherein the ocular surface pain or corneal induced pain is episodic, *i.e.*, acute.

5 Embodiment 61. The method of Embodiments 56 to 59, wherein the ocular surface pain or corneal induced pain is chronic.

Embodiment 62. The method according to any of Embodiments 56 to 61, wherein the ocular surface pain or corneal induced pain is associated with one or more of dry eye disease, Sjogren's Syndrome, conjunctivitis (including keratoconjunctivitis, vernal keratoconjunctivitis, 10 allergic conjunctivitis), Map-Dot-Fingerprint Dystrophy, acanthamoeba, fibromyalgia, Meibomian gland dysfunction, thyroid eye disease, rosacea, ptosis, keratoconus, ocular pain syndrome, Steven-Johnson's syndrome, corneal epitheliopathies, corneal neuropathies (including LASIK induced corneal neuropathies), corneal dystrophies (including recurrent corneal dystrophies), epithelial basement membrane dystrophy, corneal erosions or abrasions (including recurrent 15 corneal erosions or abrasions), ocular surface diseases, blepharitis, graft vs host disease, meibomitis, glaucoma, conjunctivochalasis, keratopathis (including herpetic keratopathy, filamentary keratopathy, band or bullous keratopathy, exposure keratopathy), keratitis (including herpes simplex virus keratitis), iritis, episclentis, corneal surgery, multiple sclerosis, trichiasis, pterygium, neuralgia, xerophthalmia, or patients recovering from neurotrophic keratitis.

20 Embodiment 63. The method according to any of Embodiments 56 to 62, wherein the ocular surface pain or corneal induced pain is associated with dry eye disease or Sjogren's Syndrome.

Embodiment 64. The method according to any of Embodiments 56 to 63, wherein the subject suffers from ocular pain persisting for at least three months after photorefractive 25 keratectomy (PRK) surgery or laser-assisted in situ keratomileusis (LASIK) surgery.

Embodiment 65. The method according to any of Embodiments 56 to 63, wherein the subject suffers from conjunctivitis, subconjunctival hemorrhage, subconjunctival scarring, conjunctival membranes, conjunctival ulceration, superficial punctate epithelial erosions, epithelial defects, lid margin ulceration, lid margin keratinization, symblepharon, ankyloblepharon, 30 trichiasis, anterior blepharitis, punctal auto-occlusion, meibomian gland disease, corneal opacification, dry eye, distichiasis, limbal stem cell failure, or corneal vascularization.

Embodiment 66. A method of treating ocular hyperemia in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of any one of Embodiments 1 to 43, or a pharmaceutically acceptable salt thereof.

35 Embodiment 67. The method of Embodiment 66, wherein wherein the ocular hyperemia is associated with one or more of dry eye disease, Sjogren's Syndrome, conjunctivitis (including keratoconjunctivitis, vernal keratoconjunctivitis, allergic conjunctivitis), Map-Dot-Fingerprint Dystrophy, acanthamoeba, fibromyalgia, Meibomian gland dysfunction, thyroid eye

disease, rosacea, ptosis, keratoconus, ocular pain syndrome, Steven-Johnson's syndrome, corneal epitheliopathies, corneal neuropathies (including LASIK induced corneal neuropathies), corneal dystrophies (including recurrent corneal dystrophies), epithelial basement membrane dystrophy, corneal erosions or abrasions (including recurrent corneal erosions or abrasions),

5 ocular surface diseases, blepharitis, graft vs host disease, meibomitis, glaucoma, conjunctivochalasis, keratopathy (including herpetic keratopathy, filamentary keratopathy, band or bullous keratopathy, exposure keratopathy), keratitis (including herpes simplex virus keratitis), iritis, episclentis, corneal surgery, multiple sclerosis, trichiasis, pterygium, neuralgia, xerophthalmia, or patients recovering from neurotrophic keratitis.

10 Embodiment 68. The method of Embodiment 66 or 67, wherein the ocular hyperemia is associated with dry eye disease.

 Embodiment 69. The method of any of Embodiments 66 to 68, wherein the ocular hyperemia persists for at least three months after photorefractive keratectomy (PRK) surgery or laser-assisted in situ keratomileusis (LASIK) surgery.

15 Embodiment 70. A compound of any of Embodiments 1 to 43 or a pharmaceutically acceptable salt thereof, for use in the treatment or reduction of ocular surface pain (e.g., corneal induced pain).

 Embodiment 71. The compound for use according to Embodiment 70, wherein the compound of any one of Embodiments 1 to 43, or a pharmaceutically acceptable salt thereof

20 results in a reduction in the subject's ocular pain, compared to a placebo. In some embodiments, the reduction in the subjects ocular pain is at least about 10%, at least about 15%, at least about 20%, or at least about 25%, compared to a placebo, when measured on a pain scale, for example, the VAS or the OPAS.

 Embodiment 72. The compound for use according to Embodiments 70 or 71, or a

25 pharmaceutically acceptable salt thereof, wherein the ocular surface pain is episodic, *i.e.*, acute.

 Embodiment 73. The compound for use according to Embodiments 70 or 71, or a pharmaceutically acceptable salt thereof, wherein the ocular surface pain is chronic. For example, the pain persists for at least 12 weeks, or at least 3 months, or at least 2 months, or at least 1 month.

30 Embodiment 74. The compound for use according to any of Embodiments 70 to 73, or a pharmaceutically acceptable salt thereof, wherein the ocular surface pain is associated with one or more of dry eye disease, Sjogren's Syndrome, conjunctivitis (including keratoconjunctivitis, vernal keratoconjunctivitis, allergic conjunctivitis), Map-Dot-Fingerprint Dystrophy, acanthamoeba, fibromyalgia, Meibomian gland dysfunction, thyroid eye disease, rosacea, ptosis,

35 keratoconus, ocular pain syndrome, Steven-Johnson's syndrome, corneal epitheliopathies, corneal neuropathies (including LASIK induced corneal neuropathies), corneal dystrophies (including recurrent corneal dystrophies), epithelial basement membrane dystrophy, corneal erosions or abrasions (including recurrent corneal erosions or abrasions), ocular surface

diseases, blepharitis, graft vs host disease, meibomitis, glaucoma, conjunctivochalasis, keratopathis (including herpetic keratopathy, filamentary keratopathy, band or bullous keratopathy, exposure keratopathy), keratitis (including herpes simplex virus keratitis), iritis, episclentis, corneal surgery, multiple sclerosis, trichiasis, pterygium, neuralgia, xerophthalmia, or
5 patients recovering from neurotrophic keratitis.

Embodiment 75. The compound for use according to any of Embodiments 70 to 74, or a pharmaceutically acceptable salt thereof, wherein the ocular surface pain is associated with dry eye disease or Sjogren's Syndrome.

Embodiment 76. A compound of any of Embodiments 1 to 43 or a pharmaceutically
10 acceptable salt thereof, for use in the treatment or reduction of ocular hyperemia.

Embodiment 77. The compound for use according to any one of Embodiments 1 to 43, or a pharmaceutically acceptable salt, wherein the administration of the compound results in reduced grade 1, grade 2, grade 3, or grade 4 hyperemia compared to placebo. In some
15 embodiments, the administration results in a reduction in ocular hyperemia score of at least about 1, at least about 2, at least about 3, at least about 4, or at least about 5, on the McMonnies scale.

Embodiment 78. The compound for use according to Embodiment 76 or 77, or a pharmaceutically acceptable salt thereof, wherein the ocular hyperemia is associated with one or more of dry eye disease, Sjogren's Syndrome, conjunctivitis (including keratoconjunctivitis, vernal keratoconjunctivitis, allergic conjunctivitis), Map-Dot-Fingerprint Dystrophy, acanthamoeba,
20 fibromyalgia, Meibomian gland dysfunction, thyroid eye disease, rosacea, ptosis, keratoconus, ocular pain syndrome, Steven-Johnson's syndrome, corneal epitheliopathies, corneal neuropathies (including LASIK induced corneal neuropathies), corneal dystrophies (including recurrent corneal dystrophies), epithelial basement membrane dystrophy, corneal erosions or abrasions (including recurrent corneal erosions or abrasions), ocular surface diseases,
25 blepharitis, graft vs host disease, meibomitis, glaucoma, conjunctivochalasis, keratopathis (including herpetic keratopathy, filamentary keratopathy, band or bullous keratopathy, exposure keratopathy), keratitis (including herpes simplex virus keratitis), iritis, episclentis, corneal surgery, multiple sclerosis, trichiasis, pterygium, neuralgia, xerophthalmia, or patients recovering from neurotrophic keratitis.

30 Embodiment 79. The compound for use according to Embodiment 76 or 77, or a pharmaceutically acceptable salt thereof, wherein the ocular hyperemia is associated with dry eye disease.

Embodiment 80. The compound for use according to any of Embodiments 76 to 78, wherein the ocular hyperemia persists for at least three months after photorefractive keratectomy
35 (PRK) surgery or laser-assisted in situ keratomileusis (LASIK) surgery.

Embodiment 81. A compound of any of Embodiments 1 to 43 or a pharmaceutically acceptable salt thereof, for use in the treatment of an ocular surface disorder.

Embodiment 82. The compound for use according to Embodiment 81, or a pharmaceutically acceptable salt thereof, wherein the ocular surface disorder is selected from chronic ocular surface pain (COSP), dry eye disease, Sjogren's Syndrome, conjunctivitis (including keratoconjunctivitis, vernal keratoconjunctivitis, allergic conjunctivitis), Map-Dot-Fingerprint Dystrophy, acanthamoeba, fibromyalgia, Meibomian gland dysfunction, thyroid eye disease, rosacea, ptosis, keratoconus, ocular pain syndrome, Steven-Johnson's syndrome, corneal epitheliopathies, corneal neuropathies (including LASIK induced corneal neuropathies), corneal dystrophies (including recurrent corneal dystrophies), epithelial basement membrane dystrophy, corneal erosions or abrasions (including recurrent corneal erosions or abrasions), ocular surface diseases, blepharitis, graft vs host disease, meibomitis, glaucoma, conjunctivochalasis, keratopathy (including herpetic keratopathy, filamentary keratopathy, band or bullous keratopathy, exposure keratopathy), keratitis (including herpes simplex virus keratitis), iritis, episcleritis, corneal surgery, multiple sclerosis, trichiasis, pterygium, neuralgia, xerophthalmia, or patients recovering from neurotrophic keratitis.

Embodiment 83. The compound for use according to any of Embodiments 68 to 72, 77, 78, or a pharmaceutically acceptable salt thereof, wherein the subject suffers from ocular pain persisting for at least three months after photorefractive keratectomy (PRK) surgery or laser-assisted in situ keratomileusis (LASIK) surgery.

Embodiment 84. The compound for use according to any of Embodiments 70 to 75, 81, 82, or a pharmaceutically acceptable salt thereof, wherein the subject suffers from conjunctivitis, subconjunctival hemorrhage, subconjunctival scarring, conjunctival membranes, conjunctival ulceration, superficial punctate epithelial erosions, epithelial defects, lid margin ulceration, lid margin keratinization, symblepharon, ankyloblepharon, trichiasis, anterior blepharitis, punctal auto-occlusion, meibomian gland disease, corneal opacification, dry eye, distichiasis, limbal stem cell failure, or corneal vascularization.

Embodiment 85. Use of a compound of any one of Embodiments 1 to 43, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating an ocular disease or disorder that is mediated by TRPV1.

Embodiment 86. Use according to Embodiment 85, wherein the ocular disease or disorder is selected from ocular surface disorder, ocular surface pain (e.g., corneal induced pain) and ocular hyperemia.

Embodiment 87. Use according to Embodiment 85 or 86, wherein the ocular surface disorder is selected from chronic ocular surface pain (COSP), dry eye disease, Sjogren's Syndrome, conjunctivitis (including keratoconjunctivitis, vernal keratoconjunctivitis, allergic conjunctivitis), Map-Dot-Fingerprint Dystrophy, acanthamoeba, fibromyalgia, Meibomian gland dysfunction, thyroid eye disease, rosacea, ptosis, keratoconus, ocular pain syndrome, Steven-Johnson's syndrome, corneal epitheliopathies, corneal neuropathies (including LASIK induced corneal neuropathies), corneal dystrophies (including recurrent corneal dystrophies), epithelial

basement membrane dystrophy, corneal erosions or abrasions (including recurrent corneal erosions or abrasions), ocular surface diseases, blepharitis, graft vs host disease, meibomitis, glaucoma, conjunctivochalasis, keratopathies (including herpetic keratopathy, filamentary keratopathy, band or bullous keratopathy, exposure keratopathy), keratitis (including herpes simplex virus keratitis), iritis, episcleritis, corneal surgery, multiple sclerosis, trichiasis, pterygium, neuralgia, xerophthalmia, and patients recovering from neurotrophic keratitis.

Embodiment 88. Use according to Embodiments 86 or 87, wherein the ocular surface disorder is dry eye disease.

Embodiment 89. Use according to Embodiment 86, wherein ocular surface pain is pain is episodic, *i.e.*, acute.

Embodiment 90. Use according to Embodiment 86, wherein ocular surface pain is pain is chronic.

Embodiment 91. Use according to any of Embodiments 86, 89 or 90, wherein the ocular surface pain is associated with one or more of dry eye disease, Sjogren's Syndrome, conjunctivitis (including keratoconjunctivitis, vernal keratoconjunctivitis, allergic conjunctivitis), Map-Dot-Fingerprint Dystrophy, acanthamoeba, fibromyalgia, Meibomian gland dysfunction, thyroid eye disease, rosacea, ptosis, keratoconus, ocular pain syndrome, Steven-Johnson's syndrome, corneal epitheliopathies, corneal neuropathies (including LASIK induced corneal neuropathies), corneal dystrophies (including recurrent corneal dystrophies), epithelial basement membrane dystrophy, corneal erosions or abrasions (including recurrent corneal erosions or abrasions), ocular surface diseases, blepharitis, graft vs host disease, meibomitis, glaucoma, conjunctivochalasis, keratopathies (including herpetic keratopathy, filamentary keratopathy, band or bullous keratopathy, exposure keratopathy), keratitis (including herpes simplex virus keratitis), iritis, episcleritis, corneal surgery, multiple sclerosis, trichiasis, pterygium, neuralgia, xerophthalmia, or patients recovering from neurotrophic keratitis.

Embodiment 92. Use according to any of Embodiments 86, 89 to 91, wherein the ocular surface pain is associated with dry eye disease or Sjogren's Syndrome.

Embodiment 93. Use according to Embodiment 86, wherein wherein the ocular hyperemia is associated with one or more of dry eye disease, Sjogren's Syndrome, conjunctivitis (including keratoconjunctivitis, vernal keratoconjunctivitis, allergic conjunctivitis), Map-Dot-Fingerprint Dystrophy, acanthamoeba, fibromyalgia, Meibomian gland dysfunction, thyroid eye disease, rosacea, ptosis, keratoconus, ocular pain syndrome, Steven-Johnson's syndrome, corneal epitheliopathies, corneal neuropathies (including LASIK induced corneal neuropathies), corneal dystrophies (including recurrent corneal dystrophies), epithelial basement membrane dystrophy, corneal erosions or abrasions (including recurrent corneal erosions or abrasions), ocular surface diseases, blepharitis, graft vs host disease, meibomitis, glaucoma, conjunctivochalasis, keratopathies (including herpetic keratopathy, filamentary keratopathy, band or bullous keratopathy, exposure keratopathy), keratitis (including herpes simplex virus keratitis),

iritis, episclentis, corneal surgery, multiple sclerosis, trichiasis, pterygium, neuralgia, xerophthalmia, or patients recovering from neurotrophic keratitis. In particular embodiments, the ocular hyperemia is associated with dry eye disease. In some embodiments of the methods described herein, the ocular hyperemia persists for at least three months after photorefractive
 5 keratectomy (PRK) surgery or laser-assisted in situ keratomileusis (LASIK) surgery.

Embodiment 94. Use of a compound of any of Embodiments 1 to 43 or a pharmaceutically acceptable salt thereof, in the treatment of an ocular disease or disorder, *e.g.*, mediated by TRPV1.

Embodiment 95. Use according to Embodiment 94, wherein the ocular disease or
 10 disorder is selected from ocular surface disorder, ocular surface pain (*e.g.*, corneal induced pain) and ocular hyperemia.

Embodiment 96. Use according to Embodiment 94 or 95, wherein the ocular surface disorder is selected from chronic ocular surface pain (COSP), dry eye disease, Sjogren's Syndrome, conjunctivitis (including keratoconjunctivitis, vernal keratoconjunctivitis, allergic
 15 conjunctivitis), Map-Dot-Fingerprint Dystrophy, acanthamoeba, fibromyalgia, Meibomian gland dysfunction, thyroid eye disease, rosacea, ptosis, keratoconus, ocular pain syndrome, Steven-Johnson's syndrome, corneal epitheliopathies, corneal neuropathies (including LASIK induced corneal neuropathies), corneal dystrophies (including recurrent corneal dystrophies), epithelial basement membrane dystrophy, corneal erosions or abrasions (including recurrent corneal
 20 erosions or abrasions), ocular surface diseases, blepharitis, graft vs host disease, meibomitis, glaucoma, conjunctivochalasis, keratopathy (including herpetic keratopathy, filamentary keratopathy, band or bullous keratopathy, exposure keratopathy), keratitis (including herpes simplex virus keratitis), iritis, episclentis, corneal surgery, multiple sclerosis, trichiasis, pterygium, neuralgia, xerophthalmia and patients recovering from neurotrophic keratitis.

Embodiment 97. Use according to any of Embodiments 94 to 96, wherein the ocular surface disorder is dry eye disease.

Embodiment 98. Use according to Embodiment 95, wherein ocular surface pain is pain is episodic, *i.e.*, acute.

Embodiment 99. Use according to Embodiment 95, wherein ocular surface pain is
 30 pain is chronic.

Embodiment 100. Use according to any of Embodiments 95, 98 or 99, wherein the ocular surface pain is associated with one or more of dry eye disease, Sjogren's Syndrome, conjunctivitis (including keratoconjunctivitis, vernal keratoconjunctivitis, allergic conjunctivitis), Map-Dot-Fingerprint Dystrophy, acanthamoeba, fibromyalgia, Meibomian gland dysfunction,
 35 thyroid eye disease, rosacea, ptosis, keratoconus, ocular pain syndrome, Steven-Johnson's syndrome, corneal epitheliopathies, corneal neuropathies (including LASIK induced corneal neuropathies), corneal dystrophies (including recurrent corneal dystrophies), epithelial basement membrane dystrophy, corneal erosions or abrasions (including recurrent corneal erosions or

abrasions), ocular surface diseases, blepharitis, graft vs host disease, meibomitis, glaucoma, conjunctivochalasis, keratopathis (including herpetic keratopathy, filamentary keratopathy, band or bullous keratopathy, exposure keratopathy), keratitis (including herpes simplex virus keratitis), iritis, episclentis, corneal surgery, multiple sclerosis, trichiasis, pterygium, neuralgia, xerophthalmia, or patients recovering from neurotrophic keratitis.

Embodiment 101. Use according to any of Embodiments 95, 98 to 100, wherein the ocular surface pain is associated with dry eye disease or Sjogren's Syndrome.

Embodiment 102. Use according to Embodiment 95, wherein the ocular hyperemia is associated with one or more of dry eye disease, Sjogren's Syndrome, conjunctivitis (including keratoconjunctivitis, vernal keratoconjunctivitis, allergic conjunctivitis), Map-Dot-Fingerprint Dystrophy, acanthamoeba, fibromyalgia, Meibomian gland dysfunction, thyroid eye disease, rosacea, ptosis, keratoconus, ocular pain syndrome, Steven-Johnson's syndrome, corneal epitheliopathies, corneal neuropathies (including LASIK induced corneal neuropathies), corneal dystrophies (including recurrent corneal dystrophies), epithelial basement membrane dystrophy, corneal erosions or abrasions (including recurrent corneal erosions or abrasions), ocular surface diseases, blepharitis, graft vs host disease, meibomitis, glaucoma, conjunctivochalasis, keratopathis (including herpetic keratopathy, filamentary keratopathy, band or bullous keratopathy, exposure keratopathy), keratitis (including herpes simplex virus keratitis), iritis, episclentis, corneal surgery, multiple sclerosis, trichiasis, pterygium, neuralgia, xerophthalmia, or patients recovering from neurotrophic keratitis.

Embodiment 103. Use according to Embodiment 95 or 102, wherein the ocular hyperemia is associated with dry eye disease.


Embodiment 104. Use according to any of Embodiments 95, 102 or 103, wherein the ocular hyperemia persists for at least three months after photorefractive keratectomy (PRK) surgery or laser-assisted in situ keratomileusis (LASIK) surgery.

Embodiment 105. A pharmaceutical combination comprising a compound of any of Embodiments 1 to 43, or a pharmaceutically acceptable salt thereof, and one or more additional therapeutic agent(s).

Depending on the choice of the starting materials and procedures, the compounds can be present in the form of one of the possible isomers or as mixtures thereof, for example as pure optical isomers, or as isomer mixtures, such as racemates and diastereomeric mixtures, depending on the number of asymmetric centres. The disclosure is meant to include all such possible isomers, including racemic mixtures, enantiomerically enriched mixtures, diastereomeric mixtures and optically pure forms. Optically active (*R*)- and (*S*)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. If the compound contains a disubstituted or trisubstituted cycloalkyl, the cycloalkyl substituent(s) may have a *cis*- or *trans*-configuration. The disclosure includes *cis* and *trans* configurations of substituted

cycloalkyl groups, *e.g.*, cyclobutyl group, as well as mixtures thereof. All tautomeric forms are also intended to be included. In particular, where a heteroaryl ring containing N as a ring atom is 2-pyridone, for example, tautomers where the carbonyl is depicted as a hydroxy (*e.g.*, 2-hydroxypyridine) are included.

Thus, it will be appreciated that in compounds of Formula (I), the cyclobutyl ring portion of the molecule can be in the *cis* or *trans* configuration. Using Formula (Ib) for illustrative purposes whereby the substituents at the 1- and 3-positions of the cyclobutyl ring have a *trans* configuration, it will be appreciated by the skilled person in the art that (Ib*) and (Ib**) are equivalent ways of drawing a molecule of Formula (Ib):



Separation of *cis* and *trans* isomers can be achieved according to methods known to a person of skill in the art, such as chromatographic methods, with tools such as HPLC (High Performance Liquid Chromatography), Thin Layer Chromatography, SFC (Supercritical Fluid Chromatography), GC (Gas Chromatography), or recrystallization techniques.

Pharmaceutically Acceptable Salts

As used herein, the terms “salt” or “salts” refers to an acid addition or base addition salt of a compound of the disclosure. “Salts” include in particular “pharmaceutically acceptable salts”. The term “pharmaceutically acceptable salts” refers to salts that retain the biological effectiveness and properties of the compounds of this disclosure and, which typically are not biologically or otherwise undesirable. The compounds of the disclosure may be capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.

Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids. Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, sulfosalicylic acid, formic acid, trifluoroacetic acid, and the like. In an embodiment, the compounds of Formula (I) are in HCl or formic acid salt form.

Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases. Inorganic bases from which salts can be derived include, for example, ammonium salts and metals from columns I to XII of the periodic table. In certain embodiments, the salts are derived from sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc, and copper; particularly suitable salts include ammonium, potassium, sodium, calcium and magnesium salts.

Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like. Certain organic amines include isopropylamine, benzathine, choline, diethanolamine, diethylamine, lysine, meglumine, piperazine and tromethamine.

In another aspect, the disclosure provides compounds in acetate, ascorbate, adipate, aspartate, benzoate, besylate, bromide/hydrobromide, bicarbonate/carbonate, bisulfate/sulfate, camphorsulfonate, caprate, chloride/hydrochloride, chlorotheophyllonate, citrate, ethandisulfonate, fumarate, gluceptate, gluconate, glucuronate, glutamate, glutarate, glycolate, hippurate, hydroiodide/iodide, isethionate, lactate, lactobionate, laurylsulfate, malate, maleate, malonate, mandelate, mesylate, methylsulphate, mucate, naphthoate, napsylate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, polygalacturonate, propionate, sebacate, stearate, succinate, sulfosalicylate, sulfate, tartrate, tosylate, trifenate, trifluoroacetate or xinafoate salt form.

In another aspect, the disclosure provides compounds in sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc, copper, isopropylamine, benzathine, choline, diethanolamine, diethylamine, lysine, meglumine, piperazine or tromethamine salt form.

Isotopically Labelled Compounds

Any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into compounds of the disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, sulfur, fluorine, chlorine and iodine, such as ^2H , ^3H , ^{11}C , ^{13}C , ^{14}C , ^{18}O , ^{15}N , ^{18}F , ^{17}O , ^{18}O , ^{35}S , ^{36}Cl , ^{123}I , ^{124}I , ^{125}I respectively. The disclosure includes various isotopically labeled compounds as defined herein, for example those into which radioactive isotopes, such as ^3H and ^{14}C , or those into which non-radioactive isotopes, such as ^2H and ^{13}C are present. Such isotopically labelled compounds are useful in metabolic studies (with ^{14}C), reaction kinetic studies (with, for example ^2H or ^3H), detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients. In particular, an ^{18}F compound may be particularly desirable for PET or SPECT studies. Isotopically-labeled compounds of formula (I), or sub-formulae thereof, can generally be prepared by conventional techniques known to those skilled in the art or by

processes analogous to those described in the accompanying Examples and General Schemes using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.

Further, substitution with heavier isotopes, particularly deuterium (*i.e.*, ^2H or D) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements or an improvement in therapeutic index. It is understood that deuterium in this context is regarded as a substituent of a compound of the formula (I), or any of the sub-formulae thereof. The concentration of such a heavier isotope, specifically deuterium, may be defined by the isotopic enrichment factor. The term "isotopic enrichment factor" as used herein means the ratio between the isotopic abundance and the natural abundance of a specified isotope. If a substituent in a compound of this disclosure is denoted deuterium, such compound has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation).

Pharmaceutically acceptable solvates in accordance with the disclosure include those wherein the solvent of crystallization may be isotopically substituted, *e.g.*, D_2O , d_6 -acetone, d_6 -DMSO.

Compounds of the disclosure, *i.e.* compounds of formulae (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (I-i), (I-ii), that contain groups capable of acting as donors and/or acceptors for hydrogen bonds may be capable of forming co-crystals with suitable co-crystal formers. These co-crystals may be prepared from compounds of formula (I), or sub-formulae thereof, by known co-crystal forming procedures. Such procedures include grinding, heating, co-subliming, co-melting, or contacting in solution compounds of (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (I-i), (I-ii), with the co-crystal former under crystallization conditions and isolating co-crystals thereby formed. Suitable co-crystal formers include those described in WO 2004/078163.

All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (*e.g.*, "such as") provided herein is intended merely to better illuminate the disclosure and does not pose a limitation on the scope of the disclosure otherwise claimed.


Any asymmetric center (*e.g.*, carbon or the like) of the compound(s) of the disclosure can be present in racemic or enantiomerically enriched, for example the (*R*)-, (*S*)- or (*R,S*)-configuration. In certain embodiments, for example, as a mixture of enantiomers, each asymmetric center is present in at least 10 % enantiomeric excess, at least 20 % enantiomeric excess, at least 30 % enantiomeric excess, at least 40 % enantiomeric excess, at least 50 %

enantiomeric excess, at least 60 % enantiomeric excess, at least 70 % enantiomeric excess, at least 80 % enantiomeric excess, at least 90 % enantiomeric excess, at least 95 % enantiomeric excess, or at least 99 % enantiomeric excess. In certain embodiments, for example, in enantiomerically enriched form, each asymmetric center is present in at least 50 % enantiomeric excess, at least 60 % enantiomeric excess, at least 70 % enantiomeric excess, at least 80 % enantiomeric excess, at least 90 % enantiomeric excess, at least 95 % enantiomeric excess, or at least 99 % enantiomeric excess. Thus, compounds of the disclosure can be present in a racemic mixture or in enantiomerically enriched form or in an enantiopure form or as a mixture of diastereoisomers.

10 In an embodiment, there is provided a compound of formula (I), or a pharmaceutically acceptable salt thereof, present in at least 90 % enantiomeric excess, at least 95 % enantiomeric excess, or at least 99 % enantiomeric excess.

In an embodiment, there is provided a compound of formula (I), or a pharmaceutically acceptable salt thereof, present in at least 90 % diastereomeric excess, at least 95 % diastereomeric excess, or at least 99 % diastereomeric excess.


In one embodiment, the compound of formula (I) is a compound of formulae (I-i):



(I-i),

or a pharmaceutically acceptable salt thereof, wherein A, L, W, X, Y, Z, R^1 , R^2 , R^A , n and m are defined according to Embodiment 1. In particular, A, L, W, X, Y, Z, R^1 , R^2 , R^A , n and m may be defined according to any of Embodiments 2 to 39.

In another embodiment, the compound of formula (I) is a compound of formulae (I-ii):



(I-ii),

or a pharmaceutically acceptable salt thereof, wherein A, L, W, X, Y, Z, R^1 , R^2 , R^A , n and m are defined according to Embodiment 1. In particular, A, L, W, X, Y, Z, R^1 , R^2 , R^A , n and m may
 5 be defined according to any of Embodiments 2 to 39.

In the formulae of the present application the term " $\blacktriangleright$ " on a C-sp³ indicates the absolute stereochemistry, either (R) or (S). In the formulae of the present application the term " $\cdots$ " on a C-sp³ indicates the absolute stereochemistry, either (R) or (S). In the formulae of the present application the term " $\diagup$ " on a C-sp³ represents a covalent bond wherein the stereochemistry of
 10 the bond is not defined. This means that the term " $\diagup$ " on a C-sp³ comprises an (S) configuration or an (R) configuration of the respective chiral centre. Furthermore, mixtures may also be present. Therefore, mixtures of stereoisomers, e.g., mixtures of enantiomers, such as racemates, and/or mixtures of diastereoisomers are encompassed by the present disclosure.

For the avoidance of doubt, where compound structures are drawn with undefined
 15 stereochemistry with respect to any R group, as represented by a bond ($\diagup$), this means the asymmetric center has either a (R)- or (S)- configuration, or exists as a mixture thereof and stated as such.

For the avoidance of doubt, in any of the formulae of the present application when the R^1 group is shown with attachment to both rings, this means that the R^1 group(s) can be attached to
 20 either ring, or multiple R^1 groups attached to either ring.

Accordingly, as used herein a compound of the disclosure can be in the form of one of the possible stereoisomers, rotamers, atropisomers, tautomers or mixtures thereof, for example, as substantially pure geometric (*cis* or *trans*) stereoisomers, diastereomers, optical isomers, racemates or mixtures thereof.

25 Any resulting mixtures of stereoisomers can be separated on the basis of the physicochemical differences of the constituents, into the pure or substantially pure geometric or optical isomers, diastereomers, racemates, for example, by chromatography and/or fractional crystallization.

Any resulting racemates of compounds of the disclosure or of intermediates can be
 30 resolved into the optical isomers (enantiomers) by known methods, e.g., by separation of the

diastereomeric salts thereof, obtained with an optically active acid or base, and liberating the optically active acidic or basic compound. In particular, a basic moiety may thus be employed to resolve the compounds of the disclosure into their optical antipodes, e.g., by fractional crystallization of a salt formed with an optically active acid, e.g., tartaric acid, dibenzoyl tartaric acid, diacetyl tartaric acid, di-O,O'-p-toluoyl tartaric acid, mandelic acid, malic acid or camphor-10-sulfonic acid. Racemic compounds of the disclosure or racemic intermediates can also be resolved by chiral chromatography, e.g., high pressure liquid chromatography (HPLC) using a chiral adsorbent.

Furthermore, the compounds of the disclosure, including their salts, can also be obtained in the form of their hydrates, or include other solvents used for their crystallization. The compounds of the disclosure may inherently or by design form solvates with pharmaceutically acceptable solvents (including water); therefore, it is intended that the disclosure embrace both solvated and unsolvated forms. The term "solvate" refers to a molecular complex of a compound of the disclosure (including pharmaceutically acceptable salts thereof) with one or more solvent molecules. Such solvent molecules are those commonly used in the pharmaceutical art, which are known to be innocuous to the recipient, e.g., water, ethanol, and the like. The term "hydrate" refers to the complex where the solvent molecule is water. The presence of solvates can be identified by a person of skill in the art with tools such as NMR.

The compounds of the disclosure, including salts, hydrates and solvates thereof, may inherently or by design form polymorphs.


Methods of Making

The compounds of the disclosure can be prepared in a number of ways well known to those skilled in the art of organic synthesis. By way of example, compounds of the present disclosure can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art.

Generally, the compounds of formula (I) can be prepared according to the Schemes provided *infra*.

Compounds provided herein can be prepared according to the following Examples. In the following Schemes, Y, R¹, L, R^A, n and m are defined according to enumerated Embodiment 1. In an embodiment, Y, R¹, L, R^A, n and m are defined according to any of enumerated Embodiments 2 to 21, 23, 26 to 30.


General Scheme 1



- Starting material **I-1** is either commercially available or can be made according to standard chemical transformations as described in the individual procedures or known in the art. **I-1** is reacted with commercially available cyclobutyl alcohol **I-2** under Mitsunobu type conditions, e.g.,
- 5 PPh_3 , DIAD, in a solvent such as THF, to provide **I-3**, which is subsequently treated under acidic conditions, e.g., HCl/dioxane, to provide amine derivative **I-4**. The resultant amine product **I-4** can undergo a reductive amination with the corresponding aldehyde **I-5** to provide final compound **I-6** after deprotection of any protected functional groups, e.g., present as a substituent of R^1 and/or R^A , e.g., under acidic conditions with hydrochloric acid in dioxane or with a fluoride source such as tetra-n-butylammonium fluoride in THF.
 - 10

Alternatively, compounds can be produced as shown in General Scheme 2 below.


General Scheme 2



In Scheme 2, compounds such as **I-1** can be reacted with **II-7** under basic conditions, e.g., CsCO_3 , to provide **I-3**, which can be treated under acidic conditions to provide amine **I-4**. The resultant amine can undergo a reductive amination with the corresponding aldehyde **I-5** (e.g., using the conditions described in General Scheme 1) to provide **I-6** after deprotection, as described in Step 4 of General scheme 1.

Alternatively, compounds can produced as shown in Genereal Scheme 3 below.


General Scheme 3



In Scheme 3, compounds such as **III-8** (wherein X is halo, e.g., Cl) can be reacted with the commercially available **III-9** under basic conditions, e.g., NaH or CsCO_3 and CuI, to provide **I-3**, which can be treated under acidic conditions to provide amine **I-4**. The resultant amine product can undergo a reductive amination with the corresponding aldehyde **I-5** (e.g., using the conditions described in General Scheme 1) to provide **I-6** after deprotection, as described in Step 4 of General Scheme 1.

Alternatively, compounds can produced as shown in General Scheme 4 below.


General Scheme 4



In Scheme 4, compounds such as **I-4** are reacted with the corresponding bromide **IV-10** under basic conditions, e.g., triethylamine, to provide **IV-11**.

Alternatively, compounds can produced as shown in General Scheme 5 below.


General Scheme 5



In Scheme 5, an aldehyde such as **V-12** can be treated with a reducing agent, such as sodium borohydride, to provide **V-13**. Bromination of **V-13** provides **V-14** using a suitable brominating reagent, such as phosphorus tribromide. Nucleophilic displacement with **III-9** in the presence of a base, such as sodium hydride, provides **V-15**. Removal of the Boc protecting group under acidic conditions, e.g., HCl/dioxane, provides amine **V-16**. Subsequent reductive amination with the corresponding aldehyde **V-17** (e.g., using the conditions described in General Scheme 1, suitably Condition 3) provides **V-18**.

Alternatively, compounds can be produced as shown in General Scheme 6 below.


10 General Scheme 6



In Scheme 6, an acid such as **VI-19** can react with **I-4** under peptide coupling conditions, e.g., HATU, DIPEA, and using a solvent such as DMF. Any protected functional groups may subsequently undergo deprotection as described in Step 4 of General Scheme 1, to provide amide **VI-20**.

Alternatively, compounds can be produced as shown in General Scheme 7 below.


General Scheme 7



Mesylate **VII-21** undergoes nucleophilic displacement with alcohol **I-1** (e.g., L is C₆-C₁₀ aryl) under basic conditions, e.g., CsCO₃, to provide **VII-22**. Deprotection of under acidic conditions, e.g., HCl/dioxane, provides amine **VII-23**. **VII-23** can undergo reductive amination with the corresponding aldehyde **I-5** (e.g., using the conditions described in General Scheme 1, suitably Condition 3) to provide **VII-24**. The cyclobutyl *cis* and *trans* isomers are then separated.

Alternatively, compounds can be produced as shown in General Scheme 8 below.

General Scheme 8




In Scheme 8, commercially available alcohol **I-2** can react with mesyl chloride under basic conditions, e.g., triethylamine, to provide **II-7**. Thio ester product **VIII-25** can be formed by treatment of **II-7** under nucleophilic conditions, e.g., with KSCOMe. Deprotection under basic conditions, e.g., NaOH, affords **VIII-26**, which can then react with the corresponding aryl bromide **VIII-27** under Buchwald type conditions using a Pd catalyst, e.g., Pd₂(dba)₃, and phosphine ligand, e.g., Xantphos, and base, e.g., DIPEA, in a solvent such as dioxane, to provide **VIII-28**. Deprotection of **VIII-28** with acid, e.g., HCl, provides amine **VIII-29**, which can undergo reductive

amination with the corresponding aldehyde **VIII-30** (e.g., using the conditions described in General Scheme 1, suitably Condition 1) to provide **VIII-31**.

Alternatively, compounds can be produced as shown in General Scheme 9 below.


General Scheme 9



Commercially available **IX-32** reacts with aniline **IX-33** under reductive amination conditions to provide **IX-34**, which is subsequently deprotected under acidic conditions, e.g., HCl/dioxane, to provide amine **IX-35**. Reaction with aldehyde **I-5** under reductive amination conditions (e.g., using the conditions described in General Scheme 1, suitably Condition 1) provides **IX-36**.

Alternatively, compounds can be produced as shown in General Scheme 10 below.


General Scheme 10



In Scheme 10, oxidation of compound **X-37**, e.g., with MnO_2 , affords **X-38**. Nucleophilic addition to aldehyde **X-38** with a cyano source, e.g., TMS-CN, gives **X-39**. Deprotection of **X-39** under acidic conditions, e.g., HCl, provides acid **X-40**.

Alternatively, compounds can be produced as shown in General Scheme 11 below.


General Scheme 11



In Scheme 11, reductive amination of aldehyde **I-5** (e.g., using the conditions described in General Scheme 1) with (1s,3s)-3-aminocyclobutan-1-ol provides **XI-41**. Reaction with **I-1** under Mitsunobu type conditions as described in Step 1 of General Scheme 1 provides **I-6**.

Alternatively, nitrated compounds can be produced as shown in General Scheme 12 below.


General Scheme 12



In Scheme 12, nitration of **XII-42**, e.g., using H_2SO_4 and HNO_3 , gives **XII-43**, which is then reduced, e.g., Zn and AcOH, to provide **XII-44**, after separation of the regioisomers.

Alternatively, compounds can be produced as shown in General Scheme 13 below.

General Scheme 13




In Scheme 13, cross coupling of **XIII-45** under Suzuki type conditions with potassium trifluoro(vinyl)borate, using a base, e.g., TEA, and a Pd catalyst, e.g., $\text{Pd(dppf)Cl}_2 \cdot \text{CH}_2\text{Cl}_2$, yields **XIII-46**, which can then be oxidized, e.g., by OsO_4 , to provide diol **XIII-47**. Treatment of diol **XIII-47** with a fluorinating reagent, e.g., DAST, gives **XIII-48**. Deprotection of **XIII-48** under acidic

conditions, e.g., TFA, provides **XIII-49** which can react with aldehyde **I-5** under reductive amination conditions (as described in Step 4 of General Scheme 1) to provide **XIII-50**.

Alternatively, compounds can be produced as shown in General Scheme 14 below.

General Scheme 14




5

Cross coupling of **XIII-45** with the corresponding boronic ester, e.g., 4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane, under Suzuki type conditions, e.g., base such as K₃PO₄, Pd catalyst such as Pd(dppf)Cl₂.CH₂Cl₂, in a suitable solvent, e.g., 1,4-dioxane, gives **XIV-51**. Reduction, e.g., under hydrogenation conditions, e.g., Pd/C and H₂, of alkene **XIV-51** gives **XIV-52**. Subsequent deprotection of **XIV-52** under acidic conditions provides **XIV-53** which undergoes a reductive amination with corresponding aldehyde **I-5** (as described in Step 4 of General Scheme 1) to provide **XIV-54**.

10

Alternatively, compounds can be produced as shown in General Scheme 15 below.


General Scheme 15



In Scheme 15, commercially available **XV-55** can be brominated, e.g., using bromine/acetic acid, to provide **XV-56**. Subsequent reaction with **I-2** under Mitsunobu type conditions (e.g., as described in Step 1 of General Scheme 1) provides **XV-57**. Pd catalysed cyanation of **XV-57** using $\text{Zn}(\text{CN})_2$ and a Pd catalyst such as $\text{Pd}_2(\text{dba})_3$ and a ligand such as dppf, gives **XV-58**, which is then deprotected under acidic conditions to provide **XV-59**. Reaction with aldehyde **I-5** under reductive amination conditions (as described in Step 4 of General Scheme 1) provides **XV-60**.

Alternatively, compounds can be produced as shown in General Scheme 16 below.


10 General Scheme 16



In Scheme 16, commercially available **XVI-61** is reacted with **III-9** under basic conditions, e.g., NaH or Cs_2CO_3 and CuI, to provide **XVI-62**. **XVI-62** is then reacted with NaOMe to provide **XVI-63**. Subsequent reaction with aldehyde **I-5** under reductive amination conditions (as described in Step 4 of General Scheme 1) provides **XVI-64**.


Alternatively, compounds can be produced as shown in General Scheme 17 below.

General Scheme 17



In Scheme 17, a Mitsunobu reaction of **I-1** (e.g., as described in Step 1 of General Scheme 1) with commercially available **III-9** provides **XVII-65**, which can be subsequently treated under acidic conditions to provide amine **XVII-66**. Further reaction with aldehyde **I-5** under reductive amination conditions (as described in Step 4 of General Scheme 1) provides **XVII-67** after deprotection of any protected functional groups, e.g., present as a substituent of R^1 and/or R^A , e.g., under acidic conditions with hydrochloric acid in dioxane or with a fluoride source such as tetra-*n*-butylammonium fluoride in THF.

In a further embodiment, provided herein is a compound of formula (X) or a salt thereof,



wherein:

Z is NH, O or S;

A is CH₂ or absent;

L is selected from 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from N, O, and S, C₆-C₁₀aryl and 6- to 10-membered partially saturated heterocyclyl having 1-3 heteroatoms independently selected from N, O, and S;

R^A is at each occurrence independently selected from halo, -CN, C₁-C₆haloalkyl, C₁-C₆alkyl, SF₅, C₃-C₆cycloalkyl, C₁-C₆alkoxyl, C₁-C₆haloalkoxyl, 4- to 6-membered heterocyclyl

having 1-2 heteroatoms independently selected from N, O, and S, $-(CH_2)_p-NR^3R^4$ and $-C(=O)-O-(C_1-C_6\text{alkyl})$,

wherein the C_3-C_6 cycloalkyl and 4- to 6-membered heterocyclyl are each independently substituted with 0-4 R^{A1} ;

5 R^{A1} is at each occurrence independently selected from halo and C_1-C_6 haloalkyl;

R^2 is selected from hydrogen and C_1-C_6 alkyl;

R^{2A} is selected from hydrogen and a nitrogen protecting group (PG) (suitably, *tert*-butyl carbamate (Boc));


R^3 is at each occurrence independently selected from hydrogen and C_1-C_6 alkyl;

10 R^4 is at each occurrence independently selected from $-SO_2R^5$, hydrogen, $-C(=O)-(C_1-C_6\text{alkyl})$ and C_1-C_6 alkyl;

R^5 is at each occurrence independently selected from NH_2 and C_1-C_6 alkyl;

m is 0, 1, 2, 3, 4 or 5.


In a further embodiment, the compound of Formula (X) is of Formula (X-a):



wherein A, L, Z, R^A , R^2 , R^{2A} and m are as defined for Formula (X).

In a further aspect, the disclosure provides a process for the preparation of a compound of formula (I), in free form or in pharmaceutically acceptable salt form, comprising the step of:

20 1) Reacting a compound of formula (X) (e.g., when R^{2A} is hydrogen) or a salt thereof, e.g., HCl, with a compound of formula (I-5):



wherein:

25 Y is selected from N and CH;

R^1 is at each occurrence independently selected from hydroxyl, C_1-C_6 alkyl, C_1-C_6 alkoxyl, halo, C_1-C_6 haloalkyl and NR^3R^4 ,

wherein the C₁-C₆alkyl and C₁-C₆haloalkyl are each independently substituted with 0-4 R^{1a};

R^{1a} is at each occurrence independently selected from hydroxyl, NR³R⁴ and -C(=O)-OH;

5 R³ is at each occurrence independently selected from hydrogen and C₁-C₆alkyl;

R⁴ is at each occurrence independently selected from -SO₂R⁵, hydrogen, -C(=O)-(C₁-C₆alkyl) and C₁-C₆alkyl;

R⁵ is at each occurrence independently selected from NH₂ and C₁-C₆alkyl;

n is 0, 1, 2, 3 or 4;

10 under reductive amination conditions, optionally followed by

2) Deprotection of any protected functional groups, e.g., present as a substituent of R¹ and/or R^A, to give a compound of formula (I).

Reductive amination reactions can be carried out as described in the procedures in the Examples section or known in the art.

15 In an embodiment, the reductive amination conditions are selected from:

1) NaBH₄, NEt₃, AcOH, solvent, such as methanol, and the reaction conducted at room temperature or heated to a suitable temperature (e.g., up to reflux temperature);

2) NaBH(OAc)₃, *i*-Pr₂NEt, solvent, such as DCM, and the reaction conducted at room temperature or heated to a suitable temperature (e.g., up to reflux temperature); and

20 3) NEt₃ and a solvent, such as benzene, and heated to a suitable temperature (e.g., up to reflux temperature), followed by addition of NaBH₄ or Na(CN)BH₃, and a solvent, such as methanol, and the reaction conducted at room temperature or heated to a suitable temperature (e.g., up to reflux temperature).

Deprotection, e.g., of protected amine or hydroxyl functional groups, can be carried out 25 as described in the procedures in the Examples section or known in the art.

In an embodiment, the deprotection conditions are selected from:

1) Acidic conditions, e.g., with neat hydrochloric acid or hydrochloric in dioxane or trifluoroacetic acid;

2) Fluoride source, such as tetra-*n*-butylammonium fluoride, in a solvent such as THF; 30 and

3) Mixture of conditions 1 and 2.

Pharmaceutical Compositions

In another aspect, the disclosure provides a pharmaceutical composition comprising one or more compounds of described herein or a pharmaceutically acceptable salt thereof, and one 35 or more pharmaceutically acceptable carriers.

In a further embodiment, the composition comprises at least two pharmaceutically acceptable carriers, such as those described herein. For purposes of the disclosure, unless designated otherwise, solvates and hydrates are generally considered compositions.

The compounds of Formula (I), and subformulae thereof, described herein may be administered alone or as an active ingredient of a pharmaceutical composition. Accordingly, provided herein are pharmaceutical compositions comprising a compounds of Formula (I), or subformulae thereof, or a pharmaceutically acceptable salt thereof, and one or more
5 pharmaceutically acceptable carriers.

Methods of preparing various pharmaceutical compositions are known to those of skill in the art and may be described in, for example, in the Handbook of Pharmaceutical Excipients, American Pharmaceutical Association (current edition); Pharmaceutical Dosage Forms Tablets (Lieberman, Lachman and Schwartz, editors) current edition, published by Marcel Dekker, Inc.,
10 as well as Remington's Pharmaceutical Sciences (Arthur Osol, editor), 1553-1593 (current edition).

The pharmaceutical composition can be formulated for particular routes of administration such as oral administration, topical administration, parenteral administration, and rectal administration, etc. In addition, the pharmaceutical compositions of the disclosure can be made
15 up in a solid form (including without limitation capsules, tablets, pills, granules, powders or suppositories), or in a liquid form (including without limitation solutions, gels, suspensions or emulsions). The pharmaceutical compositions can be subjected to conventional pharmaceutical operations such as sterilization and/or can contain conventional inert diluents, lubricating agents, or buffering agents, as well as adjuvants, such as preservatives, stabilizers, wetting agents,
20 emulsifiers and buffers, etc.

Typically, the pharmaceutical compositions are tablets or gelatin capsules comprising the active ingredient together with one or more of:

- a) diluents, *e.g.*, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine;
- b) lubricants, *e.g.*, silica, talcum, stearic acid, its magnesium or calcium salt and/or
25 polyethyleneglycol;
- c) binders, *e.g.*, magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone;
- d) disintegrants, *e.g.*, starches, agar, alginic acid or its sodium salt, or effervescent mixtures; and
- 30 e) absorbents, colorants, flavors and sweeteners.

In an embodiment, the pharmaceutical compositions are capsules comprising the active ingredient only.

Tablets may be either film coated or enteric coated according to methods known in the art.

35 The mode of administration and pharmaceutical composition are closely related to the therapeutic amounts of the compounds or compositions which are desirable and efficacious for the given treatment application. Pharmaceutical compositions provided herein can be formulated for ophthalmic, ocular, topical, and transdermal administration. In particular embodiments, the

pharmaceutical compositions provided herein are suitable for ocular administration. To prepare pharmaceutical compositions, the active ingredient may be mixed with one or more pharmaceutically acceptable carrier(s) according to conventional pharmaceutical compounding techniques. The carrier(s) may take a wide variety of forms depending on the form of preparation
5 desired for administration.

Suitable compositions for oral administration include an effective amount of a compound of the disclosure in the form of tablets, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs, solutions or solid dispersion. Compositions intended for oral use are prepared according to any method known in
10 the art for the manufacture of pharmaceutical compositions and such compositions can contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets may contain the active ingredient in admixture with nontoxic pharmaceutically acceptable excipients, which are suitable for the manufacture of tablets. These
15 excipients are, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example, starch, gelatin or acacia; and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets are uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and
20 thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate can be employed. Formulations for oral use can be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid
25 paraffin or olive oil.

Certain injectable compositions are aqueous isotonic solutions or suspensions, and suppositories are advantageously prepared from fatty emulsions or suspensions. Said compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers.
30 In addition, they may also contain other therapeutically valuable substances. Said compositions are prepared according to conventional mixing, granulating or coating methods, respectively, and contain about 0.1-75%, or contain about 1-50%, of the active ingredient.

Suitable compositions for transdermal application include an effective amount of a compound of the disclosure with a suitable carrier. Carriers suitable for transdermal delivery
35 include absorbable pharmacologically acceptable solvents to assist passage through the skin of the host. For example, transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling

barrier to deliver the compound of the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.

Suitable compositions for topical application, *e.g.*, to the skin and eyes, include aqueous solutions, suspensions, ointments, creams, gels or sprayable formulations, *e.g.*, for delivery by aerosol or the like. Such topical delivery systems will in particular be appropriate for dermal application, *e.g.*, for the treatment of skin cancer, *e.g.*, for prophylactic use in sun creams, lotions, sprays and the like. They are thus particularly suited for use in topical, including cosmetic, formulations well-known in the art. Such may contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.

As used herein a topical application may also pertain to an inhalation or to an intranasal application. They may be conveniently delivered in the form of a dry powder (either alone, as a mixture, for example a dry blend with lactose, or a mixed component particle, for example with phospholipids) from a dry powder inhaler or an aerosol spray presentation from a pressurised container, pump, spray, atomizer or nebuliser, with or without the use of a suitable propellant.

In certain embodiments, the pharmaceutical compositions provided herein are formulated as solutions, suspensions, gels, creams, ointments, liposomes, ocular inserts or other pharmaceutical compositions suitable, in particular embodiments, for topical administration to the ocular surface, the cornea, the eyelid, margins of the eye, eyelashes and/or eye lid margin in order to deliver the composition to the eye. In some embodiments, liquid (aqueous or non-aqueous) solutions may be used. In certain embodiments the pharmaceutical compositions are formulated as eye drops for topical administration to the ocular surface, the cornea, the eyelid, eye lid margins, eyelashes and/or margins of the eye in order to deliver the composition to the eye. Application of the pharmaceutical composition may be performed with an applicator, such as the subject's finger, a Weck-Cel®, Q-tip®, or other device capable of delivering a formulation to the eyelid, eyelashes and/or eyelid margin in order to deliver the formulation to the eye. The pharmaceutical compositions provided herein may be viscous or semi-viscous; liquid, solid, or semi-solid; aqueous or non-aqueous, depending on the site of application, dose, solubility of drug, and a variety of other factors that are considered by those of skill in the art.

Any of a variety of carriers may be used in a pharmaceutical composition provided herein.

In one embodiment, the pharmaceutically acceptable carrier is a non-aqueous carrier (*e.g.*, oil, or oil mixture) having a viscosity in a range from about 50 cps to about 1000 cps, about 50 cps to about 500 cps, about 50 cps to about 200 cps, or about 60 cps to about 120 cps. In certain embodiments, the non-aqueous carrier comprises an oil, *e.g.*, vegetable oils, silicone oils, mineral oil or any combination thereof. In some embodiments, the carrier may be liquid paraffin, white petrolatum, purified lanolin, gelation hydrocarbon, polyethylene glycol, hydrophilic ointment base, white ointment base, absorptive ointment base, Macrogol ointment base, simple ointment base, and the like. In certain embodiments, the pharmaceutical composition may include a monomeric polyol such as, glycerol, propylene glycol, and ethylene glycol, polymeric polyols such as

polyethylene glycol, cellulose esters such hydroxypropylmethyl cellulose, carboxy methylcellulose sodium and hydroxy propylcellulose; dextrans such as dextran 70; water soluble proteins such as gelatin, polymers such as polyvinyl alcohol, polyvinylpyrrolidone, and povidone; carbomers, such as carbomer 934P, carbomer 941, carbomer 940 and carbomer 974P; and gums
5 such as HP-guar.

Additional excipients may optionally be included in the pharmaceutical compositions provided herein. Examples of additional excipients include, for example, tonicity enhancers, preservatives, solubilizers, non-toxic excipients, demulcents, sequestering agents, pH adjusting agents, co-solvents, viscosity building agents, and combinations thereof.

10 For the adjustment of the pH, *e.g.*, to a physiological pH, buffers may be used. In certain embodiments, the pH of the pharmaceutical composition is maintained within the range of about 4.0 to about 8.0, such as, about 4.0 to about 6.0, for example, about 6.5 to about 7.8. Suitable buffers may be added, such as, *e.g.*, boric acid, sodium borate, potassium citrate, citric acid, sodium bicarbonate, tris(hydroxymethyl)aminomethane (TRIS), and various mixed phosphate
15 buffers (including combinations of Na_2HPO_4 , NaH_2PO_4 and KH_2PO_4) and mixtures thereof. Generally, buffers may be used in amounts ranging from about 0.05 to about 2.5 percent by weight, such as, from about 0.1 to about 1.5 percent by weight.

Tonicity may be adjusted, if needed, by the use of tonicity enhancing agents. Such agents may, for example, be of ionic and/or non-ionic type. Examples of ionic tonicity enhancers include,
20 for example, alkali metal or earth metal halides such as, *e.g.*, CaCl_2 , KBr, KCl, LiCl, NaI, NaBr or NaCl, Na_2SO_4 or boric acid. Non-ionic tonicity enhancing agents include, *e.g.*, urea, glycerol, sorbitol, mannitol, propylene glycol, or dextrose. In one embodiment, the pharmaceutical compositions provided herein may have an osmolality of about 225 to about 400 milliosmoles per kilogram (mOsm/kg). In one embodiment, an osmolality of about 280 to about 320 mOsm is
25 obtained.

In further embodiments, the pharmaceutical compositions provided herein, such as topical compositions, may additionally comprise a preservative. A preservative may typically be selected from a quaternary ammonium compound such as benzalkonium chloride, benzoxonium chloride (*e.g.*, N-benzyl-N-(C_8 - C_{18} dimethylammonium chloride) or the like. Examples of preservatives
30 different from quaternary ammonium salts include, *e.g.*, alkyl-mercury salts of thiosalicylic acid, such as, for example, thiomersal, phenylmercuric nitrate, phenylmercuric acetate or phenylmercuric borate, sodium perborate, sodium chlorite, parabens, such as, for example, methylparaben or propylparaben, alcohols, such as, for example, chlorobutanol, benzyl alcohol or phenylethanol, guanidine derivatives, such as, for example, chlorohexidine or
35 polyhexamethylene biguanide, sodium perborate, or sorbic acid. Where appropriate, a sufficient amount of preservative may be added to the pharmaceutical composition provided herein to ensure protection against secondary-contaminations during use caused by bacteria and fungi. In certain embodiments the pharmaceutical compositions provided herein, such as topical

compositions, may additionally comprise Polyquad®. In another embodiment, the pharmaceutical compositions provided herein do not comprise a preservative.

The pharmaceutical compositions provided herein may additionally comprise a solubilizer. Suitable solubilizers include, but are not limited to, tyloxapol, fatty acid glycerol polyethylene glycol esters, fatty acid polyethylene glycol esters, polyethylene glycols, glycerol ethers, or cyclodextrins.

The pharmaceutical compositions provided herein may further comprise non-toxic excipients, such as emulsifiers, wetting agents or fillers, by way of example, polyethylene glycols designated 200, 300, 400 and 600, or Carbowax designated 1000, 1500, 4000, 6000 and 10000. The amount and type of excipient added is in accordance with the particular requirements and is generally in the range of from approximately 0.0001 to approximately 90% by weight. Other compounds may also be added to the pharmaceutical compositions provided herein to adjust (e.g., increase) the viscosity of the carrier. Examples of viscosity enhancing agents include, but are not limited to, polysaccharides, such as hyaluronic acid and its salts, chondroitin sulfate and its salts, dextrans, various polymers of the cellulose family, vinyl polymers, and acrylic acid polymers.

The pharmaceutical composition of the disclosure may be in the form of an aqueous suspension or an aqueous solution. In one embodiment, the aqueous pharmaceutical composition of the disclosure is in the form of an aqueous suspension.

Aqueous pharmaceutical compositions according to the disclosure can be prepared using standard procedures that are familiar to the person skilled in the art, e.g., by admixture of the various components, suitably at ambient temperature and atmospheric pressure. In one embodiment, the aqueous pharmaceutical compositions of the disclosure are suitable for ocular administration.

In a further embodiment, the pharmaceutical composition of the disclosure is in the form of eye ointment, eye gel, eye cream, or eye drops.

In a further embodiment, the pharmaceutical composition of the disclosure is administered to the subject topically in the eyes.

The compounds of formula (I), in free form or in pharmaceutically acceptable salt form, exhibit valuable pharmacological properties, e.g., TRPV1 antagonizing properties e.g., as indicated in the *in vitro* tests as provided in the examples, and are therefore indicated for therapy or for use as research chemicals, e.g., as tool compounds.

Additional properties of the disclosed compounds include having good potency in the biological assays described herein, favorable safety profile, and possess favorable pharmacokinetic properties

Diseases and Disorders and Methods of Use

In a further aspect, the invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in therapy.

In a further aspect, the invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of a disease or disorder for which a TRPV1 antagonist is indicated. In one embodiment, the disease or disorder is affected by the inhibition of TRPV1 activity.

5 Compounds of formula (I) and their pharmaceutically acceptable salts have TRPV1 antagonist activity and are believed to be of potential use for the treatment or prophylaxis of certain diseases or disorders, or treatment of the pain associated with these, such as respiratory diseases, asthma, cough, chronic obstructive pulmonary disease (COPD), bronchoconstriction, rhinitis, inflammatory disorders, pain, such as acute pain, chronic pain, neuropathic pain,
 10 postoperative pain, post-rheumatoid arthritic pain, osteoarthritic pain, back pain, visceral pain, cancer pain, algesia, neuralgia, dental pain, headache, migraine, neuropathies, carpal tunnel syndrome, diabetic neuropathy, HIV-related neuropathy, post-herpetic neuralgia, fibromyalgia, neuritis, sciatica, nerve injury, ischaemia, neurodegeneration, stroke, post stroke pain, multiple sclerosis, oesophagitis, heart burn, Barrett's metaplasia, dysphagia, gastroesophageal reflux
 15 disorder (GERD), stomach and duodenal ulcers, functional dyspepsia, irritable bowel syndrome, inflammatory bowel disease, colitis, Crohn's disease, pelvic hypersensitivity, pelvic pain, menstrual pain, renal colic, urinary incontinence, cystitis, burns, itch, psoriasis, pruritis and emesis, ocular diseases or disorders.

In an embodiment, the ocular disease or disorder is an ocular surface disorder. In a further
 20 embodiment, the ocular surface disorder is selected from chronic ocular surface pain (COSP), dry eye disease (including dry eye symptoms, including symptoms of dry eye associated with refractive surgery such as LASIK surgery), Sjogren's Syndrome, conjunctivitis (including keratoconjunctivitis, vernal keratoconjunctivitis, allergic conjunctivitis), Map-Dot-Fingerprint Dystrophy, acanthamoeba, fibromyalgia, Meibomian gland dysfunction, thyroid eye disease,
 25 rosacea, ptosis, keratoconus, ocular pain syndrome, Steven-Johnson's syndrome, corneal epitheliopathies, corneal neuropathies (including LASIK induced corneal neuropathies), corneal dystrophies (including recurrent corneal dystrophies), epithelial basement membrane dystrophy, corneal erosions or abrasions (including recurrent corneal erosions or abrasions), ocular surface diseases, blepharitis, graft vs host disease, meibomitis, glaucoma, conjunctivochalasis,
 30 keratopathies (including herpetic keratopathy, filamentary keratopathy, band or bullous keratopathy, exposure keratopathy), keratitis (including herpes simplex virus keratitis), iritis, episcleritis, corneal surgery, multiple sclerosis, trichiasis, pterygium, neuralgia, xerophthalmia, or patients recovering from neurotrophic keratitis.

In an embodiment, the ocular disease or disorder is ocular surface pain. In some
 35 embodiments, the ocular surface pain is acute or episodic ocular surface pain. In some embodiments, the ocular surface pain is chronic ocular surface pain, e.g., lasting for at least 3 months.

In an embodiment, the ocular disease or disorder is ocular hyperemia.

Having regard to their activity as TRPV1 inhibitors, compounds of formula (I) and sub-formulae thereof, in free or pharmaceutically acceptable salt form, are useful in the treatment of conditions which may be treated by inhibition of TRPV1 activity. In one aspect, the disclosure provides a method of treating or preventing a disease or disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I) or sub-formula thereof, or a pharmaceutically acceptable salt thereof.

In another aspect, the disclosure provides a method of treating or preventing a disease or disorder that is affected by the inhibition of TRPV1 activity, in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I) or sub-formula thereof, or a pharmaceutically acceptable salt thereof.

In another aspect, the disclosure provides a method of inhibiting TRPV1 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I) or sub-formula thereof, or a pharmaceutically acceptable salt thereof.

In another aspect, the disclosure provides a method of antagonizing TRPV1 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I) or sub-formula thereof, or a pharmaceutically acceptable salt thereof.

In another aspect, the disclosure provides a method of treating or preventing a disease or disorder mediated by TRPV1 in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I) or sub-formula thereof, or a pharmaceutically acceptable salt thereof.

In another aspect, the disclosure provides a method of treating, reducing, or preventing pain in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I) or sub-formula thereof, or a pharmaceutically acceptable salt thereof. The pain may be acute, such as pain caused after injury or surgery, or chronic. Examples of pain include, in particular, pain, e.g., bone and joint pain (osteoarthritis), cancer pain, myofascial pain (muscular injury, fibromyalgia) and perioperative pain (general surgery, gynecologic surgery). Other examples include chronic pain, especially inflammatory, e.g., chronic inflammatory pain. Additional examples of pain include pain in which TRPV1 activation plays a role or is implicated, and therefore susceptible to treatment by the compounds disclosed herein. Such conditions include chronic pain with an inflammatory component such as rheumatoid arthritis; bone and joint pain (osteoarthritis); post-surgical pain; musculo-skeletal pain such as fibromyalgia; myofascial pain syndromes; headache, including migraine, acute or chronic tension headache, cluster headache, temporomandibular pain, and maxillary sinus pain; ear pain; episiotomy pain; burns, and especially primary hyperalgesia associated therewith; deep and visceral pain, such as heart pain, muscle pain, eye pain, orofacial pain, migraine, abdominal pain, gynaecological pain, such as dysmenorrhoea, and labour pain;

pain associated with the urogenital tract such as cystitis and vulvadynia; inflammatory skin disorders, for example psoriasis and eczema, or itch of non-specific origin; chronic pain associated with nerve injury and/or diseases affecting the nervous system, such as neuropathic pain associated with post-herpetic neuralgia, diabetic neuropathy, chemotherapy-induced neuropathy, amputations ("phantom limb pain"), nerve entrapment and brachial plexus avulsions, low back pain, sciatica and ankylosing spondylitis, reflex sympathetic dystrophy and other chronic nerve injuries; complex regional pain syndromes; central nervous system pain, such as pain due to spinal cord or brain stem damage, or stroke; gout; scar pain; pain associated with carcinoma, often referred to as cancer pain.

10 In another aspect, the disclosure provides a method of treating or preventing inflammatory diseases in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I) or sub-formula thereof, or a pharmaceutically acceptable salt thereof. Exemplary inflammatory diseases include inflammatory
15 airways disease, e.g., chronic obstructive pulmonary disease (COPD), or asthma; cough; urinary incontinence; migraine; visceral disorders, e.g., inflammatory bowel disease; rhinitis; cystitis, e.g. interstitial cystitis; pancreatitis; uveitis; inflammatory skin disorders such as eczema and psoriasis; rheumatoid arthritis; inflammatory disorders of the gut, e.g., irritable bowel syndrome; Crohn's disease; ulcerative colitis; and cystitis, e.g., interstitial cystitis, nephritis and uveitis.

In another aspect, the disclosure provides a method of relaxing smooth muscle in a subject
20 in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I) or sub-formula thereof, or a pharmaceutically acceptable salt thereof. Examples of diseases or conditions requiring smooth muscle relaxants include, e.g., treatment of spasm of the gastrointestinal tract or uterus, e.g., in the therapy of Crohn's disease, ulcerative colitis or pancreatitis.

25 In another aspect, the disclosure provides a method of treating or preventing airway hyperreactivity or treating or preventing inflammatory events associated with airways disease, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I) or sub-formula thereof, or a pharmaceutically acceptable salt thereof. Exemplary conditions include asthma, restriction or reversal of airways hyperreactivity in asthma. Other
30 conditions include both intrinsic and, especially, extrinsic asthma, such as allergic asthma, as well as, e.g., exercise induced asthma, occupational asthma, asthma induced following bacterial infection, other non-allergic asthmas and "wheezy-infant syndrome". Efficacy in the treatment of asthma will be evidenced by reduced frequency or severity of symptomatic attack, e.g., of acute asthmatic or bronchoconstrictor attack and by reduced requirement for other, symptomatic
35 therapy, e.g., anti-inflammatory, e.g., corticosteroid; or bronchodilator, e.g., β_2 adrenergic, therapy. Other inflammatory or obstructive airways diseases include pneumoconiosis (an inflammatory, commonly occupational, disease of the lungs, frequently accompanied by repeated inhalation of dusts) of whatever type or genesis including, e.g., aluminosis, anthracosis,

asbestosis, chalicosis, ptilosis, siderosis, silicosis, tabacosis and, in particular, byssinosis. Further inflammatory or obstructive airways diseases and conditions include adult respiratory distress syndrome (ARDS), chronic obstructive pulmonary or airways disease (COPD or COAD), and bronchitis, allergic and vasomotor rhinitis.

5 In another aspect, the disclosure provides a method of treating or preventing septic shock in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I) or sub-formula thereof, or a pharmaceutically acceptable salt thereof. Exemplary conditions include septic shock, e.g., as anti-hypovolaemic and/or anti-hypotensive agents; in the treatment of inflammatory bowel disease; cerebral oedema;
10 headache;

 In another aspect, the disclosure provides a method of treating an ocular surface disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I) or sub-formula thereof, or a pharmaceutically acceptable salt thereof. In some embodiments, In some embodiments, the disclosure relates to a
15 method of treating dry eye disease in a subject in need thereof, comprising administering to the subject an effective amount of a compound of formula (I) or sub-formula thereof, or a pharmaceutically acceptable salt thereof.

 In another aspect, the disclosure provides a method of treating or reducing ocular surface pain in a subject in need thereof, the method comprising administering to the subject a
20 therapeutically effective amount of a compound of formula (I) or sub-formula thereof, or a pharmaceutically acceptable salt thereof. In some embodiments, the ocular surface pain is acute or episodic ocular surface pain. In some embodiments, the ocular surface pain is chronic ocular surface pain, e.g., lasting for at least 3 months. In an embodiment, the ocular surface pain or the chronic ocular surface pain is associated with one or more of dry eye disease, Sjogren's
25 Syndrome, conjunctivitis (including keratoconjunctivitis, vernal keratoconjunctivitis, allergic conjunctivitis), Map-Dot-Fingerprint Dystrophy, acanthamoeba, fibromyalgia, Meibomian gland dysfunction, thyroid eye disease, rosacea, ptosis, keratoconus, ocular pain syndrome, Steven-Johnson's syndrome, corneal epitheliopathies, corneal neuropathies (including LASIK induced corneal neuropathies), corneal dystrophies (including recurrent corneal dystrophies), epithelial
30 basement membrane dystrophy, corneal erosions or abrasions (including recurrent corneal erosions or abrasions), ocular surface diseases, blepharitis, graft vs host disease, meibomitis, glaucoma, conjunctivochalasis, keratopathy (including herpetic keratopathy, filamentary keratopathy, band or bullous keratopathy, exposure keratopathy), keratitis (including herpes simplex virus keratitis), iritis, episcleritis, corneal surgery, multiple sclerosis, trichiasis, pterygium,
35 neuralgia, xerophthalmia, or patients recovering from neurotrophic keratitis.

 In a particular embodiment, the ocular surface pain or the chronic ocular surface pain is associated with dry eye disease or Sjogren's Syndrome. In some embodiments of the methods described herein, the subject suffers from ocular pain persisting for at least three months after

photorefractive keratectomy (PRK) surgery or laser-assisted in situ keratomileusis (LASIK) surgery. In some embodiments, the subject suffers from conjunctivitis, subconjunctival hemorrhage, subconjunctival scarring, conjunctival membranes, conjunctival ulceration, superficial punctate epithelial erosions, epithelial defects, lid margin ulceration, lid margin
5 keratinization, symblepharon, ankyloblepharon, trichiasis, anterior blepharitis, punctal auto-occlusion, meibomian gland disease, corneal opacification, dry eye, distichiasis, limbal stem cell failure, or corneal vascularization.

In another aspect, the disclosure provides a method of treating or reducing ocular hyperemia in a subject in need thereof, the method comprising administering to the subject a
10 therapeutically effective amount of a compound formula (I) or sub-formula thereof, or a pharmaceutically acceptable salt thereof. In an embodiment, the ocular hyperemia is associated with one or more of dry eye disease, Sjogren's Syndrome, conjunctivitis (including keratoconjunctivitis, vernal keratoconjunctivitis, allergic conjunctivitis), Map-Dot-Fingerprint Dystrophy, acanthamoeba, fibromyalgia, Meibomian gland dysfunction, thyroid eye disease,
15 rosacea, ptosis, keratoconus, ocular pain syndrome, Steven-Johnson's syndrome, corneal epitheliopathies, corneal neuropathies (including LASIK induced corneal neuropathies), corneal dystrophies (including recurrent corneal dystrophies), epithelial basement membrane dystrophy, corneal erosions or abrasions (including recurrent corneal erosions or abrasions), ocular surface diseases, blepharitis, graft vs host disease, meibomitis, glaucoma, conjunctivochalasis,
20 keratopathies (including herpetic keratopathy, filamentary keratopathy, band or bullous keratopathy, exposure keratopathy), keratitis (including herpes simplex virus keratitis), iritis, episclentis, corneal surgery, multiple sclerosis, trichiasis, pterygium, neuralgia, xerophthalmia, or patients recovering from neurotrophic keratitis. In a particular embodiment, the ocular hyperemia is associated with dry eye disease. In an embodiment of the methods described herein, the ocular
25 hyperemia persists for at least three months after photorefractive keratectomy (PRK) surgery or laser-assisted in situ keratomileusis (LASIK) surgery.

All the aforementioned embodiments relating to the methods of treatment of the aforementioned diseases are equally applicable to:
a compound of formula (I) or sub-formula thereof, or a pharmaceutically acceptable salt thereof,
30 for use in the treatment of the aforementioned diseases according to the present disclosure;
use of a compound of formula (I) or sub-formula thereof, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of the aforementioned diseases according to the present disclosure;
use of a compound of formula (I) or sub-formula thereof, or a pharmaceutically acceptable salt
35 thereof, for the treatment of the aforementioned diseases according to the present disclosure;
and

a pharmaceutical composition comprising a compound of formula (I) or sub-formula thereof, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, for use in the treatment of the aforementioned diseases according to the present disclosure.

Dosage

5 The pharmaceutical composition or combination of the disclosure can be in unit dosage of about 1-1000 mg of active ingredient(s) for a subject of about 50-70 kg, or about 1-500 mg or about 1-250 mg or about 1-150 mg or about 0.5-100 mg, or about 1-50 mg of active ingredients. The therapeutically effective dosage of a compound, the pharmaceutical composition, or the combinations thereof, is dependent on the species of the subject, the body weight, age and
10 individual condition, the disorder or disease or the severity thereof being treated.

The above-cited dosage properties are demonstrable *in vitro* and *in vivo* tests using advantageously mammals, *e.g.*, mice, rats, dogs, monkeys or isolated organs, tissues and preparations thereof. The compounds of the disclosure can be applied *in vitro* in the form of solutions, *e.g.*, aqueous solutions, and *in vivo* either enterally, parenterally, advantageously
15 intravenously, *e.g.*, as a suspension or in aqueous solution. The dosage *in vitro* may range between about 10^{-3} molar and 10^{-9} molar concentrations. A therapeutically effective amount *in vivo* may range depending on the route of administration, between about 0.1-500 mg/kg, or between about 1-100 mg/kg.

In certain embodiments, the disclosure provides for administration of a compound of
20 Formula (I), or subformulae thereof, or a pharmaceutically acceptable salt thereof, to a subject in need thereof in an ophthalmically compatible pharmaceutical composition, wherein said compound is present at a concentration of about 0.01% w/v to about 10.0% w/v. In some embodiments, the compound of formula I is administered, *e.g.*, to the surface of the eye, to the subject one to six times a day, *e.g.*, one, two, three, or four times a day. In some embodiments,
25 the compound of formula (I) is administered to the subject for a period of at least about one month, at least about two months, or at least about three months. The therapeutically effective dosage of a compound, the pharmaceutical composition, or the combinations thereof, is dependent on the species of the subject, the body weight, age and individual condition, the disorder or disease or the severity thereof being treated.

30 The preferred compositions of the present invention are intended for administration to a human patient suffering from an ocular disease or disorder. Preferably, such compositions will be administered topically.

The activity of a compound according to the disclosure can be assessed by the *in vitro* methods described in the Examples.

35 Combination Therapy

In another aspect, the disclosure provides a pharmaceutical combination comprising a compound of formula (I), or subformulae thereof, or a pharmaceutically acceptable salt thereof,

and one or more additional therapeutic agent(s) for simultaneous, separate or sequential use in therapy.

The compound of the disclosure may be administered either simultaneously with, or before or after, one or more other therapeutic agent. The compound of the disclosure may be administered separately, by the same or different route of administration, or together in the same pharmaceutical composition as the other agents. A therapeutic agent is, for example, a chemical compound, peptide, antibody, antibody fragment or nucleic acid, which is therapeutically active or enhances the therapeutic activity when administered to a patient in combination with a compound of the disclosure. Thus, in one embodiment, the disclosure provides a combination comprising a therapeutically effective amount of a compound of formula or subformulae thereof, or a pharmaceutically acceptable salt thereof, and one or more therapeutically active agents.

In certain embodiments, a compound of Formula (I), or subformulae thereof, or a pharmaceutically acceptable salt thereof, may be administered with an additional therapeutic agent. A non-limiting list of such agents includes pharmaceutical agents effective in the treatment of diseases and conditions in which vanilloid receptor activation plays a role or is implicated, including cyclooxygenase-2 (COX-2) inhibitors, such as specific COX-2 inhibitors, *e.g.*, celecoxib and rofecoxib; and non-steroidal anti-inflammatory drugs (NSAIDs), *e.g.*, acetylsalicylic acid and propionic acid derivatives; tricyclic anti-depressants, *e.g.*, Anafranil®, Asendin®, Aventyl®, Elavil®, Endep®, Norfranil®, Norpramin®, Pamelor®, Sinequan®, Surmontil®, Tipramine®, Tofranil®, Vivactil®, Tofranil-PM®; anti-convulsants, *e.g.*, carbamazepine, oxcarbazepine and gabapentin; bradykinin B1 or B2 antagonists; and GABA_B agonists, *e.g.*, L-baclofen.

In certain embodiments, further therapeutic agents may include, for instance, other compounds and antibodies useful for treating ocular disorders. A non-limiting list of such agents includes retinoid X receptor agonists, such as vitamin A, retinoic acid, phytanic acid, lithocholic acid, bexarotene, docosahexaenoic acid, or flurobexarotene. Other additional therapeutic agents include ophthalmic steroids such as, dexamethasone, fluocinolone, loteprednol, difluprednate, fluorometholone, prednisolone, prednisone, medrysone, triamcinolone, betamethasone, rimexolone, or pharmaceutically acceptable salts thereof. In addition, other additional therapeutic agents include those used to target ocular surface disease disorders, such as dry eye disease. Non-limiting example of such additional therapeutic agents include Xiidra® (lifitegrast), Restasis® (cyclosporine), minocycline, doxycycline, or other tetracycline antibiotics. Other examples include keratolytic agents such as selenium disulfide, salicylic acid, glycolic acid *etc.*, or pharmaceutically acceptable salts thereof.

In certain embodiments, further therapeutic agents may include, for instance, other compounds useful in the treatment of pain. In an embodiment, a compound of Formula (I), or subformula thereof, or a pharmaceutically acceptable salt thereof, may be administered with an additional analgesic agent. Such analgesic agent may be an NSAID (*e.g.*, acetylsalicylic acid and propionic acid derivatives, *e.g.*, Aleve®), opioid or steroid.

In one embodiment, the disclosure provides a product comprising a compound of formula (I), or subformula thereof, or a pharmaceutically acceptable salt thereof, and at least one other therapeutic agent as a combined preparation for simultaneous, separate or sequential use in therapy. In one embodiment, the therapy is the treatment of a disease or condition modulated by TRPV1. Products provided as a combined preparation include a composition comprising the compound of formula (I), or subformula thereof, or a pharmaceutically acceptable salt thereof, and the other therapeutic agent(s) together in the same pharmaceutical composition, or the compound of formula (I), or subformula thereof, or a pharmaceutically acceptable salt thereof, and the other therapeutic agent(s) in separate form, *e.g.*, in the form of a kit.

In one embodiment, the disclosure provides a pharmaceutical composition comprising a compound of formula (I), or subformula thereof, or a pharmaceutically acceptable salt thereof, and another therapeutic agent(s). Optionally, the pharmaceutical composition may comprise a pharmaceutically acceptable carrier, as described above.

In one embodiment, the disclosure provides a kit comprising two or more separate pharmaceutical compositions, at least one of which contains a compound of formula (I), or subformula thereof, or a pharmaceutically acceptable salt thereof. In one embodiment, the kit comprises means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet. An example of such a kit is a blister pack, as typically used for the packaging of tablets, capsules and the like.

In the combination therapies of the disclosure, the compound of the disclosure and the other therapeutic agent may be manufactured and/or formulated by the same or different manufacturers. Moreover, the compound of the disclosure and the other therapeutic may be brought together into a combination therapy: (i) prior to release of the combination product to physicians (*e.g.*, in the case of a kit comprising the compound of the disclosure and the other therapeutic agent); (ii) by the physician themselves (or under the guidance of the physician) shortly before administration; (iii) in the patient themselves, *e.g.*, during sequential administration of the compound of the disclosure and the other therapeutic agent.

Preparation of Compounds

It is understood that in the following description, combinations of substituents and/or variables of the depicted formulae are permissible only if such combinations result in stable compounds.

It will also be appreciated by those skilled in the art that in the processes described below, the functional groups of intermediate compounds may need to be protected by suitable protecting groups. Such functional groups include hydroxy, phenol, amino and carboxylic acid. Suitable protecting groups for hydroxy or phenol include trialkylsilyl or diarylalkylsilyl (*e.g.*, *t*-butyldimethylsilyl, *t*-butyldiphenylsilyl or trimethylsilyl), tetrahydropyranyl, benzyl, substituted benzyl, methyl, and the like. Suitable protecting groups for amino, amidino and guanidino include

t-butoxycarbonyl, benzyloxycarbonyl, and the like. Suitable protecting groups for carboxylic acid include alkyl, aryl or arylalkyl esters.

Protecting groups may be added or removed in accordance with standard techniques, which are well-known to those skilled in the art and as described herein. The use of protecting groups is described in detail in J. F. W. McOmie, "Protective Groups in Organic Chemistry", Plenum Press, London and New York 1973; T. W. Greene and P. G. M. Wuts, "Greene's Protective Groups in Organic Synthesis", Fourth Edition, Wiley, New York 2007; P. J. Kocienski, "Protecting Groups", Third Edition, Georg Thieme Verlag, Stuttgart and New York 2005; and in "Methoden der organischen Chemie" (Methods of Organic Chemistry), Houben Weyl, 4th edition, Volume 15/I, Georg Thieme Verlag, Stuttgart 1974.

The protecting group may also be a polymer resin, such as a Wang resin or a 2-chlorotrityl-chloride resin.

The following reaction Examples illustrate methods to make compounds of this disclosure. It is understood that one skilled in the art would be able to make these compounds by similar methods or by methods known to one skilled in the art. In general, starting components and reagents may be obtained from sources such as Sigma Aldrich, Lancaster Synthesis, Inc., Maybridge, Matrix Scientific, TCI, and Fluorochem USA, Strem, other commercial vendors, or synthesized according to sources known to those skilled in the art, or prepared as described in this disclosure.

Analytical Methods, Materials, and Instrumentation

Unless otherwise noted, reagents and solvents were used as received from commercial suppliers. Proton nuclear magnetic resonance (NMR) spectra were obtained on either Bruker Avance spectrometer or Varian Oxford 400 MHz spectrometer unless otherwise noted. Spectra are given in ppm (δ) and coupling constants, J, are reported in Hertz. Tetramethylsilane (TMS) was used as an internal standard. Chemical shifts are reported in ppm relative to dimethyl sulfoxide (δ 2.50), methanol (δ 3.31), chloroform (δ 7.26) or other solvent as indicated in NMR spectral data. A small amount of the dry sample (2-5 mg) is dissolved in an appropriate deuterated solvent (1 mL). The chemical names were generated using ChemBioDraw Ultra v12 from CambridgeSoft.

Mass spectra (ESI-MS) were collected using a Waters System (Acquity UPLC and a Micromass ZQ mass spectrometer) or Agilent-1260 Infinity (6120 Quadrupole); all masses reported are the m/z of the protonated parent ions unless recorded otherwise. The sample was dissolved in a suitable solvent such as MeCN, DMSO, or MeOH and was injected directly into the column using an automated sample handler. The analysis is performed on Waters Acquity UPLC system (Column: Waters Acquity UPLC BEH C18 1.7 μ m, 2.1 x 30mm; Flow rate: 1 mL/min; 55°C (column temperature); Solvent A: 0.05% formic acid in water, Solvent B: 0.04% formic acid in MeOH; gradient 95% Solvent A from 0 to 0.10 min; 95% Solvent A to 20% Solvent A from 0.10 to 0.50 min; 20% Solvent A to 5% Solvent A from 0.50 to 0.60 min; hold at 5% Solvent A from 0.6 min to

0.8 min; 5% Solvent A to 95% Solvent A from 0.80 to 0.90 min; and hold 95% Solvent A from 0.90 to 1.15 min.

List of abbreviations

	P(OEt) ₃	triethyl phosphite
5	rt	room temperature
	h	hour(s)
	aq	aqueous
	LCMS	liquid chromatography mass spectrometry
	MS	mass spectrometry
10	m/z	mass to charge ratio
	NMR	nuclear magnetic resonance
	br	broad
	d; dd	doublet; doublet of doublets
	m	multiplet
15	MHz	megahertz
	q	quartet
	t	triplet
	NBS	N-bromosuccinimide
	EtOAc	ethyl acetate
20	THF	tetrahydrofuran
	DMF	dimethylformamide
	TEA	triethylamine
	MeOH	methanol
25	MeCN	acetonitrile
	AcOH	acetic acid
	Pd(PPh ₃) ₂ Cl ₂	Bis(triphenylphosphine)palladium(II) dichloride
	DMAP	4-dimethylaminopyridine
	p-TsCl	p-toluenesulfonyl chloride
30	IPA	isopropyl alcohol
	t-BuOH	t-butanol
	g	grams
	mL	milliliters
	mmol	millimoles
35	mg	milligrams
	min	minutes
	TBDMS-Cl	tert-butyldimethylsilyl chloride
	M	molar

	HPLC	high performance liquid chromatography
	Et ₂ O	ethyl ether
	DMSO	dimethyl sulfoxide
	LDA	lithium diisopropylamide
5	TBAF	tetra-n-butylammonium fluoride
	MeMgBr	methylmagnesium bromide
	DIBAL-H	diisobutylaluminum hydride
	TBDMS-OTf	tert-butyldimethylsilyl trifluoromethyl sulfonate
	Rt	retention time
10	CF ₃ TMS	trifluoromethyltrimethylsilane
	NaOMe	sodium methoxide
	Boc ₂ O	di-tert-butyl dicarbonate
	PPh ₃	triphenylphosphine
	n-BuLi	n-butyllithium
15	DAST	diethylaminosulfur trifluoride
	TFA	trifluoroacetic acid
	HATU	Hexafluorophosphate Azabenzotriazole Tetramethyl Uronium
	DIPEA	N,N-diisopropylethylamine
	MeNO ₂	nitromethane
20	Ms ₂ O	methanesulfonic anhydride
	PTSA	p-toluenesulfonic acid
	MsCl	methanesulfonyl chloride
	Ac ₂ O	acetic anhydride
	Cu(OTf) ₂	copper II trifluoromethane sulfonate
25	TMSCN	trimethylsilyl cyanide
	m-CPBA	meta-chloroperoxybenzoic acid
	Pd(dppf)	
	(Cl ₂ .CH ₂ Cl ₂)	[1,1'-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane

30 **LCMS Conditions:**

LCMS Method 1A: Instrument: API 2000, Triple Quad, ESI. Column: Mercury MS Synergi 2 μ (20 x 4.0 mm), C12; Gradient: A- 0.1% formic acid in water, B- acetonitrile; Time/%B: 0.0/30, 0.5/30, 1.5/95, 2.0/95, 2.5/30, 3.0/30; Flow: 2.0 mL/min; UV detection array 190 – 400; Mass detection 100 – 1000 (electrospray ionization); column temperature 30°C.

35 **LCMS Method 2A:** Instrument: API3000, column: Synergi 2.5 μ (50 x 4.6 mm), MAX-RP 100 A; Gradient: A- 0.1% formic acid in water, B- acetonitrile; Time/%B: 0.0/20, 0.2/50, 1.0/95, 2.5/95, 2.9/50, 3.2/20, 4/20; Flow: 1.2 mL/min; UV detection array 190 – 400 (Total Wavelength

Chromatogram), Mass detection 100 – 1000 (electrospray ionization); column temperature 30°C.

LCMS Method 3A: Instrument: API 3200 Q Trap, Triple Quad, ESI. Column: Synergi 2.5 µ (50 x 4.6 mm), MAX-RP 100 A; Gradient: A- 0.1% formic acid in water, B- acetonitrile; Time/%B: 0.0/20, 0.2/50, 1.0/95, 2.7/95, 2.8/50, 4.0/20; Flow: 1.2 mL/min; UV detection array 190 – 400 (Total Wavelength Chromatogram); Mass detection 100 – 1000 (electrospray ionization); Column temperature: 30°C.

LCMS Method 4A: Instrument: Agilent 1100 series with Single Quad, Dual Mode mass spectrometer. Column: Zorbax XBD C18 (50 x 4.6 mm) 1.8 µ; Gradient: A- 0.1% formic acid in water, B- acetonitrile; Time/%B: 0.0/10, 0.5/10, 1.0/95.0, 2.0/95, 2.1/10, 3.5/10; Flow: 1.2 mL/min; UV detection array 200 – 400; Mass detection 100 – 1000 (electrospray ionization); Column temperature 40 °C.

LCMS Method 4B: Instrument: Agilent 1100 series with Single Quad, Dual Mode mass spectrometer. Column: Synergi 2.5µ MAX -RP 100 A Mercury; Gradient: A- 0.1% formic acid in water, B- acetonitrile; Time/%B: 0.0/10, 0.5/10, 1/95.0, 2.0/10, 3.0/10; Flow: 2.0 mL/min; UV detection array 200 – 400; Mass detection 100 – 1000 (electrospray ionization); Column temperature 40 °C.

LCMS Method 5A: Instrument: Agilent 1290-Infinity II. Column: Kinetex EVO 2.6 µ (50 x 4.6 mm); gradient: A- 0.1% formic acid in water, B- acetonitrile; Time/%B: 0.0/20, 0.25/20, 01.0/95.0, 2.5/95, 3.0/20, 4/20, flow 1.5 mL/min; UV detection array 200 – 400, Mass detection 100 – 1000 (electrospray ionization); Column temperature 40 °C.

LCMS Method 6A: Instrument: Shimadzu Nexera LCMS-2020 with Single Quad. Column: Synergi 2.5 µ (20 x 4.0 mm), MAX-RP 100 A Mercury; Gradient: A- 0.1% formic acid in water, B- acetonitrile; Time/%B: 0.1/5, 0.5/5, 1.0/95, 1.5/95, 2.0/5, 3.0/5; Flow: 2.0 mL/min; UV detection array 200 – 400; Mass detection 100 – 1000 (electrospray ionization); Column temperature: 40 °C.

LCMS Method 7A: Instrument: Agilent 1290 Infinity RRLC attached with Agilent 6120 Mass detector and Diode array Detector had a mobile phase (A) 2 mM ammonium acetate followed by 0.1%Formic acid in water (B) 0.1% Formic Acid in Acetonitrile, BEH C18(50*21.mm)1.7µm, column oven temperature was 22 °C, with flow rate 0.55ml/min and runtime was 3.0 min

LCMS Method 7B: Instrument: Waters H-class Acquity UPLC attached with SQ detector and Photo diode Array detector had a mobile phase (A) 2 mM ammonium acetate followed by 0.1%Formic acid in water (B) 0.1% Formic Acid in Acetonitrile, BEH C18(50*21.mm)1.7µm column and column oven temperature was 22 °C, with flow rate 0.55ml/min and runtime was 3.0 min

LCMS Method 7C: Instrument: Waters Acquity UPLC attached with Waters Acquity UPLC PDA and Waters Acquity UPLC ELSD. Mass spec: Waters Qda. Mobile phase 0.1% Formic

Acid in Water followed by 0.1% Formic Acid in Acetonitrile, Acquity UPLC BEH C18 1.7 μ m
2.1x30mm, column temperature
50 °C, with a flow rate of 1 mL/min and runtime was 5.20 min

NMR Instrument details: Nuclear magnetic resonance spectroscopy was performed using any
5 of the following instrumental conditions

NMR-300: VARIAN 300 (Mercury) equipped with ASW Probe (Proton, Carbon, Fluorine,
Phosphorous) and Z-gradient, operating VnmrJ 2.2

NMR-400: VARIAN 400 equipped with ATB Probe (Proton, Carbon, Fluorine) and Z-gradient,
operating VnmrJ 3.2

10 **NMR-600:** INOVA 600 equipped with HCN Probe (Proton, Carbon, Nitrogen) and Z-gradient,
operating VnmrJ 2.2


NMR-400-b: Bruker 400 equipped with BBFO CryoProbe (proton, carbon, fluorine and
broadband) and Z-gradient, operated by TOPSPIN 3.5

15 **NMR-400-c:** Bruker NMR 400 MHz Avance III HD equipped with 5 mm PABBO BB/19F-1H/D Z-
GRD

EXPERIMENTAL PROCEDURES:


Example 1: Synthesis of (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-*N*-((6-methylisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl

Step 1.1: Synthesis of 6-methylisoquinoline-5-carbaldehyde




20 To the solution of 5-bromo-6-methylisoquinoline [CAS No. 1146298-61-4] (0.4 g, 1.80 mmol) in
dry THF (10 mL), *n*-BuLi (2.5M in THF) (1.1 mL, 2.70 mmol) was added dropwise at -78 °C and
stirred for 30 min under argon atmosphere. DMF (0.27 mL, 3.60 mmol) was added dropwise at -
78 °C, temperature was raised to rt gradually and stirred for 1 h. Reaction mixture was
25 quenched with 10% NH₄Cl solution and extracted with EtOAc 3x's. The combined organic
portion was washed with brine solution, dried over anhydrous Na₂SO₄, filtered and concentrated
in *vacuo* to yield the crude product. The crude was purified by flash chromatography (12 g
SiliCycle column, 0 – 50% EtOAc in Hexane elution) to provide 6-methylisoquinoline-5-
carbaldehyde (0.16 g, 52%). MS (ESI+) [Method 1A]: *m/z* 172.0 (M+H); Rt 0.14 min. ¹H NMR
30 (400 MHz, CD₃OD) δ 10.89 (s, 1H), 9.22 (s, 1H), 8.88 (d, *J* = 6.4 Hz, 1H), 8.51 (d, *J* = 6.0 Hz,
1H), 8.23 (d, *J* = 8.0 Hz, 1H), 7.63 (d, *J* = 8.0 Hz, 1H), 2.89 (s, 3H).

Step 1.2: Synthesis of *tert*-butyl ((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)carbamate




To the solution of *tert*-butyl ((1*s*,3*s*)-3-hydroxycyclobutyl)carbamate (6.0 g, 32.04 mmol) in THF (60 mL), 4-fluoro-3-(trifluoromethyl)phenol [CAS No. 61721-07-1] (6.3 g, 35.25 mmol), PPh₃ (12.6 g, 48.07 mmol) and diisopropyl azodicarboxylate (9.4 mL, 48.07 mmol) were added at rt. The reaction mixture was stirred at 50 °C for 16 h under N₂ atmosphere. The reaction mixture
 5 was concentrated and the residue was purified by flash chromatography (40 g SiliCycle column, 0 – 30% EtOAc in Hexane elution) to provide *tert*-butyl ((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)carbamate (8.4 g, 75%). ¹H NMR (300 MHz, CDCl₃) δ 7.12 – 7.08 (m, 1H), 6.95 – 6.87 (m, 2H), 4.79 – 4.72 (m, 1H), 4.31 – 4.27 (m, 1H), 2.59 – 2.50 (m, 2H), 2.43 – 2.37 (m, 2H), 1.45 (s, 9H).

10 Step 1.3: Synthesis of (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl



A round bottom flask was charged with *tert*-butyl ((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)carbamate (8.4 g, 28.05 mmol) and HCl solution (20% in 1,4-dioxane) (80 mL), and stirred at rt for 16 h. Then the reaction mixture was concentrated in
 15 *vacuo*. The residue was triturated with pentane, the solid appeared was filtered and dried to yield (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl (5.1 g crude). LCMS [Method 6A]: m/z 250.1 [M+H]⁺; Rt 1.29 min.

Step 1.4: Synthesis of (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-N-((6-methylisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl




20 The solution of (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl (80 mg, 0.28 mmol) and TEA (40 mg, 0.28 mmol) in MeOH (2 mL) was stirred at rt for 15 min; then 6-methylisoquinoline-5-carbaldehyde (43 mg, 0.25 mmol) and AcOH (0.01 mL) were added, and stirred at rt for 16 h under argon. Then NaBH₄ (22 mg, 0.56 mmol) was added at 0 °C and
 25 stirred at rt for further 1 h. Reaction mixture was concentrated in *vacuo*, residue was diluted with water and extracted 3x with EtOAc. The combined organic portion was washed with brine solution, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. Prep-HPLC (Column: XBRIDGE C18, (150 mm x 19 mm), 5.0 μ; Mobile Phase: 0.1% NH₄OH in water and Acetonitrile) of the crude afforded (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-N-((6-
 30 methylisoquinolin-5-yl)methyl)cyclobutan-1-amine. To the solution of the isolated product in 1,4-dioxane (1 mL), was added HCl solution (4M in 1,4-dioxane) (2 mL) at 10 °C, stirred at rt for 4 h, and then concentrated in *vacuo* to afford (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-N-((6-

methylisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl (80 mg, 93%). MS (ESI+) [Method 5A]: m/z 405.1 (M+H); Rt 1.32 min. ^1H NMR (400 MHz, CD_3OD) δ 9.78 (s, 1H), 8.72 (s, 2H), 8.52 (d, $J = 8.8$ Hz, 1H), 8.04 (d, $J = 8.0$ Hz, 1H), 7.30 (t, $J = 9.6$ Hz, 1H), 7.16 – 7.10 (m, 2H), 5.06 – 5.04 (m, 1H), 4.84 (s, 2H), 4.41 – 4.38 (m, 1H), 2.94 – 2.90 (m, 2H), 2.88 (s, 3H), 2.78 – 2.72 (m, 2H).

Example 2: Synthesis of (1*r*,3*r*)-*N*-((6-methylisoquinolin-5-yl)methyl)-3-((6-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutan-1-amine, HCl


Step 2.1: Synthesis of *tert*-butyl ((1*r*,3*r*)-3-((6-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutyl)carbamate



10


To the solution of *tert*-butyl ((1*s*,3*s*)-3-hydroxycyclobutyl)carbamate (200 mg, 1.07 mmol) in THF (5 mL), 6-(trifluoromethyl)pyridin-3-ol [CAS No. 216766-12-0] (191 mg, 1.17 mmol), PPh_3 (420 mg, 1.60 mmol) and diisopropyl azodicarboxylate (0.25 mL, 1.60 mmol) were added at rt. The reaction mixture was stirred at 50 °C for 16 h under N_2 atmosphere. Reaction mixture was diluted with water and extracted 3x with EtOAc. The combined organic portion was washed with brine solution, dried over anhydrous Na_2SO_4 , filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 20% EtOAc in Hexane elution) to provide *tert*-butyl ((1*r*,3*r*)-3-((6-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutyl)carbamate (300 mg, 71%). ^1H NMR (300 MHz, CDCl_3) δ 8.26 (d, $J = 2.8$ Hz, 1H), 7.60 (s, 1H), 7.14 (dd, $J = 8.8, 3.2$ Hz, 1H), 4.90 – 4.85 (m, 1H), 4.78 (br, 1H), 4.33 – 4.29 (m, 1H), 2.62 – 2.56 (m, 2H), 2.50 – 2.46 (m, 2H), 1.45 (s, 9H).

Step 2.2: Synthesis of (1*r*,3*r*)-3-((6-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutan-1-amine, HCl [C-07838-037]



To the solution of with *tert*-butyl ((1*r*,3*r*)-3-((6-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutyl)carbamate (300 mg, 0.90 mmol) in CH_2Cl_2 , HCl solution (4M in 1,4-dioxane) (3 mL) was added, and stirred at rt for 16 h. Then the reaction mixture was concentrated in *vacuo* to afford crude (1*r*,3*r*)-3-((6-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutan-1-amine, HCl (300 mg, 109%). LCMS [Method 6A]: m/z 233.1 $[\text{M}+\text{H}]^+$; Rt 1.22 min.


Step 2.3: Synthesis of (1*r*,3*r*)-*N*-((6-methylisoquinolin-5-yl)methyl)-3-((6-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutan-1-amine, HCl



The title compound was synthesized in a similar manner as described in Step 1.4, using (1*r*,3*r*)-3-((6-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutan-1-amine, HCl (100 mg, 0.37 mmol) and 6-methylisoquinoline-5-carbaldehyde (Example, 1, Step 1.1, 55 mg, 0.34 mmol). Purification of the crude by flash chromatography (12 g SiliCycle column, 0 – 8% MeOH in CH₂Cl₂ elution), followed by treatment with HCl solution (4M in 1,4-dioxane) afforded (1*r*,3*r*)-*N*-((6-methylisoquinolin-5-yl)methyl)-3-((6-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutan-1-amine, HCl (40 mg, 34%). MS (ESI+) [Method 6A]: *m/z* 388.3 (M+H); Rt 1.24 min. ¹H NMR (400 MHz, CD₃OD) δ 9.76 (s, 1H), 8.71 (s, 2H), 8.51 (d, *J* = 8.4 Hz, 1H), 8.34 (d, *J* = 2.8 Hz, 1H), 8.02 (d, *J* = 8.8 Hz, 1H), 7.78 (d, *J* = 8.4 Hz, 1H), 7.48 – 7.46 (m, 1H), 5.21 – 5.17 (m, 1H), 4.85 (s, 2H), 4.43 – 4.39 (m, 1H), 3.02 – 2.97 (m, 2H), 2.88 (s, 3H), 2.81 – 2.77 (m, 2H).


Example 3: Synthesis of (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl

Step 3.1: Synthesis of 6-fluoroisoquinoline-5-carbaldehyde




To the solution of 6-fluoroisoquinoline [CAS No. 1075-11-2] (0.4 g, 2.72 mmol) in anhydrous THF (10 mL), LDA (2M in THF) (2.04 mL, 4.08 mmol) was added dropwise at -78 °C and stirred for 2.5 h under N₂ atmosphere. Piperidine-1-carbaldehyde [CAS No. 2591-86-8] (0.92 g, 8.15 mmol) dissolved in THF (5 mL) was added dropwise at -78 °C over a period of 0.5 h and stirred for 1 h, while temperature was raised slowly to 0 °C. Then the reaction was quenched with saturated NH₄Cl solution and extracted with EtOAc twice. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo* to yield the crude product. The crude was purified by flash chromatography (12 g SiliCycle column, 0 – 20% EtOAc in Hexane elution) to provide 6-fluoroisoquinoline-5-carbaldehyde (0.17 g, 35%). MS (ESI+) [Method 6A]: *m/z* 175.9 (M+H); Rt 0.86 min.

Step 3.2: Synthesis of (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl




- (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl was prepared in a similar manner as described in Step 1.4, using (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl (Step 1.3, 200 mg, 0.70 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (111 mg, 0.63 mmol). The residue was purified by prep-
 5 HPLC (Column: LUNA Phenomenex (150 mm x 21.2 mm), 5.0 μ ; Mobile Phase: 0.1% HCO₂H in water and acetonitrile) to afford the product. To the isolated product, HCl solution (4M in 1,4-dioxane) (4 mL) was added at 10 °C, stirred at rt for 2 h, concentrated in *vacuo*, then lyophilized to afford (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl (139 mg, 44%). MS (ESI+) [Method 6A]: *m/z* 409.1 (M+H);
 10 Rt 1.31 min. ¹H NMR (400 MHz, CD₃OD) δ 9.90 (s, 1H), 8.87 – 8.85 (m, 1H), 8.81 – 8.77 (m, 2H), 8.02 (t, *J* = 9.2 Hz, 1H), 7.28 (t, *J* = 9.6 Hz, 1H), 7.15 – 7.09 (m, 2H), 5.09 – 5.05 (m, 1H), 4.84 (s, 2H), 4.31 – 4.27 (m, 1H), 2.97 – 2.90 (m, 2H), 2.73 – 2.68 (m, 2H).

- Example 4: Synthesis of 3-fluoro-6-((1*r*,3*r*)-3-(((6-fluoroisoquinolin-5-yl)methyl)amino)cyclobutoxy)-2-(trifluoromethyl)aniline, HCl and 5-fluoro-2-((1*r*,3*r*)-3-(((6-fluoroisoquinolin-5-yl)methyl)amino)cyclobutoxy)-4-(trifluoromethyl)aniline, HCl**
 15 **Step 4.1: Synthesis of (1*r*,3*r*)-3-(4-fluoro-2-nitro-3-(trifluoromethyl)phenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine**



- To a round bottom flask, charged with concentrated H₂SO₄ (2 mL), KNO₃ (68 mg, 0.68 mmol)
 20 was added at 0 °C. Then (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine (Step 3.2, 230 mg, 0.56 mmol), dissolved in H₂SO₄ (2 mL), was added dropwise at 0 °C and stirred at rt for 16 h. Reaction mixture was poured dropwise onto ice, basified with aqueous NH₄OH (30%) and extracted 3x with EtOAc. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in
 25 *vacuo* to afford mixture of (1*r*,3*r*)-3-(4-fluoro-2-nitro-3-(trifluoromethyl)phenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine and (1*r*,3*r*)-3-(4-fluoro-2-nitro-5-(trifluoromethyl)phenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine (200 mg crude). MS (ESI+) [Method 6A]: *m/z* 454.1 (M+H); Rt 1.32 min.


- Step 4.2: Synthesis of 5-fluoro-2-((1*r*,3*r*)-3-(((6-fluoroisoquinolin-5-yl)methyl)amino)cyclobutoxy)-4-(trifluoromethyl)aniline, HCl**
 30 **4-(trifluoromethyl)aniline, HCl**




To the solution of (1*r*,3*r*)-3-(4-fluoro-2-nitro-5-(trifluoromethyl)phenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine and (1*r*,3*r*)-3-(4-fluoro-2-nitro-3-(trifluoromethyl)phenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine (200 mg, 0.44 mmol) in AcOH (2 mL), Zn-dust
 5 (50 mg, 0.75 mmol) was added at 0 °C and stirred at rt for 4 h. The reaction mixture was basified with 2N NaOH solution and extracted 3x with EtOAc. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by prep-HPLC (Column: XBRIDGE (150 mm x 21.20 mm), 5.0 μ; Mobile Phase: 0.02% NH₄OH in water and acetonitrile) to afford the products, 5-fluoro-2-((1*r*,3*r*)-3-(((6-fluoroisoquinolin-5-yl)methyl)amino)cyclobutoxy)-4-(trifluoromethyl)aniline and 3-fluoro-6-
 10 ((1*r*,3*r*)-3-(((6-fluoroisoquinolin-5-yl)methyl)amino)cyclobutoxy)-2-(trifluoromethyl)aniline. To the isolated products, HCl solution (4M in 1,4-dioxane) (2 mL) was added at 10 °C, stirred at rt for 2 h, concentrated, the residue was washed with Et₂O - Pentane and in *vacuo* to afford the HCl salts. 3-fluoro-6-((1*r*,3*r*)-3-(((6-fluoroisoquinolin-5-yl)methyl)amino)cyclobutoxy)-2-
 15 (trifluoromethyl)aniline, HCl (15 mg, 7%): R_f 11.684 min (Column: WATERS XBRIDGE C18 (150 mm x 4.6 mm) 5.0 μ; Mobile phase: 0.05% NH₄OH in water and acetonitrile). MS (ESI+) [Method 6A]: m/z 424.2 (M+H); R_t 1.31 min. ¹H NMR (400 MHz, CD₃OD) δ 9.92 (s, 1H), 8.92 – 8.90 (m, 1H), 8.83 – 8.78 (m, 2H), 8.04 (t, J = 9.2 Hz, 1H), 6.95 – 6.92 (m, 2H), 5.15 – 5.12 (m, 1H), 4.85 (s, 2H), 4.37 – 4.41 (m, 1H), 2.95 – 2.92 (m, 2H), 2.79 – 2.76 (m, 2H).

20 **Example 5: Synthesis of (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl**


Step 5.1: Synthesis of 8-nitro-5-vinylisoquinoline




The stirred solution of 5-bromo-8-nitroisoquinoline [CAS No. 63927-23-1] (0.50 g, 1.98 mmol)
 25 and tributyl(vinyl)stannane (0.72 g, 2.37 mmol) in toluene (10 mL) was degassed with argon for 10 min. Then Pd(PPh₃)₂Cl₂ (0.13 g, 0.19 mmol) was added, degassed and heated at 100°C for 13 h under argon atmosphere. Reaction mixture was cooled to rt, filtered through a celite bed and the bed was washed with EtOAc. The combined filtrate was washed with water, brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash
 30 chromatography (12 g SiliCycle column, 0 – 20% EtOAc in Hexane elution) to provide 8-nitro-5-vinylisoquinoline (0.10 g, 25%). MS (ESI+) [Method 6A]: m/z 201.0 (M+H); R_t 1.47 min.

Step 5.2: Synthesis of 8-nitroisoquinoline-5-carbaldehyde

To the solution of 8-nitro-5-vinylisoquinoline (0.15 g, 0.75 mmol) in *t*-BuOH – 1,4-dioxane (15 mL, 1:2 v/v), OsO₄ (6 mg, 0.02 mmol) was added at rt and stirred for 15 min. Then NaIO₄ (0.8 g, 3.76 mmol) dissolved in water (3 mL) was added dropwise and stirred at rt for 16 h. Reaction mixture was diluted with water and extracted with EtOAc twice. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 25% EtOAc in Hexane elution) to provide 8-nitroisoquinoline-5-carbaldehyde (60 mg, 40%). MS (ESI+) [Method 6A]: *m/z* 202.9 (M+H); Rt 0.40 min.

Step 5.3: Synthesis of (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-*N*-((8-nitroisoquinolin-5-yl)methyl)cyclobutan-1-amine

The title compound was synthesized following the procedure as described in step 1.4, using (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl (Step 1.3, 85 mg, 0.30 mmol) and 8-nitroisoquinoline-5-carbaldehyde (54 mg, 0.27 mmol). MS (ESI+) [Method 1A]: *m/z* 435.6 (M+H); Rt 0.45 min.


Step 5.4: Synthesis of 5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-amine, HCl [C-07482-074]

To the solution of (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-*N*-((8-nitroisoquinolin-5-yl)methyl)cyclobutan-1-amine (70 mg, 0.16 mmol) in AcOH (5 mL), was added Zn dust (53 mg,

0.80 mmol) at rt and stirred for 2 h. The reaction mixture was filtered through celite bed, bed was washed with AcOH. The combined filtrate was concentrated in *vacuo*. The residue was basified with saturated NaHCO₃ solution and extracted with CH₂Cl₂ twice. The combined organic portion was washed with brine solution, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by prep-HPLC (Column: GEMINI-NX-C18 (150 mm x 21.20 mm), 5.0 μ ; Mobile Phase: 0.01% NH₄OH in water and acetonitrile – MeOH (1:1)). To the isolated product, HCl solution (4M in 1,4-dioxane) (1 mL) was added at 10 °C, stirred at rt for 1 h, concentrated in *vacuo*, triturated with Et₂O-Pentane, collected solid was dried to provide 5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-amine, HCl (8 mg, 11%). MS (ESI+) [Method 6A]: m/z 406.3 (M+H); Rt 1.29 min. ¹H NMR (400 MHz, CD₃OD) δ 9.73 (s, 1H), 8.43 (d, *J* = 7.2 Hz, 1H), 8.33 (d, *J* = 7.2 Hz, 1H), 8.00 (d, *J* = 8.4 Hz, 1H), 7.28 (d, *J* = 7.2 Hz, 1H), 7.12 – 7.08 (m, 3H), 5.02 – 4.98 (m, 1H), 4.55 (s, 2H), 4.20 – 4.18 (m, 1H), 2.86 – 2.80 (m, 2H), 2.67 – 2.61 (m, 2H).


Example 6: Synthesis of (6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)methanol, HCl (or *trans*-(6-fluoro-5-(((3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)methanol)

Step 6.1: Synthesis of 1-(2-bromo-4-fluorophenyl)-N-(2,2-dimethoxyethyl)methanimine



A two necked round bottom flask, fitted with Dean Stark apparatus, was charged with 2-bromo-4-fluorobenzaldehyde [CAS No. 59142-68-6] (250.0 g, 1231.47 mmol), 2,2-dimethoxyethan-1-amine (268 mL, 2459.77 mmol) and toluene (1000 mL). The reaction mixture was stirred at 130 °C for 16 h, during azeotropic removal of H₂O. Then the reaction mixture was concentrated in *vacuo* to afford crude 1-(2-bromo-4-fluorophenyl)-N-(2,2-dimethoxyethyl)methanimine. ¹H NMR (300 MHz, CDCl₃) δ 8.58 (s, 1H), 8.04 (dd, *J* = 8.7, 6.3 Hz, 1H), 7.30 (dd, *J* = 8.1, 2.4 Hz, 1H), 7.05 (td, *J* = 8.7, 2.4 Hz, 1H), 4.68 (t, *J* = 5.4 Hz, 1H), 3.81 (d, *J* = 5.4 Hz, 1H), 3.42 (s, 6H).


Step 6.2: Synthesis of N-(2-bromo-4-fluorobenzyl)-2,2-dimethoxyethan-1-amine



To the stirred solution of 1-(2-bromo-4-fluorophenyl)-N-(2,2-dimethoxyethyl)methanimine (404.0 g, 1392.4 mmol) in MeOH (2000 mL), NaBH₄ (105.3 g, 2784.9 mmol) was added portion wise at 0 °C. The reaction mixture was stirred at rt for 16 h. Then the reaction mixture was concentrated in *vacuo*, residue was diluted with water and extracted 3x with EtOAc. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo* to afford crude N-(2-bromo-4-fluorobenzyl)-2,2-dimethoxyethan-1-amine (378.0 g, 92%). MS (ESI+) [Method 6A]: m/z 292.1 (M+H); Rt 1.25 min. ¹H NMR (400 MHz, CDCl₃) δ 7.36 (dd, *J*


= 8.4, 2.0 Hz, 1H), 7.27 (dd, J = 8.4, 2.8 Hz, 1H), 7.01 – 6.98 (m, 1H), 4.48 (t, J = 5.6 Hz, 1H), 3.84 (s, 2H), 3.36 (s, 6H), 2.72 (d, J = 5.2 Hz, 2H).

Step 6.3: Synthesis of N-(2-bromo-4-fluorobenzyl)-N-(2,2-dimethoxyethyl)-4-methylbenzenesulfonamide




To the solution of N-(2-bromo-4-fluorobenzyl)-2,2-dimethoxyethan-1-amine (378.0 g, 1293.8 mmol), TEA (541 mL, 1940.7 mmol) and DMAP (15.8 g, 129.4 mmol) in CH_2Cl_2 (2000 mL), *p*-TsCl was added portion wise at 0 °C, and the reaction mixture was stirred at rt for 16 h. Then the reaction mixture was diluted with water and extracted with CH_2Cl_2 twice. The combined organic portion was washed with brine, dried over anhydrous Na_2SO_4 , filtered and concentrated in *vacuo*. The residue was purified by column chromatography (Silica-gel 60-120 mesh size, 0 – 30% EtOAc in Hexane elution) to provide N-(2-bromo-4-fluorobenzyl)-N-(2,2-dimethoxyethyl)-4-methylbenzenesulfonamide (568 g, 98%). MS (ESI+) [Method 6A]: m/z 414.0 (M+H); Rt 1.67 min. ^1H NMR (600 MHz, CDCl_3) δ 7.72 (d, J = 8.4 Hz, 2H), 7.50 (dd, J = 9.0, 6.0 Hz, 1H), 7.33 (d, J = 8.4 Hz, 2H), 7.26 – 7.24 (m, 1H), 7.03 (td, J = 9.0, 3.0 Hz, 1H), 4.48 (s, 2H), 4.36 (t, J = 5.4, 1H), 3.29 (d, J = 5.4 Hz, 2H), 3.23 (s, 6H), 2.45 (s, 3H),

Step 6.4: Synthesis of 8-bromo-6-fluoroisoquinoline




To the stirred solution of AlCl_3 (836.0 g, 6269.68 mmol) in anhydrous CH_2Cl_2 (2200 mL), N-(2-bromo-4-fluorobenzyl)-N-(2,2-dimethoxyethyl)-4-methylbenzenesulfonamide (560.0 g, 1254.68 mmol) dissolved in CH_2Cl_2 (800 mL) was added dropwise at -10 °C. Then the reaction mixture was stirred at rt for 16 h under N_2 . The reaction mixture was poured onto ice, basified with 30% NaOH solution. The solid formed was filtered through a celite bed, and the bed was washed with CH_2Cl_2 . The organic portion was separated and the aqueous layer was extracted with CH_2Cl_2 twice. The combined organic layer was washed with brine, anhydrous Na_2SO_4 , filtered and concentrated in *vacuo* to afford crude 8-bromo-6-fluoroisoquinoline (300 g, 106%). MS (ESI+) [Method 6A]: m/z 226.0, 228.0 (M+H); Rt 1.41 min. ^1H NMR (600 MHz, CDCl_3) δ 9.56 (s, 1H), 8.60 (d, J = 6.0 Hz, 1H), 7.66 (dd, J = 7.8, 1.6 Hz, 1H), 7.59 (d, J = 6.0 Hz, 1H), 7.42 (dd, J = 8.4, 1.8 Hz, 1H).

Step 6.5: Synthesis of 6-fluoro-8-vinylisoquinoline




The stirred solution of 8-bromo-6-fluoroisoquinoline [CAS No. 1258833-77-0] (25.0 g, 110.5 mmol), potassium trifluoro(vinyl)borate (29.6 g, 221.1 mmol) and TEA (61.6 mL, 442.3 mmol) in IPA (400 mL), was degassed with N₂ for 10 min. Then Pd(dppf)Cl₂.CH₂Cl₂ (9.03 g, 11.05 mmol) was added, degassed and heated at 100°C for 2 h under N₂ atmosphere. Reaction mixture was cooled to rt, diluted with water and extracted with EtOAc twice. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo* to yield the crude product. The crude was purified by flash chromatography (80 g SiliCycle column, 0 – 20% EtOAc in Hexane elution) to provide 6-fluoro-8-vinylisoquinoline (15.0 g, 78%). MS (ESI+) [Method 8]: m/z 174.1 (M+H); Rt 1.186 min.

10 Step 6.6: Synthesis of 6-fluoroisoquinoline-8-carbaldehyde




The title compound was prepared according to the procedure in Step 5.2. The residue was purified by flash chromatography (80 g SiliCycle column, 0 – 25% EtOAc in Hexane elution) to provide 6-fluoroisoquinoline-8-carbaldehyde (11.0 g, 72%). MS (ESI+) [Method 1A]: m/z 176.1 (M+H); Rt 0.17 min.

Step 6.7: Synthesis of (6-fluoroisoquinolin-8-yl)methanol



To the stirred solution of 6-fluoroisoquinoline-8-carbaldehyde (11.0 g, 62.79 mmol) in MeOH (220 mL), NaBH₄ (3.56 g, 94.19 mmol) was added portion wise at 0 °C. The reaction mixture was stirred at 0 °C for 1 h. Then the reaction mixture was concentrated in *vacuo*, residue was diluted with water and extracted with EtOAc twice. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo* to afford crude (6-fluoroisoquinolin-8-yl)methanol (11.0 g, 99%). MS (ESI+) [Method 1A]: m/z 178.2 (M+H); Rt 0.12 min.


25 Step 6.8: Synthesis of 8-(((tert)-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinoline



To the stirred solution of (6-fluoroisoquinolin-8-yl)methanol (11.0 g, 62.08 mmol) and imidazole (21.1 g, 309.98 mmol) in DMF (110 mL), TBDMS-Cl (28.0 g, 185.77 mmol) was added portion wise at 0 °C. The reaction mixture was stirred at rt for 16 h. Then the reaction mixture was diluted with water and extracted with CH₂Cl₂ twice. The combined organic portion was washed


with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (80 g SiliCycle column, 0 – 15% EtOAc in Hexane elution) to afford 8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinoline (11.0 g, 61%). MS (ESI+) [Method 1A]: m/z 292.2 (M+H); Rt 1.78 min.

5 Step 6.9: Synthesis of 8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinoline-5-carbaldehyde




To the stirred solution of 8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinoline (5.0 g, 17.16 mmol) in anhydrous THF (50 mL), LDA (2M in THF) (25.7 mL, 51.46 mmol) was added dropwise at -78 °C under N₂ atmosphere. After 2.5 h, ethyl formate (6.35 g, 85.78 mmol) dissolved in THF (25 mL) was added dropwise at -78 °C, and stirred for another 1 h. The reaction was quenched with saturated NH₄Cl solution and extracted with EtOAc twice. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (40 g SiliCycle column, 0 – 10% EtOAc in Hexane elution) to provide 8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinoline-5-carbaldehyde (3.4 g, 62%). MS (ESI+) [Method 4A]: m/z 320.2 (M+H); Rt 2.30 min.

Step 6.10: Synthesis of (1*r*,3*r*)-N-((8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinolin-5-yl)methyl)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine



20 The title compound was synthesized following the procedure as described in step 1.4, using (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl (Step 1.3, 500 mg, 1.75 mmol) and 8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinoline-5-carbaldehyde (830 mg, 2.63 mmol). The crude was purified by flash chromatography (12 g SiliCycle column, 0 – 25% EtOAc in Hexane elution) to provide (1*r*,3*r*)-N-((8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinolin-5-yl)methyl)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine (920 mg, 95%). MS (ESI+) [Method 6A]: m/z 553.4 (M+H); Rt 1.42 min.


Step 6.11: Synthesis of (6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)methanol, HCl



To the solution of (1*r*,3*r*)-*N*-((8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinolin-5-yl)methyl)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine (920 mg, 1.66 mmol) in THF (15 mL), TBAF solution (1M in THF) (1.6 mL, 1.66 mmol) was added dropwise as 0 °C and stirred for 1 h. Reaction mixture was diluted with water and extracted with EtOAc twice. The combined organic portion was washed with brine solution, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by prep-HPLC (Column: EPIC (150 mm x 21.2 mm), 5.0 μ; Mobile Phase: 0.02% NH₄OH in water and acetonitrile). To the isolated product, HCl solution (4M in 1,4-dioxane) (4 mL) was added at 10 °C, stirred at rt for 2 h, concentrated in *vacuo*, triturated with Et₂O-Pentane, collected solid was dried to provide (6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)methanol, HCl (260 mg, 35%). MS (ESI+) [Method 6A]: *m/z* 439.2 (M+H); Rt 1.30 min. ¹H NMR (400 MHz, CD₃OD) δ 9.96 (s, 1H), 8.84 (d, *J* = 7.2 Hz, 1H), 8.79 (d, *J* = 7.2 Hz, 1H), 8.04 (d, *J* = 10.4 Hz, 1H), 7.29 (t, *J* = 9.6 Hz, 1H), 7.15 – 7.09 (m, 2H), 5.31 (s, 2H), 5.07 – 5.04 (m, 1H), 4.81 (d, *J* = 1.2 Hz, 2H), 4.31 – 4.26 (m, 1H), 2.95 – 2.88 (m, 2H), 2.74 – 2.67 (m, 2H).

Example 7: Synthesis of (S)-1-(6-fluoro-5-(((1*r*,3*S*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethane-1,2-diol (or *trans*-(S)-1-(6-fluoro-5-(((3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethane-1,2-diol) and (R)-1-(6-fluoro-5-(((1*r*,3*R*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethane-1,2-diol (or *trans*-(R)-1-(6-fluoro-5-(((3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethane-1,2-diol)


Step 7.1: Synthesis of 6-fluoro-8-(oxiran-2-yl)isoquinoline



To the solution of NaH (1.0 g, 41.45 mmol) and anhydrous DMSO (40 mL), trimethylsulfoxonium iodide (8.3 g, 37.68 mmol) was added at rt and stirred for 30 min. Then 6-fluoroisoquinoline-8-


carbaldehyde (Step 6.5, 3.3 g, 18.84 mmol), dissolved in DMSO (20 mL), was added dropwise at rt. After 5 min, the reaction was quenched with ice-water and extracted with EtOAc 3x's. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 20% EtOAc in Hexane elution) to provide 6-fluoro-8-(oxiran-2-yl)isoquinoline (2.3 g, 64%). MS (ESI+) [Method 6A]: m/z 190.1 (M+H); Rt 0.79 min. ¹H NMR (600 MHz, CDCl₃) δ 9.55 (s, 1H), 8.58 (d, *J* = 5.4 Hz, 1H), 7.65 (d, *J* = 5.4 Hz, 1H), 7.37 (d, *J* = 9.0 Hz, 2H), 4.60 – 4.59 (m, 1H), 3.37 – 3.35 (m, 1H), 2.82 – 2.80 (m, 1H).

Step 7.2: Synthesis of 1-(6-fluoroisoquinolin-8-yl)ethane-1,2-diol



To the solution of 6-fluoro-8-(oxiran-2-yl)isoquinoline (2.1 g, 11.11 mmol) in THF – H₂O (12 mL, 2:1 v/v), H₂SO₄ (5 mL) was added dropwise at rt and stirred at 60 °C for 16 h. The reaction mixture was basified with saturated NaHCO₃ solution and extracted with EtOAc twice. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 5% MeOH in CH₂Cl₂ elution) to provide 1-(6-fluoroisoquinolin-8-yl)ethane-1,2-diol (1.6 g, 69%). MS (ESI+) [Method 4A]: m/z 208.3 (M+H); Rt 0.40 min. ¹H NMR (600 MHz, CDCl₃) δ 9.49 (s, 1H), 8.49 (d, *J* = 6.0 Hz, 1H), 7.67 – 7.63 (m, 2H), 7.35 (dd, *J* = 8.4, 1.8 Hz, 1H), 4.13 – 4.10 (m, 1H), 4.06 (dd, *J* = 12.6, 3.6 Hz, 1H), 3.76 (dd, *J* = 11.4, 3.6 Hz, 1H).


Step 7.3: Synthesis of 6-fluoro-8-(2,2,3,3,8,8,9,9-octamethyl-4,7-dioxo-3,8-disiladecan-5-yl)isoquinoline



To the solution of 1-(6-fluoroisoquinolin-8-yl)ethane-1,2-diol (1.5 g, 7.24 mmol) and imidazole (3.4 g, 50.68 mmol) in DMF (15 mL), TBDMS-Cl (5.4 g, 36.17 mmol) was added portion wise at 0 °C and stirred at rt for 16 h. Then the reaction mixture was diluted with water and extracted 3x with EtOAc. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 10% EtOAc in Hexane elution) to afford 6-fluoro-8-(2,2,3,3,8,8,9,9-octamethyl-4,7-dioxo-3,8-disiladecan-5-yl)isoquinoline (2.7 g, 85%). MS (ESI+) [Method 6A]: m/z 436.3 (M+H); Rt 2.15 min. ¹H NMR (600 MHz, CDCl₃) δ 9.59 (s, 1H), 8.52 (d, *J* = 4.8 Hz, 1H), 7.61 (d, *J* = 5.4 Hz, 1H), 7.55 (dd, *J* = 10.2, 1.8 Hz, 1H), 7.33 (dd, *J* = 9.0, 2.4 Hz, 1H), 5.54

(d, $J = 6.0$ Hz, 1H), 3.87 – 3.85 (m, 1H), 3.77 – 3.74 (m, 1H), 0.92 (s, 9H), 0.90 (s, 9H), 0.13 (s, 6H), 0.09 (s, 6H).

Step 7.4: Synthesis of 6-fluoro-8-(2,2,3,3,8,8,9,9-octamethyl-4,7-dioxa-3,8-disiladecan-5-yl)isoquinoline-5-carbaldehyde




5

The title compound was prepared according to the procedure in Step 6.8. The residue was purified by flash chromatography (40 g SiliCycle column, 0 – 15% EtOAc in Hexane elution) to provide 6-fluoro-8-(2,2,3,3,8,8,9,9-octamethyl-4,7-dioxa-3,8-disiladecan-5-yl)isoquinoline-5-carbaldehyde (2.0 g, 62%). MS (ESI+) [Method 4A]: m/z 464.4 (M+H); Rt 1.77 min. ^1H NMR (600 MHz, CDCl_3) δ 9.57 (s, 1H), 8.50 (d, $J = 5.4$ Hz, 1H), 7.60 (d, $J = 5.4$ Hz, 1H), 7.54 (dd, $J = 7.8, 2.4$ Hz, 1H), 7.32 (dd, $J = 9.0, 2.4$ Hz, 1H), 5.53 (d, $J = 6.0$ Hz, 1H), 3.87 – 3.84 (m, 1H), 3.76 – 3.73 (m, 1H), 0.89 (s, 9H), 0.75 (s, 9H), 0.12 (s, 6H), -0.05 (s, 6H).

10

Step 7.5: Synthesis of (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-N-((6-fluoro-8-(2,2,3,3,8,8,9,9-octamethyl-4,7-dioxa-3,8-disiladecan-5-yl)isoquinolin-5-yl)methyl)cyclobutan-1-amine

15




The title compound was synthesized following the procedure as described in step 1.4, using (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl (Step 1.3, 1.0 g, 3.50 mmol) and 6-fluoro-8-(2,2,3,3,8,8,9,9-octamethyl-4,7-dioxa-3,8-disiladecan-5-yl)isoquinoline-5-carbaldehyde (1.46 g, 3.15 mmol). The crude was purified by flash chromatography (24 g SiliCycle column, 0 – 5% MeOH in CHCl_3 elution) to provide (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-N-((6-fluoro-8-(2,2,3,3,8,8,9,9-octamethyl-4,7-dioxa-3,8-disiladecan-5-yl)isoquinolin-5-yl)methyl)cyclobutan-1-amine (1.5 g, 62%). MS (ESI+) [Method 6A]: m/z 697.3 (M+H); Rt 1.63 min.

20

25

Step 7.6: Synthesis of (S)-1-(6-fluoro-5-(((1*r*,3*S*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethane-1,2-diol

and (R)-1-(6-fluoro-5-(((1*r*,3*R*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethane-1,2-diol



To the solution (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-N-((6-fluoro-8-(2,2,3,3,8,8,9,9-octamethyl-4,7-dioxa-3,8-disiladecan-5-yl)isoquinolin-5-yl)methyl)cyclobutan-1-amine_ (1.5 g, 2.15 mmol) in THF (25 mL), TBAF solution (1M in THF) (5.4 mL, 5.38 mmol) was added dropwise as 0 °C and stirred for 2 h. Reaction mixture was diluted with water and extracted with EtOAc twice. The combined organic portion was washed with a brine solution, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (24 g SiliCycle column, 0 – 10% MeOH in CH₂Cl₂ elution) to afford 1-(6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethane-1,2-diol (1.0 g, 98%). MS (ESI+) [Method 6A]: *m/z* 469.2 (M+H); Rt 1.29 min. ¹H NMR (400 MHz, CD₃OD) δ 9.57 (s, 1H), 8.52 (d, *J* = 6.0 Hz, 1H), 8.12 (d, *J* = 5.6 Hz, 1H), 7.67 (d, *J* = 10.6 Hz, 1H), 7.22 (t, *J* = 9.6 Hz, 1H), 7.05 – 7.01 (m, 2H), 5.58 – 5.56 (m, 1H), 4.85 – 4.82 (m, 1H), 4.17 (d, *J* = 1.6 Hz, 2H), 3.86 – 3.82 (m, 1H), 3.78 – 3.74 (m, 1H), 3.60 – 3.57 (m, 1H), 2.36 – 2.33 (m, 4H).


Chiral prep-HPLC (Column: CHIRALPAK IG (250 mm x 20 mm); Mobile Phase: Hexane and IPA : MeOH (1:1); Isocratic: 60/40; Flow: 15 mL/min) of the racemate provided (S)-1-(6-fluoro-5-(((1*r*,3*S*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethane-1,2-diol as a white solid Peak 1 (395 mg, 40%): Chiral HPLC: 99% (Rf 7.840 min; Column: CHIRALPAK-IG (150 mm x 4.6 mm), 5.0 μ; Mobile phase: *n*-Hexane and EtOH; Isocratic : 80/20; Flow: 1 mL/min). MS (ESI+) [Method 1A]: *m/z* 469.2 (M+H); Rt 1.29 min. ¹H NMR (400 MHz, CD₃OD) δ 9.57 (s, 1H), 8.53 (d, *J* = 6.0 Hz, 1H), 8.13 (d, *J* = 5.6 Hz, 1H), 7.68 (d, *J* = 10.6 Hz, 1H), 7.23 (t, *J* = 9.6 Hz, 1H), 7.06 – 7.01 (m, 2H), 5.59 – 5.56 (m, 1H), 4.85 – 4.82 (m, 1H), 4.19 (s, 2H), 3.87 – 3.83 (m, 1H), 3.78 – 3.74 (m, 1H), 3.60 – 3.57 (m, 1H), 2.37 – 2.34 (m, 4H); and (R)-1-(6-fluoro-5-(((1*r*,3*R*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethane-1,2-diol as a white solid Peak 2 (345 mg, 35%) Chiral HPLC: 97% (Rf 17.481 min; Column: CHIRALPAK-IG (150 mm x 4.6 mm), 5.0 μ; Mobile phase: *n*-Hexane and EtOH; Isocratic : 80/20; Flow: 1 mL/min). MS (ESI+) [Method 3A]: *m/z* 469.0 (M+H); Rt 1.25 min. ¹H NMR (400 MHz, CD₃OD) δ 9.57 (s,

1H), 8.53 (d, $J = 6.0$ Hz, 1H), 8.13 (d, $J = 5.6$ Hz, 1H), 7.68 (d, $J = 10.6$ Hz, 1H), 7.23 (t, $J = 9.6$ Hz, 1H), 7.06 – 7.01 (m, 2H), 5.59 – 5.56 (m, 1H), 4.85 – 4.82 (m, 1H), 4.18 (d, $J = 1.2$ Hz, 2H), 3.87 – 3.83 (m, 1H), 3.78 – 3.74 (m, 1H), 3.60 – 3.57 (m, 1H), 2.37 – 2.34 (m, 4H).

Example 8: Synthesis of 1-(6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-


5 (trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethan-1-ol, HCl

Step 8.1: Synthesis of 1-(6-fluoroisoquinolin-8-yl)ethan-1-ol




To the stirred solution of 6-fluoroisoquinoline-8-carbaldehyde (Step 6.5, 0.7 g, 4.0 mmol) in anhydrous THF (10 mL), MeMgBr (3M in Et₂O) (4.0 mL, 11.98 mmol) was added dropwise at 0 °C under N₂ atmosphere. The reaction mixture was stirred at 0 °C for 2 h, before quenching with saturated NH₄Cl solution. Then the reaction mixture was extracted with EtOAc twice. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo* to provide 1-(6-fluoroisoquinolin-8-yl)ethan-1-ol (0.8 g crude). MS (ESI+) [Method 4B]: m/z 192.0 (M+H); Rt 0.20 min.

Step 8.2: Synthesis of 8-(1-((*tert*-butyldimethylsilyl)oxy)ethyl)-6-fluoroisoquinoline




The title compound was prepared according to Step 6.7. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 15% EtOAc in Hexane elution) to afford 8-(1-((*tert*-butyldimethylsilyl)oxy)ethyl)-6-fluoroisoquinoline (0.9 g, 70%). MS (ESI+) [Method 6A]: m/z 306.2 (M+H); Rt 1.72 min. ¹H NMR (300 MHz, CDCl₃) δ 9.49 (s, 1H), 8.51 (d, $J = 5.4$ Hz, 1H), 7.62 (d, $J = 4.5$ Hz, 1H), 7.55 (dd, $J = 10.5, 2.7$ Hz, 1H), 7.29 (dd, $J = 9.3, 2.7$ Hz, 1H), 5.66 – 5.62 (m, 1H), 1.60 (d, $J = 6.6$ Hz, 3H), 0.93 (s, 9H), 0.11 (s, 3H), 0.00 (s, 3H).

Step 8.3: Synthesis of 8-(1-((*tert*-butyldimethylsilyl)oxy)ethyl)-6-fluoroisoquinoline-5-carbaldehyde




The title compound was prepared according to Step 3.1 except that after addition of piperidine-1-carbaldehyde, the reaction mixture was stirred for a further 1 h at -78 °C. The residue was purified by flash chromatography (40 g SiliCycle column, 0 – 10% EtOAc in Hexane elution) to provide 8-(1-((*tert*-butyldimethylsilyl)oxy)ethyl)-6-fluoroisoquinoline-5-carbaldehyde (0.7 g, 71%). MS (ESI+) [Method 6A]: m/z 334.1 (M+H); Rt 1.79 min.

Step 8.4: Synthesis of (1*r*,3*r*)-*N*-((8-(1-((*tert*-butyldimethylsilyl)oxy)ethyl)-6-fluoroisoquinolin-5-yl)methyl)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine



The title compound was synthesized following the procedure as described in step 1.4, using
 5 (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl (Step 1.3, 0.3 g, 1.05 mmol) and 8-(1-((*tert*-butyldimethylsilyl)oxy)ethyl)-6-fluoroisoquinoline-5-carbaldehyde (0.42 g, 1.26 mmol). The crude product was purified by flash chromatography (12 g SiliCycle column, 0 – 5% MeOH in CHCl₃ elution) to provide (1*r*,3*r*)-*N*-((8-(1-((*tert*-butyldimethylsilyl)oxy)ethyl)-6-fluoroisoquinolin-5-yl)methyl)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine (0.5 g,
 10 84%). MS (ESI+) [Method 6A]: *m/z* 567.2 (M+H); Rt 1.49 min.

Step 8.5: Synthesis of 1-(6-fluoro-5-((((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethan-1-ol, HCl




To the solution of (1*r*,3*r*)-*N*-((8-(1-((*tert*-butyldimethylsilyl)oxy)ethyl)-6-fluoroisoquinolin-5-yl)methyl)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine (0.5 g, 0.88 mmol) in THF
 15 (10 mL), TBAF solution (1M in THF) (1.06 mL, 1.06 mmol) was added dropwise as 0 °C and stirred at rt for 2 h. Reaction mixture was diluted with water and extracted with EtOAc twice. The combined organic portion was washed with brine solution, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle
 20 column, 0 – 5% MeOH in CH₂Cl₂ elution) to provide 1-(6-fluoro-5-((((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethan-1-ol (0.4 g, quantitative). MS (ESI+) [Method 6A]: *m/z* 453.1 (M+H); Rt 1.33 min.

100 mg product was re-purified by prep-HPLC (Column: GEMINI NX (150 mm x 21.2 mm), 5.0 μ; Mobile Phase: 0.02% NH₄OH in water and acetonitrile); to the isolated product, HCl solution
 25 (4M in 1,4-dioxane) (2 mL) was added at 10 °C, stirred at rt for 1 h, concentrated in *vacuo*,

triturated with Et₂O, collected solid was dried in *vacuo* to provide 1-(6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethan-1-ol, HCl as white solid (33 mg, 33%). MS (ESI+) [Method 4A]: *m/z* 453.2 (M+H); Rt 1.47 min. ¹H NMR (400 MHz, CD₃OD) δ 10.20 (s, 1H), 8.90 (d, *J* = 6.8 Hz, 1H), 8.78 (d, *J* = 6.8 Hz, 1H), 8.06 (d, *J* = 10.8 Hz, 1H), 7.30 (t, *J* = 9.6 Hz, 1H), 7.15 – 7.09 (m, 2H), 5.73 – 5.70 (m, 1H), 5.09 – 5.05 (m, 1H), 4.82 (s, 2H), 4.31 – 4.27 (m, 1H), 2.97 – 2.90 (m, 2H), 2.73 – 2.67 (m, 2H), 1.68 (d, *J* = 6.8 Hz, 3H).


Example 9: Synthesis of 1-(6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)propane-1,3-diol, (S)-
1-(6-fluoro-5-(((1*r*,3*S*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)propane-1,3-diol and
(R)-1-(6-fluoro-5-(((1*r*,3*R*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)propane-1,3-diol

Step 9.1: Synthesis of ethyl 3-(6-fluoroisoquinolin-8-yl)-3-hydroxypropanoate




A two necked round bottom flask was charged with EtOAc (1.51 mL, 15.41 mmol) and anhydrous THF (25 mL). Then LDA (2M in Hexane) (8.6 mL, 17.12 mol) was added drop wise at -78 °C and stirred for 30 min under argon. Finally 6-fluoroisoquinoline-8-carbaldehyde (Step 6.5, 1.5 g, 8.56 mmol), dissolved in THF (5 mL) was added dropwise at -78 °C and stirred for 2.5 h. The reaction was quenched with saturated NH₄Cl solution and extracted with EtOAc 3x's. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (24 g SiliCycle column, 0 – 20% EtOAc in Hexane elution) to provide ethyl 3-(6-fluoroisoquinolin-8-yl)-3-hydroxypropanoate (2.0 g, 88%). MS (ESI+) [Method 6A]: *m/z* 264.1 (M+H); Rt 1.24 min.

Step 9.2: Synthesis of 1-(6-fluoroisoquinolin-8-yl)propane-1,3-diol




To the solution of ethyl 3-(6-fluoroisoquinolin-8-yl)-3-hydroxypropanoate (2.0 g, 7.59 mmol) in anhydrous THF (40 mL), DIBAL-H (1M in toluene) (19.0 mL, 18.99 mmol) was added drop wise at -78 °C and stirred for 1 h, before warming the reaction mixture to rt over 30 min. Then the reaction mixture was quenched with saturated NH₄Cl solution and extracted with EtOAc 3x's. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo* to provide crude 1-(6-fluoroisoquinolin-8-yl)propane-1,3-diol (1.8 g crude). MS (ESI+) [Method 6A]: *m/z* 222.1 (M+H); Rt 0.29 min.

Step 9.3: Synthesis of 6-fluoro-8-(2,2,3,3,9,9,10,10-octamethyl-4,8-dioxa-3,9-disilaundecan-5-yl)isoquinoline




- To the stirred solution of 1-(6-fluoroisoquinolin-8-yl)propane-1,3-diol (1.8 g, 8.14 mmol),
 5 imidazole (2.7 g, 40.68 mmol) and DMAP (0.5 g, 4.07 mmol) in anhydrous DMF (35 mL),
 TBDMS-Cl (3.6 g, 24.4 mmol) was added at 0 °C and stirred at rt for 16 h under N₂ atmosphere.
 The reaction was diluted with water and extracted with CH₂Cl₂ twice. The combined organic
 portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in
vacuo. The residue was purified by flash chromatography (24 g SiliCycle column, 0 – 10%
 10 EtOAc in Hexane elution) to provide 6-fluoro-8-(2,2,3,3,9,9,10,10-octamethyl-4,8-dioxa-3,9-
 disilaundecan-5-yl)isoquinoline (1.2 g, 30%). MS (ESI+) [Method 6A]: m/z 450.5 (M+H); Rt 2.44
 min.

Step 9.4: Synthesis of 6-fluoro-8-(2,2,3,3,9,9,10,10-octamethyl-4,8-dioxa-3,9-disilaundecan-5-yl)isoquinoline-5-carbaldehyde



- 15 The title compound was prepared according to the procedure in Step 6.8. The residue was
 purified by flash chromatography (24 g SiliCycle column, 0 – 15% EtOAc in Hexane elution) to
 provide 6-fluoro-8-(2,2,3,3,9,9,10,10-octamethyl-4,8-dioxa-3,9-disilaundecan-5-yl)isoquinoline-
 5-carbaldehyde (0.8 g, 75%). MS (ESI+) [Method 1A]: m/z 478.3 (M+H); Rt 2.41 min.

- 20 Step 9.5: Synthesis of (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-*N*-((6-fluoro-8-
 (2,2,3,3,9,9,10,10-octamethyl-4,8-dioxa-3,9-disilaundecan-5-yl)isoquinolin-5-
 yl)methyl)cyclobutan-1-amine



- The title compound was synthesized following the procedure as described in step 1.4, using
 25 (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl (Step 1.3, 0.4 g, 1.40
 mmol) and 6-fluoro-8-(2,2,3,3,9,9,10,10-octamethyl-4,8-dioxa-3,9-disilaundecan-5-

yl)isoquinoline-5-carbaldehyde (0.8 g, 1.68 mmol). The crude was purified by flash chromatography (24 g SiliCycle column, 0 – 5% MeOH in CH₂Cl₂ elution) to provide (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-*N*-((6-fluoro-8-(2,2,3,3,9,9,10,10-octamethyl-4,8-dioxo-3,9-disilaundecan-5-yl)isoquinolin-5-yl)methyl)cyclobutan-1-amine (0.97 g, 97%). MS (ESI+)

5 [Method 6A]: *m/z* 711.3 (M+H); *Rt* 1.64 min.

Step 9.6: Synthesis of 1-(6-fluoro-5-((((1*r*,3*r*)-3-(4-fluoro-3-


(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)propane-1,3-diol, (S)-1-(6-

fluoro-5-((((1*r*,3*S*)-3-(4-fluoro-3-

(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)propane-1,3-diol and

10 (R)-1-(6-fluoro-5-((((1*r*,3*R*)-3-(4-fluoro-3-

(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)propane-1,3-diol



The title compound was prepared according to the procedure in Step 7.6. Prep-HPLC (Column: WATERS X BRIDGE C18 (150 mm x 19.0 mm), 5.0 μ; Mobile Phase: 0.02% NH₄OH in water

15 and acetonitrile) of the residue provided 1-(6-fluoro-5-((((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)propane-1,3-diol (335 mg, 51%). MS (ESI+) [Method 6A]: *m/z* 483.2 (M+H); *Rt* 1.30 min. ¹H NMR (400 MHz, CD₃OD) δ 9.64 (s, 1H), 8.59 (d, *J* = 6.0 Hz, 1H), 8.13 (d, *J* = 6.0 Hz, 1H), 7.72 (d, *J* = 11.6 Hz, 1H), 7.25 (t, *J* = 9.2 Hz, 1H), 7.10 – 7.04 (m, 2H), 5.76 (dd, *J* = 8.8, 2.8 Hz, 1H), 4.92 – 4.89 (m, 1H), 4.17 (s, 2H), 3.92 – 3.86 (m, 2H), 3.75 – 3.70 (m, 1H), 2.56 – 2.47 (m, 4H), 2.10 – 2.05 (m, 1H), 2.02 – 1.95 (m, 1H).

Chiral prep-HPLC (Column: LUX AMYLOSE-1 (250 mm x 21.2 mm); Mobile Phase: Hexane and EtOH : MeOH (1:1); Isocratic: 75/25; Flow: 15 mL/min) of the racemate (300 mg) provided (S)-1-(6-fluoro-5-((((1*r*,3*S*)-3-(4-fluoro-3-

25 (trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)propane-1,3-diol and (R)-1-(6-fluoro-5-((((1*r*,3*R*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)propane-1,3-diol as white solids (Peak 1: 130 mg, 43% and Peak 2: 130 mg, 43%). Peak 1: Chiral HPLC: 98% (*Rf* 2.508 min; Column: LUX, AMYLOSE-1 (150 mm x 4.6 mm), 5.0 μ; Mobile phase: *n*-Hexane and 0.1% DEA in EtOH : MeOH (70:30); Isocratic: 50/50; Flow: 1 mL/min). MS (ESI+) [Method 5A]: *m/z* 483.2 (M+H); *Rt* 0.97 min. ¹H NMR (400 MHz, CD₃OD) δ 9.59 (s, 1H), 8.53 (d, *J* = 5.6 Hz, 1H), 8.12 (d, *J* = 5.6 Hz, 1H), 7.65 (d, *J* = 11.2 Hz, 1H), 7.22 (t, *J* = 9.2 Hz, 1H), 7.06 – 7.01 (m, 2H), 5.73 (dd, *J* = 8.8, 3.2 Hz, 1H), 4.85 – 4.82 (m, 1H), 4.17 (d,


$J = 1.6$ Hz, 2H), 3.91 – 3.85 (m, 1H), 3.74 – 3.69 (m, 1H), 3.61 – 3.57 (m, 1H), 2.45–2.35 (m, 4H), 2.10 – 2.04 (m, 1H), 2.02 – 1.95 (m, 1H).

Peak 2: Chiral HPLC: 99% (R_f 3.035 min; Column: LUX, AMYLOSE-1 (150 mm x 4.6 mm), 5.0 μ ; Mobile phase: *n*-Hexane and 0.1% DEA in EtOH : MeOH (70:30); Isocratic: 50/50; Flow: 1

5 mL/min). MS (ESI+) [Method 6A]: m/z 483.2 (M+H); Rt 1.32 min. ¹H NMR (400 MHz, CD₃OD) δ 9.59 (s, 1H), 8.53 (d, $J = 6.0$ Hz, 1H), 8.12 (d, $J = 6.0$ Hz, 1H), 7.65 (d, $J = 11.6$ Hz, 1H), 7.22 (t, $J = 10.0$ Hz, 1H), 7.06 – 7.01 (m, 2H), 5.73 (dd, $J = 8.8, 3.6$ Hz, 1H), 4.85 – 4.82 (m, 1H), 4.17 (d, $J = 2.0$ Hz, 2H), 3.91 – 3.85 (m, 1H), 3.74 – 3.69 (m, 1H), 3.61 – 3.58 (m, 1H), 2.36 – 2.33 (m, 4H), 2.08 – 2.06 (m, 1H), 2.02 – 1.95 (m, 1H).

10 Example 10: Synthesis of 2-(6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethan-1-ol, HCl

Step 10.1: Synthesis of (*E*)-8-(2-ethoxyvinyl)-6-fluoroisoquinoline




To the stirred solution of 8-bromo-6-fluoroisoquinoline (Step 6.5, 1.0 g, 4.42 mmol) and (*E*)-2-(2-ethoxyvinyl)-4,4,5,5-tetra methyl-1,3,2-dioxaborolane (1.05 g, 5.31 mmol) in 1,4-dioxane-water (20 mL, 3:1 v/v), K₃PO₄ (2.81 g, 13.27 mmol) was added, and degassed with N₂ for 10 min.

Then Pd(dppf)Cl₂.CH₂Cl₂ (0.36 g, 0.44 mmol) was added, degassed and heated at 90°C for 16 h under N₂ atmosphere. Reaction mixture was cooled to rt, diluted with water and extracted with EtOAc twice. The combined organic portion was washed with brine, dried over anhydrous

20 Na₂SO₄, filtered and concentrated in *vacuo* to yield the crude product. The crude product was purified by flash chromatography (12 g SiliCycle column, 0 – 20% EtOAc in Hexane elution) to provide (*E*)-8-(2-ethoxyvinyl)-6-fluoroisoquinoline (1.0 g, 108%). MS (ESI+) [Method 6A]: m/z 218.0 (M+H); Rt 1.34 min. ¹H NMR (400 MHz, CDCl₃) δ 9.43 (s, 1H), 8.49 (d, $J = 5.6$ Hz, 1H), 7.55 (d, $J = 5.6$ Hz, 1H), 7.26 – 7.22 (m, 2H), 7.04 (d, $J = 12.4$ Hz, 1H), 6.52 (d, $J = 12.8$ Hz, 1H), 4.04 (q, $J = 7.2$ Hz, 2H), 1.41 (t, $J = 7.2$ Hz, 3H).

Step 10.2: Synthesis of 2-(6-fluoroisoquinolin-8-yl)acetaldehyde




To the stirred solution of (*E*)-8-(2-ethoxyvinyl)-6-fluoroisoquinoline (0.5 g, 2.30 mmol) in THF (5 mL), aqueous 2N HCl (5 mL) was added and heated at 70°C for 2 h. Reaction mixture was cooled to rt, quenched with saturated NaHCO₃ solution and extracted with EtOAc twice. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and

concentrated in *vacuo* to yield the crude 2-(6-fluoroisoquinolin-8-yl)acetaldehyde (0.5 g, 87%).


MS (ESI+) [Method 6A]: m/z 190.0 (M+H); Rt 1.37 min.

Step 10.3: Synthesis of 2-(6-fluoroisoquinolin-8-yl)ethan-1-ol




- 5 To the solution of 2-(6-fluoroisoquinolin-8-yl)acetaldehyde (0.5 g, 2.64 mmol) in MeOH (5 mL), NaBH₄ (0.15 g, 3.96 mmol) was added portion wise at 0 °C and stirred for 1 h. Then the reaction mixture was concentrated in *vacuo*, residue was diluted with water and extracted with EtOAc 3x's. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo* to afford crude 2-(6-fluoroisoquinolin-8-yl)ethan-1-ol (0.5 g, 10 99%). MS (ESI+) [Method 6A]: m/z 192.2 (M+H); Rt 1.34 min.

Step 10.4: Synthesis of 8-(2-((*tert*-butyldimethylsilyl)oxy)ethyl)-6-fluoroisoquinoline



- The title compound was prepared according to Step 6.7. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 15% EtOAc in Hexane elution) to afford 8-(2-((*tert*- 15 butyldimethylsilyl)oxy)ethyl)-6-fluoroisoquinoline (0.11 g, 13%). MS (ESI+) [Method 6A]: m/z 306.0 (M+H); Rt 1.60 min.


Step 10.5: Synthesis of 8-(2-((*tert*-butyldimethylsilyl)oxy)ethyl)-6-fluoroisoquinoline-5-carbaldehyde



- 20 To the stirred solution of 8-(2-((*tert*-butyldimethylsilyl)oxy)ethyl)-6-fluoroisoquinoline (0.11 g, 0.36 mmol) in anhydrous THF (1.5 mL), LDA (2M in THF) (0.36 mL, 0.72 mmol) was added dropwise at -78 °C under N₂ atmosphere. After 2.5 h, piperidine-1-carbaldehyde (0.12 g, 1.08 mmol) dissolved in THF (0.5 mL) was added dropwise at -78 °C, and stirred for another 1 h, while temperature was slowly raised to 0 °C. The reaction was quenched with saturated NH₄Cl 25 solution and extracted with EtOAc twice. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 10% EtOAc in Hexane elution) to provide 8-


(2-((tert-butyldimethylsilyl)oxy)ethyl)-6-fluoroisoquinoline-5-carbaldehyde (70 mg, 58%). MS (ESI+) [Method 6A]: m/z 334.1 (M+H); Rt 1.70 min.

Step 10.6: Synthesis of (1*r*,3*r*)-N-((8-(2-((tert-butyldimethylsilyl)oxy)ethyl)-6-fluoroisoquinolin-5-yl)methyl)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine



The title compound was synthesized following the procedure as described in step 1.4, using (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl (Step 1.3, 70 mg, 0.25 mmol) and 8-(2-((tert-butyldimethylsilyl)oxy)ethyl)-6-fluoroisoquinoline-5-carbaldehyde (65 mg, 0.20 mmol). The crude was purified by flash chromatography (12 g SiliCycle column, 0 – 5% MeOH in CHCl₃ elution) to provide (1*r*,3*r*)-N-((8-(2-((tert-butyldimethylsilyl)oxy)ethyl)-6-fluoroisoquinolin-5-yl)methyl)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine (100 mg, 72%). MS (ESI+) [Method 6A]: m/z 567.2 (M+H); Rt 1.45 min.


Step 10.7: Synthesis of 2-(6-fluoro-5-((((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethan-1-ol, HCl



Deprotection was carried out using the procedure of Step 8.5. The residue was purified by prep-HPLC (Column: X BRIDGE (150 mm x 19 mm), 5.0 μ; Mobile Phase: 0.02% NH₄OH in water and acetonitrile). To the isolated product, HCl solution (4M in 1,4-dioxane) (2 mL) was added at 10 °C, stirred at rt for 1 h, concentrated in *vacuo*, triturated with Et₂O, collected solid was dried in *vacuo* to provide 2-(6-fluoro-5-((((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethan-1-ol, HCl (22 mg, 25%). MS (ESI+) [Method 6A]: m/z 453.1 (M+H); Rt 1.33 min. ¹H NMR (400 MHz, CD₃OD) δ 10.01 (s, 1H), 8.82 (d, *J* = 6.8 Hz, 1H), 8.76 (d, *J* = 6.8 Hz, 1H), 7.95 (d, *J* = 10.4 Hz, 1H), 7.28 (t, *J* = 9.2 Hz, 1H), 7.14 – 7.09 (m, 2H), 5.06 – 5.03 (m, 1H), 4.81 (d, *J* = 1.6 Hz, 2H), 4.27 – 4.23 (m, 1H), 3.99 (t, *J* = 6.0 Hz, 2H), 3.55 (t, *J* = 6.0 Hz, 2H), 2.93 – 2.87 (m, 2H), 2.73 – 2.67 (m, 2H).


Example 11: Synthesis of 3,3,3-trifluoro-1-(6-fluoro-5-((((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)propan-1-ol

Step 11.1: Synthesis of 3,3,3-trifluoro-1-(6-fluoroisoquinolin-8-yl)propan-1-ol




- A round bottom flask charge with AgF (1.09 g, 8.66 mmol), was degassed and flushed with oxygen (3x's). Then 6-fluoro-8-vinylisoquinoline (Step 6.5, 1.0 g, 5.77 mmol) and CF₃TMS (0.85 mL, 5.77 mmol), dissolved in anhydrous DMF (10 mL), was added at a time at 0°C. The
- 5 reaction mixture was stirred at 0°C under oxygen atmosphere. After 1 h, once again CF₃TMS (0.85 mL, 5.77 mmol) was added and stirred for 2 h, under same condition. The reaction mixture was diluted with Et₂O, filtered through celite bed. The celite bed was thoroughly washed with Et₂O. The filtrate was collected, washed with water (twice), brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The crude was purified by flash chromatography
- 10 (12 g SiliCycle column, 0 – 20% EtOAc in Hexane elution) to provide 3,3,3-trifluoro-1-(6-fluoroisoquinolin-8-yl)propan-1-ol (0.3 g, 20%). MS (ESI+) [Method 1A]: m/z 259.9 (M+H); Rt 0.17 min.

Step 11.2: Synthesis of 8-(1-((*tert*-butyldimethylsilyl)oxy)-3,3,3-trifluoropropyl)-6-fluoroisoquinoline [C-08422-047]




- 15 To the solution of 3,3,3-trifluoro-1-(6-fluoroisoquinolin-8-yl)propan-1-ol (0.24 g, 0.93 mmol) and imidazole (0.31 g, 2.78 mmol) in DMF (5 mL), TBDMS-OTf (0.63 mL, 2.78 mmol) was added drop wise at 0 °C and stirred at rt. After 16 h, once again imidazole (0.31 g, 2.78 mmol) and TBDMS-OTf (0.63 mL, 2.78 mmol) were added at 0 °C and stirred at rt for 20 h. The reaction
- 20 mixture was diluted with water and extracted with EtOAc twice. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 10% EtOAc in Hexane elution) to afford 8-(1-((*tert*-butyldimethylsilyl)oxy)-3,3,3-trifluoropropyl)-6-fluoroisoquinoline (0.25 g, 72%). MS (ESI+) [Method 1A]: m/z 374.3 (M+H); Rt 2.03 min.

- 25 Step 11.3: Synthesis of 8-(1-((*tert*-butyldimethylsilyl)oxy)-3,3,3-trifluoropropyl)-6-fluoroisoquinoline-5-carbaldehyde




The title compound was prepared according to the procedure in Step 10.5. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 20% EtOAc in Hexane elution) to provide 8-(1-((*tert*-butyldimethylsilyl)oxy)-3,3,3-trifluoropropyl)-6-fluoroisoquinoline-5-carbaldehyde (0.15 g, 70%). MS (ESI+) [Method 1A]: *m/z* 402.5 (M+H); Rt 2.08 min.

5 Step 11.4: Synthesis of (1*r*,3*r*)-*N*-((8-(1-((*tert*-butyldimethylsilyl)oxy)-3,3,3-trifluoropropyl)-6-fluoroisoquinolin-5-yl)methyl)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine



The title compound was synthesized following the procedure as described in step 1.4, using (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl (Step 1.3, 120 mg, 0.42 mmol) and 8-(1-((*tert*-butyldimethylsilyl)oxy)-3,3,3-trifluoropropyl)-6-fluoroisoquinoline-5-carbaldehyde (150 mg, 0.38 mmol). The crude was purified by flash chromatography (12 g SiliCycle column, 0 – 5% MeOH in CHCl₃ elution) to provide (1*r*,3*r*)-*N*-((8-(1-((*tert*-butyldimethylsilyl)oxy)-3,3,3-trifluoropropyl)-6-fluoroisoquinolin-5-yl)methyl)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine (130 mg, 48%). MS (ESI+) [Method 1A]: *m/z* 635.1 (M+H); Rt 1.65 min.

15 Step 11.5: Synthesis of 3,3,3-trifluoro-1-(6-fluoro-5-((((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)propan-1-ol [C-08422-059]




Deprotection was carried out using the procedure of Step 8.5. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 5% MeOH in CHCl₃ elution). The isolated product was re-purified by reverse phase MPLC (C18 Gold column, 0 – 100% MeCN in H₂O elution) to provide 3,3,3-trifluoro-1-(6-fluoro-5-((((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)propan-1-ol (44 mg, 41%).

MS (ESI+) [Method 5A]: m/z 521.2 (M+H); Rt 1.10 min. ^1H NMR (400 MHz, CD_3OD) δ 9.53 (s, 1H), 8.56 (d, J = 6.0 Hz, 1H), 8.13 (d, J = 6.0 Hz, 1H), 7.67 (d, J = 11.6 Hz, 1H), 7.22 (t, J = 10.0 Hz, 1H), 7.06 – 6.99 (m, 2H), 5.86 – 5.82 (m, 1H), 4.87 – 4.82 (m, 1H), 4.19 (d, J = 1.6 Hz, 2H), 3.51 – 3.55 (m, 1H), 2.82 – 2.73 (m, 2H), 2.34 (t, J = 6.0 Hz, 4H).


5 **Example 12: Synthesis of 6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-amine**

Step 12.1: Synthesis of *N*-(6-fluoroisoquinolin-8-yl)-1,1-diphenylmethanimine




To a stirred solution of 8-bromo-6-fluoroisoquinoline (Step 6.4, 0.5 g, 2.23 mmol),
 10 diphenylmethanimine (0.6 g, 3.31 mmol) in 1,4-dioxane (30 mL), Cs_2CO_3 (1.7 g, 5.22 mmol) was added, and purged with N_2 for 10 min. Then $\text{Pd}_2(\text{dba})_3$ (0.18 g, 0.20 mmol) and Xantphos (0.23 g, 0.40 mmol) were added and the reaction mixture was heated at 90°C for 16 h under N_2 . The reaction mixture was cooled to rt, filtered through a celite bed and washed with ethyl acetate. The filtrate was concentrated in *vacuo* and the crude was purified by flash
 15 chromatography (24 g SiliCycle column, 0 – 20% EtOAc in Hexane elution) to provide *N*-(6-fluoroisoquinolin-8-yl)-1,1-diphenylmethanimine (0.8 g, quantitative). MS (ESI+) [Method 6A]: m/z 327.2 (M+H); Rt 1.48 min. ^1H NMR (300 MHz, CDCl_3) δ 9.37 (s, 1H), 8.49 (d, J = 6.0 Hz, 1H), 7.89 – 7.86 (m, 2H), 7.57 – 7.47 (m, 4H), 7.26 – 7.18 (m, 3H), 7.10 – 7.06 (m, 2H), 6.99 (dd, J = 9.0, 1.8 Hz, 1H), 6.36 (dd, J = 10.2, 1.2 Hz, 1H).

20 Step 12.2: Synthesis of *N*-(5-bromo-6-fluoroisoquinolin-8-yl)-1,1-diphenylmethanimine




To a stirred solution of *N*-(6-fluoroisoquinolin-8-yl)-1,1-diphenylmethanimine (0.5 g, 1.53 mmol), in MeCN (10 mL), NBS (0.4 g, 2.25 mmol) was added at 0°C , and stirred for 1 h under N_2 , while temperature was raised slowly to rt. Reaction mixture was diluted with water and extracted with
 25 EtOAc twice. The combined organic portion was washed with brine, dried over anhydrous Na_2SO_4 , filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 10% EtOAc in Hexane elution) to provide *N*-(5-bromo-6-fluoroisoquinolin-8-yl)-1,1-diphenylmethanimine (0.5 g, 82%). MS (ESI+) [Method 6A]: m/z 405.1 (M+H); Rt 1.74 min.

30 Step 12.3: Synthesis of *N*-(6-fluoro-5-vinylisoquinolin-8-yl)-1,1-diphenylmethanimine




The stirred solution of *N*-(5-bromo-6-fluoroisoquinolin-8-yl)-1,1-diphenylmethanimine (0.3 g, 0.74 mmol), VinylSnBu_3 (0.25 g, 0.79 mmol) in 1,4-dioxane (20 mL), was degassed with argon for 10 min. Then $\text{Pd(PPh}_3)_4$ (80 mg, 0.07 mmol) was added, degassed and heated at 100°C for 16 h under argon atmosphere. Reaction mixture was cooled to rt, diluted with water and extracted with EtOAc 3x's. The combined organic portion was washed with brine, dried over anhydrous Na_2SO_4 , filtered and concentrated in *vacuo* to yield the crude product. The crude was purified by flash chromatography (24 g SiliCycle column, 0 – 15% EtOAc in Hexane elution) to provide *N*-(6-fluoro-5-vinylisoquinolin-8-yl)-1,1-diphenylmethanimine (0.3 g, 100%). MS (ESI+) [Method 6A]: m/z 353.2 (M+H); Rt 1.59 min.

Step 12.4: Synthesis of 8-((diphenylmethylene)amino)-6-fluoroisoquinoline-5-carbaldehyde




To the solution of *N*-(6-fluoro-5-vinylisoquinolin-8-yl)-1,1-diphenylmethanimine (0.2 g, 0.57 mmol) in *t*-BuOH – 1,4-dioxane (15 mL, 1:2 v/v), OsO_4 (10% in *t*-BuOH) (0.1 mL, 0.04 mmol) was added at rt and stirred for 15 min. Then NaIO_4 (0.5 g, 2.35 mmol) dissolved in water (5 mL) was added dropwise and stirred at rt for 1 h. Reaction mixture was diluted with water and extracted with EtOAc 3x's. The combined organic portion was washed with brine, dried over anhydrous Na_2SO_4 , filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 15% EtOAc in Hexane elution) to provide 8-((diphenylmethylene)amino)-6-fluoroisoquinoline-5-carbaldehyde (90 mg, 47%). MS (ESI+) [Method 4A]: m/z 355.1 (M+H); Rt 1.28 min.

Step 12.5: Synthesis of (1*r*,3*r*)-*N*-((8-((diphenylmethylene)amino)-6-fluoroisoquinolin-5-yl)methyl)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine



The title compound was synthesized following the procedure as described in step 1.4, using (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl (65 mg, 0.22 mmol) and 8-((diphenylmethylene)amino)-6-fluoroisoquinoline-5-carbaldehyde (90 mg, 0.25 mmol). The crude (1*r*,3*r*)-*N*-((8-((diphenylmethylene)amino)-6-fluoroisoquinolin-5-yl)methyl)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine (100 mg, 77%) was used in next step without purification. MS (ESI+) [Method 6A]: *m/z* 588.3 (M+H); *Rt* 1.40 min.

Step 12.6: Synthesis of 6-fluoro-5-((((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-amine




10

The solution of (1*r*,3*r*)-*N*-((8-((diphenylmethylene)amino)-6-fluoroisoquinolin-5-yl)methyl)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine (100 mg, 0.17 mmol) and HCl solution (4M in 1,4-dioxane) (2 mL) was stirred at rt for 1 h. Then the reaction mixture was concentrated in *vacuo* and purified by prep-HPLC (Column: LUNA Phenomenex (250 mm x 21.2 mm), 5.0 μ ; Mobile Phase: 0.01% NH₄OH in water and acetonitrile) to provide 6-fluoro-5-((((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-amine (6 mg, 8%). MS (ESI+) [Method 6A]: *m/z* 424.1 (M+H); *Rt* 1.30 min. ¹H NMR (400 MHz, CD₃OD) δ 9.41 (s, 1H), 8.49 – 8.47 (m, 2H), 7.92 (d, *J* = 10.0 Hz, 1H), 7.89 (t, *J* = 11.6 Hz, 1H), 7.13 – 7.08 (m, 2H), 6.68 (d, *J* = 13.2 Hz, 1H), 4.96 – 4.92 (m, 1H), 4.40 (s, 2H), 4.04 – 3.99 (m, 1H), 2.70 – 2.64 (m, 2H), 2.62 – 2.57 (m, 2H).

20


Example 13: Synthesis of 5-((((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-3-amine

Step 13.1: Synthesis of *tert*-butyl (5-bromoisoquinolin-3-yl)(*tert*-butoxycarbonyl)carbamate




The stirred solution of 5-bromoisoquinolin-3-amine [CAS No. 1192815-01-2] (2.0 g, 8.97 mmol) in THF (20 mL) was cooled to 0 °C. Then DMAP (2.19 g, 17.93 mmol) and Boc₂O (3.9 g, 17.93 mmol) were added and stirred at rt for 16 h. Reaction mixture was diluted with water and extracted with EtOAc twice. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The crude was purified by flash chromatography (12 g SiliCycle column, 0 – 8% EtOAc in Hexane elution) to provide *tert*-butyl (5-bromoisoquinolin-3-yl)(*tert*-butoxycarbonyl)carbamate (1.2 g, 30%). MS (ESI+) [Method 6A]: m/z 423.2, 425.2 (M+H); Rt 1.70 min. ¹H NMR (600 MHz, CDCl₃) δ 9.09 (s, 1H), 8.16 (s, 1H), 7.78 – 7.76 (m, 1H), 7.72 (d, *J* = 9.0 Hz, 1H), 7.59 (s, 1H), 1.44 (s, 18H).

10 Step 13.2: Synthesis of *tert*-butyl (*tert*-butoxycarbonyl)(5-vinylisoquinolin-3-yl)carbamate



The stirred solution of *tert*-butyl (5-bromoisoquinolin-3-yl)(*tert*-butoxycarbonyl)carbamate (1.2 g, 2.83 mmol), potassium trifluoro(vinyl)borate (0.76 g, 5.67 mmol) and TEA (0.79 mL, 5.67 mmol) in IPA (20 mL) was degassed with argon for 10 min. Then Pd(dppf)Cl₂·CH₂Cl₂ (185 mg, 0.23 mmol) was added, degassed and heated at 80 °C for 16 h under argon atmosphere. Reaction mixture was cooled to rt, diluted with water and extracted with EtOAc twice. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo* to yield the crude product. The crude was purified by flash chromatography (12 g SiliCycle column, 0 – 10% EtOAc in Hexane elution) to provide *tert*-butyl (*tert*-butoxycarbonyl)(5-vinylisoquinolin-3-yl)carbamate (0.8 g, 80%). MS (ESI+) [Method 6A]: m/z 370.9 (M+H); Rt 1.67 min. ¹H NMR (300 MHz, CDCl₃) δ 9.12 (s, 1H), 7.88 – 7.77 (m, 3H), 7.55 (s, 1H), 6.89 (dd, *J* = 17.4, 10.5 Hz, 1H), 5.92 (d, *J* = 17.7 Hz, 1H), 5.43 (d, *J* = 11.1 Hz, 1H), 1.44 (s, 18H).


Step 13.3: Synthesis of *tert*-butyl (*tert*-butoxycarbonyl)(5-formylisoquinolin-3-yl)carbamate



25 To the solution of *tert*-butyl (*tert*-butoxycarbonyl)(5-vinylisoquinolin-3-yl)carbamate (0.8 g, 2.16 mmol) in *t*-BuOH – 1,4-dioxane (18 mL, 1:2 v/v), OsO₄ (16 mg, 0.06 mmol) was added at 0 °C and stirred at rt for 20 min. Then NaIO₄ (1.38 g, 6.48 mmol) dissolved in water (4 mL) was added dropwise and stirred at rt for 1 h. Reaction mixture was diluted with water and extracted with EtOAc 3x's. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 15% EtOAc in Hexane elution) to provide *tert*-butyl (*tert*-butoxycarbonyl)(5-formylisoquinolin-3-yl)carbamate (0.6 g, 62%). MS (ESI+) [Method 6A]: m/z

373.2 (M+H); Rt 1.60 min. ¹H NMR (400 MHz, CDCl₃) δ 10.19 (s, 1H), 9.30 (s, 1H), 8.48 (d, *J* = 0.8 Hz, 1H), 8.16 (dd, *J* = 8.8, 1.6 Hz, 1H), 7.94 (d, *J* = 8.8 Hz, 1H), 7.74 (s, 1H), 1.48 (s, 18H).

Step 13.4: Synthesis of *tert*-butyl (*tert*-butoxycarbonyl)(5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-3-yl)carbamate




5

The title compound was synthesized following the procedure as described in step 1.4, using (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl (Step 1.3, 200 mg, 0.70 mmol) and *tert*-butyl (*tert*-butoxycarbonyl)(5-formylisoquinolin-3-yl)carbamate (260 mg, 0.70 mmol). The crude *tert*-butyl (*tert*-butoxycarbonyl)(5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-3-yl)carbamate (250 mg, 59%) was used in next step without purification. MS (ESI+) [Method 1A]: *m/z* 606.0 (M+H); Rt 1.36 min.

10

Step 13.5: Synthesis of 5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-3-amine




15


The solution of *tert*-butyl (*tert*-butoxycarbonyl)(5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-3-yl)carbamate (250 mg, 0.41 mmol) and HCl solution (4M in 1,4-dioxane) (5 mL) was stirred at rt for 16 h. Then the reaction mixture was concentrated in *vacuo* and purified by prep-HPLC (Column: KINETEX EVO C18 (150 mm x 21.0 mm), 5.0 μ; Mobile Phase: 0.02% NH₄OH in water and acetonitrile) to provide 5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-3-amine (100 mg, 59%). MS (ESI+) [Method 6A]: *m/z* 406.2 (M+H); Rt 1.30 min. ¹H NMR (400 MHz, CD₃OD) δ 9.23 (s, 1H), 8.13 (d, *J* = 8.8 Hz, 1H), 8.00 (d, *J* = 6.8 Hz, 1H), 7.53 – 7.50 (m, 2H), 7.30 (t, *J* = 10.2 Hz, 1H), 7.17 – 7.11 (m, 2H), 5.08 – 5.04 (m, 1H), 4.58 (s, 2H), 4.27 – 4.23 (m, 1H), 2.94 – 2.89 (m, 2H), 2.72 – 2.67 (m, 2H).

25


Example 14: Synthesis of 6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-3-amine, HCl

Step 14.1: Synthesis of *tert*-butyl (*tert*-butoxycarbonyl)(6-fluoroisoquinolin-3-yl)carbamate

The stirred solution of 6-fluoroisoquinolin-3-amine [CAS No. 1260760-86-8] (17.0 g, 104.43 mmol) in THF (100 mL) was cooled to 0 °C. Then DMAP (51.2 g, 419.09 mmol) and Boc₂O (120.0 mL, 522.34 mmol) were added and stirred at rt for 24 h. Reaction mixture was diluted with water and extracted with EtOAc 3x's. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The crude was purified by flash chromatography (80 g SiliCycle column, 0 – 15% EtOAc in Hexane elution) to provide *tert*-butyl (*tert*-butoxycarbonyl)(6-fluoroisoquinolin-3-yl)carbamate (15.0 g, 39%). MS (ESI+) [Method 6A]: *m/z* 363.2 (M+H); Rt 1.64 min.

Step 14.2: Synthesis of *tert*-butyl (*tert*-butoxycarbonyl)(6-fluoro-5-formylisoquinolin-3-yl)carbamate


To the stirred solution of *tert*-butyl (*tert*-butoxycarbonyl)(6-fluoroisoquinolin-3-yl)carbamate (4.0 g, 11.03 mmol) in anhydrous THF (40 mL), LDA (2M in THF) (13.8 mL, 27.59 mmol) was added dropwise at -78 °C under N₂ atmosphere. After 2.5 h, piperidine-1-carbaldehyde (2.7 mL g, 33.11 mmol) dissolved in THF (10 mL) was added dropwise at -78 °C, and stirred for another 1 h. The reaction was quenched with saturated NH₄Cl solution and extracted with EtOAc 3x's. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (24 g SiliCycle column, 0 – 20% EtOAc in Hexane elution) to provide *tert*-butyl (*tert*-butoxycarbonyl)(6-fluoro-5-formylisoquinolin-3-yl)carbamate (2.5 g, 58%). MS (ESI+) [Method 6A]: *m/z* 391.2 (M+H); Rt 1.63 min.

Step 14.3: Synthesis of *tert*-butyl (*tert*-butoxycarbonyl)(6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-3-yl)carbamate

The title compound was synthesized following the procedure as described in step 1.4, using (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl (Step 1.3, 1.1 g, 3.85 mmol) and *tert*-butyl (*tert*-butoxycarbonyl)(6-fluoro-5-formylisoquinolin-3-yl)carbamate (2.1 g,

5.39 mmol). The crude was purified by flash chromatography (24 g SiliCycle column, 0 – 2% MeOH in CH₂Cl₂ elution) to provide *tert*-butyl (*tert*-butoxycarbonyl)(6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-3-yl)carbamate (2.0 g, 82%). MS (ESI+) [Method 6A]: *m/z* 624.3 (M+H); *Rt* 1.43 min.


5 **Step 14.4: Synthesis of 6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-3-amine, HCl**



Deprotection was carried out according to Step 13.5. The reaction mixture was concentrated in *vacuo* and purified by prep-HPLC (Column: WATERS XBRIDGE C18 (150 mm x 20.0 mm), 5.0 μ; Mobile Phase: 0.02% NH₄OH in water and acetonitrile). To the isolated product, HCl solution (4M in 1,4-dioxane) (5 mL) was added, stirred at rt for 1 h, concentrated in *vacuo*, triturated with Et₂O, collected solid was dried in *vacuo* to provide 6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-3-amine, HCl (360 mg, 24%). MS (ESI+) [Method 5A]: *m/z* 424.3 (M+H); *Rt* 0.30 min. ¹H NMR (400 MHz, CD₃OD) δ 9.10 (s, 1H), 8.26 – 8.22 (m, 1H), 7.45 (s, 1H), 7.37 (t, *J* = 10.0 Hz, 1H), 7.31 (t, *J* = 9.6 Hz, 1H), 7.15 – 7.08 (m, 2H), 5.05 – 5.01 (m, 1H), 4.56 (d, *J* = 1.6 Hz, 2H), 4.26 – 4.21 (m, 1H), 2.91 – 2.84 (m, 2H), 2.73 – 2.66 (m, 2H).


Example 15: Synthesis of 5-(((1*r*,3*r*)-3-(2,4-difluorophenoxy)cyclobutyl)amino)methyl)-6-fluoroisoquinolin-3-amine, HCl

20 **Step 15.1: Synthesis of *tert*-butyl ((1*r*,3*r*)-3-(2,4-difluorophenoxy)cyclobutyl)carbamate**




The title compound was synthesized following the procedure as described in step 1.2, using *tert*-butyl ((1*s*,3*s*)-3-hydroxycyclobutyl)carbamate (1.0 g, 5.34 mmol) and 2,4-difluorophenol [CAS No. 367-27-1] (0.7 g, 5.34 mmol). The residue was purified by flash chromatography (24 g SiliCycle column, 0 – 20% EtOAc in Hexane elution) to provide *tert*-butyl ((1*r*,3*r*)-3-(2,4-difluorophenoxy)cyclobutyl)carbamate (2.0 g, 124%). ¹H NMR (300 MHz, CDCl₃) δ 6.88 – 6.81 (m, 1H), 6.75 – 6.65 (m, 2H), 4.99 – 4.94 (m, 1H), 4.30 – 4.26 (m, 1H), 2.63 – 2.54 (m, 2H), 2.40 – 2.33 (m, 2H), 1.44 (s, 9H).

Step 15.2: Synthesis of (1*r*,3*r*)-3-(2,4-difluorophenoxy)cyclobutan-1-amine, HCl




A round bottom flask was charge with *tert*-butyl ((1*r*,3*r*)-3-(2,4-difluorophenoxy)cyclobutyl)carbamate (2.0 g, 6.69 mmol) and HCl solution (20% in 1,4-dioxane) (10 mL), and stirred at rt for 16 h. Then the reaction mixture was concentrated in *vacuo*. The residue was triturated with pentane, the solid appeared was filtered and dried to yield (1*r*,3*r*)-3-(2,4-difluorophenoxy)cyclobutan-1-amine, HCl (1.3 g, 103%). ¹H NMR (300 MHz, CDCl₃) δ 7.04 – 6.97 (m, 1H), 6.92 – 6.86 (m, 2H), 4.97 – 4.92 (m, 1H), 4.01 – 3.96 (m, 1H), 2.64 – 2.60 (m, 4H).

Step 15.3: Synthesis of *tert*-butyl (*tert*-butoxycarbonyl)(5-(((1*r*,3*r*)-3-(2,4-difluorophenoxy)cyclobutyl)amino)methyl)-6-fluoroisoquinolin-3-yl)carbamate



The title compound was synthesized following the procedure as described in step 1.4, using (1*r*,3*r*)-3-(2,4-difluorophenoxy)cyclobutan-1-amine, HCl (120 mg, 0.51 mmol) and *tert*-butyl (*tert*-butoxycarbonyl)(6-fluoro-5-formylisoquinolin-3-yl)carbamate (Step 14.2, 240 mg, 0.61 mmol). The crude was purified by flash chromatography (12 g SiliCycle column, 0 – 4% MeOH in CHCl₃ elution) to provide *tert*-butyl (*tert*-butoxycarbonyl)(5-(((1*r*,3*r*)-3-(2,4-difluorophenoxy)cyclobutyl)amino)methyl)-6-fluoroisoquinolin-3-yl)carbamate (200 mg, 68%). MS (ESI+) [Method 6A]: *m/z* 574.4 (M+H); Rt 1.38 min.

Step 15.4: Synthesis of 5-(((1*r*,3*r*)-3-(2,4-difluorophenoxy)cyclobutyl)amino)methyl)-6-fluoroisoquinolin-3-amine, HCl




Deprotection was carried out according to Step 13.5. The reaction mixture was concentrated in *vacuo* and purified by prep-HPLC (Column: GEMINI NX (150 mm x 21.2 mm), 5.0 μ; Mobile Phase: 0.02% NH₄OH in water and acetonitrile). To the isolated product, HCl solution (4M in 1,4-dioxane) (1 mL) was added and stirred at rt for 1 h. Solvent was evaporated, and the

residue was triturated with Et₂O. The solid formed was collected by filtration and dried in *vacuo* to provide 5-((((1*r*,3*r*)-3-(2,4-difluorophenoxy)cyclobutyl)amino)methyl)-6-fluoroisoquinolin-3-amine, HCl (33 mg, 23%). MS (ESI+) [Method 6A]: *m/z* 374.2 (M+H); Rt 1.29 min. ¹H NMR (400 MHz, CD₃OD) δ 9.11 (s, 1H), 8.28 – 8.23 (m, 1H), 7.43 (s, 1H), 7.38 (t, *J* = 10.0 Hz, 1H), 7.08 – 6.90 (m, 3H), 5.05 – 5.01 (m, 1H), 4.56 (s, 2H), 4.28 – 4.23 (m, 1H), 2.88 – 2.83 (m, 2H), 2.77 – 2.72 (m, 2H).


Example 16: Synthesis of 6-fluoro-5-((((1*r*,3*r*)-3-((2-(trifluoromethyl)pyridin-4-yl)oxy)cyclobutyl)amino)methyl)isoquinolin-3-amine, HCl

Step 16.1: Synthesis of *tert*-butyl ((1*r*,3*r*)-3-((2-(trifluoromethyl)pyridin-4-yl)oxy)cyclobutyl)carbamate




To the solution of NaH (60% on mineral oil) (66 mg, 1.65 mmol) in DMF (2 mL), was added 4-chloro-2-(trifluoromethyl)pyridine [CAS No. 131748-14-6] (200 mg, 1.10 mmol), followed by *tert*-butyl ((1*r*,3*r*)-3-hydroxycyclobutyl)carbamate [CAS No. 389890-42-0] (207 mg, 1.10 mmol) at 0 °C and stirred at rt for 16 h. The reaction was quenched with ice-water, extracted with EtOAc 3x's. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 6% EtOAc in Hexane elution) to provide *tert*-butyl ((1*r*,3*r*)-3-((2-(trifluoromethyl)pyridin-4-yl)oxy)cyclobutyl)carbamate (250 mg, 68%). MS (ESI+) [Method 6A]: *m/z* 333.1 (M+H); Rt 1.57 min.

Step 16.2: Synthesis of (1*r*,3*r*)-3-((2-(trifluoromethyl)pyridin-4-yl)oxy)cyclobutan-1-amine




A round bottom flask was charge with *tert*-butyl ((1*r*,3*r*)-3-((2-(trifluoromethyl)pyridin-4-yl)oxy)cyclobutyl)carbamate (250 mg, 1.14 mmol) and HCl solution (4M in 1,4-dioxane) (5 mL), and stirred at rt for 16 h. Then the reaction mixture was concentrated in *vacuo*. The residue was triturated with pentane, the solid appeared was filtered and dried to yield (1*r*,3*r*)-3-((2-(trifluoromethyl)pyridin-4-yl)oxy)cyclobutan-1-amine, HCl (300 mg crude). LCMS [Method 6A]: *m/z* 233.1 [M+H]⁺; Rt 0.70 min.

Step 16.3: Synthesis of *tert*-butyl (tert-butoxycarbonyl)(6-fluoro-5-((((1*r*,3*r*)-3-((2-(trifluoromethyl)pyridin-4-yl)oxy)cyclobutyl)amino)methyl)isoquinolin-3-yl)carbamate [C-07860-048]



The title compound was synthesized following the procedure as described in step 1.4, using (1*r*,3*r*)-3-((2-(trifluoromethyl)pyridin-4-yl)oxy)cyclobutan-1-amine, HCl (130 mg, 0.48 mmol) and *tert*-butyl ((*tert*-butoxycarbonyl)(6-fluoro-5-formylisoquinolin-3-yl)carbamate (Step 14.2, 220 mg, 0.58 mmol). The crude was purified by flash chromatography (12 g SiliCycle column, 0 – 4% MeOH in CHCl₃ elution) to provide *tert*-butyl ((*tert*-butoxycarbonyl)(6-fluoro-5-(((1*r*,3*r*)-3-((2-(trifluoromethyl)pyridin-4-yl)oxy)cyclobutyl)amino)methyl)isoquinolin-3-yl)carbamate (200 mg, 68%). MS (ESI+) [Method 6A]: *m/z* 607.4 (M+H); Rt 1.36 min.


Step 16.4: Synthesis of 6-fluoro-5-(((1*r*,3*r*)-3-((2-(trifluoromethyl)pyridin-4-yl)oxy)cyclobutyl)amino)methyl)isoquinolin-3-amine, HCl [C-07860-054]



Deprotection was carried out according to Step 13.5. Then the reaction mixture was concentrated in *vacuo* and purified by prep-HPLC (Column: KINETEX EVO C18, (150 mm x 21.2 mm), 5.0 μ; Mobile Phase: 0.05% NH₄OH in water and acetonitrile). To the isolated product, HCl solution (4M in 1,4-dioxane) (1 mL) was added and stirred at rt for 1 h. Solvent was evaporated, and the residue was triturated with Et₂O. The solid formed was collected by filtration and dried in *vacuo* to provide 6-fluoro-5-(((1*r*,3*r*)-3-((2-(trifluoromethyl)pyridin-4-yl)oxy)cyclobutyl)amino)methyl)isoquinolin-3-amine, HCl (30 mg, 20%). MS (ESI+) [Method 6A]: *m/z* 407.2 (M+H); Rt 1.26 min. ¹H NMR (400 MHz, CD₃OD) δ 9.15 (s, 1H), 8.58 (d, *J* = 6.0 Hz, 1H), 8.31 – 8.27 (m, 1H), 7.54 (s, 1H), 7.42 (t, *J* = 9.6 Hz, 1H), 7.34 (d, *J* = 2.4 Hz, 1H), 7.17 – 7.15 (m, 1H), 5.26 – 5.22 (m, 1H), 4.60 (d, *J* = 2.0 Hz, 2H), 4.32 – 4.28 (m, 1H), 3.02 – 2.96 (m, 2H), 2.82 – 2.75 (m, 2H).


Example 17: Synthesis of 6-fluoro-5-(((1*r*,3*r*)-3-((6-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutyl)amino)methyl)isoquinolin-3-amine, HCl

Step 17.1: Synthesis of *tert*-butyl ((*tert*-butoxycarbonyl)(6-fluoro-5-(((1*r*,3*r*)-3-((6-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutyl)amino)methyl)isoquinolin-3-yl)carbamate



The title compound was synthesized following the procedure as described in step 1.4, using (1*r*,3*r*)-3-((6-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutan-1-amine, HCl (Step 2.2, 130 mg, 0.48 mmol) and *tert*-butyl (*tert*-butoxycarbonyl)(6-fluoro-5-formylisoquinolin-3-yl)carbamate (Step 5 14.2, 220 mg, 0.58 mmol). The crude was purified by flash chromatography (12 g SiliCycle column, 0 – 4% MeOH in CHCl₃ elution) to provide *tert*-butyl (*tert*-butoxycarbonyl)(6-fluoro-5-(((1*r*,3*r*)-3-((6-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutyl)amino)methyl)isoquinolin-3-yl)carbamate (200 mg, 68%). MS (ESI+) [Method 6A]: *m/z* 607.4 (M+H); Rt 1.38 min.


Step 17.2: Synthesis of 6-fluoro-5-(((1*r*,3*r*)-3-((6-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutyl)amino)methyl)isoquinolin-3-amine, HCl



Deprotection was carried out according to Step 13.5. The reaction mixture was concentrated in *vacuo* and purified by prep-HPLC (Column: KINETEX EVO C18 (150 mm x 21.2 mm), 5.0 μ; Mobile Phase: 0.02% NH₄OH in water and acetonitrile). To the isolated product, HCl solution (4M in 1,4-dioxane) (1 mL) was added and stirred at rt for 1 h. Solvent was evaporated, and the residue was triturated with Et₂O. The solid formed was collected by filtration and dried in *vacuo* to provide 6-fluoro-5-(((1*r*,3*r*)-3-((6-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutyl)amino)methyl)isoquinolin-3-amine, HCl (35 mg, 24%). MS (ESI+) [Method 4B]: *m/z* 407.2 (M+H); Rt 0.97 min. ¹H NMR (400 MHz, CD₃OD) δ 9.10 (s, 1H), 8.32 (d, *J* = 2.8 Hz, 1H), 8.26 – 8.22 (m, 1H), 7.77 (d, *J* = 8.8, 1H), 7.46 – 7.43 (m, 2H), 7.37 (t, *J* = 9.6 Hz, 1H), 5.19 – 5.15 (m, 1H), 4.57 (d, *J* = 2.0 Hz, 2H), 4.28 – 4.23 (m, 1H), 2.98 – 2.91 (m, 2H), 2.78 – 2.72 (m, 2H).


Example 18: Synthesis of (3-amino-6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)methanol, HCl

Step 18.1: Synthesis of 2-bromo-4-fluorobenzaldehyde oxime




To the solution of 2-bromo-4-fluorobenzaldehyde [59142-68-6] (50.0 g, 246.29 mmol) in EtOH (600 mL), a solution of NaHCO₃ (41.4 g, 492.58 mmol) and hydroxylamine hydrochloride (25.7 g, 369.44 mmol) in water (600 mL), was added at rt and stirred for 16 h. Reaction mixture was concentrated in *vacuo* to remove EtOH, diluted with water and extracted with EtOAc 3x's. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo* to afford crude 2-bromo-4-fluorobenzaldehyde oxime (53.0 g, 98%). MS (ESI+) [Method 6A]: m/z 217.9 (M+H); Rt 1.50 min. ¹H NMR (300 MHz, CDCl₃) δ 8.47 (s, 1H), 7.89 (brs, 1H), 7.84 – 7.80 (m, 1H), 7.34 – 7.32 (m, 1H), 7.08 – 7.03 (m, 1H).

Step 18.2: Synthesis of (2-bromo-4-fluorophenyl)methanamine




To the stirred solution of 2-bromo-4-fluorobenzaldehyde oxime (48.0 g, 220.15 mmol) in EtOH (480 mL), concentrated HCl (240 mL) was added at 0 °C. Then Zn-dust was added portion wise at 0 °C and stirred at rt for 4 h. Reaction mixture was concentrated in *vacuo* to remove EtOH, diluted with water, basified with aqueous NH₄OH and extracted with EtOAc 3x's. The combined organic layer was washed with brine and dried over Na₂SO₄, filtered and concentrated in *vacuo* to afford crude (2-bromo-4-fluorophenyl)methanamine (33.0 g, 73%). MS (ESI+) [Method 6A]: m/z 203.9 (M+H); Rt 0.29 min.

Step 18.3: Synthesis of *N*-(2-bromo-4-fluorobenzyl)-2,2-diethoxyacetimidamide



To the solution of (2-bromo-4-fluorophenyl)methanamine (33.0 g, 161.73 mmol) in MeOH (350 mL), methyl 2,2-diethoxyacetimidate (31.3 g, 194.07 mmol) was added drop wise at rt and stirred at 70 °C for 16 h. Reaction mixture was concentrated in *vacuo* to provide crude *N*-(2-bromo-4-fluorobenzyl)-2,2-diethoxyacetimidamide (54.8 g, 101%). MS (ESI+) [Method 6A]: m/z 333.1 (M+H); Rt 1.29 min. ¹H NMR (300 MHz, CDCl₃) δ 7.46 – 7.42 (m, 1H), 7.30 – 7.27 (m, 1H), 7.02 – 6.99 (m, 1H), 4.93 (s, 1H), 4.48 (s, 2H), 3.64 – 3.54 (m, 4H), 1.25 – 1.20 (m, 6H).


Step 18.4: Synthesis of 8-bromo-6-fluoroisoquinolin-3-amine



To a round bottomed flask, charged with *N*-(2-bromo-4-fluorobenzyl)-2,2-diethoxyacetimidamide (54.8 g, 164.61 mmol), concentrated H₂SO₄ (351 mL, 6458.40 mmol) was added dropwise at 0 °C. The reaction mixture was stirred at 80 °C for 3 h. Then the reaction mixture was cooled to 0 °C and poured into ice-water. The resulting solution was basified with 50% NaOH solution, extracted with EtOAc twice. The combined organic layer was washed with brine and dried over Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by column


chromatography (Silica gel, 60 – 120 mesh size, 35% EtOAc in Hexane elution) to provide 8-bromo-6-fluoroisoquinolin-3-amine (14.0 g, 32%). MS (ESI+) [Method 6A]: m/z 240.9, 242.9 (M+H); Rt 1.42 min. ¹H NMR (300 MHz, CDCl₃) δ 9.12 (s, 1H), 7.29 – 7.26 (m, 1H), 7.09 (d, J = 9.3 Hz, 1H), 6.61 (s, 1H), 2.62 (brs, 2H).

5 Step 18.5: Synthesis of *tert*-butyl (8-bromo-6-fluoroisoquinolin-3-yl)(*tert*-butoxycarbonyl)carbamate




The stirred solution of 8-bromo-6-fluoroisoquinolin-3-amine (13.0 g, 53.93 mmol) and DMAP (9.9 g, 80.89 mmol) in THF (150 mL), Boc₂O (35.3 g, 161.78 mmol) was added at 0 °C, then
 10 stirred at rt for 16 h. Reaction mixture was diluted with water and extracted with EtOAc 3x's. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The crude product was purified by column chromatography (Silica gel, 60 – 120 mesh size, 20% EtOAc in Hexane elution) to provide *tert*-butyl (8-bromo-6-fluoroisoquinolin-3-yl)(*tert*-butoxycarbonyl)carbamate (12.0 g, 50%). MS (ESI+) [Method 6A]:
 15 m/z 443.0 (M+H); Rt 1.74 min. ¹H NMR (300 MHz, CDCl₃) δ 9.43 (s, 1H), 7.64 (dd, J = 8.1, 2.1 Hz, 1H), 7.59 (s, 1H), 7.42 (dd, J = 9.0, 2.1 Hz, 1H), 1.47 (s, 18H).

Step 18.6: Synthesis of *tert*-butyl (8-bromo-6-fluoroisoquinolin-3-yl)(*tert*-butoxycarbonyl)carbamate




20 The stirred solution of *tert*-butyl (8-bromo-6-fluoroisoquinolin-3-yl)(*tert*-butoxycarbonyl)carbamate (8.0 g, 18.13 mmol), potassium trifluoro(vinyl)borate (4.05 g, 36.26 mmol) and TEA (5.05 mL, 36.26 mmol) in IPA (80 mL) was degassed with N₂ for 10 min. Then Pd(dppf)Cl₂.CH₂Cl₂ (1.48 g, 1.81 mmol) was added, degassed and heated at 100 °C for 2 h under N₂. Reaction mixture was cooled to rt, diluted with water and extracted with EtOAc twice.
 25 The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo* to yield the crude product. The crude product was purified by flash chromatography (40 g SiliCycle column, 0 – 10% EtOAc in Hexane elution) to provide *tert*-butyl (8-bromo-6-fluoroisoquinolin-3-yl)(*tert*-butoxycarbonyl)carbamate (3.7 g, 51%). MS (ESI+) [Method 5A]: m/z 389.2 (M+H); Rt 1.83 min. ¹H NMR (300 MHz, CDCl₃) δ 9.39 (s, 1H), 7.56 (s, 1H), 7.49 - 7.41 (m, 2H), 7.37 – 7.34 (m, 1H), 5.91 (d, J = 17.1 Hz, 1H), 5.67 (d, J = 10.8 Hz, 1H), 1.45 (s, 18H).
 30

Step 18.7: Synthesis of *tert*-butyl (8-bromo-6-fluoroisoquinolin-3-yl)(*tert*-butoxycarbonyl)carbamate




To the solution of *tert*-butyl (*tert*-butoxycarbonyl)(6-fluoro-8-vinylisoquinolin-3-yl)carbamate (2.8 g, 7.21 mmol) in *t*-BuOH – 1,4-dioxane (45 mL, 1:2 v/v), OsO₄ (55 mg, 0.22 mmol) was added and stirred at rt for 15 min. Then NaIO₄ (7.7 g, 36.04 mmol) dissolved in water (30 mL) was added dropwise and stirred at rt for 16 h. Reaction mixture was diluted with water and extracted with EtOAc 3x's. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 15% EtOAc in Hexane elution) to provide *tert*-butyl (*tert*-butoxycarbonyl)(6-fluoro-8-formylisoquinolin-3-yl)carbamate (1.9 g, 67%). MS (ESI+) [Method 6A]: m/z 391.1 (M+H); Rt 1.64 min.

Step 18.8: Synthesis of *tert*-butyl (*tert*-butoxycarbonyl)(6-fluoro-8-(hydroxymethyl)isoquinolin-3-yl)carbamate




The solution of *tert*-butyl (*tert*-butoxycarbonyl)(6-fluoro-8-formylisoquinolin-3-yl)carbamate (1.9 g, 4.87 mmol) in MeOH (30 mL) was cooled to 0 °C. Then NaBH₄ (0.27 g, 7.30 mmol) was added portion wise and stirred for 1 h. The reaction mixture was concentrated in *vacuo*, residue was diluted with water and extracted with EtOAc 3x's. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo* to afford crude *tert*-butyl (*tert*-butoxycarbonyl)(6-fluoro-8-(hydroxymethyl)isoquinolin-3-yl)carbamate (1.9 g, 99%). MS (ESI+) [Method 1A]: m/z 393.1 (M+H); Rt 1.68 min.

Step 18.9: Synthesis of *tert*-butyl (*tert*-butoxycarbonyl)(8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinolin-3-yl)carbamate




The title compound was prepared according to Step 6.7. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 15% EtOAc in Hexane elution) to afford *tert*-butyl (*tert*-butoxycarbonyl)(8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinolin-3-yl)carbamate (2.0 g, 81%). MS (ESI+) [Method 1A]: m/z 507.4 (M+H); Rt 2.03 min. ¹H NMR (300 MHz, CDCl₃) δ 9.25 (s, 1H), 7.57 (s, 1H), 7.46 (dd, *J* = 9.3, 2.4 Hz, 1H), 7.31 (dd, *J* = 9.3, 2.4 Hz, 1H), 5.26 (s, 2H), 1.44 (s, 18H), 0.96 (s, 9H), 0.16 (s, 6H).

Step 18.10: Synthesis of *tert*-butyl (*tert*-butoxycarbonyl)(8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoro-5-formylisoquinolin-3-yl)carbamate




The title compound was prepared according to Step 14.2. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 10% EtOAc in Hexane elution) to provide *tert*-butyl (*tert*-butoxycarbonyl)(8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoro-5-formylisoquinolin-3-yl)carbamate (0.5 g, 47%). MS (ESI+) [Method 6A]: *m/z* 535.4 (M+H); Rt 2.02 min.

Step 18.11: Synthesis of *tert*-butyl (*tert*-butoxycarbonyl)(8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-3-yl)carbamate



The title compound was synthesized following the procedure as described in step 1.4, using (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl (Step 1.3, 300 mg, 1.05 mmol) and *tert*-butyl (*tert*-butoxycarbonyl)(8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoro-5-formylisoquinolin-3-yl)carbamate (560 mg, 1.05 mmol). The crude was purified by flash chromatography (12 g SiliCycle column, 0 – 4% MeOH in CHCl₃ elution) to provide *tert*-butyl (*tert*-butoxycarbonyl)(8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-3-yl)carbamate (550 mg, 68%). MS (ESI+) [Method 6A]: *m/z* 768.5 (M+H); Rt 1.55 min.


Step 18.12: Synthesis of *tert*-butyl (*tert*-butoxycarbonyl)(6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)-8-(hydroxymethyl)isoquinolin-3-yl)carbamate



Deprotection was carried out according to Step 8.5. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 5% MeOH in CH₂Cl₂ elution) to provide *tert*-butyl (tert-butoxycarbonyl)(6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-

- 5 (trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)-8-(hydroxymethyl)isoquinolin-3-yl)carbamate (450 mg, 96%). MS (ESI+) [Method 4B]: *m/z* 654.2 (M+H); Rt 1.10 min.

Step 18.13: Synthesis of (3-amino-6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)methanol, HCl




- 10 Deprotection was carried out according to Step 13.5. The product was purified by prep-HPLC (Column: WATERS X BRIDGE C18 (150 mm x 19.0 mm), 5.0 μ; Mobile Phase: 0.02% NH₄OH in water and acetonitrile). To the isolated product, HCl solution (4M in 1,4-dioxane) (2 mL) was added and stirred at rt for 1 h. Solvent was evaporated, and the residue was triturated with Et₂O. The solid formed was collected by filtration and dried in *vacuo* to provide (3-amino-6-
- 15 fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)methanol, HCl (130 mg, 38%). MS (ESI+) [Method 4B]: *m/z* 454.2 (M+H); Rt 0.99 min. ¹H NMR (400 MHz, CD₃OD) δ 9.14 (s, 1H), 7.49 (s, 1H), 7.40 (d, *J* = 10.8 Hz, 1H), 7.29 (t, *J* = 9.6 Hz, 1H), 7.15 – 7.09 (m, 2H), 5.06 – 5.02 (m, 3H), 4.54 (d, *J* = 1.6 Hz, 2H), 4.25 – 4.22 (m, 1H), 2.90 – 2.85 (m, 2H), 2.73 – 2.66 (m, 2H).

- 20 **Example 19: Synthesis of (3-amino-5-(((1*r*,3*r*)-3-(2,4-**

difluorophenoxy)cyclobutyl)amino)methyl)-6-fluoroisoquinolin-8-yl)methanol, HCl


Step 19.1: Synthesis of *tert*-butyl (tert-butoxycarbonyl)(8-(((tert-butyldimethylsilyl)oxy)methyl)-5-(((1*r*,3*r*)-3-(2,4-difluorophenoxy)cyclobutyl)amino)methyl)-6-fluoroisoquinolin-3-yl)carbamate



The title compound was synthesized following the procedure as described in step 1.4, using (1*r*,3*r*)-3-(2,4-difluorophenoxy)cyclobutan-1-amine, HCl (Step 15.2, 120 mg, 0.51 mmol) and *tert*-butyl (*tert*-butoxycarbonyl)(8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoro-5-


- 5 formylisoquinolin-3-yl)carbamate (Step 18.10, 240 mg, 0.46 mmol). The crude was purified by flash chromatography (12 g SiliCycle column, 0 – 4% MeOH in CHCl₃ elution) to provide *tert*-butyl (*tert*-butoxycarbonyl)(8-(((*tert*-butyldimethylsilyl)oxy)methyl)-5-(((1*r*,3*r*)-3-(2,4-difluorophenoxy)cyclobutyl)amino)methyl)-6-fluoroisoquinolin-3-yl)carbamate (200 mg, 54%). MS (ESI+) [Method 6A]: *m/z* 718.3 (M+H); Rt 1.53 min.

- 10 Step 19.2: Synthesis of *tert*-butyl (*tert*-butoxycarbonyl)(5-(((1*r*,3*r*)-3-(2,4-difluorophenoxy)cyclobutyl)amino)methyl)-6-fluoro-8-(hydroxymethyl)isoquinolin-3-yl)carbamate



Deprotection was carried out according to Step 8.5. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 5% MeOH in CH₂Cl₂ elution) to provide *tert*-butyl (*tert*-butoxycarbonyl)(5-(((1*r*,3*r*)-3-(2,4-difluorophenoxy)cyclobutyl)amino)methyl)-6-fluoro-8-(hydroxymethyl)isoquinolin-3-yl)carbamate (120 mg, 71%). MS (ESI+) [Method 6A]: *m/z* 604.4 (M+H); Rt 1.38 min.


Step 19.3: Synthesis of (3-amino-5-(((1*r*,3*r*)-3-(2,4-difluorophenoxy)cyclobutyl)amino)methyl)-6-fluoroisoquinolin-8-yl)methanol, HCl [C-07860-067]



Deprotection was carried out according to Step 13.5. The product was purified by prep-HPLC (Column: GEMINI NX C18 (150 mm x 21.0 mm), 5.0 μ ; Mobile Phase: 0.02% NH_4OH in water and acetonitrile). To the isolated product, HCl solution (4M in 1,4-dioxane) (1 mL) was added and stirred at rt for 1 h. Solvent was evaporated, and the residue was triturated with Et_2O . The solid formed was collected by filtration and dried in *vacuo* to provide (3-amino-5-(((1*r*,3*r*)-3-(2,4-difluorophenoxy)cyclobutyl)amino)methyl)-6-fluoroisoquinolin-8-yl)methanol, HCl (18 mg, 20%). MS (ESI+) [Method 6A]: m/z 404.2 (M+H); Rt 1.27 min. ^1H NMR (400 MHz, CD_3OD) δ 9.14 (s, 1H), 7.43 (s, 1H), 7.39 (d, J = 10.8 Hz, 1H), 7.03 – 6.87 (m, 3H), 5.05 (s, 2H), 5.01 – 4.97 (m, 1H), 4.53 (s, 2H), 4.23 – 4.20 (m, 1H), 2.83 – 2.78 (m, 2H), 2.73 – 2.68 (m, 2H).


Example 20: Synthesis of (3-amino-6-fluoro-5-(((1*r*,3*r*)-3-((2-(trifluoromethyl)pyridin-4-yl)oxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)methanol, HCl

Step 20.1: Synthesis of *tert*-butyl (*tert*-butoxycarbonyl)(8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoro-5-(((1*r*,3*r*)-3-((2-(trifluoromethyl)pyridin-4-yl)oxy)cyclobutyl)amino)methyl)isoquinolin-3-yl)carbamate




The title compound was synthesized following the procedure as described in step 1.4, using (1*r*,3*r*)-3-((2-(trifluoromethyl)pyridin-4-yl)oxy)cyclobutan-1-amine, HCl (Step 16.2, 70 mg, 0.26 mmol) and *tert*-butyl (*tert*-butoxycarbonyl)(8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoro-5-formylisoquinolin-3-yl)carbamate (Step 18.10, 98 mg, 0.18 mmol). The crude was purified by flash chromatography (12 g SiliCycle column, 0 – 4% MeOH in CHCl_3 elution) to provide *tert*-butyl (*tert*-butoxycarbonyl)(8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoro-5-(((1*r*,3*r*)-3-((2-(trifluoromethyl)pyridin-4-yl)oxy)cyclobutyl)amino)methyl)isoquinolin-3-yl)carbamate (100 mg, 51%). MS (ESI+) [Method 6A]: m/z 751.5 (M+H), Rt 1.49 min; 651.4 (M-Boc+H), Rt 1.44 min.

Step 20.2: Synthesis of *tert*-butyl (*tert*-butoxycarbonyl)(6-fluoro-8-(hydroxymethyl)-5-((((1*r*,3*r*)-3-((2-(trifluoromethyl)pyridin-4-yl)oxy)cyclobutyl)amino)methyl)isoquinolin-3-yl)carbamate



Deprotection was carried out according to Step 8.5. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 5% MeOH in CH₂Cl₂ elution) to provide *tert*-butyl (*tert*-butoxycarbonyl)(6-fluoro-8-(hydroxymethyl)-5-((((1*r*,3*r*)-3-((2-(trifluoromethyl)pyridin-4-yl)oxy)cyclobutyl)amino)methyl)isoquinolin-3-yl)carbamate (60 mg, 71%). MS (ESI+) [Method 6A]: *m/z* 637.4 (M+H), *Rt* 1.36 min; 535.2 (M-Boc+H), *Rt* 1.33 min.


Step 20.3: Synthesis of (3-amino-6-fluoro-5-((((1*r*,3*r*)-3-((2-(trifluoromethyl)pyridin-4-yl)oxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)methanol, HCl



Deprotection was carried out according to Step 13.5. Then the reaction mixture was concentrated in *vacuo* and purified by prep-HPLC (Column: : WATERS X BRIDGE C18 (150 mm x 19.0 mm), 5.0 μ ; Mobile Phase: 0.02% NH₄OH in water and acetonitrile). To the isolated product, HCl solution (4M in 1,4-dioxane) (1 mL) was added and stirred at rt for 1 h. Solvent was evaporated, and the residue was triturated with Et₂O. The solid formed was collected by filtration and dried in *vacuo* to provide (3-amino-6-fluoro-5-((((1*r*,3*r*)-3-((2-(trifluoromethyl)pyridin-4-yl)oxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)methanol, HCl (14 mg, 31%). MS (ESI+) [Method 6A]: *m/z* 437.0 (M+H); *Rt* 1.27 min. ¹H NMR (400 MHz, CD₃OD) δ 9.18 (s, 1H), 8.57 (d, *J* = 9.0 Hz, 1H), 7.56 (s, 1H), 7.44 (d, *J* = 9.0 Hz, 1H), 7.34 (d, *J* = 2.4 Hz, 1H), 7.17 – 7.14 (m, 1H), 5.26 – 5.21 (m, 1H), 5.08 (s, 2H), 4.58 (s, 2H), 4.32 – 4.28 (m, 1H), 3.02 – 2.97 (m, 2H), 2.80 – 2.75 (m, 2H).


Example 21: Synthesis of 1-(3-amino-6-fluoro-5-((((1*r*,3*r*)-3-((4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethane-1,2-diol

Step 21.1: Synthesis of *tert*-butyl (*tert*-butoxycarbonyl)(8-(1,2-dihydroxyethyl)-6-fluoroisoquinolin-3-yl)carbamate




To the solution of *tert*-butyl (*tert*-butoxycarbonyl)(6-fluoro-8-vinylisoquinolin-3-yl)carbamate (Step 18.6, 3.7 g, 9.53 mmol) in acetone (40 mL), 4-methylmorpholine N-oxide (2.8 g, 23.82 mmol), dissolved in water (4 mL), was added at rt, followed by OsO₄ (0.12 g, 0.48 mmol). Then the reaction mixture was stirred at rt for 16 h. The reaction mixture was concentrated in *vacuo*, residue was diluted with water and extracted 20% MeOH in CH₂Cl₂ 3x's. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 8% MeOH in CH₂Cl₂ elution) to provide *tert*-butyl (*tert*-butoxycarbonyl)(8-(1,2-dihydroxyethyl)-6-fluoroisoquinolin-3-yl)carbamate (2.9 g, 72%). MS (ESI+) [Method 6A]: m/z 423.2 (M+H); Rt 1.48 min.

Step 21.2: Synthesis of *tert*-butyl (*tert*-butoxycarbonyl)(6-fluoro-8-(2,2,3,3,8,8,9,9-octamethyl-4,7-dioxa-3,8-disiladecan-5-yl)isoquinolin-3-yl)carbamate




To the stirred solution of *tert*-butyl (*tert*-butoxycarbonyl)(8-(1,2-dihydroxyethyl)-6-fluoroisoquinolin-3-yl)carbamate (2.9 g, 6.87 mmol) and imidazole (2.8 g, 41.21 mmol) in DMF - DCM (35 mL, 1:6 v/v), TBDMS-Cl (5.43 g, 34.34 mmol) was added portion wise at 0 °C. The reaction mixture was stirred at rt for 16 h. Then the reaction mixture was diluted with water and extracted with CH₂Cl₂ twice. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (24 g SiliCycle column, 0 – 15% EtOAc in Hexane elution) to afford *tert*-butyl (*tert*-butoxycarbonyl)(6-fluoro-8-(2,2,3,3,8,8,9,9-octamethyl-4,7-dioxa-3,8-disiladecan-5-yl)isoquinolin-3-yl)carbamate (3.6 g, 80%). MS (ESI+) [Method 1A]: m/z 651.4 (M+H); Rt 2.54 min. ¹H NMR (600 MHz, CDCl₃) δ 9.50 (s, 1H), 7.56 (s, 1H), 7.48 (d, *J* = 9.0 Hz, 1H), 7.31 (d, *J* = 9.0 Hz, 1H), 4.12 – 4.09 (m, 1H), 3.87 – 3.84 (m, 1H), 3.79 – 3.77 (m, 1H), 1.43 (s, 18 H), 0.86 (s, 9H), 0.78 (s, 9H), 0.10 (s, 6H), -0.08 (s, 6H).

Step 21.3: Synthesis of *tert*-butyl (*tert*-butoxycarbonyl)(6-fluoro-5-formyl-8-(2,2,3,3,8,8,9,9-octamethyl-4,7-dioxa-3,8-disiladecan-5-yl)isoquinolin-3-yl)carbamate




The title compound was prepared according to Step 14.2. The residue was purified by flash chromatography (40 g SiliCycle column, 0 – 15% EtOAc in Hexane elution) to provide *tert*-butyl (*tert*-butoxycarbonyl)(6-fluoro-5-formyl-8-((2,2,3,3,8,8,9,9-octamethyl-4,7-dioxo-3,8-disiladecan-5-yl)isoquinolin-3-yl)carbamate (0.74 g, 39%). MS (ESI+) [Method 1A]: *m/z* 679.6 (M+H); Rt 2.89 min. ¹H NMR (300 MHz, CDCl₃) δ 10.72 (s, 1H), 9.50 (s, 1H), 9.10 (s, 1H), 7.58 (d, *J* = 9.0 Hz, 1H), 5.53 – 5.50 (m, 1H), 3.87 – 3.79 (m, 2H), 1.46 (s, 18H), 0.90 (s, 9H), 0.78 (s, 9H), 0.14 (s, 3H), -0.03 (s, 3H), -0.09 (s, 3H), -0.14 (s, 3H).

Step 21.4: Synthesis of *tert*-butyl (*tert*-butoxycarbonyl)(6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)-8-((2,2,3,3,8,8,9,9-octamethyl-4,7-dioxo-3,8-disiladecan-5-yl)isoquinolin-3-yl)carbamate



The title compound was synthesized following the procedure as described in step 1.4, using (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl (Step 1.3, 0.59 g, 2.07 mmol) and *tert*-butyl (*tert*-butoxycarbonyl)(6-fluoro-5-formyl-8-((2,2,3,3,8,8,9,9-octamethyl-4,7-dioxo-3,8-disiladecan-5-yl)isoquinolin-3-yl)carbamate (1.4 g, 2.07 mmol). The crude was purified by flash chromatography (12 g SiliCycle column, 0 – 10% MeOH in CH₂Cl₂ elution) to provide *tert*-butyl (*tert*-butoxycarbonyl)(6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)-8-((2,2,3,3,8,8,9,9-octamethyl-4,7-dioxo-3,8-disiladecan-5-yl)isoquinolin-3-yl)carbamate (1.16 g, 61%). MS (ESI+) [Method 1A]: *m/z* 912.3 (M+H), Rt 2.10 min.


Step 21.5: Synthesis of *tert*-butyl (*tert*-butoxycarbonyl)(8-(1,2-dihydroxyethyl)-6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-3-yl)carbamate



The title compound was prepared according to the procedure in Step 7.6 to provide the title compound. MS (ESI+) [Method 1A]: m/z 684.4 (M+H), Rt 1.39 min.

Step 21.6: Synthesis of 1-(3-amino-6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-

5 (trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethane-1,2-diol




Deprotection was carried out according to Step 13.5 to afford racemic 1-(3-amino-6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethane-1,2-diol, HCl (0.65 g, 85%). MS (ESI+) [Method 1A]: m/z 484.3 (M+H); Rt 0.10 min.

- 10 Chiral prep-HPLC (Column: CHIRALPAK IG (250 mm x 20 mm); Mobile Phase: Hexane and 0.1% DEA in EtOH : MeOH (1:1); Isocratic: 60/40; Flow: 16 mL/min) of the racemate (650 mg) provided (*R*)-1-(3-amino-6-fluoro-5-(((1*r*,3*R*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethane-1,2-diol and (*S*)-1-(3-amino-6-fluoro-5-(((1*r*,3*S*)-3-(4-fluoro-3-
- 15 (trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethane-1,2-diol as white solids (Peak 1: 155 mg, 24% and Peak 2: 180 mg, 27%). Peak 1: Chiral HPLC: 99% (Rf 5.315 min; Column: CHIRAL PAK IG (150 mm x 4.6 mm), 5.0 μ ; Mobile phase: *n*-Hexane and 0.1% DEA in EtOH : MeOH (70:30); Isocratic: 70/30; Flow: 1 mL/min). MS (ESI+) [Method 6A]: m/z 484.1 (M+H); Rt 1.32 min. ^1H NMR (400 MHz, CD_3OD) δ 9.11 (s, 1H), 7.25 – 7.22 (m, 2H), 7.09 – 7.04 (m, 2H), 6.95 (s, 1H), 5.45 – 5.42 (m, 1H), 4.92 – 4.89 (m, 1H), 4.24 (d, J = 1.6 Hz, 2H), 3.87 – 3.79 (m, 2H), 3.72 – 3.68 (m, 1H), 2.57 – 2.48 (m, 4H).
- 20

Peak 2: Chiral HPLC: 98% (Rf 7.812 min; Column: CHIRAL PAK IG (150 mm x 4.6 mm), 5.0 μ ; Mobile phase: *n*-Hexane and 0.1% DEA in EtOH : MeOH (70:30); Isocratic: 70/30; Flow: 1 mL/min). MS (ESI+) [Method 6A]: m/z 484.2 (M+H); Rt 1.32 min. ^1H NMR (400 MHz, CD_3OD) δ

9.12 (s, 1H), 7.26 – 7.23 (m, 2H), 7.09 – 7.05 (m, 2H), 6.95 (s, 1H), 5.47 – 5.43 (m, 1H), 4.92 – 4.89 (m, 1H), 4.29 (s, 2H), 3.93 – 3.88 (m, 1H), 3.82 – 3.79 (m, 1H), 3.73 – 3.69 (m, 1H), 2.61 – 2.52 (m, 4H).


Example 22: Synthesis of (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-N-(isoquinolin-5-ylmethyl)cyclobutan-1-amine, HCl



The title compound was synthesized following the procedure as described in step 1.4, using (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl (Step 1.3, 300 mg, 1.05 mmol) and isoquinoline-5-carbaldehyde (150 mg, 0.96 mmol). Prep-HPLC (Column: XBRIDGE C18 (150 mm x 21.2 mm), 5.0 μ ; Mobile Phase: 0.01% NH₄OH in water and acetonitrile) of the crude, followed by treatment with HCl solution (4M in 1,4-dioxane) afforded (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-N-(isoquinolin-5-ylmethyl)cyclobutan-1-amine, HCl (250 mg, 55%). MS (ESI+) [Method 6A]: *m/z* 391.1 (M+H); Rt 1.32 min. ¹H NMR (400 MHz, CD₃OD) δ 9.92 (s, 1H), 8.85 – 8.83 (m, 1H), 8.79 – 8.77 (m, 1H), 8.67 (d, *J* = 8.0 Hz, 1H), 8.51 (d, *J* = 7.6 Hz, 1H), 8.16 (t, *J* = 8.0 Hz, 1H), 7.31 (t, *J* = 9.6 Hz, 1H), 7.17 – 7.11 (m, 2H), 5.11 – 5.06 (m, 1H), 4.87 (s, 2H), 4.33 – 4.29 (m, 1H), 3.00 – 2.92 (m, 2H), 2.74 – 2.68 (m, 2H).


Example 23: Synthesis of 5-((((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-ol, HCl

Step 23.1: Synthesis of 1-(5-bromo-2-methoxyphenyl)-N-(2,2-dimethoxyethyl)methanimine




A two necked round bottom flask, fitted with Dean Stark apparatus, was charged with 5-bromo-2-methoxybenzaldehyde [CAS No. 25016-01-7] (3.0 g, 13.95 mmol), 2,2-dimethoxyethan-1-amine (1.5 mL, 13.95 mmol) and toluene (50 mL). The reaction mixture was stirred at 140 °C for 16 h, while azeotropic removal of H₂O. Then the reaction mixture was concentrated in *vacuo* to afford crude 1-(5-bromo-2-methoxyphenyl)-N-(2,2-dimethoxyethyl)methanimine (5.4 g, 128%). ¹H NMR (300 MHz, CDCl₃) δ 8.63 (d, *J* = 1.2 Hz, 1H), 8.07 (d, *J* = 3.0 Hz, 1H), 7.46 (dd, *J* = 8.7, 3.0 Hz, 1H), 6.79 (d, *J* = 8.7 Hz, 1H), 4.68 (t, *J* = 5.4 Hz, 1H), 3.85 (s, 3H), 3.78 (dd, *J* = 5.4, 1.2 Hz, 2H), 3.42 (s, 6H).

Step 23.2: Synthesis of 5-bromo-8-methoxyisoquinoline




To the solution of 1-(5-bromo-2-methoxyphenyl)-*N*-(2,2-dimethoxyethyl)methanimine (5.4 g, 17.87 mmol) in CHCl_3 (50 mL), ethyl carbonochloridate (1.7 mL, 17.87 mmol) and $\text{P}(\text{OEt})_3$ (2.5 mL, 21.45 mmol) were added at 0 °C and stirred at 60 °C for 16 h. The reaction mixture was cooled to rt, poured into ice water and the organic portion was separated. The aqueous portion was washed with CH_2Cl_2 twice and basified with aqueous NH_4OH , then extracted with CH_2Cl_2 twice. The combined organic portion was washed with brine, dried over anhydrous Na_2SO_4 , filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 30% EtOAc in Hexane elution) to provide 5-bromo-8-methoxyisoquinoline (1.0 g, 28%). ^1H NMR (600 MHz, CDCl_3) δ 9.61 (s, 1H), 8.65 (d, J = 6.0 Hz, 1H), 7.89 (d, J = 6.0 Hz, 1H), 7.84 (d, J = 8.4 Hz, 1H), 6.78 (d, J = 8.4 Hz, 1H), 4.03 (s, 3H).

Step 23.3: Synthesis of 8-methoxy-5-vinylisoquinoline




The stirred solution of 5-bromo-8-methoxyisoquinoline (1.0 g, 4.20 mmol), potassium trifluoro(vinyl)borate (1.12 g, 8.40 mmol) and TEA (1.2 mL, 8.40 mmol) in IPA (10 mL), was degassed with N_2 for 10 min. Then $\text{Pd}(\text{dppf})\text{Cl}_2 \cdot \text{CH}_2\text{Cl}_2$ (343 mg, 0.04 mmol) was added, degassed and heated at 90°C for 3 h under N_2 . Reaction mixture was cooled to rt, diluted with water and extracted with EtOAc twice. The combined organic portion was washed with brine, dried over anhydrous Na_2SO_4 , filtered and concentrated in *vacuo* to yield the crude product. The crude was purified by flash chromatography (12 g SiliCycle column, 0 – 30% EtOAc in Hexane elution) to provide 8-methoxy-5-vinylisoquinoline (0.56 g, 71%). MS (ESI+) [Method 6A]: m/z 185.9 (M+H); Rt 1.28 min.

Step 23.4: Synthesis of 8-methoxyisoquinoline-5-carbaldehyde




The compound was prepared by analogy to Step 5.2 from 8-methoxy-5-vinylisoquinoline (560 mg, 3.02 mmol). The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 50% EtOAc in Hexane elution) to provide 8-methoxyisoquinoline-5-carbaldehyde (188 mg, 33%). MS (ESI+) [Method 6A]: m/z 187.9 (M+H); Rt 0.62 min.

Step 23.5: Synthesis of 8-hydroxyisoquinoline-5-carbaldehyde




- To the solution of 8-methoxyisoquinoline-5-carbaldehyde (188 mg, 1.00 mmol) in CH₂Cl₂ (5 mL), BBr₃ (1M in heptane) (5.0 mL, 5.02 mmol) was added at 0 °C and stirred at rt for 16 h. To the reaction mixture MeOH was added, stirred for 15 min and then concentrated in *vacuo* to provide
- 5 crude 8-hydroxyisoquinoline-5-carbaldehyde (230 mg, 132%). MS (ESI+) [Method 6A]: m/z 174.2 (M+H); Rt 0.38 min.

Step 23.6: Synthesis of 5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-ol, HCl




- 10 The title compound was synthesized following the procedure as described in step 1.4. The solution of (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl (Step 1.3, 350 mg, 1.23 mmol) and TEA (0.2 mL, 1.47 mmol) in MeOH (5 mL) was stirred for 15 min, then 8-hydroxyisoquinoline-5-carbaldehyde (191 mg, 1.10 mmol) and AcOH (0.01 mL) were added, and stirred at rt for 16 h under argon. Then NaBH₄ (232 mg, 6.13 mmol) was added at 0 °C and
- 15 stirred at rt for further 2 h. The reaction mixture was quenched with water and extracted with EtOAc twice. The combined organic portion was acidified with HCl solution (4M in 1,4-dioxane) (5.0 mL), washed with brine and dried over Na₂SO₄, filtered and concentrated in *vacuo*. Prep-HPLC (Column: KINETEX EVO (150 mm x 21.2 mm), 5.0 μ; Mobile Phase: 0.1% HCO₂H in water and acetonitrile) of the crude, followed by treatment with HCl solution (4M in 1,4-dioxane)
- 20 of the isolated product afforded 5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-ol, HCl. MS (ESI+) [Method 6A]: m/z 407.2 (M+H); Rt 1.28 min. ¹H NMR (400 MHz, CD₃OD) δ 9.84 (brs, 1H), 8.63 (brs, 2H), 8.29 (d, *J* = 8.4 Hz, 1H), 7.34 (d, *J* = 8.0 Hz, 1H), 7.28 (t, *J* = 9.2 Hz, 1H), 7.14 – 7.08 (m, 2H), 5.06 – 5.02 (m, 1H), 4.68 (s, 2H), 4.25 – 4.21 (m, 1H), 2.91 – 2.85 (m, 2H), 2.70 – 2.63 (m, 2H).
- 25 **Example 24: Synthesis of (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-*N*-((8-methylisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl**

Step 24.1: Synthesis of 8-methylisoquinoline




A sealed tube was charged with 8-bromoisoquinoline [CAS No. 63927-22-0] (1.5 g, 7.20 mmol), methylboronic acid (0.86 g, 14.40 mmol), K_3PO_4 (6.1 g, 28.74 mmol) and toluene (20 mL), degassed (argon) for 10 min. Then $Pd_2(dba)_3$ (0.65 g, 0.72 mmol) and S-PHOS (0.59 g, 1.44 mmol) were added, degassed, sealed tube was closed and heated at 125°C for 20 h. Reaction mixture was cooled to rt, diluted with water and extracted with EtOAc 3x's. The combined organic portion was washed with brine, dried over anhydrous Na_2SO_4 , filtered and concentrated in *vacuo* to yield the crude product. The crude was purified by flash chromatography (24 g SiliCycle column, 0 – 20% EtOAc in Hexane elution) to provide 8-methylisoquinoline (1.0 g, 95%). MS (ESI+) [Method 2A]: m/z 143.6 (M+H); Rt 0.46 min. 1H NMR (300 MHz, $CDCl_3$) δ 9.47 (s, 1H), 8.55 (d, J = 5.7 Hz, 1H), 7.89 – 7.55 (m, 3H), 7.40 (d, J = 6.9 Hz, 1H), 2.80 (s, 3H).

Step 24.2: Synthesis of 5-bromo-8-methylisoquinoline



To the solution of 8-methylisoquinoline (0.5 g, 3.49 mmol) in concentrated H_2SO_4 (5 mL), NBS (0.62 g, 3.49 mmol) was added at -10 °C, and stirred at rt for 16 h. The reaction mixture was poured dropwise onto ice, extracted with CH_2Cl_2 3x's. The combined organic portion was washed with brine, dried over anhydrous Na_2SO_4 , filtered and concentrated in *vacuo* to yield the crude product. The crude was purified by flash chromatography (12 g SiliCycle column, 0 – 20% EtOAc in Hexane elution) to provide 5-bromo-8-methylisoquinoline (0.55 g, 71%). MS (ESI+) [Method 1A]: m/z 221.8 (M+H); Rt 0.40 min. 1H NMR (400 MHz, CD_3OD) δ 9.38 (s, 1H), 8.56 (d, J = 6.0 Hz, 1H), 8.03 (d, J = 6.0 Hz, 1H), 7.92 (d, J = 8.0 Hz, 1H), 7.36 (d, J = 7.2 Hz, 1H), 2.75 (s, 3H).


Step 24.3: Synthesis of 8-methylisoquinoline-5-carbaldehyde



To the solution of 5-bromo-8-methylisoquinoline (0.25 g, 1.12 mmol) in dry THF (5 mL), n -BuLi (2.5M in THF) (0.65 mL, 1.68 mmol) was added dropwise at -78 °C and stirred for 30 min under argon atmosphere. Then anhydrous DMF (0.17 mL, 2.25 mmol) was added dropwise at -78 °C, temperature was raised to rt gradually and stirred for 1 h. Reaction mixture was quenched with 10% NH_4Cl solution and extracted with EtOAc 3x's. The combined organic portion was washed with brine solution, dried over anhydrous Na_2SO_4 , filtered and concentrated in *vacuo* to yield the crude product. The crude was purified by flash chromatography (12 g SiliCycle column, 0 – 30% EtOAc in Hexane elution) to provide 8-methylisoquinoline-5-carbaldehyde (80 mg, 41%). MS (ESI+) [Method 1A]: m/z 172.1 (M+H); Rt 0.15 min. 1H NMR (300 MHz, CD_3OD) δ 10.30 (s, 1H),

9.53 (s, 1H), 9.11 (dd, $J = 6.9, 1.2$ Hz, 1H), 8.63 (d, $J = 6.0$ Hz, 1H), 8.26 (d, $J = 7.2$ Hz, 1H), 7.70 (dd, $J = 7.8, 1.2$ Hz, 1H), 2.90 (s, 3H).

Step 24.4: Synthesis of (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-*N*-((8-methylisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl




5

The title compound was synthesized following the procedure as described in step 1.4, using (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl (Step 1.3, 70 mg, 0.24 mmol) and 8-methylisoquinoline-5-carbaldehyde (42 mg, 0.24 mmol). Prep-HPLC (Column: KINETEX EVO C18 (150 mm x 21.2 mm), 5.0 μ ; Mobile Phase: 0.02% NH_4OH in water and acetonitrile) of the crude, followed by treatment with HCl solution (4M in 1,4-dioxane) afforded (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-*N*-((8-methylisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl as brown solid (40 mg, 41%). MS (ESI+) [Method 1A]: m/z 404.8 (M+H); Rt 0.19 min. ^1H NMR (400 MHz, CD_3OD) δ 9.92 (brs, 1H), 8.75 (brs, 2H), 8.30 (d, $J = 7.6$ Hz, 1H), 7.94 (dd, $J = 7.6, 0.8$ Hz, 1H), 7.28 (t, $J = 9.6$ Hz, 1H), 7.15 – 7.08 (m, 2H), 5.06 – 5.01 (m, 1H), 4.79 (s, 2H), 4.28 – 4.24 (m, 1H), 2.96 (s, 3H), 2.94 – 2.87 (m, 2H), 2.71 – 2.63 (m, 2H).

15

Example 25: Synthesis of (5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)methanol, HCl

Step 25.1: Synthesis of 5,8-dibromoisquinoline



To the solution of isoquinoline [CAS No. 119-65-3] (2.0 g, 15.48 mmol) in concentrated H_2SO_4 (20 mL), NBS (8.26 g, 46.45 mmol) was added at -15°C , and stirred for 2 h. The reaction mixture was poured dropwise onto ice, basified with aqueous NH_4OH solution, extracted with EtOAc twice. The combined organic portion was washed with brine, dried over anhydrous Na_2SO_4 , filtered and concentrated in *vacuo* to yield the crude product. The crude was purified by flash chromatography (24 g SiliCycle column, 0 – 10% EtOAc in Hexane elution) to provide 5,8-dibromoisquinoline (4.0 g, 90%). MS (ESI+) [Method 1A]: m/z 285.8, 287.8, 289.8 (M+H); Rt 1.55 min. ^1H NMR (600 MHz, CDCl_3) δ 9.61 (s, 1H), 8.73 (d, $J = 4.8$ Hz, 1H), 7.99 (d, $J = 4.8$ Hz, 1H), 7.82 (d, $J = 7.8$ Hz, 1H), 7.22 (d, $J = 7.8$ Hz, 1H).


25

Step 25.2: Synthesis of 5-bromoisquinoline-8-carbaldehyde




The title compound was synthesized following the protocol reported in the patent WO2017/79162. To the solution of 5,8-dibromoisoquinoline (2.0 g, 6.97 mmol) in dry THF (20 mL), *n*-BuLi (2.5M in THF) (3.6 mL, 9.06 mmol) was added dropwise at -78 °C and stirred for 30 min under N₂ atmosphere. Then anhydrous DMF (1.88 mL, 2.36 mmol) was added dropwise at -78 °C, and stirred for 1 h. Reaction mixture was quenched with saturated NH₄Cl solution and extracted with EtOAc twice. The combined organic portion was washed with brine solution, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo* to yield the crude product. The crude was purified by flash chromatography (24 g SiliCycle column, 0 – 20% EtOAc in Hexane elution) to provide 5-bromoisoquinoline-8-carbaldehyde (300 mg, 18%) (30 mg 8-bromoisoquinoline-5-carbaldehyde was isolated as byproduct). MS (ESI+) [Method 1A]: *m/z* 235.8, 237.8 (M+H); Rt 1.69 min. ¹H NMR (400 MHz, CDCl₃) δ 10.57 (d, *J* = 1.6 Hz, 1H), 10.40 (s, 1H), 8.81 (d, *J* = 8.0 Hz, 1H), 8.17 (d, *J* = 10.4 Hz, 1H), 8.11 (dd, *J* = 7.6, 1.6 Hz, 1H), 7.94 (d, *J* = 10.4 Hz, 1H).

15 Step 25.3: Synthesis of (5-bromoisoquinolin-8-yl)methanol




To the stirred solution of 5-bromoisoquinoline-8-carbaldehyde (300 mg, 1.27 mmol) in anhydrous THF (5 mL), NaBH₄ (72 mg, 1.91 mmol) was added portion wise at 0 °C. Then MeOH (5 mL) was added dropwise and stirred at 0 °C for 2 h. Reaction was quenched with water and extracted with EtOAc twice. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The crude product obtained from two batches was combined and purified by flash chromatography (12 g SiliCycle column, 0 – 30% EtOAc in Hexane elution) to provide (5-bromoisoquinolin-8-yl)methanol (360 mg, 59%). MS (ESI+) [Method 1A]: *m/z* 238.0, 240.0 (M+H); Rt 0.16 min. ¹H NMR (300 MHz, CDCl₃) δ 9.54 (s, 1H), 8.67 (d, *J* = 5.7 Hz, 1H), 8.03 (dd, *J* = 6.0, 0.9 Hz, 1H), 7.95 (d, *J* = 7.8 Hz, 1H), 7.51 (d, *J* = 7.8 Hz, 1H), 5.24 (s, 2H).

25 Step 25.4: Synthesis of (5-vinylisoquinolin-8-yl)methanol




The stirred solution of (5-bromoisoquinolin-8-yl)methanol (300 mg, 1.26 mmol), potassium trifluoro(vinyl)borate (330 mg, 2.52 mmol) and TEA (0.35 mL, 2.52 mmol) in IPA (10 mL), was degassed with N₂ for 10 min. Then Pd(dppf)Cl₂.CH₂Cl₂ (100 mg, 0.13 mmol) was added, degassed and heated at 100 °C for 3 h under N₂. Reaction mixture was cooled to rt, diluted with water and extracted with EtOAc twice. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo* to yield the crude product. The crude was purified by flash chromatography (12 g SiliCycle column, 0 – 30% EtOAc in Hexane elution) to provide (5-vinylisoquinolin-8-yl)methanol (200 mg, 85%). MS (ESI+) [Method 6A]: m/z 185.9 (M+H); Rt 0.69 min.

10 Step 25.5: Synthesis of 8-(hydroxymethyl)isoquinoline-5-carbaldehyde



The title compound was prepared according to Step 5.2. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 30% EtOAc in Hexane elution) to provide 8-(hydroxymethyl)isoquinoline-5-carbaldehyde (120 mg, 59%). MS (ESI+) [Method 2A]: m/z 188.0 (M+H); Rt 0.56 min. ¹H NMR (400 MHz, DMSO-d₆) δ 10.38 (s, 1H), 9.59 (s, 1H), 8.95 (d, *J* = 6.0 Hz, 1H), 8.72 (d, *J* = 6.0 Hz, 1H), 8.42 (d, *J* = 7.6 Hz, 1H), 7.94 (d, *J* = 7.6 Hz, 1H), 5.73 (t, *J* = 5.6 Hz, 1H), 5.20 (d, *J* = 5.2 Hz, 2H).


Step 25.6: Synthesis of (5-((((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)methanol, HCl



20 A solution of (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl (Step 1.3, 60 mg, 0.21 mmol) and TEA (0.03 mL, 0.21 mmol) in MeOH (3 mL) was stirred at rt for 10 min. Then 8-(hydroxymethyl)isoquinoline-5-carbaldehyde (36 mg, 0.19 mmol) was added and stirred for 2 h. Finally NaBH₄ (16 mg, 0.42 mmol) was added at 0 °C and stirred at rt for further 3 h. The reaction mixture was diluted with water and extracted with EtOAc twice. The combined organic portion was washed with brine solution, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by prep-HPLC (Column: KINETEX C18 (150 mm x 21.2 mm), 5.0 μ; Mobile Phase: 0.02% NH₄OH in water and acetonitrile). The isolated product was stirred with HCl solution (4M in 1,4-dioxane) (1 mL) at rt for 1 h; then concentrated to dryness to afford (5-((((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-

yl)methanol, HCl (23 mg, 26%). MS (ESI+) [Method 6A]: m/z 421.30 (M+H); Rt 1.303 min. ^1H NMR (400 MHz, CD_3OD) δ 10.01 (s, 1H), 8.78 (s, 2H), 8.38 (d, $J = 7.6$ Hz, 1H), 8.10 (d, $J = 7.6$ Hz, 1H), 7.28 (t, $J = 9.6$ Hz, 1H), 7.14 – 7.08 (m, 2H), 5.27 (s, 2H), 5.07 – 5.03 (m, 1H), 4.82 (s, 2H), 4.29 – 4.26 (m, 1H), 2.93 – 2.89 (m, 2H), 2.72 – 2.66 (m, 2H).


5 **Example 26: Synthesis of (1*r*,3*r*)-3-(2,4-difluorophenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine**



The title compound was synthesized following the procedure as described in Step 25.6, using (1*r*,3*r*)-3-(2,4-difluorophenoxy)cyclobutan-1-amine, HCl (Step 15.2, 80 mg, 0.40 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 70 mg, 0.40 mmol). The residue was purified by prep-HPLC (Column: LUNA (250 mm x 21.20 mm), 5.0 μ ; Mobile Phase: 0.1% HCO_2H in water and acetonitrile) to afford (1*r*,3*r*)-3-(2,4-difluorophenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine (40 mg, 28%). MS (ESI+) [Method 6A]: m/z 359.2 (M+H); Rt 1.28 min. ^1H NMR (400 MHz, CD_3OD) δ 9.30 (s, 1H), 8.58 (d, $J = 6.4$ Hz, 1H), 8.26 (dd, $J = 9.2, 5.6$ Hz, 1H), 8.13 (d, $J = 6.0$ Hz, 1H), 7.60 (t, $J = 9.2$ Hz, 1H), 7.02 – 6.98 (m, 1H), 6.90 – 6.85 (m, 2H), 4.91 – 4.87 (m, 1H), 4.40 (d, $J = 2.0$ Hz, 2H), 3.87 – 3.83 (m, 1H), 2.51 – 2.48 (m, 4H).


Example 27: Synthesis of (1*r*,3*r*)-3-(3,4-difluorophenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl

Step 27.1: Synthesis of *tert*-butyl ((1*r*,3*r*)-3-(3,4-difluorophenoxy)cyclobutyl)




To the solution of *tert*-butyl ((1*s*,3*s*)-3-hydroxycyclobutyl)carbamate (0.4 g, 2.08 mmol) in THF (10 mL), 3,4-difluorophenol [CAS No. 2713-33-9] (0.27 g, 2.08 mmol), PPh_3 (0.8 g, 3.12 mmol) and diisopropyl azodicarboxylate (0.61 g, 3.12 mmol) were added at rt. The reaction mixture was stirred at 50 $^\circ\text{C}$ for 16 h under N_2 atmosphere. Reaction mixture was diluted with water and extracted with EtOAc 3x's. The combined organic portion was washed with brine solution, dried over anhydrous Na_2SO_4 , filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (8 g SiliCycle column, 0 – 20% EtOAc in Hexane elution) to provide *tert*-butyl ((1*r*,3*r*)-3-(3,4-difluorophenoxy)cyclobutyl)carbamate (0.5 g, 96%). ^1H NMR (300 MHz, CDCl_3) δ 7.08 – 6.96 (m, 1H), 6.71 – 6.43 (m, 2H), 4.72 – 4.67 (m, 1H), 4.31 – 4.26 (m, 1H), 2.58 – 2.49 (m, 2H), 2.40 – 2.34 (m, 2H), 1.45 (s, 9H).

Step 27.2: Synthesis of (1*r*,3*r*)-3-(3,4-difluorophenoxy)cyclobutan-1-amine, HCl



The solution of *tert*-butyl ((1*r*,3*r*)-3-(3,4-difluorophenoxy)cyclobutyl)carbamate (0.5 g, 1.67 mmol) and HCl (20% in 1,4-dioxane) (2.0 mL) was stirred at rt for 1 h. The reaction mixture was concentrated in *vacuo* and the residue was triturated with pentane, the solid appeared was
 5 filtered and dried to yield (1*r*,3*r*)-3-(3,4-difluorophenoxy)cyclobutan-1-amine, HCl (0.3 g, 75%).
¹H NMR (400 MHz, CD₃OD) δ 7.19 – 7.15 (m, 1H), 6.77 – 6.73 (m, 1H), 6.61 – 6.58 (m, 1H), 4.91 – 4.88 (m, 1H), 3.98 – 3.93 (m, 1H), 2.62 – 2.56 (m, 4H).


Step 27.3: Synthesis of (1*r*,3*r*)-3-(3,4-difluorophenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl



10 The title compound was synthesized following procedure as described in step 1.4, using (1*r*,3*r*)-3-(3,4-difluorophenoxy)cyclobutan-1-amine, HCl (70 mg, 0.14 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 45 mg, 0.12 mmol). Prep-HPLC (Column: YMC-ACTUS TRIART C18 (150 mm x 21.2 mm), 5.0 μ; Mobile Phase: 0.02% NH₄OH in water and acetonitrile) of the
 15 crude, followed by treatment with HCl solution (4M in 1,4-dioxane) afforded (1*r*,3*r*)-3-(3,4-difluorophenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl (10 mg, 18%). MS (ESI+) [Method 6A]: *m/z* 359.2 (M+H); Rt 1.30 min. ¹H NMR (400 MHz, CD₃OD) δ 9.88 (s, 1H), 8.80 – 8.76 (m, 3H), 8.03 (t, *J* = 9.6 Hz, 1H), 7.25 – 7.18 (m, 1H), 6.84 – 6.79 (m, 1H), 6.68 – 6.63 (m, 1H), 5.01 – 4.97 (m, 1H), 4.84 (d, *J* = 2.0 Hz, 2H), 4.32 – 4.27 (m, 1H), 2.92 – 2.85 (m,
 20 2H), 2.74 – 2.67 (m, 2H).

Example 28: Synthesis of (1*r*,3*r*)-3-(3-chloro-4-fluorophenoxy)-*N*-(isoquinolin-5-ylmethyl)cyclobutan-1-amine, HCl


Step 28.1: Synthesis of *tert*-butyl ((1*r*,3*r*)-3-(3-chloro-4-fluorophenoxy)cyclobutyl)carbamate



25 The following compound was synthesized following the procedure as described in Step 1.2, using *tert*-butyl ((1*s*,3*s*)-3-hydroxycyclobutyl)carbamate (0.6 g, 3.20 mmol) and 3-chloro-4-fluorophenol [CAS No. 2613-23-2] (0.46 g, 3.20 mmol). Reaction mixture was concentrated in *vacuo* and the residue was purified by flash chromatography (12 g SiliCycle column, 0 – 10% EtOAc in Hexane elution) to provide *tert*-butyl ((1*r*,3*r*)-3-(3-chloro-4-
 30 fluorophenoxy)cyclobutyl)carbamate (0.8 g, 79%). ¹H NMR (600 MHz, CDCl₃) δ 7.02 – 7.00 (m,


1H), 6.77 – 6.76 (m, 2H), 6.63 – 6.61 (m, 1H), 4.71 – 4.69 (m, 1H), 4.30 – 4.27 (m, 1H), 2.55 – 2.51 (m, 2H), 2.39 – 2.35 (m, 2H), 1.45 (s, 9H).

Step 28.2: Synthesis of (1*r*,3*r*)-3-(3-chloro-4-fluorophenoxy)cyclobutan-1-amine, HCl



- 5 A round bottom flask was charge with *tert*-butyl ((1*r*,3*r*)-3-(3-chloro-4-fluorophenoxy)cyclobutyl)carbamate (0.8 g, 2.53 mmol) and HCl solution (20% in 1,4-dioxane) (10 mL), and stirred at rt for 16 h. Then the reaction mixture was concentrated in *vacuo*. To the residue Et₂O was added, stirred for 10 min, the solid was collected by filtration and dried to yield (1*r*,3*r*)-3-(3-chloro-4-fluorophenoxy)cyclobutan-1-amine, HCl (0.5 g, 78%). MS (ESI+) [Method 6A]: *m/z* 216.1 (M+H); Rt 1.29 min. ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.38 (brs, 3H), 7.33 (t, *J* = 9.6 Hz, 1H), 7.01 – 6.98 (m, 1H), 6.84 – 6.78 (m, 1H), 5.02 – 4.96 (m, 1H), 3.81 – 3.77 (m, 1H), 2.64 – 2.55 (m, 2H), 2.42 – 2.35 (m, 2H).
- 10


Step 28.3: Synthesis of (1*r*,3*r*)-3-(3-chloro-4-fluorophenoxy)-*N*-(isoquinolin-5-ylmethyl)cyclobutan-1-amine, HCl



- 15 The title compound was synthesized following the procedure as described in step 1.4, using (1*r*,3*r*)-3-(3-chloro-4-fluorophenoxy)cyclobutan-1-amine, HCl (80 mg, 0.32 mmol) and isoquinoline-5-carbaldehyde (45 mg, 0.29 mmol). Prep-HPLC (Column: KINETEX C18 (150 mm x 21.2 mm), 5.0 μ; Mobile Phase: 0.02% NH₄OH in water and acetonitrile) of the crude, followed by treatment with HCl solution (4M in 1,4-dioxane) afforded (1*r*,3*r*)-3-(3-chloro-4-fluorophenoxy)-*N*-(isoquinolin-5-ylmethyl)cyclobutan-1-amine, HCl (110 mg, 88%). MS (ESI+) [Method 6A]: *m/z* 357.3 (M+H); Rt 0.14 min. ¹H NMR (400 MHz, CD₃OD) δ 9.91 (s, 1H), 8.83 (d, *J* = 6.8 Hz, 1H), 8.75 (d, *J* = 6.8 Hz, 1H), 8.64 (d, *J* = 8.0 Hz, 1H), 8.48 (d, *J* = 7.2 Hz, 1H), 8.14 (dd, *J* = 8.4, 7.6 Hz, 1H), 7.17 (d, *J* = 8.8 Hz, 1H), 6.97 – 6.95 (m, 1H), 6.83 – 6.79 (m, 1H), 5.02 – 4.98 (m, 1H), 4.85 (s, 2H), 4.29 – 4.25 (m, 1H), 2.95 – 2.88 (m, 2H), 2.70 – 2.63 (m, 2H).
- 20
- 25


Example 29: Synthesis of (1*r*,3*r*)-3-(3-(difluoromethoxy)phenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl

Step 29.1: Synthesis of *tert*-butyl ((1*r*,3*r*)-3-(3-(difluoromethoxy)phenoxy)cyclobutyl)carbamate




The title compound was synthesized following the procedure as described in Step 1.2, using *tert*-butyl ((1*s*,3*s*)-3-hydroxycyclobutyl)carbamate (0.4 g, 2.14 mmol) and 3-(difluoromethoxy)phenol [CAS No. 88798-13-4] (0.35 g, 2.14 mmol). *tert*-butyl ((1*r*,3*r*)-3-(3-(difluoromethoxy)phenoxy)cyclobutyl)carbamate was isolated (0.6 g, 84%). ¹H NMR (600 MHz, CDCl₃) δ 7.23 – 7.18 (m, 2H), 6.68 – 6.61 (m, 1H), 6.61 – 6.59 (m, 1H), 6.51 (t, *J* = 95.4 Hz, 1H), 4.75 – 4.73 (m, 1H), 4.30 – 4.27 (m, 1H), 2.55 – 2.53 (m, 2H), 2.39 – 2.35 (m, 2H), 1.44 (s, 9H).

Step 29.2: Synthesis of (1*r*,3*r*)-3-(3-(difluoromethoxy)phenoxy)cyclobutan-1-amine, HCl




A round bottom flask was charged with *tert*-butyl ((1*r*,3*r*)-3-(3-(difluoromethoxy)phenoxy)cyclobutyl)carbamate (0.6 g, 1.81 mmol) and HCl solution (20% in 1,4-dioxane) (5 mL), and stirred at rt for 1 h. Then the reaction mixture was concentrated in *vacuo*. The residue was triturated with Et₂O, solid was collected by filtration and dried to yield (1*r*,3*r*)-3-(3-(difluoromethoxy)phenoxy)cyclobutan-1-amine, HCl (0.35 g, 72%). ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.24 (brs, 3H), 7.34 (t, *J* = 8.4 Hz, 1H), 7.25 (t, *J* = 74.4 Hz, 1H), 6.78 – 6.75 (m, 1H), 6.71 – 6.68 (m, 1H), 6.62 – 6.60 (m, 1H), 5.02 – 4.97 (m, 1H), 3.84 – 3.79 (m, 1H), 2.63 – 2.57 (m, 2H), 2.46 – 2.41 (m, 2H).


Step 29.3: Synthesis of (1*r*,3*r*)-3-(3-(difluoromethoxy)phenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl




The title compound was synthesized following the procedure as described in Step 25.6, using (1*r*,3*r*)-3-(3-(difluoromethoxy)phenoxy)cyclobutan-1-amine, HCl (300 mg, 1.13 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 176 mg, 1.01 mmol). Prep-HPLC (Column: LUNA Phenomenex (250 mm x 21.2 mm), 5.0 μ; Mobile Phase: 0.01% HCO₂H in water and acetonitrile-MeOH) of the crude, followed by treatment with HCl solution (4M in 1,4-dioxane) afforded (1*r*,3*r*)-3-(3-(difluoromethoxy)phenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl (140 mg, 30%). MS (ESI+) [Method 6A]: *m/z* 389.1 (M+H); Rt 1.29 min. ¹H NMR (400 MHz, CD₃OD) δ 9.83 (s, 1H), 8.80 – 8.71 (m, 3H), 8.00 (t, *J* = 9.2 Hz, 1H), 7.33 (d, *J* = 8.0 Hz, 1H), 6.84 (t, *J* = 74.0 Hz, 1H), 6.78 (dd, *J* = 8.0, 2.0 Hz, 1H), 6.74 – 6.71 (m, 1H), 6.64 – 6.62 (m, 1H), 5.05 – 4.99 (m, 1H), 4.83 (d, *J* = 2.0 Hz, 2H), 4.31 – 4.26 (m, 1H), 2.91 – 2.84 (m, 2H), 2.75 – 2.68 (m, 2H).

Example 30: Synthesis of (1*r*,3*r*)-3-(4-(difluoromethoxy)phenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HClStep 30.1: Synthesis of 1-(benzyloxy)-4-(difluoromethoxy)benzene

- 5 To the solution of 4-(benzyloxy)phenol [CAS No. 103-16-2] (1.0 g, 4.99 mmol) in DMF – water (8.2 mL, 40:1 v/v), sodium 2-chloro-2,2-difluoroacetate (1.14 g, 7.49 mmol) and NaOH (0.24 g, 5.99 mmol) were added and the reaction mixture was heated as 130 °C for 2 h under N₂. Reaction mixture was diluted with water and extracted with EtOAc twice. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in
- 10 *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, Hexane elution) to provide 1-(benzyloxy)-4-(difluoromethoxy)benzene (0.15 g, 12%). MS (ESI+) [Method 6A]: m/z 249.1 (M-H); Rt 1.63 min.


Step 30.2: Synthesis of 4-(difluoromethoxy)phenol

- 15 To the solution of 1-(benzyloxy)-4-(difluoromethoxy)benzene (300 mg, 1.20 mmol) in THF (10 mL), Pd/C (10% w/w) (50 mg) was added under argon. Reaction mixture was degassed, connected with H₂ balloon and stirred at rt for 2 h. Reaction mixture was filtered through celite bed, the bed was washed with EtOAc. The combined filtrate was concentrated in *vacuo* to afford 4-(difluoromethoxy)phenol (200 mg, 104%). MS (ESI+) [Method 6A]: m/z 159.1 (M-H); Rt
- 20 1.44 min. ¹H NMR (300 MHz, CDCl₃) δ 7.02 (d, *J* = 8.7 Hz, 2H), 6.80 (dd, *J* = 6.6, 2.1 Hz, 2H), 6.41 (t, *J* = 74.1 Hz, 1H).

Step 30.3: Synthesis of *tert*-butyl ((1*r*,3*r*)-3-(4-(difluoromethoxy)phenoxy)cyclobutyl)carbamate

- The title compound was synthesized following the procedure as described in Step 1.2, using
- 25 *tert*-butyl ((1*s*,3*s*)-3-hydroxycyclobutyl)carbamate (230 mg, 1.25 mmol) and 4-(difluoromethoxy)phenol (200 mg, 1.25 mmol). The crude product was purified by flash chromatography (12 g SiliCycle column, 0 – 10% EtOAc in Hexane elution) to provide *tert*-butyl ((1*r*,3*r*)-3-(4-(difluoromethoxy)phenoxy)cyclobutyl)carbamate (200 mg, 48%). MS (ESI+) [Method 6A]: m/z 659.2 (2M+H); Rt 1.44 min. ¹H NMR (300 MHz, CDCl₃) δ 7.04 (d, *J* = 8.7 Hz, 2H), 6.73 (d, *J* = 9.3 Hz, 2H), 6.41 (t, *J* = 74.1 Hz, 1H), 4.77 – 4.71 (m, 1H), 4.32 – 4.28 (m, 1H),
- 30 2.59 – 2.50 (m, 2H), 2.41 – 2.35 (m, 2H), 1.45 (s, 9H).


Step 30.4: Synthesis of (1*r*,3*r*)-3-(4-(difluoromethoxy)phenoxy)cyclobutan-1-amine, HCl



The solution of *tert*-butyl ((1*r*,3*r*)-3-(4-(difluoromethoxy)phenoxy)cyclobutyl)carbamate (0.2 g, 0.61 mmol) and HCl solution (20% in 1,4-dioxane) (4 mL) was stirred at rt for 4 h. Then the reaction mixture was concentrated in *vacuo* to yield crude (1*r*,3*r*)-3-(4-

- 5 (difluoromethoxy)phenoxy)cyclobutan-1-amine, HCl (0.2 g, 124%). MS (ESI+) [Method 6A]: *m/z* 230.7 (M-H); Rt 1.28 min.


Step 30.5: Synthesis of (1*r*,3*r*)-3-(4-(difluoromethoxy)phenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl



- 10 The title compound was synthesized following the procedure as described in Step 25.6, using (1*r*,3*r*)-3-(4-(difluoromethoxy)phenoxy)cyclobutan-1-amine, HCl (200 mg, 0.87 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 152 mg, 0.87 mmol). Prep-HPLC (Column: LUNA C18 (250 mm x 21.2 mm), 5.0 μ ; Mobile Phase: 0.01% HCO₂H in water and acetonitrile-MeOH (1:1)) of the crude, followed by treatment with HCl solution (4M in 1,4-dioxane) afforded (1*r*,3*r*)-
- 15 3-(4-(difluoromethoxy)phenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl (120 mg, 36%). MS (ESI+) [Method 6A]: *m/z* 389.2 (M+H); Rt 1.28 min. ¹H NMR (400 MHz, CD₃OD) δ 9.91 (s, 1H), 8.86 – 8.78 (m, 3H), 8.04 (t, *J* = 9.6 Hz, 1H), 7.09 (dd, *J* = 6.8, 1.6 Hz, 2H), 6.87 – 6.85 (m, 2H), 6.69 (t, *J* = 74.4 Hz, 1H), 5.01 – 4.98 (m, 1H), 4.83 (d, *J* = 2.0 Hz, 2H), 4.28 – 4.24 (m, 1H), 2.89 – 2.84 (m, 2H), 2.72 – 2.65 (m, 2H).


- 20 **Example 31: Synthesis of (1*r*,3*r*)-*N*-((6-fluoroisoquinolin-5-yl)methyl)-3-(naphthalen-2-yloxy)cyclobutan-1-amine, HCl**

Step 31.1: Synthesis of *tert*-butyl ((1*r*,3*r*)-3-(naphthalen-2-yloxy)cyclobutyl)carbamate




- The title compound was synthesized following the procedure as described in Step 1.2, using
- 25 *tert*-butyl ((1*s*,3*s*)-3-hydroxycyclobutyl)carbamate (250 mg, 1.34 mmol) and naphthalen-2-ol [CAS No. 135-19-3] (212 mg, 1.47 mmol). Product was purified by flash chromatography (12 g SiliCycle column, 0 – 30% EtOAc in Hexane elution) to provide *tert*-butyl ((1*r*,3*r*)-3-(naphthalen-2-yloxy)cyclobutyl)carbamate (220 mg, 52%). ¹H NMR (400 MHz, CDCl₃) δ 7.78 – 7.72 (m, 2H), 7.70 – 7.66 (m, 1H), 7.44 – 7.39 (m, 1H), 7.34 – 7.29 (m, 1H), 7.15 – 7.08 (m, 2H), 4.95 – 4.90
- 30 (m, 1H), 4.34 – 4.29 (m, 1H), 2.67 – 2.58 (m, 2H), 2.49 – 2.42 (m, 2H), 1.46 (s, 9H).

Step 31.2: Synthesis of (1*r*,3*r*)-3-(naphthalen-2-yloxy)cyclobutan-1-amine, HCl




The solution of *tert*-butyl ((1*r*,3*r*)-3-(naphthalen-2-yloxy)cyclobutyl)carbamate (220 mg, 0.70 mmol) and HCl solution (20% in 1,4-dioxane) (3 mL) was stirred at rt for 3 h. Then the reaction mixture was concentrated in *vacuo*, and triturated with Et₂O to yield (1*r*,3*r*)-3-(naphthalen-2-yloxy)cyclobutan-1-amine, HCl (90 mg, 51%). MS (ESI+) [Method 6A]: *m/z* 214.0 (M+H); Rt 1.32 min.

Step 31.3: Synthesis of (1*r*,3*r*)-*N*-((6-fluoroisoquinolin-5-yl)methyl)-3-(naphthalen-2-yloxy)cyclobutan-1-amine, HCl




- 10 The title compound was synthesized following the procedure as described in Step 1.4, using (1*r*,3*r*)-3-(naphthalen-2-yloxy)cyclobutan-1-amine, HCl (90 mg, 0.36 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 64 mg, 0.36 mmol). Prep-HPLC (Column: GEMINI NX C18 (150 mm x 21.2 mm), 5.0 μ; Mobile Phase: 0.02% NH₄OH in water and acetonitrile) of the crude, followed by treatment with HCl solution (4M in 1,4-dioxane) afforded (1*r*,3*r*)-*N*-((6-fluoroisoquinolin-5-yl)methyl)-3-(naphthalen-2-yloxy)cyclobutan-1-amine, HCl (90 mg, 63%). MS (ESI+) [Method 6A]: *m/z* 373.2 (M+H); Rt 1.30 min. ¹H NMR (400 MHz, CD₃OD) δ 9.85 (s, 1H), 8.78 – 8.73 (m, 3H), 8.01 (t, *J* = 9.6 Hz, 1H), 7.80 – 7.73 (m, 3H), 7.43 (td, *J* = 6.8, 1.2 Hz, 1H), 7.33 (td, *J* = 6.8, 1.2 Hz, 1H), 7.12 (dd, *J* = 8.8, 2.4 Hz, 1H), 7.05 – 7.04 (m, 1H), 5.16 – 5.12 (m, 1H), 4.84 (d, *J* = 2.0 Hz, 2H), 4.32 – 4.29 (m, 1H), 2.98 – 2.92 (m, 2H), 2.80 – 2.73 (m, 2H).
- 15
- 20 **Example 32: Synthesis of (1*r*,3*r*)-*N*-((6-fluoroisoquinolin-5-yl)methyl)-3-((7-fluoronaphthalen-2-yl)oxy)cyclobutan-1-amine, HCl**


Step 32.1: Synthesis of *tert*-butyl ((1*r*,3*r*)-3-((7-fluoronaphthalen-2-yl)oxy)cyclobutyl)carbamate




- The title compound was synthesized following the procedure as described in Step 1.2, using *tert*-butyl ((1*s*,3*s*)-3-hydroxycyclobutyl)carbamate (200 g, 1.23 mmol) and 7-fluoronaphthalen-2-ol [CAS No. 889884-94-0] (231 g, 1.23 mmol). The crude product was purified by flash chromatography (12 g SiliCycle column, 0 – 30% EtOAc in Hexane elution) to provide *tert*-butyl ((1*r*,3*r*)-3-((7-fluoronaphthalen-2-yl)oxy)cyclobutyl)carbamate (240 g, 58%). ¹H NMR (300 MHz, CDCl₃) δ 7.75 – 7.70 (m, 2H), 7.32 – 7.28 (m, 1H), 7.12 – 7.02 (m, 2H), 6.83 (d, *J* = 3.0 Hz, 1H), 4.94 – 4.87 (m, 1H), 4.36 – 4.30 (m, 1H), 2.67 – 2.59 (m, 2H), 2.49 – 2.42 (m, 2H), 1.46 (s, 9H).
- 25
- 30

Step 32.2: Synthesis of (1*r*,3*r*)-3-((7-fluoronaphthalen-2-yl)oxy)cyclobutan-1-amine, HCl

The solution of *tert*-butyl ((1*r*,3*r*)-3-((7-fluoronaphthalen-2-yl)oxy)cyclobutyl)carbamate (240 mg, 0.72 mmol) and HCl solution (20% in 1,4-dioxane) (6 mL) was stirred at rt for 1 h. Then the reaction mixture was concentrated in *vacuo*, and triturated with Et₂O to yield (1*r*,3*r*)-3-((7-fluoronaphthalen-2-yl)oxy)cyclobutan-1-amine, HCl (170 mg, 87%). MS (ESI+) [Method 6A]: *m/z* 232.2 (M+H); Rt 1.29 min.

Step 32.3: Synthesis of (1*r*,3*r*)-*N*-((6-fluoroisoquinolin-5-yl)methyl)-3-((7-fluoronaphthalen-2-yl)oxy)cyclobutan-1-amine, HCl


The title compound was synthesized following the procedure as described in Step 1.4, using (1*r*,3*r*)-3-((7-fluoronaphthalen-2-yl)oxy)cyclobutan-1-amine, HCl (170 mg, 0.64 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 100 mg, 0.57 mmol). Crude product was purified by prep-HPLC (Column: LUNA Phenomenex (250 mm x 21.2 mm), 5.0 μ; Mobile Phase: 0.1% HCO₂H in water and acetonitrile). The isolated product was stirred with HCl solution (4M in 1,4-dioxane) (3 mL) at rt for 1 h. Then concentrated and the residue was triturated with Et₂O to provide (1*r*,3*r*)-*N*-((6-fluoroisoquinolin-5-yl)methyl)-3-((7-fluoronaphthalen-2-yl)oxy)cyclobutan-1-amine, HCl (90 mg, 33%). MS (ESI+) [Method 6A]: *m/z* 391.0 (M+H); Rt 1.35 min. ¹H NMR (400 MHz, CD₃OD) δ 9.79 (s, 1H), 8.88 – 8.69 (m, 3H), 8.01 (t, *J* = 9.2 Hz, 1H), 7.83 – 7.80 (m, 2H), 7.41 (d, *J* = 7.6 Hz, 1H), 7.16 – 7.08 (m, 2H), 7.04 – 7.02 (m, 1H), 5.15 – 5.11 (m, 1H), 4.84 (s, 2H), 4.32 – 4.28 (m, 1H), 2.96 – 2.89 (m, 2H), 2.79 – 2.74 (m, 2H).

Example 33: Synthesis of (1*r*,3*r*)-*N*-((6-fluoroisoquinolin-5-yl)methyl)-3-(3-(pentafluoro-λ⁶-sulfaneyl)phenoxy)cyclobutan-1-amine, HClStep 33.1: Synthesis of *tert*-butyl ((1*r*,3*r*)-3-(3-(pentafluoro-λ⁶-sulfaneyl)phenoxy)cyclobutyl)carbamate [C-07717-111]

The title compound was synthesized following the procedure as described in Step 1.2, using *tert*-butyl ((1*s*,3*s*)-3-hydroxycyclobutyl)carbamate (120 mg, 0.64 mmol) and 3-(pentafluoro-λ⁶-sulfaneyl)phenol [CAS No. 672-31-1] (150 g, 0.68 mmol). The crude was purified by flash

chromatography (8 g SiliCycle column, 0 – 8% EtOAc in Hexane elution) to provide *tert*-butyl ((1*r*,3*r*)-3-(3-(pentafluoro- λ^6 -sulfaneyl)phenoxy)cyclobutyl)carbamate (150 mg, 60%). ¹H NMR (300 MHz, CDCl₃) δ 7.34 – 7.32 (m, 2H), 7.15 (s, 1H), 6.90 – 6.87 (m, 1H), 4.83 – 4.77 (m, 1H), 4.32 – 4.27 (m, 1H), 2.59 – 2.53 (m, 2H), 2.46 – 2.37 (m, 2H), 1.45 (s, 9H).


5 Step 33.2: Synthesis of (1*r*,3*r*)-3-(3-(pentafluoro- λ^6 -sulfaneyl)phenoxy)cyclobutan-1-amine, HCl



The solution of *tert*-butyl ((1*r*,3*r*)-3-(3-(pentafluoro- λ^6 -sulfaneyl)phenoxy)cyclobutyl)carbamate (150 mg, 0.39 mmol) and HCl solution (20% in 1,4-dioxane) (2 mL) was stirred at rt for 1 h.

Then the reaction mixture was concentrated in *vacuo*, and triturated with Et₂O to yield (1*r*,3*r*)-3-(3-(pentafluoro- λ^6 -sulfaneyl)phenoxy)cyclobutan-1-amine, HCl (100 mg, 91%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.31 (s, 3H), 7.65 – 7.48 (m, 2H), 7.33 (dd, *J* = 7.2, 2.0 Hz, 1H), 7.13 (dd, *J* = 8.0, 2.0 Hz, 1H), 5.12 – 5.08 (m, 1H), 3.87 – 3.81 (m, 1H), 2.64 – 2.59 (m, 2H), 2.49 – 2.43 (m, 2H).


15 Step 33.3: Synthesis of (1*r*,3*r*)-*N*-((6-fluoroisoquinolin-5-yl)methyl)-3-(3-(pentafluoro- λ^6 -sulfaneyl)phenoxy)cyclobutan-1-amine, HCl



The title compound was synthesized following the procedure as described in Step 25.6, using (1*r*,3*r*)-3-(3-(pentafluoro- λ^6 -sulfaneyl)phenoxy)cyclobutan-1-amine, HCl (70 mg, 0.21 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 32 mg, 0.18 mmol). Crude product was purified by prep-HPLC (Column: GEMINI-NX (150 mm x 21.2 mm), 5.0 μ ; Mobile Phase: 0.02% NH₄OH in water and acetonitrile). The isolated product was stirred with HCl solution (4M in 1,4-dioxane) (1 mL) at rt for 1 h. Then concentrated to provide (1*r*,3*r*)-*N*-((6-fluoroisoquinolin-5-yl)methyl)-3-(3-(pentafluoro- λ^6 -sulfaneyl)phenoxy)cyclobutan-1-amine, HCl (20 mg, 20%). MS (ESI+) [Method 6A]: *m/z* 449.1 (*M*+*H*); *Rt* 1.34 min. ¹H NMR (400 MHz, CD₃OD) δ 9.85 (s, 1H), 8.80 – 8.73 (m, 3H), 8.01 (t, *J* = 9.6 Hz, 1H), 7.51 (t, *J* = 8.4 Hz, 1H), 7.46 – 7.43 (m, 1H), 7.28 – 7.27 (m, 1H), 7.10 (dd, *J* = 8.4, 2.0 Hz, 1H), 5.12 – 5.07 (m, 1H), 4.84 (d, *J* = 2.0 Hz, 2H), 4.32 – 4.28 (m, 1H), 2.95 – 2.88 (m, 2H), 2.70 – 2.67 (m, 2H).

Example 34: Synthesis of ethyl 3-((1*r*,3*r*)-3-(((6-fluoroisoquinolin-5-yl)methyl)amino)cyclobutoxy)benzoate, HCl


30 Step 34.1: Synthesis of ethyl 3-((1*r*,3*r*)-3-((*tert*-butoxycarbonyl)amino)cyclobutoxy)benzoate



The title compound was synthesized following the procedure as described under Step 1.2, using *tert*-butyl ((1*s*,3*s*)-3-hydroxycyclobutyl)carbamate (200 mg, 1.07 mmol) and ethyl 3-hydroxybenzoate [CAS No. 7781-98-8] (195 g, 1.18 mmol). The crude product was purified by

- 5 flash chromatography (12 g SiliCycle column, 0 – 40% EtOAc in Hexane elution) to provide ethyl 3-((1*r*,3*r*)-3-((*tert*-butoxycarbonyl)amino)cyclobutoxy)benzoate as off white solid (220 mg, 61%). ¹H NMR (300 MHz, DMSO-*d*₆) δ 7.54 – 7.51 (m, 1H), 7.42 (t, *J* = 7.5 Hz, 1H), 7.34 – 7.30 (m, 2H), 7.12 – 7.08 (m, 1H), 4.88 – 4.84 (m, 1H), 4.30 (q, *J* = 6.9 Hz, 2H), 4.12 – 3.97 (m, 1H), 2.38 – 2.31 (m, 4H), 1.38 (s, 9H), 1.31 (t, *J* = 6.9 Hz, 3H).

10 Step 34.2: Synthesis of ethyl 3-((1*r*,3*r*)-3-aminocyclobutoxy)benzoate, HCl




The solution of ethyl 3-((1*r*,3*r*)-3-((*tert*-butoxycarbonyl)amino)cyclobutoxy)benzoate (220 mg, 0.66 mmol) and HCl solution (20% in 1,4-dioxane) (5 mL) was stirred at rt for 2 h. Then the reaction mixture was concentrated in *vacuo*, and triturated with Et₂O to yield ethyl 3-((1*r*,3*r*)-3-

- 15 aminocyclobutoxy)benzoate, HCl (120 mg, 67%). MS (ESI+) [Method 6A]: *m/z* 236.2 (M+H); Rt 1.31 min. ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.22 (s, 3H), 7.58 – 7.55 (m, 1H), 7.46 (t, *J* = 8.1 Hz, 1H), 7.31 (s, 1H), 7.11 (dd, *J* = 8.1, 1.8 Hz, 1H), 5.08 – 5.04 (m, 1H), 4.31 (q, *J* = 6.9 Hz, 2H), 3.87 – 3.83 (m, 1H), 2.60 – 2.49 (m, 4H), 1.31 (t, *J* = 6.9 Hz, 3H).

Step 34.3: Synthesis of ethyl 3-((1*r*,3*r*)-3-(((6-fluoroisoquinolin-5-

- 20 yl)methyl)amino)cyclobutoxy)benzoate, HCl




The title compound was synthesized following the procedure as described in Step 1.4, using ethyl 3-((1*r*,3*r*)-3-aminocyclobutoxy)benzoate, HCl (80 mg, 0.30 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 46 mg, 0.27 mmol). Crude product was purified by prep-HPLC

- 25 (Column: LUNA C18 (250 mm x 21.0 mm), 5.0 μ ; Mobile Phase: 0.01% HCO₂H in water and acetonitrile). The isolated product was stirred with HCl solution (4M in 1,4-dioxane) (2 mL) at rt for 1 h. Then concentrated and then the residue was triturated with Et₂O to provide ethyl 3-((1*r*,3*r*)-3-(((6-fluoroisoquinolin-5-yl)methyl)amino)cyclobutoxy)benzoate, HCl (40 mg, 31%). MS (ESI+) [Method 6A]: *m/z* 395.1 (M+H); Rt 1.32 min. ¹H NMR (400 MHz, CD₃OD) δ 9.85 (s, 1H), 8.81 – 8.75 (m, 3H), 8.02 (t, *J* = 9.2 Hz, 1H), 7.67 (dt, *J* = 9.2, 1.6 Hz, m, 1H), 7.45 – 7.41 (m,
- 30

2H), 7.12 (ddd, $J = 8.4, 2.8, 0.8$ Hz, 1H), 5.09 – 5.06 (m, 1H), 4.85 (d, $J = 2.0$ Hz, 2H), 4.38 (q, $J = 7.2$ Hz, 2H), 4.33 – 4.28 (m, 1H), 2.92 – 2.87 (m, 2H), 2.77 – 2.71 (m, 2H), 1.40 (t, $J = 7.2$ Hz, 3H).


Example 35: Synthesis of (1*r*,3*r*)-3-(2,3-difluorophenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine

Step 35.1: Synthesis of *tert*-butyl ((1*r*,3*r*)-3-(2,3-difluorophenoxy)cyclobutyl)carbamate




The title compound was synthesized following the procedure as described in Step 1.2, using *tert*-butyl ((1*s*,3*s*)-3-hydroxycyclobutyl)carbamate (100 mg, 0.53 mmol) and 2,3-difluorophenol [6418-38-8] (70 mg, 0.53 mmol). The crude product was purified by flash chromatography (4 g SiliCycle column, 0 – 10% EtOAc in Hexane elution) to provide *tert*-butyl ((1*r*,3*r*)-3-(2,3-difluorophenoxy)cyclobutyl)carbamate (110 mg, 68%). ¹H NMR (600 MHz, CDCl₃) δ 6.94 – 6.91 (m, 1H), 6.76 – 6.73 (m, 1H), 6.52 – 6.49 (m, 1H), 4.74 – 4.71 (m, 1H), 4.32 – 4.28 (m, 1H), 2.63 – 2.59 (m, 2H), 2.43 – 2.38 (m, 2H), 1.45 (s, 9H).

Step 35.2: Synthesis of (1*r*,3*r*)-3-(2,3-difluorophenoxy)cyclobutan-1-amine, HCl



A round bottom flask was charged with *tert*-butyl ((1*r*,3*r*)-3-(2,3-difluorophenoxy)cyclobutyl)carbamate (110 mg, 0.37 mmol) and HCl solution (20% in 1,4-dioxane) (2 mL), and stirred at rt for 16 h. Then the reaction mixture was concentrated in *vacuo* to yield crude (1*r*,3*r*)-3-(2,3-difluorophenoxy)cyclobutan-1-amine, HCl (90 mg, 122%). MS (ESI+) [Method 6A]: m/z 200.1 (M+H); Rt 1.25 min.

Step 35.3: Synthesis of (1*r*,3*r*)-3-(2,3-difluorophenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine




The title compound was synthesized following the procedure as described in Step 25.6, using (1*r*,3*r*)-3-(2,3-difluorophenoxy)cyclobutan-1-amine, HCl (110 mg, 0.55 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 96 mg, 0.55 mmol). Crude product was purified by prep-HPLC (Column: LUNA C18 (250 mm x 21.0 mm), 5.0 μ ; Mobile Phase: 0.01% HCO₂H in water and acetonitrile) to provide (1*r*,3*r*)-3-(2,3-difluorophenoxy)-*N*-((6-fluoroisoquinolin-5-

yl)methyl)cyclobutan-1-amine (40 mg, 21%). MS (ESI+) [Method 1A]: m/z 359.0 (M+H); Rt 0.13 min. ^1H NMR (400 MHz, CD_3OD) δ 9.33 (s, 1H), 8.61 (s, 1H), 8.29 (dd, J = 9.6, 6.0 Hz, 1H), 8.15 (d, J = 6.0 Hz, 1H), 7.62 (t, J = 9.6 Hz, 1H), 7.09 – 7.02 (m, 1H), 6.89 – 6.82 (m, 1H), 6.72 – 6.68 (m, 1H), 4.98 – 4.94 (m, 1H), 4.47 (s, 2H), 3.97 – 3.93 (m, 1H), 2.58 (t, J = 5.6 Hz, 4H).


5 Example 36: Synthesis of (1*r*,3*r*)-*N*-((6-fluoroisoquinolin-5-yl)methyl)-3-(4-(trifluoromethoxy)phenoxy)cyclobutan-1-amine, HCl

Step 36.1: Synthesis of *tert*-butyl ((1*r*,3*r*)-3-(4-(trifluoromethoxy)phenoxy)cyclobutyl)carbamate




The title compound was synthesized following the procedure as described in Step 1.2, using *tert*-butyl ((1*s*,3*s*)-3-hydroxycyclobutyl)carbamate (380 mg, 2.14 mmol) and 4-(trifluoromethoxy)phenol [CAS No. 828-27-3] (400 mg, 2.14 mmol). The crude product was purified by flash chromatography (12 g SiliCycle column, 0 – 20% EtOAc in Hexane elution) to provide *tert*-butyl ((1*r*,3*r*)-3-(4-(trifluoromethoxy)phenoxy)cyclobutyl)carbamate (330 mg, 44%). ^1H NMR (600 MHz, CDCl_3) δ 7.11 (d, J = 7.8 Hz, 2H), 6.74 (d, J = 9.0 Hz, 2H), 4.76 – 4.74 (m, 1H), 4.31 – 4.27 (m, 1H), 2.57 – 2.53 (m, 2H), 2.40 – 2.37 (m, 2H), 1.45 (s, 9H).

Step 36.2: Synthesis of (1*r*,3*r*)-3-(4-(trifluoromethoxy)phenoxy)cyclobutan-1-amine, HCl



A round bottom flask was charged with *tert*-butyl ((1*r*,3*r*)-3-(4-(trifluoromethoxy)phenoxy)cyclobutyl)carbamate (330 mg, 0.95 mmol) and HCl solution (20% in 1,4-dioxane) (5 mL), and stirred at rt for 2 h. Then the reaction mixture was concentrated in *vacuo*, the residue was triturated with Et_2O , solid collected by filtration and dried to provide (1*r*,3*r*)-3-(4-(trifluoromethoxy)phenoxy)cyclobutan-1-amine, HCl (210 mg, 77%). MS (ESI+) [Method 6A]: m/z 248.1 (M+H); Rt 1.35 min. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 8.26 (s, 3H), 7.31 (d, J = 8.0 Hz, 2H), 6.90 (d, J = 8.8 Hz, 2H), 5.01 – 4.98 (m, 1H), 3.85 – 3.81 (m, 1H), 2.63 – 2.57 (m, 2H), 2.46 – 2.42 (m, 2H).

Step 36.3: Synthesis of (1*r*,3*r*)-*N*-((6-fluoroisoquinolin-5-yl)methyl)-3-(4-(trifluoromethoxy)phenoxy)cyclobutan-1-amine, HCl




The title compound was synthesized following the procedure as described in Step 25.6, using (1*r*,3*r*)-3-(4-(trifluoromethoxy)phenoxy)cyclobutan-1-amine, HCl (210 mg, 0.74 mmol) and 6-

fluoroisoquinoline-5-carbaldehyde (Step 3.1, 110 mg, 0.67 mmol). Crude product was purified by prep-HPLC (Column: LUNA C18 (250 mm x 21.0 mm), 5.0 μ ; Mobile Phase: 0.01% HCO₂H in water and acetonitrile). The isolated product was stirred with HCl solution (4M in 1,4-dioxane) (1 mL) at rt for 1 h. Then concentrated in *vacuo*, residue was triturated with Et₂O, solid formed was collected by filtration and dried to provide (1*r*,3*r*)-*N*-((6-fluoroisoquinolin-5-yl)methyl)-3-(4-(trifluoromethoxy)phenoxy)cyclobutan-1-amine, HCl (37 mg, 12%). MS (ESI+) [Method 1A]: *m/z* 407.1 (M+H); Rt 1.36 min. ¹H NMR (400 MHz, CD₃OD) δ 9.80 (s, 1H), 8.78 (d, *J* = 6.4 Hz, 1H), 8.74 – 8.66 (m, 2H), 7.98 (d, *J* = 8.8 Hz, 1H), 7.24 (dd, *J* = 8.8, 0.8 Hz, 2H), 6.92 (dd, *J* = 6.8, 2.4 Hz, 2H), 5.03 – 4.99 (m, 1H), 4.83 (d, *J* = 2.0 Hz, 2H), 4.31 – 4.27 (m, 1H), 2.90 – 2.83 (m, 2H), 2.75 – 2.68 (m, 2H).


Example 37: Synthesis of (1*r*,3*r*)-*N*-((6-fluoroisoquinolin-5-yl)methyl)-3-(3-(trifluoromethoxy)phenoxy)cyclobutan-1-amine, HCl

Step 37.1: Synthesis of *tert*-butyl ((1*r*,3*r*)-3-(3-(trifluoromethoxy)phenoxy)cyclobutyl)carbamate




The title compound was synthesized following the procedure as described in Step 1.2, using *tert*-butyl ((1*s*,3*s*)-3-hydroxycyclobutyl)carbamate (150 mg, 0.80 mmol) and 3-(trifluoromethoxy)phenol [CAS No. 827-99-6] (150 mg, 0.84 mmol). The crude was purified by flash chromatography (8 g SiliCycle column, 0 – 8% EtOAc in Hexane elution) to provide *tert*-butyl ((1*r*,3*r*)-3-(3-(trifluoromethoxy)phenoxy)cyclobutyl)carbamate (150 mg, 51%). ¹H NMR (600 MHz, CDCl₃) δ 6.80 – 6.73 (m, 2H), 6.69 (dd, *J* = 7.8, 1.8 Hz, 1H), 6.61 (s, 1H), 4.79 – 4.75 (m, 1H), 4.32 – 4.28 (m, 1H), 2.58 – 2.54 (m, 2H), 2.41 – 2.37 (m, 2H), 1.44 (s, 9H).

Step 37.2: Synthesis of (1*r*,3*r*)-3-(3-(trifluoromethoxy)phenoxy)cyclobutan-1-amine, HCl



A round bottom flask was charge with *tert*-butyl ((1*r*,3*r*)-3-(3-(trifluoromethoxy)phenoxy)cyclobutyl)carbamate (150 mg, 0.43 mmol) and HCl solution (20% in 1,4-dioxane) (5 mL), and stirred at rt for 1 h. Then the reaction mixture was concentrated in *vacuo*, the residue was triturated with Et₂O, solid collected by filtration and dried to yield (1*r*,3*r*)-3-(3-(trifluoromethoxy)phenoxy)cyclobutan-1-amine, HCl (100 mg, 83%). MS (ESI+) [Method 6A]: *m/z* 247.9 (M+H); Rt 1.31 min.


Step 37.3: Synthesis of (1*r*,3*r*)-*N*-((6-fluoroisoquinolin-5-yl)methyl)-3-(3-(trifluoromethoxy)phenoxy)cyclobutan-1-amine, HCl



The title compound was synthesized following the procedure as described in Step 1.4, using (1*r*,3*r*)-3-(3-(trifluoromethoxy)phenoxy)cyclobutan-1-amine, HCl (70 mg, 0.25 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 38 mg, 0.22 mmol). Crude product was purified by
 5 prep-HPLC (Column: KINETEX EVO C18 (150 mm x 21.2 mm), 5.0 μ ; Mobile Phase: 0.01% NH_4OH in water and acetonitrile). The isolated product was stirred with HCl solution (4M in 1,4-dioxane) (1 mL) at rt for 1 h. Then concentrated in *vacuo*, and lyophilized to provide (1*r*,3*r*)-*N*-((6-fluoroisoquinolin-5-yl)methyl)-3-(3-(trifluoromethoxy)phenoxy)cyclobutan-1-amine, HCl (40 mg, 37%). MS (ESI+) [Method 6A]: m/z 407.2 (M+H); Rt 1.32 min. ^1H NMR (400 MHz, CD_3OD)
 10 δ 9.91 (s, 1H), 8.86 – 8.79 (m, 3H), 8.06 (t, J = 8.8 Hz, 1H), 8.41 (t, J = 8.8 Hz, 1H), 6.93 – 6.87 (m, 2H), 6.78 (s, 1H), 5.10 – 5.05 (m, 1H), 4.86 (d, J = 2.0 Hz, 2H), 4.33 – 4.29 (m, 1H), 2.97 – 2.91 (m, 2H), 2.77 – 2.71 (m, 2H).


Example 38: Synthesis of (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethoxy)phenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl

15 Step 38.1: Synthesis of *tert*-butyl ((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethoxy)phenoxy)cyclobutyl)carbamate



The title compound was synthesized following the procedure as described in Step 1.2, using *tert*-butyl ((1*s*,3*s*)-3-hydroxycyclobutyl)carbamate (95 mg, 0.51 mmol) and 4-fluoro-3-(trifluoromethoxy)phenol [CAS No. 886501-26-4] (100 mg, 0.51 mmol). The crude product, *tert*-butyl ((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethoxy)phenoxy)cyclobutyl)carbamate (170 mg, 91%) was
 20 isolated as brown gummy oil. ^1H NMR (300 MHz, CDCl_3) δ 7.08 (t, J = 9.0 Hz, 1H), 6.71 – 6.61 (m, 2H), 4.74 – 4.69 (m, 1H), 4.32 – 4.27 (m, 1H), 2.59 – 2.50 (m, 2H), 2.42 – 2.35 (m, 2H), 1.45 (s, 9H).

25 Step 38.2: Synthesis of (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethoxy)phenoxy)cyclobutan-1-amine, HCl




To the crude *tert*-butyl ((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethoxy)phenoxy)cyclobutyl)carbamate (170 mg, 0.47 mmol), HCl solution (20% in 1,4-dioxane) (5 mL) was added and stirred at rt for 1 h. Then the reaction mixture was concentrated in *vacuo*, the residue was triturated with Et_2O ,
 30 filtered and dried to yield (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethoxy)phenoxy)cyclobutan-1-amine,

HCl (100 mg, 71%). MS (ESI+) [Method 6A]: m/z 266.1 (M+H); Rt 1.33 min. ^1H NMR (400 MHz, DMSO- d_6) δ 8.25 (brs, 3H), 7.46 (t, J = 9.2 Hz, 1H), 7.02 – 6.99 (m, 1H), 6.92 – 6.88 (m, 1H), 5.02 – 4.97 (m, 1H), 3.85 – 3.81 (m, 1H), 2.64 – 2.57 (m, 2H), 2.45 – 2.38 (m, 2H).

Step 38.3: Synthesis of (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethoxy)phenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl


5 5-yl)methyl)cyclobutan-1-amine, HCl



The title compound was synthesized following the procedure as described in Step 1.4, using (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethoxy)phenoxy)cyclobutan-1-amine, HCl (70 mg, 0.23 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 40 mg, 0.23 mmol). The crude product was purified by prep-HPLC (Column: WATERS XBRIDGE C18 (150 mm x 21.2 mm), 5.0 μ ; Mobile Phase: 0.02% NH_4OH in water and acetonitrile). The isolated product was stirred with HCl solution (4M in 1,4-dioxane) (1 mL) at rt for 1 h. Then concentrated in *vacuo*, and lyophilized to provide (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethoxy)phenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl (18 mg, 15%). MS (ESI+) [Method 6A]: m/z 425.1 (M+H); Rt 1.33 min. ^1H NMR (400 MHz, CD_3OD) δ 9.88 (s, 1H), 8.80 – 8.76 (m, 3H), 8.03 (t, J = 9.6 Hz, 1H), 7.29 (t, J = 9.6 Hz, 1H), 6.93 – 6.87 (m, 2H), 5.05 – 4.99 (m, 1H), 4.84 (d, J = 2.0 Hz, 2H), 4.32 – 4.28 (m, 1H), 2.94 – 2.87 (m, 2H), 2.75 – 2.68 (m, 2H).


Example 39: Synthesis of (1*r*,3*r*)-*N*-((6-fluoroisoquinolin-5-yl)methyl)-3-((2,2,3,3-tetrafluoro-2,3-dihydrobenzo[*b*][1,4]dioxin-6-yl)oxy)cyclobutan-1-amine, HCl

20 Step 39.1: Synthesis of *tert*-butyl ((1*r*,3*r*)-3-((2,2,3,3-tetrafluoro-2,3-dihydrobenzo[*b*][1,4]dioxin-6-yl)oxy)cyclobutyl)carbamate




The title compound was synthesized following the procedure as described in Step 1.2, using *tert*-butyl ((1*s*,3*s*)-3-hydroxycyclobutyl)carbamate (125 mg, 0.67 mmol) and 2,2,3,3-tetrafluoro-2,3-dihydrobenzo[*b*][1,4]dioxin-6-ol [CAS No. 103467-50-1] (150 mg, 0.67 mmol). The crude was purified by flash chromatography (12 g SiliCycle column, 0 – 30% EtOAc in Hexane elution) to provide as *tert*-butyl ((1*r*,3*r*)-3-((2,2,3,3-tetrafluoro-2,3-dihydrobenzo[*b*][1,4]dioxin-6-yl)oxy)cyclobutyl)carbamate (200 mg, 76%). ^1H NMR (300 MHz, CDCl_3) δ 7.02 (d, J = 9.0 Hz, 2H), 6.60 – 6.56 (m, 1H), 6.50 (d, J = 2.7 Hz, 1H), 4.24 – 4.69 (m, 1H), 4.32 – 4.27 (m, 1H), 2.56 – 2.50 (m, 2H), 2.42 – 2.37 (m, 2H), 1.45 (s, 9H).

Step 39.2: Synthesis of (1*r*,3*r*)-3-((2,2,3,3-tetrafluoro-2,3-dihydrobenzo[*b*][1,4]dioxin-6-yl)oxy)cyclobutan-1-amine, HCl



The solution of *tert*-butyl ((1*r*,3*r*)-3-((2,2,3,3-tetrafluoro-2,3-dihydrobenzo[*b*][1,4]dioxin-6-yl)oxy)cyclobutyl)carbamate (200 mg, 0.67 mmol) and HCl solution (20% in 1,4-dioxane) (3 mL) was stirred at rt for 3 h. Then the reaction mixture was concentrated in *vacuo*, the residue was triturated with Et₂O, solid was filtered and dried to yield (1*r*,3*r*)-3-((2,2,3,3-tetrafluoro-2,3-dihydrobenzo[*b*][1,4]dioxin-6-yl)oxy)cyclobutan-1-amine, HCl (150 mg, 68%). MS (ESI+) [Method 6A]: *m/z* 294.1 (M+H); Rt 1.32 min.


Step 39.3: Synthesis of (1*r*,3*r*)-N-((6-fluoroisoquinolin-5-yl)methyl)-3-((2,2,3,3-tetrafluoro-2,3-dihydrobenzo[*b*][1,4]dioxin-6-yl)oxy)cyclobutan-1-amine, HCl



The title compound was synthesized following the procedure as described in Step 1.4, using (1*r*,3*r*)-3-((2,2,3,3-tetrafluoro-2,3-dihydrobenzo[*b*][1,4]dioxin-6-yl)oxy)cyclobutan-1-amine, HCl (150 mg, 0.45 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 80 mg, 0.45 mmol). Crude product was purified by prep-HPLC (Column: ZORBAX (150 mm x 21.2 mm), 5.0 μ; Mobile Phase: 0.1% HCO₂H in water and acetonitrile). The isolated product was stirred with HCl solution (4M in 1,4-dioxane) (2 mL) at rt for 2 h. Then concentrated in *vacuo*, and lyophilized to provide (1*r*,3*r*)-N-((6-fluoroisoquinolin-5-yl)methyl)-3-((2,2,3,3-tetrafluoro-2,3-dihydrobenzo[*b*][1,4]dioxin-6-yl)oxy)cyclobutan-1-amine, HCl (40 mg, 19%). MS (ESI+) [Method 1A]: *m/z* 453.3 (M+H); Rt 0.51 min. ¹H NMR (400 MHz, CD₃OD) δ 9.82 (s, 1H), 8.79 – 8.70 (m, 3H), 7.99 (t, *J* = 9.2 Hz, 1H), 7.23 (t, *J* = 10.0 Hz, 1H), 6.80 – 6.78 (m, 2H), 5.02 – 4.97 (m, 1H), 4.82 (d, *J* = 2.0 Hz, 2H), 4.29 – 4.25 (m, 1H), 2.88 – 2.83 (m, 2H), 2.73 – 2.68 (m, 2H).


Example 40: Synthesis of (1*r*,3*r*)-3-(3-(1,2-difluoroethyl)-4-fluorophenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine

Step 40.1: Synthesis of *tert*-butyl ((1*r*,3*r*)-3-(3-bromo-4-fluorophenoxy)cyclobutyl)carbamate




The title compound was synthesized following the procedure as described in Step 1.2, using *tert*-butyl ((1*s*,3*s*)-3-hydroxycyclobutyl)carbamate (196 mg, 1.05 mmol) and 3-bromo-4-fluorophenol [CAS No. 27407-11-0] (200 mg, 1.05 mmol). The crude product was purified by flash chromatography (4 g SiliCycle column, 0 – 10% EtOAc in Hexane elution) to provide *tert*-butyl ((1*r*,3*r*)-3-(3-bromo-4-fluorophenoxy)cyclobutyl)carbamate (300 mg, 81%). ¹H NMR (300 MHz, CDCl₃) δ 7.01 (t, *J* = 8.7 Hz, 1H), 6.92 (dd, *J* = 5.7, 3.0 Hz, 1H), 6.70 – 6.65 (m, 1H), 4.74 – 4.67 (m, 1H), 4.30 – 4.25 (m, 1H), 2.57 – 2.49 (m, 2H), 2.41 – 2.34 (m, 2H), 1.45 (s, 9H).

Step 40.2: Synthesis of *tert*-butyl ((1*r*,3*r*)-3-(4-fluoro-3-vinylphenoxy)cyclobutyl)carbamate




The stirred solution of *tert*-butyl ((1*r*,3*r*)-3-(3-bromo-4-fluorophenoxy)cyclobutyl)carbamate (300 mg, 0.83 mmol), potassium trifluoro(vinyl)borate (223 g, 1.67 mmol) and TEA (0.23 mL, 1.67 mmol) in IPA (10 mL) was degassed with argon for 10 min. Then Pd(dppf)Cl₂.CH₂Cl₂ (54 mg, 0.67 mmol) was added, degassed and heated at 80°C for 16 h under argon atmosphere. Reaction mixture was cooled to rt, diluted with water and extracted with EtOAc twice. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo* to yield the crude product. The crude was purified by flash chromatography (12 g SiliCycle column, 0 – 20% EtOAc in Hexane elution) to provide *tert*-butyl ((1*r*,3*r*)-3-(4-fluoro-3-vinylphenoxy)cyclobutyl)carbamate (200 mg, 78%). MS (ESI+) [Method 1A]: *m/z* 252.2 (M-*t*-Bu +H); Rt 0.22 min. ¹H NMR (300 MHz, CDCl₃) δ 7.04 – 6.77 (m, 3H), 6.70 – 6.58 (m, 1H), 5.65 (dd, *J* = 18.9, 1.2 Hz, 1H), 5.36 (dd, *J* = 11.1, 1.2 Hz, 1H), 4.87 – 4.68 (M, 1H), 4.31 – 4.26 (m, 1H), 2.59 – 2.49 (m, 2H), 2.41 – 2.33 (m, 2H), 1.45 (s, 9H).

Step 40.3: Synthesis of *tert*-butyl ((1*r*,3*r*)-3-(3-(1,2-dihydroxyethyl)-4-fluorophenoxy)cyclobutyl)carbamate




To the solution of *tert*-butyl ((1*r*,3*r*)-3-(4-fluoro-3-vinylphenoxy)cyclobutyl)carbamate (200 mg, 0.65 mmol) and *N*-Methyl morpholine *N*-oxide monohydrate (1.31 g, 9.76 mmol) in acetone-*t*-BuOH-water (21 mL, 10:10:1), OsO₄ (5 mg, 0.02 mmol) was added; and the reaction mixture was stirred at rt for 16 h. The reaction mixture was diluted with water and extracted with EtOAc twice. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (24 g SiliCycle column, 0 – 50% EtOAc in Hexane elution) to provide *tert*-butyl ((1*r*,3*r*)-3-(3-(1,2-dihydroxyethyl)-4-fluorophenoxy)cyclobutyl)carbamate (100 mg, 54%). MS (ESI+) [Method 4A]: *m/z* 242.0 (M-Boc+H); Rt 1.12 min. ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.32 (d, *J* = 7.2 Hz, 1H), 7.02 (t, *J* = 9.2 Hz, 1H), 6.89 – 6.87 (m, 1H), 6.69 – 6.65 (m, 1H), 5.38 (d, *J* = 4.8 Hz, 1H), 4.82 – 4.72 (M, 3H), 4.07 – 4.00 (m, 1H), 3.45 – 3.36 (m, 2H), 2.35 – 2.27 (m, 4H), 1.38 (s, 9H).

Step 40.4: Synthesis of *tert*-butyl ((1*r*,3*r*)-3-(3-(1,2-difluoroethyl)-4-fluorophenoxy)cyclobutyl)carbamate




- To the solution of *tert*-butyl ((1*r*,3*r*)-3-(3-(1,2-dihydroxyethyl)-4-fluorophenoxy)cyclobutyl)carbamate (100 mg, 0.29 mmol) in CH₂Cl₂ (4 mL), DAST (0.11 mL, 0.88 mmol) was added drop wise at rt and stirred for 16 h. The reaction mixture was diluted with water and extracted with EtOAc twice. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (4 g SiliCycle column, 0 – 4% EtOAc in Hexane elution) to provide *tert*-butyl ((1*r*,3*r*)-3-(3-(1,2-difluoroethyl)-4-fluorophenoxy)cyclobutyl)carbamate (60 mg, 60%). ¹H NMR (300 MHz, CDCl₃) δ 6.98 (t, *J* = 9.3 Hz, 1H), 6.85 – 6.82 (m, 1H), 6.76 – 6.70 (m, 1H), 6.03 – 5.82 (m, 1H), 4.79 – 4.69 (m, 2H), 4.67 – 4.49 (m, 1H), 4.32 – 4.28 (m, 1H), 2.58 – 2.50 (m, 2H), 2.42 – 2.34 (m, 2H), 1.45 (s, 9H).

Step 40.5: Synthesis of (1*r*,3*r*)-3-(3-(1,2-difluoroethyl)-4-fluorophenoxy)cyclobutan-1-amine, TFA



- To the solution of *tert*-butyl ((1*r*,3*r*)-3-(3-(1,2-difluoroethyl)-4-fluorophenoxy)cyclobutyl)carbamate (60 mg, 0.17 mmol) in CH₂Cl₂ (3 mL), CF₃CO₂H (1 mL) was added at 0 °C and stirred for 4 h under argon. Then the reaction mixture was concentrated in *vacuo* to afford crude (1*r*,3*r*)-3-(3-(1,2-difluoroethyl)-4-fluorophenoxy)cyclobutan-1-amine, TFA (50 mg, 80%). MS (ESI+) [Method 6A]: *m/z* 246.0 (M+H); Rt 1.29 min.

Step 40.6: Synthesis of (1*r*,3*r*)-3-(3-(1,2-difluoroethyl)-4-fluorophenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine




- The title compound was synthesized following the procedure as described in Step 1.4, using (1*r*,3*r*)-3-(3-(1,2-difluoroethyl)-4-fluorophenoxy)cyclobutan-1-amine, TFA (50 mg, 0.20 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 35 mg, 0.20 mmol). The residue was purified by prep-HPLC (Column: GEMINI NX C18 (150 mm x 21.2 mm), 5.0 μ; Mobile Phase:

0.02% NH₄OH in water and acetonitrile) to afford (1*r*,3*r*)-3-(3-(1,2-difluoroethyl)-4-fluorophenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine (10 mg, 35%). MS (ESI+) [Method 6A]: *m/z* 405.3 (M+H); Rt 1.32 min. ¹H NMR (400 MHz, CD₃OD) δ 9.24 (d, *J* = 0.8 Hz, 1H), 8.52 (d, *J* = 6.0 Hz, 1H), 8.16 (dd, *J* = 8.4, 5.6 Hz, 1H), 8.11 (d, *J* = 6.0 Hz, 1H), 7.53 (t, *J* = 9.6 Hz, 1H), 7.05 (d, *J* = 8.8 Hz, 1H), 6.88 – 6.85 (m, 1H), 6.83 – 6.80 (m, 1H), 6.01 – 5.83 (m, 1H), 4.82 – 4.79 (m, 1H), 4.74 – 4.67 (m, 1H), 4.63 – 4.55 (m, 1H), 4.19 (d, *J* = 2.0 Hz, 2H), 3.61 – 3.57 (m, 1H), 2.33 (t, *J* = 6.0 Hz, 4H).


Example 41: Synthesis of (1*r*,3*r*)-3-(4-fluoro-3-(fluoromethyl)phenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl

10 Step 41.1: Synthesis of 4-fluoro-3-formylphenyl benzoate




To the solution of 2-fluoro-5-hydroxy benzaldehyde [CAS No. 103438-84-2] (0.75 g, 5.35 mmol), TEA (2.25 mL, 16.05 mmol) and DMAP (65 mg, 0.54 mmol) in anhydrous THF (50 mL), PhCOCl (1.0 g, 5.89 mmol) was added dropwise at rt and stirred for 16 h. The reaction mixture was diluted with EtOAc, then washed with water, aqueous HCl solution (1M) and saturated NaHCO₃ solution. The organic portion was dried over anhydrous Mg₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 5% EtOAc in Hexane elution) to provide 4-fluoro-3-formylphenyl benzoate (1.0 g, 76%). ¹H NMR (600 MHz, CDCl₃) δ 10.37 (s, 1H), 8.19 (d, *J* = 7.2 Hz, 2H), 7.72 – 7.71 (m, 1H), 7.67 (t, *J* = 7.8 Hz, 1H), 7.54 – 7.52 (m, 2H), 7.49 – 7.47 (m, 1H), 7.28 – 7.25 (m, 1H).

20 Step 41.2: Synthesis of 4-fluoro-3-(hydroxymethyl)phenyl benzoate




To the solution of 4-fluoro-3-formylphenyl benzoate (600 mg, 2.45 mmol) in THF (50 mL), NaBH₄ (185 mg, 4.90 mmol) and MeOH (3 drops) were added at -78 °C and stirred for 1 h. Then the reaction mixture was diluted with water and extracted with EtOAc twice. The combined organic portion was washed with brine, dried over anhydrous Mg₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 10% EtOAc in Hexane elution) to provide 4-fluoro-3-(hydroxymethyl)phenyl benzoate (400 mg, 66%). ¹H NMR (400 MHz, CDCl₃) δ 8.19 (d, *J* = 7.2 Hz, 2H), 7.67 – 7.63 (m, 1H), 7.52 (t, *J* = 8.0 Hz, 2H), 7.33 – 7.31 (m, 1H), 7.12 – 7.09 (m, 2H), 4.79 (s, 2H).

30 Step 41.3: Synthesis of 4-fluoro-3-(fluoromethyl)phenyl benzoate



To the solution of 4-fluoro-3-(hydroxymethyl)phenyl benzoate (400 mg, 1.62 mmol) in CH_2Cl_2 (30 mL), DAST (0.52 mL, 3.24 mmol) was added drop wise at 0 °C and stirred at rt for 16 h. The reaction was quenched with saturated NaHCO_3 solution, and extracted with EtOAc 3x's. The combined organic portion was washed with brine, dried over anhydrous Na_2SO_4 , filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 8% EtOAc in Hexane elution) to provide 4-fluoro-3-(fluoromethyl)phenyl benzoate (250 mg, 61%). ^1H NMR (400 MHz, CDCl_3) δ 8.21 – 8.17 (m, 2H), 7.68 – 7.62 (m, 1H), 7.55 – 7.49 (m, 2H), 7.32 – 7.29 (m, 1H), 7.25 – 7.11 (m, 2H), 5.54 (s, 1H), 5.43 (s, 1H).


10 Step 41.4: Synthesis of 4-fluoro-3-(fluoromethyl)phenol




To the solution of 4-fluoro-3-(fluoromethyl)phenyl benzoate (350 mg, 1.41 mmol) in THF - MeOH (17 mL, 15:2 v/v), NaOH solution (3M) (1.4 mL, 4.23 mmol) was added and stirred at rt for 16 h. Reaction mixture was concentrated in *vacuo*, residue was diluted with water, acidified with HCl solution (2N) and then extracted with EtOAc twice. The combined organic portion was washed with saturated NaHCO_3 solution, dried over anhydrous Na_2SO_4 , filtered and concentrated in *vacuo* to afford crude 4-fluoro-3-(fluoromethyl)phenol (170 mg, 83%). ^1H NMR (400 MHz, CDCl_3) δ 6.98 – 6.91 (m, 1H), 6.90 – 6.87 (m, 1H), 6.82 – 6.75 (m, 1H), 5.47 (d, J = 1.2 Hz, 1H), 5.35 (d, J = 1.2 Hz, 1H).

20 Step 41.5: Synthesis of

tert-butyl ((1*r*,3*r*)-3-(4-fluoro-3-(fluoromethyl)phenoxy)cyclobutyl)carbamate




The title compound was synthesized following the procedure as described in Step 1.2, using *tert*-butyl ((1*s*,3*s*)-3-hydroxycyclobutyl)carbamate (221 mg, 1.18 mmol) and 4-fluoro-3-(fluoromethyl)phenol (170 mg, 1.18 mmol). The crude product was purified by flash chromatography (12 g SiliCycle column, 0 – 8% EtOAc in Hexane elution) to provide *tert*-butyl ((1*r*,3*r*)-3-(4-fluoro-3-(fluoromethyl)phenoxy)cyclobutyl)carbamate (170 mg, 45%). ^1H NMR (400 MHz, CDCl_3) δ 6.99 – 6.94 (m, 1H), 6.81 – 6.77 (m, 1H), 6.74 – 6.69 (m, 1H), 5.42 (dd, J = 47.6, 0.8 Hz, 2H), 4.57 – 4.52 (m, 1H), 4.32 – 4.26 (m, 1H), 2.57 – 2.51 (m, 2H), 2.39 – 2.33 (m, 2H), 1.45 (s, 9H).

Step 41.6: Synthesis of (1*r*,3*r*)-3-(4-fluoro-3-(fluoromethyl)phenoxy)cyclobutan-1-amine, HCl


The solution of *tert*-butyl ((1*r*,3*r*)-3-(4-fluoro-3-(fluoromethyl)phenoxy)cyclobutyl)carbamate (170 mg, 0.54 mmol) and HCl solution (4M in 1,4-dioxane) (2 mL) was stirred at rt for 16 h. Then the reaction mixture was concentrated in *vacuo*, the residue was triturated with Et₂O, solid was filtered and dried to yield (1*r*,3*r*)-3-(4-fluoro-3-(fluoromethyl)phenoxy)cyclobutan-1-amine, HCl (140 mg, 100%). ¹H NMR (400 MHz, CD₃OD) δ 7.12 – 7.05 (m, 1H), 7.08 – 6.86 (m, 1H), 6.87 – 6.83 (m, 1H), 5.47 (d, *J* = 0.8 Hz, 1H), 5.35 (d, *J* = 0.8 Hz, 1H), 4.97 – 4.90 (m, 1H), 4.05 – 3.45 (m, 1H), 2.70 – 2.55 (m, 4H).

10 Step 41.7: Synthesis of (1*r*,3*r*)-3-(4-fluoro-3-(fluoromethyl)phenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl



The title compound was synthesized following the procedure as described in Step 1.4, using (1*r*,3*r*)-3-(4-fluoro-3-(fluoromethyl)phenoxy)cyclobutan-1-amine, HCl (140 mg, 0.54 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 94 mg, 0.54 mmol). Crude product was purified by prep-HPLC (Column: KINETEX EVO C18 (150 mm x 21.2 mm), 5.0 μ; Mobile Phase: 0.1% HCO₂H in water and acetonitrile). The isolated product was stirred with HCl solution (4M in 1,4-dioxane) (2 mL) at rt for 2 h. Then concentrated in *vacuo*, and lyophilized to afford (1*r*,3*r*)-3-(4-fluoro-3-(fluoromethyl)phenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl (30 mg, 14%). MS (ESI+) [Method 1A]: *m/z* 373.0 (M+H); Rt 0.17 min. ¹H NMR (400 MHz, CD₃OD) δ 9.85 (s, 1H), 8.80 – 8.70 (m, 3H), 8.05 – 7.95 (m, 1H), 7.15 – 7.05 (m, 1H), 6.95 – 6.85 (m, 2H), 5.46 (s, 1H), 5.35 (s, 1H), 5.05 – 4.95 (m, 1H), 4.83 (d, *J* = 1.2 Hz, 2H), 4.35 – 4.20 (m, 1H), 2.90 – 2.85 (m, 2H), 2.22 – 2.13 (m, 2H).


25 **Example 42: Synthesis of (1*r*,3*r*)-3-(4-(2,2-difluorocyclopropyl)phenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCO₂H**

Step 42.1: Synthesis of 1-methoxy-4-vinylbenzene

To the solution of methyl triphenylphosphonium bromide (7.87 g, 22.03 mmol) in anhydrous THF (15 mL), *n*-BuLi (2.5M in THF) (8.8 mL, 22.03 mmol) was added drop wise at 0 °C and stirred for


1 h under argon atmosphere, while temperature was slowly raised to rt. The reaction mixture was cooled to 0 °C and then 4-methoxybenzaldehyde [CAS No. 123-11-5] (2.0 g, 14.69 mmol), dissolved in anhydrous THF (5 mL), was added drop wise. Reaction temperature was allowed to raise slowly to rt while stirring for 3 h. Reaction was quenched with saturated NH₄Cl solution, and
 5 extracted with EtOAc twice. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 10% EtOAc in Hexane elution) to provide 1-methoxy-4-vinylbenzene (1.4 g, 71%). ¹H NMR (300 MHz, CDCl₃) δ 7.35 (d, *J* = 9 Hz, 2 H), 6.87 (d, *J* = 9 Hz, 2 H), 6.72 – 6.62 (m, 1H), 5.61 (d, *J* = 17.4 Hz, 1H), 5.13 (d, *J* = 11.1 Hz, 1H), 3.81 (s, 3H).

10 Step 42.2: Synthesis of 1-(2,2-difluorocyclopropyl)-4-methoxybenzene



To the stirred solution of 1-methoxy-4-vinylbenzene (500 mg, 3.73 mmol) and NaI (280 mg, 1.86 mmol) in anhydrous THF (5 mL), TMSCF₃ (2.8 mL, 18.63 mmol) was added drop wise at rt, over a period of 10 min. Then the reaction vessel was sealed and stirred at 120 °C (pre-heated oil
 15 bath) for 16 h. Reaction was quenched with water, and extracted with EtOAc twice. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo* to get crude 1-(2,2-difluorocyclopropyl)-4-methoxybenzene (500 mg, 73%). ¹H NMR (300 MHz, CDCl₃) δ 7.15 (d, *J* = 9 Hz, 2 H), 6.85 (d, *J* = 9 Hz, 2 H), 3.80 (s, 3H), 2.78 – 2.60 (m, 1H), 1.82 – 1.70 (m, 1H), 1.62 – 1.50 (m, 1H).


20 Step 42.3: Synthesis of 4-(2,2-difluorocyclopropyl)phenol



To the stirred solution of 1-(2,2-difluorocyclopropyl)-4-methoxybenzene (500 mg, 2.71 mmol) in anhydrous CH₂Cl₂ (5 mL), BBr₃ (0.31 mL, 3.25 mmol) was added drop wise at 0 °C, over a period of 5 min. Then the reaction temperature was allowed to raise to rt, and stirred for 4 h. Reaction
 25 was quenched with saturated NaHCO₃ solution and extracted with EtOAc twice. The combined organic portion was washed with brine, anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 20% EtOAc in Hexane elution) to provide 4-(2,2-difluorocyclopropyl)phenol (350 mg, 75%). ¹H NMR (300 MHz, CDCl₃) δ 7.10 (d, *J* = 8.7 Hz, 2 H), 6.79 (d, *J* = 8.7 Hz, 2 H), 2.78 – 2.61 (m, 1H), 1.85 – 1.20 (m,
 30 1H), 1.55 – 1.49 (m, 1H).

Step 42.4: Synthesis of


tert-butyl ((1*r*,3*r*)-3-(4-(2,2-difluorocyclopropyl)phenoxy)cyclobutyl)carbamate



The title compound was synthesized following the procedure as described in Step 1.2, using *tert*-butyl ((1*s*,3*s*)-3-hydroxycyclobutyl)carbamate (150 mg, 0.80 mmol) and 4-(2,2-difluorocyclopropyl)phenol (150 mg, 0.88 mmol). The crude product was purified by flash chromatography (12 g SiliCycle column, 0 – 20% EtOAc in Hexane elution) to provide *tert*-butyl ((1*r*,3*r*)-3-(4-(2,2-difluorocyclopropyl)phenoxy)cyclobutyl)carbamate (180 mg, 54%). ¹H NMR (300 MHz, CDCl₃) δ 7.26 – 7.15 (m, 2H), 6.83 – 6.67 (m, 2H), 4.79 – 4.72 (m, 1H), 4.28 (bs, 1H), 2.74 – 2.62 (m, 1H), 2.60 – 2.50 (m, 2H), 2.40 – 2.30 (m, 2H), 1.83 – 1.70 (m, 1H), 1.55 – 1.43 (m, 1H), 1.45 (s, 9H).

Step 42.5: Synthesis of (1*r*,3*r*)-3-(4-(2,2-difluorocyclopropyl)phenoxy)cyclobutan-1-amine, HCl


10



The solution of *tert*-butyl ((1*r*,3*r*)-3-(4-(2,2-difluorocyclopropyl)phenoxy)cyclobutyl)carbamate (120 mg, 0.35 mmol) and HCl solution (4M in 1,4-dioxane) (2 mL) was stirred at rt for 16 h. Then the reaction mixture was concentrated in *vacuo*, the residue was triturated with *n*-pentane, solid was filtered and dried to yield (1*r*,3*r*)-3-(4-(2,2-difluorocyclopropyl)phenoxy)cyclobutan-1-amine, HCl (80 mg, 82%). MS (ESI+) [Method 6A]: *m/z* 240.1 (M+H); Rt 1.29 min. ¹H NMR (300 MHz, CD₃OD) δ 7.15 (d, *J* = 8.7 Hz, 2H), 6.77 (d, *J* = 8.7 Hz, 2H), 4.95 – 4.90 (m, 1H), 4.02 – 3.90 (m, 1H), 2.82 – 2.70 (m, 1H), 2.63 – 2.55 (m, 4H), 1.90 – 1.75 (m, 1H), 1.75 – 1.55 (m, 1H).

Step 42.6: Synthesis of (1*r*,3*r*)-3-(4-(2,2-difluorocyclopropyl)phenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCO₂H


20



The title compound was synthesized following the procedure as described in Step 1.4, using (1*r*,3*r*)-3-(4-(2,2-difluorocyclopropyl)phenoxy)cyclobutan-1-amine, HCl (100 mg, 0.36 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (58 mg, 0.33 mmol). Crude product was purified by prep-HPLC (Column: LUNA Phenomenex (250 mm x 21.2 mm), 5.0 μ; Mobile Phase: 0.1% HCO₂H in water and acetonitrile-MeOH (1:1)) to afford (1*r*,3*r*)-3-(4-(2,2-difluorocyclopropyl)phenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCO₂H (30 mg, 23%). MS (ESI+) [Method 1A]: *m/z* 399.1 (M+H); Rt 0.19 min. ¹H NMR (400 MHz, CD₃OD) δ 9.31 (s, 1H), 8.60 (d, *J* = 6.4 Hz, 1H), 8.34 – 8.29 (m, 1H), 8.27 (s, 1H), 8.12 (d, *J* = 6.4 Hz, 1H), 7.62 (t, *J* = 9.6 Hz, 1H), 7.15 (d, *J* = 8.4 Hz, 2H), 6.76 (d, *J* = 8.4 Hz, 2H), 4.51 (d, *J* = 2 Hz, 2H), 4.02 – 3.93 (m, 1H), 2.82 – 2.70 (m, 1H), 2.62 – 2.95 (m, 4H), 1.86 – 1.75 (m, 1H), 1.68 – 1.55 (m, 1H).

Example 43: Synthesis of (1*r*,3*r*)-3-(4-fluoro-3-isopropylphenoxy)-*N*-(isoquinolin-5-ylmethyl)cyclobutan-1-amine, HCl


Step 43.1: Synthesis of *tert*-butyl ((1*r*,3*r*)-3-(3-bromo-4-fluorophenoxy)cyclobutyl)carbamate



- 5 The title compound was synthesized following the procedure as described in Step 1.2, using *tert*-butyl ((1*s*,3*s*)-3-hydroxycyclobutyl)carbamate (490 mg, 2.62 mmol) and 3-bromo-4-fluorophenol [CAS No. 27407-11-0] (500 mg, 2.62 mmol). The crude was purified by flash chromatography (12 g SiliCycle column, 0 – 20% EtOAc in Hexane elution) to provide *tert*-butyl ((1*r*,3*r*)-3-(3-bromo-4-fluorophenoxy)cyclobutyl)carbamate (730 mg, 77%). ¹H NMR (600 MHz, CDCl₃) δ 7.02 -6.99 (m, 1H), 6.92 – 6.90 (m, 1H), 6.68 – 6.66 (m, 1H), 4.80 – 4.58 (m, 2H), 4.70 (bs, 1H), 2.58 – 2.49 (m, 2H), 2.40 – 2.30 (m, 2H), 1.44 (s, 9H).
- 10


Step 43.2: Synthesis of

tert-butyl ((1*r*,3*r*)-3-(4-fluoro-3-(prop-1-en-2-yl)phenoxy)cyclobutyl)carbamate



- 15 The stirred solution of *tert*-butyl ((1*r*,3*r*)-3-(3-bromo-4-fluorophenoxy)cyclobutyl)carbamate (0.63 g, 1.75 mmol), 4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane (0.35 g, 2.10 mmol) and K₃PO₄ (0.91 g, 5.25 mmol) in 1,4-dioxane - water (30 mL, 4:1 v/v) was degassed with argon for 20 min. Then Pd(dppf)Cl₂.CH₂Cl₂ (0.14 g, 0.17 mmol) was added, degassed and heated at 100 °C for 16 h under argon atmosphere. Reaction mixture was cooled to rt, diluted with water
- 20 and extracted with EtOAc twice. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo* to yield the crude product. The crude product was purified by flash chromatography (12 g SiliCycle column, 0 – 20% EtOAc in Hexane elution) to provide *tert*-butyl ((1*r*,3*r*)-3-(4-fluoro-3-(prop-1-en-2-yl)phenoxy)cyclobutyl)carbamate (0.6 g, 92%). MS (ESI+) [Method 1A]: *m/z* 266.1 (M-56+H); Rt 1.68 min. ¹H NMR (600 MHz, CDCl₃) δ 6.92 (t, *J* = 9.6 Hz, 1H), 6.69 – 6.68 (m, 1H), 6.60 – 6.58 (m, 1H), 5.21 (s, 2H), 4.75 – 4.72 (m, 1H), 4.31 – 4.26 (m, 1H), 2.57 – 2.52 (m, 2H), 2.38 – 2.34 (m, 2H), 2.11 (s, 3H), 1.45 (s, 9H).
- 25


Step 43.3: Synthesis of *tert*-butyl ((1*r*,3*r*)-3-(4-fluoro-3-isopropylphenoxy)cyclobutyl)carbamate



- 30 To the solution of *tert*-butyl ((1*r*,3*r*)-3-(4-fluoro-3-(prop-1-en-2-yl)phenoxy)cyclobutyl)carbamate (0.6 g, 2.02 mmol) in EtOH (10 mL), Pd/C (10% w/w) (0.2 g) was added under N₂. Reaction mixture was degassed, connected with H₂ balloon and stirred at rt for 4 h. Reaction mixture was filtered through celite bed, the bed was washed with EtOH. The combined filtrate was


concentrated in *vacuo* to afford *tert*-butyl ((1*r*,3*r*)-3-(4-fluoro-3-isopropylphenoxy)cyclobutyl)carbamate (0.55 g, 84%). ¹H NMR (600 MHz, CDCl₃) δ 6.87 (t, *J* = 9.0 Hz, 1H), 6.67 – 6.65 (m, 1H), 6.49 – 6.46 (m, 1H), 4.76 – 4.72 (m, 1H), 4.31 – 4.27 (m, 1H), 3.20 – 3.15 (m, 1H), 2.57 – 2.52 (m, 2H), 2.38 – 2.32 (m, 2H), 1.45 (s, 9H), 1.22 (s, 6H).

5 Step 43.4: Synthesis of (1*r*,3*r*)-3-(4-fluoro-3-isopropylphenoxy)cyclobutan-1-amine, HCl




The solution of *tert*-butyl ((1*r*,3*r*)-3-(4-fluoro-3-isopropylphenoxy)cyclobutyl)carbamate (0.55 g, 0.17 mmol) and HCl solution (4M in 1,4-dioxane) (5 mL) was stirred at rt for 16 h. Then the reaction mixture was concentrated in *vacuo*, the residue was triturated with Et₂O, solid was filtered and dried to yield (1*r*,3*r*)-3-(4-fluoro-3-isopropylphenoxy)cyclobutan-1-amine, HCl (0.33 g, 74%). ¹H NMR (600 MHz, DMSO-d₆) δ 8.21 9 (bs, 3H), 7.09 – 7.00 (m, 1H), 6.75 – 6.71 (m, 1H), 6.65 – 6.55 (m, 1H), 5.00 – 4.90 (m, 1H), 3.88 – 3.78 (m, 1H), 3.15 – 3.05 (m, 1H), 2.60 – 2.55 (m, 2H), 2.45 – 2.35 (m, 2H), 1.22 – 1.15 (m, 6H).

15 Step 43.5: Synthesis of (1*r*,3*r*)-3-(4-fluoro-3-isopropylphenoxy)-*N*-(isoquinolin-5-ylmethyl)cyclobutan-1-amine, HCl




The title compound was synthesized following the procedure as described in Step 1.4, using (1*r*,3*r*)-3-(4-fluoro-3-isopropylphenoxy)cyclobutan-1-amine, HCl (100 mg, 0.39 mmol) and isoquinoline-5-carbaldehyde (54 mg, 0.35 mmol). Crude product was purified by prep-HPLC (Column: KINETEX EVO C18 (150 mm x 21.2 mm), 5.0 μ; Mobile Phase: 0.02% NH₄OH in water and acetonitrile). The isolated product was stirred with HCl solution (4M in 1,4-dioxane) (2 mL) at rt for 1 h. Then concentrated in *vacuo*, and the residue was triturated with Et₂O, and solid was filtered and dried to afford (1*r*,3*r*)-3-(4-fluoro-3-isopropylphenoxy)-*N*-(isoquinolin-5-ylmethyl)cyclobutan-1-amine, HCl (50 mg, 35%). MS (ESI+) [Method 1A]: *m/z* 364.9 (M+H); Rt 1.35 min. ¹H NMR (300 MHz, CD₃OD) δ 9.85 (s, 1H), 8.78 – 8.70 (m, 2H), 8.61 (d, *J* = 8.4 Hz, 1H), 8.41 (d, *J* = 6.9 Hz, 1H), 8.14 – 8.09 (m, 1H), 6.94 (t, *J* = 8.7 Hz, 1H), 6.80 – 6.70 (m, 1H), 6.65 – 6.55 (m, 1H), 5.00 – 4.99 (m, 1H), 4.83 (m, 2H), 4.30 – 4.20 (m, 1H), 3.25 – 3.10 (m, 1H), 2.90 – 2.80 (m, 2H), 2.70 – 2.60 (m, 2H), 1.30 – 1.20 (m, 6H).


30 **Example 44: Synthesis of (1*r*,3*r*)-*N*-((6-fluoroisoquinolin-5-yl)methyl)-3-(2-(trifluoromethyl)oxetan-2-yl)phenoxy)cyclobutan-1-amine**

Step 44.1: Synthesis of 3-(benzyloxy)benzaldehyde

To the solution of 3-hydroxybenzaldehyde [CAS No. 100-83-4] (2.0 g, 16.37 mmol) and K_2CO_3 (4.52 g, 24.56 mmol) in anhydrous DMF (20 mL), BnBr (2.91 mL, 24.56 mmol) was added drop wise at rt and stirred for 16 h. The reaction mixture was diluted with water and extracted with EtOAc twice. The combined organic portion was washed with brine, dried over anhydrous Na_2SO_4 , filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (24 g SiliCycle column, 0 – 10% EtOAc in Hexane elution) to provide 3-(benzyloxy)benzaldehyde (3.0 g, 86%). 1H NMR (600 MHz, $CDCl_3$) δ 9.98 (s, 1H), 7.50 – 7.35 (m, 8H), 7.30 – 7.25 (m, 1H), 5.13 (s, 2H).


Step 44.2: Synthesis of 1-(3-(benzyloxy)phenyl)-2,2,2-trifluoroethan-1-ol

To the stirred solution of 3-(benzyloxy)benzaldehyde (2.5 g, 11.77 mmol) in anhydrous DMF (30 mL), $TMSCF_3$ (2.08 mL, 14.13 mmol) was added drop wise at rt. Then K_2CO_3 (0.32 g, 2.36 mmol) was added and stirred at rt for 4 h under N_2 . The reaction mixture was diluted with water and extracted with EtOAc twice. The combined organic portion was washed with brine, dried over anhydrous Na_2SO_4 , filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 10% EtOAc in Hexane elution) to afford 1-(3-(benzyloxy)phenyl)-2,2,2-trifluoroethan-1-ol (3.0 g, 90%). 1H NMR (600 MHz, $CDCl_3$) δ 7.46 – 7.44 (m, 2H), 7.40 (t, J = 7.8 Hz, 2H), 7.36 – 7.32 (m, 2H), 7.13 (s, 1H), 7.07 (d, J = 7.8 Hz, 1H), 7.03 (dd, J = 8.4, 1.8 Hz, 1H), 5.09 (s, 2H), 5.02 – 4.97 (m, 1H), 2.57 (d, J = 4.2 Hz, 1H).

Step 44.3: Synthesis of 1-(3-(benzyloxy)phenyl)-2,2,2-trifluoroethan-1-one


To the solution of 1-(3-(benzyloxy)phenyl)-2,2,2-trifluoroethan-1-ol (1.0 g, 3.54 mmol) in anhydrous CH_2Cl_2 (20 mL), Dess-Martin periodinane (1.95 g, 4.61 mmol) was added portion wise at 0 °C and stirred at rt for 16 h. The reaction was quenched with saturated $NaHCO_3$ solution and extracted with CH_2Cl_2 twice. The combined organic portion was washed successively with saturated $NaHCO_3$ solution, water and brine, dried over anhydrous Na_2SO_4 , filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 10% EtOAc in Hexane elution) to provide 1-(3-(benzyloxy)phenyl)-2,2,2-trifluoroethan-1-one (0.8 g, 80%). 1H NMR (300 MHz, $CDCl_3$) δ 7.70 – 7.60 (m, 2H), 7.50 – 7.30 (m, 7H), 5.13 (s, 2H).

Step 44.4: Synthesis of 2-(3-(benzyloxy)phenyl)-2-(trifluoromethyl)oxetane



To the solution of KO^t-Bu (1.2 g, 1.07 mmol) in anhydrous DMSO (10 mL), trimethylsulfoxonium iodide (2.35 g, 10.70 mmol) was added and stirred at rt for 10 min. Then 1-(3-(benzyloxy)phenyl)-2,2,2-trifluoroethan-1-one (1.0 g, 3.57 mmol), dissolved in DMSO (5 mL), was added drop wise at rt and stirred for 16 h. Reaction was quenched with water and extracted with EtOAc twice. The combined organic portion was washed successively with water and brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 6% EtOAc in Hexane elution) to provide 2-(3-(benzyloxy)phenyl)-2-(trifluoromethyl)oxetane (0.5 g, 45%). ¹H NMR (600 MHz, CDCl₃) δ 7.45 (d, *J* = 7.2 Hz, 2H), 7.40 (t, *J* = 19.8 Hz, 2H), 7.34 (t, *J* = 8.4 Hz, 2H), 7.08 (s, 1H), 7.00 (t, *J* = 7.2 Hz, 2H), 5.07 (s, 2H), 4.84 – 4.80 (m, 1H), 4.62 – 4.57 (m, 1H), 3.28 – 3.20 (m, 1H), 2.94 – 2.87 (m, 1H).


Step 44.5: Synthesis of 3-(2-(trifluoromethyl)oxetan-2-yl)phenol




To the solution of 2-(3-(benzyloxy)phenyl)-2-(trifluoromethyl)oxetane (450 mg, 1.46 mmol) in EtOAc (3 mL), Pd/C (10% w/w) (10 mg) was added under argon. Reaction mixture was degassed, connected with H₂ balloon and stirred at rt for 2 h. Reaction mixture was filtered through celite bed, the bed was washed with EtOAc. The combined filtrate was concentrated in *vacuo* to afford crude 3-(2-(trifluoromethyl)oxetan-2-yl)phenol (300 mg, 94%). ¹H NMR (300 MHz, CDCl₃) δ 7.30 – 7.26 (m, 1H), 7.00 – 6.90 (m, 2H), 6.88 – 6.70 (m, 1H), 5.10 (bs, 1H), 4.85 – 4.78 (m, 1H), 4.63 – 4.56 (m, 1H), 3.28 – 3.19 (m, 1H), 2.44 – 2.85 (m, 1H).

Step 44.6: Synthesis of


tert-butyl ((1*r*,3*r*)-3-(3-(2-(trifluoromethyl)oxetan-2-yl)phenoxy)cyclobutyl)carbamate



The title compound was synthesized following the procedure as described in Step 1.2, using *tert*-butyl ((1*s*,3*s*)-3-hydroxycyclobutyl)carbamate (200 mg, 1.07 mmol) and 3-(2-(trifluoromethyl)oxetan-2-yl)phenol (230 mg, 1.07 mmol). The crude was purified by flash chromatography (12 g SiliCycle column, 0 – 25% EtOAc in Hexane elution) to provide *tert*-butyl ((1*r*,3*r*)-3-(3-(2-(trifluoromethyl)oxetan-2-yl)phenoxy)cyclobutyl)carbamate (200 mg, 48%). ¹H NMR (300 MHz, CDCl₃) δ 7.33 – 7.27 (m, 1H), 6.98 – 6.93 (m, 1H), 6.87 – 6.84 (m, 1H), 6.78 – 6.75 (m, 1H), 4.85 – 4.78 (m, 2H), 4.62 – 4.55 (m, 1H), 4.32 – 4.27 (m, 1H), 3.28 – 3.19 (m, 1H), 2.94 – 2.85 (m, 1H), 2.61 – 2.53 (m, 2H), 2.41 – 2.35 (m, 2H), 1.45 (s, 9H).


Step 44.7: Synthesis of (1*r*,3*r*)-3-(3-(2-(trifluoromethyl)oxetan-2-yl)phenoxy)cyclobutan-1-amine

To the solution of *tert*-butyl ((1*r*,3*r*)-3-(3-(2-(trifluoromethyl)oxetan-2-yl)phenoxy)cyclobutyl)carbamate (180 mg, 0.46 mmol) in CH₂Cl₂ (5 mL), TFA (1.0 mL) was added at 0 °C and stirred for 4 h. Solvent was removed by N₂ flush. Then the residue was basified with saturated NaHCO₃ solution and extracted with CH₂Cl₂ twice. The combined organic portion was washed successively with water and brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo* to afford crude (1*r*,3*r*)-3-(3-(2-(trifluoromethyl)oxetan-2-yl)phenoxy)cyclobutan-1-amine (120 mg, 90%). MS (ESI+) [Method 6A]: *m/z* 288.1 (M+H); Rt 1.29 min.

Step 44.8: Synthesis of(1*r*,3*r*)-*N*-((6-fluoroisoquinolin-5-yl)methyl)-3-(3-(2-(trifluoromethyl)oxetan-2-yl)phenoxy)cyclobutan-1-amine


The title compound was synthesized following the procedure as described in Step 1.4, using (1*r*,3*r*)-3-(3-(2-(trifluoromethyl)oxetan-2-yl)phenoxy)cyclobutan-1-amine (80 mg, 0.28 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (44 mg, 0.25 mmol). Crude product was purified by prep-HPLC (Column: XBRIDGE C18 (150 mm x 19 mm), 5.0 μ; Mobile Phase: 0.01% NH₄OH in water and acetonitrile) to afford (1*r*,3*r*)-*N*-((6-fluoroisoquinolin-5-yl)methyl)-3-(3-(2-(trifluoromethyl)oxetan-2-yl)phenoxy)cyclobutan-1-amine (32 mg, 25%). MS (ESI+) [Method 1A]: *m/z* 447.3 (M+H); Rt 0.23 min. ¹H NMR (400 MHz, CD₃OD) δ 9.27 (s, 1H), 8.60 – 8.53 (m, 1H), 8.43 (bs, 1H), 8.24 – 8.20 (m, 1H), 8.12 (d, *J* = 6 Hz, 1H), 7.57 (t, *J* = 9.2 Hz, 1H), 7.32 (t, *J* = 8.0 Hz, 1H), 6.97 (d, *J* = 8.0 Hz, 1H), 6.88 – 6.80 (m, 2H), 4.82 – 4.72 (m, 1H), 4.62 – 4.55 (m, 1H), 4.34 (m, 2H), 3.82 – 3.73 (m, 1H), 3.33 – 3.23 (m, 1H), 2.85 – 2.75 (m, 1H), 2.54 (t, *J* = 5.0 Hz, 4H).

Example 45: Synthesis of (5-(((1*r*,3*r*)-3-(4-(*tert*-butyl)-3,5-**difluorophenoxy)cyclobutyl)amino)methyl)-6-fluoroisoquinolin-8-yl)methanol**Step 45.1: Synthesis of *tert*-butyl ((1*r*,3*r*)-3-(4-(*tert*-butyl)-3,5-difluorophenoxy)cyclobutyl)carbamate



The title compound was synthesized following the procedure as described in Step 1.2, using *tert*-butyl ((1*r*,3*s*)-3-hydroxycyclobutyl)carbamate (0.18 g, 0.97 mmol) and 4-(*tert*-butyl)-3,5-difluorophenol [CAS No. 910486-78-1] (0.2 g, 1.07 mmol). Crude was purified by flash chromatography (12 g SiliCycle column, 0 – 25% EtOAc in Hexane elution) to provide *tert*-butyl ((1*r*,3*r*)-3-(4-(*tert*-butyl)-3,5-difluorophenoxy)cyclobutyl)carbamate (0.3 g, 78%). ¹H NMR (300 MHz, CDCl₃) δ 6.24 (s, 1H), 6.20 (s, 1H), 4.72 – 4.66 (m, 1H), 4.16 – 4.12 (m, 1H), 2.56 – 2.49 (m, 2H), 2.40 – 2.35 (m, 2H), 1.45 (s, 9H), 1.41 (s, 9H).


Step 45.2: Synthesis of (1*r*,3*r*)-3-(4-(*tert*-butyl)-3,5-difluorophenoxy)cyclobutan-1-amine, HCl



10

A round bottom flask was charged with *tert*-butyl ((1*r*,3*r*)-3-(4-(*tert*-butyl)-3,5-difluorophenoxy)cyclobutyl)carbamate (0.3 g, 0.84 mmol) and HCl solution (4M in 1,4-dioxane) (2 mL), and stirred at rt for 4 h. Then the reaction mixture was concentrated in *vacuo*. The residue was triturated with Et₂O, solid was filtered and dried to yield (1*r*,3*r*)-3-(4-(*tert*-butyl)-3,5-difluorophenoxy)cyclobutan-1-amine, HCl (0.22 g, 89%). MS (ESI+) [Method 1A]: *m/z* 256.2 (M+H); Rt 1.33 min. ¹H NMR (300 MHz, DMSO-*d*₆) δ 6.38 (s, 1H), 6.35 (s, 1H), 4.92 – 4.87 (m, 1H), 3.99 – 3.95 (m, 1H), 2.64 – 2.58 (m, 4H), 1.42 (s, 9H).


Step 45.3: Synthesis of (1*r*,3*r*)-3-(4-(*tert*-butyl)-3,5-difluorophenoxy)-*N*-((8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine



20

The title compound was synthesized following the procedure as described in Step 1.4, using (1*r*,3*r*)-3-(4-(*tert*-butyl)-3,5-difluorophenoxy)cyclobutan-1-amine, HCl (200 mg, 0.69 mmol) and 8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinoline-5-carbaldehyde (Step 6.8, 320 mg, 1.03 mmol). The crude was purified by flash chromatography (12 g SiliCycle column, 0 – 5% MeOH in CH₂Cl₂ elution) to provide (1*r*,3*r*)-3-(4-(*tert*-butyl)-3,5-difluorophenoxy)-*N*-((8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine (250 mg, 65%). MS (ESI+) [Method 6A]: *m/z* 559.2 (M+H); Rt 1.51 min.


Step 45.4: Synthesis of (5-((((1*r*,3*r*)-3-(4-(*tert*-butyl)-3,5-difluorophenoxy)cyclobutyl)amino)methyl)-6-fluoroisoquinolin-8-yl)methanol



Deprotection was carried out according to Step 6.11. The residue was purified by prep-HPLC (Column: XBRIDGE C18 (150 mm x 21.2 mm), 5.0 μ ; Mobile Phase: 0.02% NH_4OH in water and acetonitrile) to afford (5-((((1*r*,3*r*)-3-(4-(*tert*-butyl)-3,5-difluorophenoxy)cyclobutyl)amino)methyl)-6-fluoroisoquinolin-8-yl)methanol (60 mg, 30%). MS (ESI+) [Method 6A]: m/z 445.2 (M+H); Rt 1.35 min. ^1H NMR (400 MHz, CD_3OD) δ 9.45 (s, 1H), 8.55 (d, J = 6 Hz, 1H), 8.12 (d, J = 6 Hz, 1H), 7.56 (d, J = 10.4 Hz, 1H), 6.31 (d, J = 13.2 Hz, 2H), 5.18 (s, 2H), 4.80 – 4.70 (m, 1H), 4.16 (d, J = 1.6 Hz, 2H), 3.60 – 3.50 (m, 1H), 2.38 – 2.28 (m, 4H), 1.41 (s, 9H).

Example 46: Synthesis of (1*r*,3*r*)-3-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)oxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl


Step 46.1: Synthesis of 2,2-difluorobenzo[d][1,3]dioxol-5-ol



The sealed tube charged with 5-bromo-2,2-difluorobenzo[d][1,3]dioxole [CAS No. 33070-32-5] (1.0 g, 4.22 mmol), KOH (474 mg, 8.44 mmol), *t*-BuXPPhOS (25 mg, 0.05 mmol) and 1,4-dioxane – water (6 mL, 1:1 v/v), was purged with N_2 for 10 min. Then $\text{Pd}_2(\text{dba})_3$ (194 mg, 0.21 mmol) was added, purged with N_2 , sealed tube was closed and stirred at 100 $^\circ\text{C}$ for 16 h. Reaction was cooled to rt, quenched with HCl solution (1M) and extracted with EtOAc twice. The combined filtrate was concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 20% EtOAc in Hexane elution) to afford 2,2-difluorobenzo[d][1,3]dioxol-5-ol (0.41 g, 55%). MS (ESI+) [Method 6A]: m/z 173.1 (M+H); Rt 1.49 min. ^1H NMR (400 MHz, CDCl_3) δ 6.88 (d, J = 8.4 Hz, 1H), 6.62 (s, 1H), 6.49 – 6.46 (m, 1H).

Step 46.2: Synthesis of


tert-butyl ((1*r*,3*r*)-3-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)oxy)cyclobutyl)carbamate



The title compound was synthesized following the procedure as described in Step 1.2, using *tert*-butyl ((1*s*,3*s*)-3-hydroxycyclobutyl)carbamate (0.40 g, 2.14 mmol) and 2,2-difluorobenzo[d][1,3]dioxol-5-ol (0.41 g, 2.35 mmol). Crude product was purified by flash


chromatography (12 g SiliCycle column, 0 – 30% EtOAc in Hexane elution) to provide *tert*-butyl ((1*r*,3*r*)-3-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)oxy)cyclobutyl)carbamate (0.45 g, 61%). ¹H NMR (300 MHz, CDCl₃) δ 6.91 (d, *J* = 8.4 Hz, 1H), 6.55 (d, *J* = 2.4 Hz, 1H), 6.41 (dd, *J* = 8.4, 2.1 Hz, 1H), 4.74 – 4.67 (m, 1H), 4.31 – 4.26 (m, 1H), 2.58 – 2.50 (m, 2H), 2.40 – 2.34 (m, 2H), 1.45 (s, 9H).

Step 46.3: Synthesis of (1*r*,3*r*)-3-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)oxy)cyclobutan-1-amine, HCl



A solution of *tert*-butyl ((1*r*,3*r*)-3-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)oxy)cyclobutyl)carbamate (110 mg, 0.32 mmol) and HCl solution (4M in 1,4-dioxane) (2 mL) was stirred at rt for 1 h. Then the reaction mixture was concentrated in *vacuo*. The residue was triturated with Et₂O, solid was filtered and dried to yield (1*r*,3*r*)-3-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)oxy)cyclobutan-1-amine, HCl (90 mg, 99%). MS (ESI+) [Method 6A]: *m/z* 244.1 (M+H); Rt 1.29 min. ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.16 (s, 3H), 7.33 (d, *J* = 8.7 Hz, 1H), 7.00 (d, *J* = 2.7 Hz, 1H), 6.61 (dd, *J* = 9.3, 2.7 Hz, 1H), 4.95 – 4.91 (m, 1H), 3.85 – 3.81 (m, 1H), 2.61 – 2.55 (m, 2H), 2.45 – 2.38 (m, 2H).


Step 46.4: Synthesis of (1*r*,3*r*)-3-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)oxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl



The title compound was synthesized following the procedure as described in Step 1.4, using (1*r*,3*r*)-3-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)oxy)cyclobutan-1-amine, HCl (85 mg, 0.31 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 175 mg, 0.28 mmol). Crude product was purified by prep-HPLC (Column: LUNA Phenomenex (250 mm x 21.2 mm), 5.0 μ; Mobile Phase: 0.1% HCO₂H in water and acetonitrile). The isolated product was stirred with HCl solution (4M in 1,4-dioxane) (2 mL) at rt for 1 h. Then concentrated in *vacuo* to afford (1*r*,3*r*)-3-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)oxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl (30 mg, 22%). MS (ESI+) [Method 1A]: *m/z* 403.1 (M+H); Rt 1.32 min. ¹H NMR (400 MHz, CD₃OD) δ 9.85 (s, 1H), 8.80 – 8.70 (m, 3H), 8.01 (t, *J* = 8.4 Hz, 1H), 7.10 (d, *J* = 8.8 Hz, 1H), 6.81 (d, *J* = 2.8 Hz, 1H), 6.60 (d, *J* = 8.4 Hz, 1H), 5.00 – 4.98 (m, 1H), 4.82 (d, *J* = 2.0 Hz, 2H), 4.30 – 4.20 (m, 1H), 2.89 – 2.82 (m, 2H), 2.71 – 2.64 (m, 2H).


Example 47: Synthesis of (5-(((1*r*,3*r*)-3-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)oxy)cyclobutyl)amino)methyl)-6-fluoroisoquinolin-8-yl)methanol, HCl

Step 47.1: Synthesis of (1*r*,3*r*)-*N*-((8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinolin-5-yl)methyl)-3-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)oxy)cyclobutan-1-amine




The title compound was synthesized following the procedure as described in Step 1.4, using (1*r*,3*r*)-3-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)oxy)cyclobutan-1-amine, HCl (Step 46.3, 180 mg, 0.64 mmol) and 8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinoline-5-carbaldehyde (Step 6.8, 206 mg, 0.64 mmol). The crude was purified by flash chromatography (12 g SiliCycle column, 0 – 10% MeOH in CH₂Cl₂ elution) to provide (1*r*,3*r*)-*N*-((8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinolin-5-yl)methyl)-3-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)oxy)cyclobutan-1-amine (160 mg, 45%). MS (ESI+) [Method 6A]: *m/z* 547.3 (M+H); Rt 1.42 min.

Step 47.2: Synthesis of (5-(((1*r*,3*r*)-3-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)oxy)cyclobutyl)amino)methyl)-6-fluoroisoquinolin-8-yl)methanol, HCl




Deprotection was carried out according to Step 6.11. The residue was purified by prep-HPLC (Column: WATERS X BRIDGE (250 mm x 21.2 mm), 5.0 μ; Mobile Phase: 0.02% NH₄OH in water and acetonitrile). The isolated product was stirred with HCl solution (4M in 1,4-dioxane) (2 mL) at rt for 1 h. Then concentrated in *vacuo* and then lyophilized to afford (5-(((1*r*,3*r*)-3-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)oxy)cyclobutyl)amino)methyl)-6-fluoroisoquinolin-8-yl)methanol, HCl (20 mg, 14%). MS (ESI+) [Method 6A]: *m/z* 433.2 (M+H); Rt 1.30 min. ¹H NMR (400 MHz, CD₃OD) δ 9.93 (s, 1H), 8.83 – 8.78 (m, 2H), 8.01 (d, *J* = 10.4 Hz, 1H), 7.10 (d, *J* = 8.8 Hz, 1H), 6.81 (d, *J* = 2.4 Hz, 1H), 6.60 (dd, *J* = 1.2 & 8.8 Hz, 1H), 5.30 (s, 2H), 5.02 – 4.96 (m, 1H), 4.80 (s, 2H), 4.28 – 4.23 (m, 1H), 2.91 – 2.84 (m, 2H), 2.72 – 2.64 (m, 2H).


Example 48: Synthesis of (5-(((1*r*,3*r*)-3-(3,5-difluoro-4-methoxyphenoxy)cyclobutyl)amino)methyl)-6-fluoroisoquinolin-8-yl)methanol

Step 48.1: Synthesis of 3,5-difluoro-4-methoxyphenol

A sealed tube charged with 5-bromo-1,3-difluoro-2-methoxybenzene [CAS No. 104197-14-0] (500 mg, 2.24 mmol), KOH (237 mg, 4.48 mmol), *t*-BuXPHOS (13 mg, 0.03 mmol) and 1,4-dioxane – water (3 mL, 1:1 v/v), was purged with N₂ for 10 min. Then Pd₂(dba)₃ (103 mg, 0.11 mmol) was added, purged with N₂, sealed tube was closed and stirred at 100 °C for 16 h. Reaction was cooled to rt, quenched with HCl solution (1M) and extracted with EtOAc twice. The combined filtrate was concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 20% EtOAc in Hexane elution) to afford 3,5-difluoro-4-methoxyphenol (330 g, 91%). MS (ESI+) [Method 6A]: *m/z* 159.0 (M+H); Rt 1.43 min.


Step 48.2: Synthesis of*tert*-butyl ((1*r*,3*r*)-3-(3,5-difluoro-4-methoxyphenoxy)cyclobutyl)carbamate

The title compound was synthesized following the procedure as described in Step 1.2, using *tert*-butyl ((1*s*,3*s*)-3-hydroxycyclobutyl)carbamate (0.35 g, 1.87 mmol) and 3,5-difluoro-4-methoxyphenol (0.33 g, 2.06 mmol). Crude was purified by flash chromatography (12 g SiliCycle column, 0 – 30% EtOAc in Hexane elution) to provide *tert*-butyl ((1*r*,3*r*)-3-(3,5-difluoro-4-methoxyphenoxy)cyclobutyl)carbamate (0.43 g, 69%). ¹H NMR (400 MHz, CDCl₃) δ 6.32 (d, *J* = 8.0 Hz, 2H), 4.68 – 4.64 (m, 1H), 4.31 – 4.27 (m, 1H), 3.88 (s, 3H), 2.56 – 2.49 (m, 2H), 2.39 – 2.34 (m, 2H), 1.45 (s, 9H).

Step 48.3: Synthesis of (1*r*,3*r*)-3-(3,5-difluoro-4-methoxyphenoxy)cyclobutan-1-amine, HCl

A solution of *tert*-butyl ((1*r*,3*r*)-3-(3,5-difluoro-4-methoxyphenoxy)cyclobutyl)carbamate (430 mg, 1.31 mmol) and HCl solution (4M in 1,4-dioxane) (5 mL) was stirred at rt for 16 h. Then the reaction mixture was concentrated in *vacuo*. The residue was triturated with Et₂O, solid was filtered and dried to yield (1*r*,3*r*)-3-(3,5-difluoro-4-methoxyphenoxy)cyclobutan-1-amine, HCl (300 mg, 86%). MS (ESI+) [Method 6A]: *m/z* 230.1 (M+H); Rt 1.26 min.


Step 48.4: Synthesis of (1*r*,3*r*)-*N*-((8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinolin-5-yl)methyl)-3-(3,5-difluoro-4-methoxyphenoxy)cyclobutan-1-amine



The title compound was synthesized following the procedure as described in Step 1.4, using (1*r*,3*r*)-3-(3,5-difluoro-4-methoxyphenoxy)cyclobutan-1-amine, HCl (100 mg, 0.38 mmol) and 8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinoline-5-carbaldehyde (Step 6.8, 121 mg, 0.38 mmol). The crude product was purified by flash chromatography (12 g SiliCycle column, 0 – 10% MeOH in CH₂Cl₂ elution) to provide (1*r*,3*r*)-*N*-(((8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinolin-5-yl)methyl)-3-(3,5-difluoro-4-methoxyphenoxy)cyclobutan-1-amine (170 mg, 84%). MS (ESI+) [Method 6A]: *m/z* 533.4 (M+H); Rt 1.41 min.


Step 48.5: Synthesis of (5-(((1*r*,3*r*)-3-(3,5-difluoro-4-

methoxyphenoxy)cyclobutyl)amino)methyl)-6-fluoroisoquinolin-8-yl)methanol



Deprotection was carried out according to Step 6.11. The residue was purified by prep-HPLC (Column: KINETEX EVO (250 mm x 21.2 mm), 5.0 μ ; Mobile Phase: 0.02% NH₄OH in water and acetonitrile) to afford (5-(((1*r*,3*r*)-3-(3,5-difluoro-4-methoxyphenoxy)cyclobutyl)amino)methyl)-6-fluoroisoquinolin-8-yl)methanol (35 mg, 26%). MS (ESI+) [Method 6A]: *m/z* 419.2 (M+H); Rt 1.26 min. ¹H NMR (400 MHz, CD₃OD) δ 9.47 (s, 1H), 8.57 (d, *J* = 6.0 Hz, 1H), 8.14 (d, *J* = 6.0 Hz, 1H), 7.59 (d, *J* = 10.4 Hz, 1H), 6.47 – 6.43 (m, 2H), 5.21 (s, 2H), 4.78 – 4.75 (m, 1H), 4.18 (d, *J* = 2.0 Hz, 2H), 3.86 (s, 3H), 3.61 – 3.57 (m, 1H), 2.36 – 2.33 (m, 4H).


Example 49: Synthesis of (1*r*,3*r*)-3-(3,5-difluoro-4-methoxyphenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl



The title compound was synthesized following the procedure as described in Step 1.4, using (1*r*,3*r*)-3-(3,5-difluoro-4-methoxyphenoxy)cyclobutan-1-amine, HCl (Step 48.3, 150 mg, 0.56 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 79 mg, 0.45 mmol). Crude product was purified by prep-HPLC (Column: LUNA Phenomenex (250 mm x 21.2 mm), 5.0 μ ; Mobile Phase: 0.1% HCO₂H in water and acetonitrile). The isolated product was stirred with HCl solution (4M in 1,4-dioxane) (2 mL) at rt for 1 h. Then concentrated in *vacuo* to afford (1*r*,3*r*)-3-(3,5-difluoro-4-methoxyphenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl (70 mg, 29%). MS (ESI+) [Method 1A]: *m/z* 389.1 (M+H); Rt 0.19 min. ¹H NMR (400 MHz, CD₃OD) δ 9.84 (s, 1H), 8.80 – 8.72 (m, 3H), 8.00 (t, *J* = 9.2 Hz, 1H), 6.55 – 6.50 (m, 2H), 4.95 – 4.90 (m, 1H), 4.81 (d, *J* = 2.0 Hz, 2H), 4.27 – 4.20 (m, 1H), 3.85 (s, 3H), 2.89 – 2.81 (m, 2H), 2.71 – 2.64 (m, 2H).


Example 50: Synthesis of (1*r*,3*r*)-3-(3-(difluoromethoxy)-4-fluorophenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl

Step 50.1: Synthesis of 4-bromo-2-(difluoromethoxy)-1-fluorobenzene



To the solution of 5-bromo-2-fluorophenol [CAS No. 112204-58-7] (3.0 g, 15.69 mmol) in DMF (50 mL), sodium 2-chloro-2,2-difluoroacetate (5.9 g, 39.71 mmol) and Cs₂CO₃ (7.6 g, 23.37 mmol) were added at rt. Then water (5.0 mL) was added and the reaction mixture was stirred at 70 °C for 16 h. Reaction was cooled to rt, diluted with water and extracted with EtOAc 3x's. The combined filtrate was concentrated in *vacuo*. The residue was to be purified by flash chromatography (8 g SiliCycle column, 0 – 10% EtOAc in Hexane elution) to afford 4-bromo-2-(difluoromethoxy)-1-fluorobenzene (1.0 g, 26%). ¹H NMR (400 MHz, CDCl₃) δ 7.42 – 7.40 (m, 1H), 7.35 – 7.31 (m, 1H), 7.07 (t, *J* = 9.2 Hz, 1H), 6.55 (t, *J* = 72.8 Hz, 1H).

Step 50.2: Synthesis of 3-(difluoromethoxy)-4-fluorophenol




The sealed tube charged with 4-bromo-2-(difluoromethoxy)-1-fluorobenzene (1.0 g, 4.14 mmol), bis(pinacolato)diboron (2.3 g, 9.05 mmol), KOAc (1.8 g, 18.34 mmol) and 1,4-dioxane (50 mL) was purged with N₂ for 10 min. Then Pd(dppf)Cl₂.CH₂Cl₂ (0.45 g, 0.62 mmol) was added, vessel was closed and stirred at 80 °C for 16 h. Reaction mixture was cooled, acetone (20 mL) and

oxone (5.7 g, 9.28 mmol) dissolved in water (10 mL) were added, and stirred at rt for 1 h. Reaction mixture was then diluted with water and extracted with EtOAc 3x's. The combined filtrate was concentrated in *vacuo*. The residue was purified by flash chromatography (24 g SiliCycle column, 0 – 10% EtOAc in Hexane elution) to afford 3-(difluoromethoxy)-4-fluorophenol (0.15 g, 21%).¹H NMR (400 MHz, DMSO-d₆) δ 9.77 (s, 1H), 7.20 (t, *J* = 71.6 Hz, 1H), 7.19 – 7.15 (m, 1H), 6.70 (dd, *J* = 6.8, 2.8 Hz, 1H), 6.65 – 6.61 (m, 1H).


Step 50.3: Synthesis of

tert-butyl ((1*r*,3*r*)-3-(3-(difluoromethoxy)-4-fluorophenoxy)cyclobutyl)carbamate




- 10 The title compound was synthesized following the procedure as described in Step 1.2, using *tert*-butyl ((1*s*,3*s*)-3-hydroxycyclobutyl)carbamate (0.15 g, 0.80 mmol) and 3-(difluoromethoxy)-4-fluorophenol (0.15 g, 0.84 mmol). Crude product was purified by flash chromatography (12 g SiliCycle column, 0 – 20% EtOAc in Hexane elution) to provide *tert*-butyl ((1*r*,3*r*)-3-(3-(difluoromethoxy)-4-fluorophenoxy)cyclobutyl)carbamate (0.3 g, 102%). ¹H NMR (600 MHz, CDCl₃) δ 7.05 (t, *J* = 9.0 Hz, 1H), 6.65 – 6.63 (m, 1H), 6.57 – 6.54 (m, 1H), 6.53 (t, *J* = 73.8 Hz, 1H), 4.73 – 4.69 (m, 1H), 4.31 – 4.27 (m, 1H), 2.56 – 2.51 (m, 2H), 2.39 – 2.35 (m, 2H), 1.44 (s, 9H).

Step 50.4: Synthesis of (1*r*,3*r*)-3-(3-(difluoromethoxy)-4-fluorophenoxy)cyclobutan-1-amine, HCl



- 20 A solution of *tert*-butyl ((1*r*,3*r*)-3-(3-(difluoromethoxy)-4-fluorophenoxy)cyclobutyl)carbamate (300 mg, 0.86 mmol) and HCl solution (4M in 1,4-dioxane) (2 mL) was stirred at rt for 1 h. Then the reaction mixture was concentrated in *vacuo*. The residue was triturated with Et₂O, solid was filtered and dried to yield (1*r*,3*r*)-3-(3-(difluoromethoxy)-4-fluorophenoxy)cyclobutan-1-amine, HCl (200 mg, 87%). ¹H NMR (300 MHz, CD₃OD) δ 7.19 – 7.15 (m, 1H), 6.83 (t, *J* = 72.4 Hz, 1H), 6.75 – 6.66 (m, 2H), 4.92 – 4.87 (m, 1H), 3.97 – 3.93 (m, 1H), 2.61 – 2.54 (m, 4H).

Step 50.5: Synthesis of (1*r*,3*r*)-3-(3-(difluoromethoxy)-4-fluorophenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl




- The title compound was synthesized following the procedure as described in Step 1.4, using (1*r*,3*r*)-3-(3-(difluoromethoxy)-4-fluorophenoxy)cyclobutan-1-amine, HCl (200 mg, 0.71 mmol)

and 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 110 mg, 0.63 mmol). Crude product was purified by prep-HPLC (Column: YMC-ACTUS TRIART C-18 (150 mm x 21.2 mm), 5.0 μ ; Mobile Phase: 0.01% NH_4OH in water and acetonitrile). The isolated product was stirred with HCl solution (4M in 1,4-dioxane) (1 mL) at rt for 1 h. Then concentrated in *vacuo* and lyophilized to afford (1*r*,3*r*)-3-(3-(difluoromethoxy)-4-fluorophenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl (85 mg, 29%). MS (ESI+) [Method 6A]: m/z 407.1 (M+H); Rt 1.30 min. ^1H NMR (400 MHz, CD_3OD) δ 9.85 (s, 1H), 8.76 – 8.72 (m, 3H), 7.99 (t, J = 9.2 Hz, 1H), 7.21 – 7.16 (m, 1H), 6.84 (t, J = 73.6 Hz, 1H), 6.79 – 6.76 (m, 1H), 7.74 – 7.70 (m, 1H), 4.99 – 4.95 (m, 1H), 4.82 (d, J = 2.0 Hz, 2H), 4.29 – 4.24 (m, 1H), 2.90 – 2.82 (m, 2H), 2.72 – 2.65 (m, 2H).

Example 51: Synthesis of (1*r*,3*r*)-3-(4-(difluoromethoxy)-3-fluorophenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl


Step 51.1: Synthesis of 4-bromo-1-(difluoromethoxy)-2-fluorobenzene



To the solution of 4-bromo-2-fluorophenol [CAS No. 2105-94-4] (5.0 g, 26.31 mmol) in DMF (40 mL), sodium 2-chloro-2,2-difluoroacetate (10.03 g, 65.78 mmol) and Cs_2CO_3 (12.86 g, 39.47 mmol) were added at rt. Then water (4.0 mL) was added and reaction mixture was stirred at 70 $^\circ\text{C}$ for 16 h. Reaction was cooled to rt, diluted with water and extracted with EtOAc twice. The combined filtrate was concentrated in *vacuo*. The residue was purified by flash chromatography (24 g SiliCycle column, Hexane elution) to afford 4-bromo-1-(difluoromethoxy)-2-fluorobenzene (4.0 g, 63%). ^1H NMR (300 MHz, CDCl_3) δ 7.38 – 7.28 (m, 2H), 7.14 (t, J = 8.7 Hz, 1H), 6.53 (t, J = 73.2 Hz, 1H).

Step 51.2: Synthesis of


2-(4-(difluoromethoxy)-3-fluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane]



The sealed tube charged with 4-bromo-1-(difluoromethoxy)-2-fluorobenzene (3.5 g, 14.52 mmol), bis(pinacolato)diboron (5.53 g, 21.78 mmol), KOAc (4.27 g, 43.56 mmol) and 1,4-dioxane (50 mL) was purged with N_2 for 10 min. Then $\text{Pd}(\text{dppf})\text{Cl}_2 \cdot \text{CH}_2\text{Cl}_2$ (0.45 g, 0.62 mmol) was added, vessel was closed and stirred at 80 $^\circ\text{C}$ for 16 h. Reaction mixture was cooled, filtered through celite bed and the bed was washed with EtOAc. The filtrate was concentrated in *vacuo* and the residue was purified by flash chromatography (24 g SiliCycle column, 0 – 10% EtOAc in Hexane elution) to afford 2-(4-(difluoromethoxy)-3-fluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (4.0 g,

93%). ¹H NMR (300 MHz, CDCl₃) δ 7.61 -7.54 (m, 2H), 7.23 – 7.99 (m, 1H), 6.58 (t, *J* = 73.5 Hz, 1H), 1.34 (s, 12H).


Step 51.3: Synthesis of 4-(difluoromethoxy)-3-fluorophenol



- 5 To the solution of 2-(4-(difluoromethoxy)-3-fluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1.0 g, 3.47 mmol) in acetone (10 mL), oxone (1.28 g, 4.17 mmol) dissolved in water (10mL) was added dropwise at 0 °C and stirred for 1 h. Reaction mixture was then diluted with water and extracted with EtOAc twice. The combined filtrate was concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 10% EtOAc in Hexane elution) to afford 4-(difluoromethoxy)-3-fluorophenol (0.5 g, 80%). ¹H NMR (400 MHz, DMSO-d₆) δ 9.99 (s, 1H), 7.16 (t, *J* = 9.3 Hz, 1H), 7.04 (t, *J* = 74.4 Hz, 1H), 6.74 – 6.69 (m, 1H), 6.62 – 6.58 (m, 1H).
- 10


Step 51.4: Synthesis of

tert-butyl ((1*r*,3*r*)-3-(4-(difluoromethoxy)-3-fluorophenoxy)cyclobutyl)carbamate




- 15 The title compound was synthesized following the procedure as described in Step 1.2, using *tert*-butyl ((1*s*,3*s*)-3-hydroxycyclobutyl)carbamate (0.4 g, 2.14 mmol) and 4-(difluoromethoxy)-3-fluorophenol (0.46 g, 2.56 mmol). Crude product was purified by flash chromatography (12 g SiliCycle column, 0 – 10% EtOAc in Hexane elution) to provide *tert*-butyl ((1*r*,3*r*)-3-(4-(difluoromethoxy)-3-fluorophenoxy)cyclobutyl)carbamate (0.4 g, 53%). ¹H NMR (300 MHz, CDCl₃) δ 7.12 (t, *J* = 9.3 Hz, 1H), 6.60 – 6.49 (m, 2H), 6.45 (t, *J* = 74.1 Hz, 1H), 4.75 – 4.69 (m, 1H), 4.32 – 4.27 (m, 1H), 2.59 – 2.50 (m, 2H), 2.42 – 2.35 (m, 2H), 1.45 (s, 9H).
- 20

Step 51.5: Synthesis of (1*r*,3*r*)-3-(4-(difluoromethoxy)-3-fluorophenoxy)cyclobutan-1-amine, HCl



- A solution of *tert*-butyl ((1*r*,3*r*)-3-(4-(difluoromethoxy)-3-fluorophenoxy)cyclobutyl)carbamate (0.6 g, 1.73 mmol) and HCl solution (4M in 1,4-dioxane) (10 mL) was stirred at rt for 4 h. Then the reaction mixture was concentrated in *vacuo*. The residue was triturated with Et₂O, solid was filtered and dried to yield (1*r*,3*r*)-3-(4-(difluoromethoxy)-3-fluorophenoxy)cyclobutan-1-amine, HCl (0.45 g, 91%). MS (ESI+) [Method 6A]: *m/z* 248.1 (*M*+*H*); *R*_t 1.29 min. ¹H NMR (300 MHz, DMSO-d₆) δ 7.19 – 7.15 (m, 1H), 6.83 (t, *J* = 72.4 Hz, 1H), 6.75 – 6.66 (m, 2H), 4.92 – 4.87 (m, 1H), 3.97 – 3.93 (m, 1H), 2.61 – 2.54 (m, 4H).
- 25
- 30


Step 51.6: Synthesis of (1*r*,3*r*)-3-(4-(difluoromethoxy)-3-fluorophenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl



The title compound was synthesized following the procedure as described in Step 1.4, using (1*r*,3*r*)-3-(4-(difluoromethoxy)-3-fluorophenoxy)cyclobutan-1-amine, HCl (450 mg, 1.59 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 250 mg, 1.43 mmol). Crude product was purified by prep-HPLC (Column: ZORBAX (150 mm x 21.2 mm), 5.0 μ ; Mobile Phase: 0.1% HCO₂H in water and acetonitrile-MeOH). The isolated product was stirred with HCl solution (4M in 1,4-dioxane) (2 mL) at rt for 1 h. Then concentrated in *vacuo* to afford (1*r*,3*r*)-3-(4-(difluoromethoxy)-3-fluorophenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl (280 mg, 39%). MS (ESI+) [Method 1A]: *m/z* 407.1 (M+H); Rt 1.30 min. ¹H NMR (400 MHz, CD₃OD) δ 9.88 (s, 1H), 8.82 – 8.75 (m, 3H), 8.02 (t, *J* = 9.6 Hz, 1H), 7.23 (t, *J* = 8.8 Hz, 1H), 6.78 (dd, *J* = 8.0, 2.8 Hz, 1H), 6.72 (t, *J* = 74.0 Hz, 1H), 6.68 (dq, *J* = 9.2, 1.6 Hz, 1H), 5.02 – 4.97 (m, 1H), 4.83 (d, *J* = 2.0 Hz, 2H), 4.29 – 4.25 (m, 1H), 2.92 – 2.85 (m, 2H), 2.73 – 2.65 (m, 2H).


Example 52: Synthesis of (1*r*,3*r*)-3-(3,5-difluoro-4-methylphenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCO₂H

Step 52.1: Synthesis of 2-(3,5-difluoro-4-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane




The sealed tube charged with 5-bromo-1,3-difluoro-2-methylbenzene [CAS No. 179617-08-4] (500 mg, 2.42 mmol), bis(pinacolato)diboron (675 mg, 2.66 mmol), KOAc (474 mg, 4.83 mmol) and 1,4-dioxane (15 mL) was purged with N₂ for 10 min. Then Pd(dppf)Cl₂.CH₂Cl₂ (88 mg, 0.12 mmol) was added, vessel was closed and stirred at 100 °C for 16 h. Reaction mixture was cooled, filtered through celite bed and the bed was washed with EtOAc. The filtrate was concentrated in *vacuo* and the residue was purified by flash chromatography (12 g SiliCycle column, 0 – 5% EtOAc in Hexane elution) to afford 2-(3,5-difluoro-4-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (380 mg, 68%). ¹H NMR (300 MHz, CDCl₃) δ 7.27 – 7.21 (m, 2H), 2.06 (t, *J* = 1.8 Hz, 3H), 1.33 (s, 12H).

Step 52.2: Synthesis of 3,5-difluoro-4-methylphenol




To the solution of 2-(3,5-difluoro-4-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.28 g, 1.10 mmol) in acetone (5 mL), oxone (1.01 g, 1.65 mmol) dissolved in water (5 mL) was added dropwise at 0 °C and stirred for 1 h. Reaction mixture was then diluted with water and extracted with EtOAc twice. The combined filtrate was concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 8% EtOAc in Hexane elution) to afford 3,5-difluoro-4-methylphenol (0.13 g, 81%). ¹H NMR (400 MHz, DMSO-d₆) δ 10.08 (s, 1H), 6.41 (d, *J* = 9.3 Hz, 2H), 2.06 (s, 3H).

10 Step 52.3: Synthesis of *tert*-butyl ((1*r*,3*r*)-3-(3,5-difluoro-4-methylphenoxy)cyclobutyl)carbamate




The title compound was synthesized following the procedure as described in Step 1.2, using *tert*-butyl ((1*s*,3*s*)-3-hydroxycyclobutyl)carbamate (104 mg, 0.56 mmol) and 3,5-difluoro-4-methylphenol (80 mg, 0.56 mmol). Crude product was purified by flash chromatography (12 g SiliCycle column, 0 – 10% EtOAc in Hexane elution) to provide *tert*-butyl ((1*r*,3*r*)-3-(3,5-difluoro-4-methylphenoxy)cyclobutyl)carbamate (70 mg, 40%). ¹H NMR (300 MHz, CDCl₃) δ 6.27 (d, *J* = 8.7 Hz, 2H), 4.73 – 4.66 (m, 1H), 4.31 – 4.26 (m, 1H), 2.57 – 2.49 (m, 2H), 2.40 – 2.32 (m, 2H), 2.09 (s, 3H), 1.45 (s, 9H).

Step 52.4: Synthesis of (1*r*,3*r*)-3-(3,5-difluoro-4-methylphenoxy)cyclobutan-1-amine, HCl



To the solution of *tert*-butyl ((1*r*,3*r*)-3-(3,5-difluoro-4-methylphenoxy)cyclobutyl)carbamate (170 mg, 0.69 mmol) in 1,4-dioxane (0.5 mL), HCl solution (4M in 1,4-dioxane) (2 mL) was added dropwise at 0 °C and stirred at rt for 4 h. Then the reaction mixture was concentrated in *vacuo*. The residue was triturated with Et₂O, solid was filtered and dried to yield (1*r*,3*r*)-3-(3,5-difluoro-4-methylphenoxy)cyclobutan-1-amine, HCl (120 mg, 88%). MS (ESI+) [Method 6A]: *m/z* 214.2 (*M*+*H*); Rt 1.31 min. ¹H NMR (300 MHz, DMSO-d₆) δ 8.32 (brs, 3H), 6.57 (d, *J* = 8.4 Hz, 2H), 5.03 – 4.96 (m, 1H), 3.84 – 3.78 (m, 1H), 2.66 – 2.57 (m, 2H), 2.43 – 2.34 (m, 2H), 2.05 (s, 3H).

Step 52.5: Synthesis of (1*r*,3*r*)-3-(3,5-difluoro-4-methylphenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCO₂H




The title compound was synthesized following the procedure as described in Step 1.4, using (1*r*,3*r*)-3-(3,5-difluoro-4-methylphenoxy)cyclobutan-1-amine, HCl (120 mg, 0.48 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 76 mg, 0.43 mmol). Crude product was purified by prep-HPLC (Column: WATERS X BRIDGE C18 (150 mm x 19.0 mm), 5.0 μ ; Mobile Phase: 0.1% HCO₂H in water and acetonitrile) to afford (1*r*,3*r*)-3-(3,5-difluoro-4-methylphenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCO₂H (50 mg, 28%). MS (ESI+) [Method 1A]: *m/z* 373.2 (M+H); Rt 1.30 min. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.32 (s, 1H), 8.56 – 8.53 (m, 1H), 8.18 – 8.15 (m, 2H), 8.09 – 8.07 (m, 1H), 7.58 (t, *J* = 8.8 Hz, 1H), 6.53 (d, *J* = 8.8 Hz, 1H), 4.82 – 4.77 (m, 1H), 4.06 (d, *J* = 2.0 Hz, 2H), 3.44 – 3.39 (m, 1H), 2.30 – 2.23 (m, 2H), 2.20 – 2.15 (m, 2H), 2.04 (m, 3H).

Example 53: Synthesis of (5-(((1*r*,3*r*)-3-(3,5-difluoro-4-


methylphenoxy)cyclobutyl)amino)methyl)-6-fluoroisoquinolin-8-yl)methanol, HCl

Step 53.1: Synthesis of (1*r*,3*r*)-*N*-((8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinolin-5-yl)methyl)-3-(3,5-difluoro-4-methylphenoxy)cyclobutan-1-amine



The title compound was synthesized following the procedure as described in Step 1.4, using (1*r*,3*r*)-3-(3,5-difluoro-4-methylphenoxy)cyclobutan-1-amine, HCl (Step 52.4, 100 mg, 0.40 mmol) and 8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinoline-5-carbaldehyde (Step 6.8, 128 mg, 0.40 mmol). The crude (1*r*,3*r*)-*N*-((8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinolin-5-yl)methyl)-3-(3,5-difluoro-4-methylphenoxy)cyclobutan-1-amine was obtained (250 mg, 120% crude). MS (ESI+) [Method 6A]: *m/z* 517.2 (M+H); Rt 1.45.


Step 53.2: Synthesis of (5-(((1*r*,3*r*)-3-(3,5-difluoro-4-methylphenoxy)cyclobutyl)amino)methyl)-6-fluoroisoquinolin-8-yl)methanol, HCl



Deprotection was carried out according to Step 6.11. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 20% MeOH in CH₂Cl₂ elution), followed by prep-HPLC (Column: LUNA Phenomenex (150 mm x 21.2 mm), 5.0 μ ; Mobile Phase: 0.1% HCO₂H in water and acetonitrile). The isolated product was stirred with HCl solution (4M in 1,4-dioxane) (2 mL) at rt for 1 h, then concentrated in *vacuo* and lyophilized to afford (5-(((1*r*,3*r*)-3-(3,5-difluoro-4-methylphenoxy)cyclobutyl)amino)methyl)-6-fluoroisoquinolin-8-yl)methanol, HCl (20 mg, 9%). MS (ESI+) [Method 6A]: *m/z* 403.1 (M+H); Rt 1.32 min. ¹H NMR (400 MHz, CD₃OD) δ 9.88 (s, 1H), 8.79 – 8.76 (m, 1H), 8.70 – 8.68 (m, 1H), 7.98 (d, *J* = 10.8 Hz, 1H), 6.45 (d, *J* = 8.8 Hz, 2H), 5.29 (s, 2H), 4.96 – 4.92 (m, 1H), 4.78 (d, *J* = 1.6 Hz, 2H), 4.26 – 4.22 (m, 1H), 2.89 – 2.81 (m, 2H), 2.71 – 2.64 (m, 2H), 2.08 (s, 3H).


Example 54: Synthesis of (1*r*,3*r*)-3-(3,4-difluoro-5-methylphenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl

Step 54.1: Synthesis of 5-bromo-2,3-difluorobenzaldehyde



To the solution of 2,3-difluorobenzaldehyde [CAS No. 2646-91-5] (5.0 g, 35.19 mmol) in concentrated H₂SO₄ (38 mL), NBS (7.51 g, 42.23 mmol) was added portion wise at 60 °C, and stirred for 16 h. The reaction mixture was cooled, poured dropwise onto ice-water, extracted with Et₂O 3x's. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo* to yield the crude product. The crude was purified by flash chromatography (40 g SiliCycle column, 0 – 5% EtOAc in Hexane elution) to provide 5-bromo-2,3-difluorobenzaldehyde (2.04 g, 26%). ¹H NMR (300 MHz, CDCl₃) δ 10.29 (s, 1H), 7.78 – 7.75 (m, 1H), 7.62 – 7.56 (m, 1H).


Step 54.2: Synthesis of (5-bromo-2,3-difluorophenyl)methanol



To the stirred solution of 5-bromo-2,3-difluorobenzaldehyde (2.04 g, 9.23 mmol) in MeOH (10 mL), NaBH₄ (0.69 g, 18.46 mmol) was added portion wise at 0 °C. The reaction mixture was


stirred at rt for 2 h. Then the reaction mixture was diluted with water and extracted with EtOAc 3x's. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo* to afford crude (5-bromo-2,3-difluorophenyl)methanol (1.7 g, 82%). ¹H NMR (600 MHz, CDCl₃) δ 7.39 – 7.38 (m, 1H), 7.29 – 7.25 (m, 1H), 4.77 (s, 2H).

5 Step 54.3: Synthesis of 5-bromo-2,3-difluorobenzyl methanesulfonate




To the stirred solution of (5-bromo-2,3-difluorophenyl)methanol (1.7 g, 2.62 mmol) and TEA (2.12 mL, 15.25 mmol) in CH₂Cl₂ (25 mL), MsCl (0.71 mL, 9.15 mmol) was added drop wise at 0 °C and stirred for 1 h under N₂. Then the reaction mixture was diluted with water and extracted with CH₂Cl₂ 3x's. The combined organic portion was washed with 1N HCl solution, saturated NaHCO₃ solution and brine successively, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo* to afford crude 5-bromo-2,3-difluorobenzyl methanesulfonate (2.2 g, 95%) which was used as is in the next reaction.

Step 54.4: Synthesis of 5-bromo-1,2-difluoro-3-methylbenzene



15 To the stirred solution of 5-bromo-2,3-difluorobenzyl methanesulfonate (2.2 g, 7.31 mmol) in anhydrous THF (20 mL), LiEt₃BH (1M in THF) (15.34 mL, 15.34 mmol) was added drop wise at 0 °C and stirred for 5 min; then at rt for 1 h under N₂. The reaction mixture was cooled to 0 °C, diluted with water and extracted with Et₂O 3x's. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The crude product was purified by flash chromatography (24 g SiliCycle column, Hexane elution) to afford 5-bromo-1,2-difluoro-3-methylbenzene (1.4 g, 92%). ¹H NMR (600 MHz, CDCl₃) δ 7.17 – 7.14 (m, 1H), 7.11 – 7.09 (m, 1H), 2.28 (s, 3H).


Step 54.5: Synthesis of 2-(3,4-difluoro-5-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane



25 The sealed tube charged with 5-bromo-1,2-difluoro-3-methylbenzene (1.4 g, 6.76 mmol), bis(pinacolato)diboron (2.06 g, 8.12 mmol), KOAc (1.32 g, 13.53 mmol) and 1,4-dioxane (20 mL) was purged with N₂ for 10 min. Then Pd(dppf)Cl₂.CH₂Cl₂ (0.25 g, 0.34 mmol) was added, vessel was closed and stirred at 100 °C for 16 h. Reaction mixture was cooled, filtered through celite bed and the bed was washed with Et₂O. The filtrate was concentrated in *vacuo* and the residue was


purified by flash chromatography (24 g SiliCycle column, Hexane elution) to afford 2-(3,4-difluoro-5-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1.17 g, 68%). ^1H NMR (300 MHz, CDCl_3) δ 7.42 – 7.37 (m, 2H), 2.30 (d, J = 2.4 Hz, 3H), 1.33 (s, 12H).

Step 54.6: Synthesis of 3,4-difluoro-5-methylphenol




To the solution of 2-(3,4-difluoro-5-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.57 g, 2.24 mmol) in acetone (10 mL), oxone (2.06 g, 3.37 mmol) dissolved in water (10 mL) was added dropwise at 0 °C and stirred for 1 h. Reaction mixture was then diluted with water and extracted with Et_2O twice. The combined organic portion was washed with brine, dried over anhydrous Na_2SO_4 , filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 10% EtOAc in Hexane elution) to afford 3,4-difluoro-5-methylphenol (0.23 g, 71%). ^1H NMR (400 MHz, DMSO-d_6) δ 9.68 (s, 1H), 6.57 – 6.52 (m, 1H), 6.47 – 6.44 (m, 1H), 2.19 (d, J = 2.4 Hz, 3H).

Step 54.7: Synthesis of *tert*-butyl ((1*r*,3*r*)-3-(3,4-difluoro-5-methylphenoxy)cyclobutyl)carbamate



To the stirred solution of 3,4-difluoro-5-methylphenol (100 mg, 0.69 mmol) and Cs_2CO_3 (452 mg, 1.39 mmol) in anhydrous DMF (3 mL), (1*s*,3*s*)-3-((*tert*-butoxycarbonyl)amino)cyclobutyl methanesulfonate (Step 99.1, 184 mg, 0.69 mmol) was added at rt and heated at 70 °C for 16 h under N_2 . Reaction mixture was diluted with water and extracted with EtOAc twice. The combined organic portion was concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 10% EtOAc in Hexane elution) to afford *tert*-butyl ((1*r*,3*r*)-3-(3,4-difluoro-5-methylphenoxy)cyclobutyl)carbamate (100 mg, 46%). ^1H NMR (300 MHz, CDCl_3) δ 6.43 – 6.32 (m, 2H), 4.70 – 4.65 (m, 1H), 4.27 – 4.23 (m, 1H), 2.54 – 2.47 (m, 2H), 2.39 – 2.33 (m, 2H), 2.26 (d, J = 2.4 Hz, 3H), 1.45 (s, 9H).


Step 54.8: Synthesis of (1*r*,3*r*)-3-(3,4-difluoro-5-methylphenoxy)cyclobutan-1-amine, HCl



To the solution of *tert*-butyl ((1*r*,3*r*)-3-(3,4-difluoro-5-methylphenoxy)cyclobutyl)carbamate (180 mg, 0.57 mmol) in 1,4-dioxane (0.5 mL), HCl solution (4M in 1,4-dioxane) (2 mL) was added dropwise at 0 °C and stirred at rt for 4 h. Then the reaction mixture was concentrated in *vacuo*. The residue was triturated with Et_2O , solid was filtered and dried to yield to afford (1*r*,3*r*)-3-(3,4-difluoro-5-methylphenoxy)cyclobutan-1-amine, HCl (120 mg, 83%). MS (ESI+) [Method 1A]: m/z 214.1 ($\text{M}+\text{H}$); Rt 0.14 min. ^1H NMR (300 MHz, DMSO-d_6) δ 8.28 (brs, 3H), 6.77 – 6.70 (m, 1H),

6.58 – 6.55 (m, 1H), 4.97 – 4.91 (m, 1H), 3.85 – 3.78 (m, 1H), 2.65 – 2.56 (m, 2H), 2.44 – 2.33 (m, 2H), 2.25 (d, $J = 1.2$ Hz, 3H).

Step 54.9: Synthesis of (1*r*,3*r*)-3-(3,4-difluoro-5-methylphenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl




5

The title compound was synthesized following the procedure as described in Step 1.4, using (1*r*,3*r*)-3-(3,4-difluoro-5-methylphenoxy)cyclobutan-1-amine, HCl (120 mg, 0.48 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 76 mg, 0.43 mmol). Crude product was purified by prep-HPLC (Column: KINETEX EVO (150 mm x 19.0 mm), 5.0 μ ; Mobile Phase: 0.1% HCO₂H in water and acetonitrile). The isolated product was stirred with HCl solution (4M in 1,4-dioxane) (2 mL) at rt for 1 h, then concentrated in *vacuo* and lyophilized to afford (1*r*,3*r*)-3-(3,4-difluoro-5-methylphenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl (85 mg, 47%). MS (ESI+) [Method 1A]: m/z 373.1 (M+H); Rt 0.19 min. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.82 (s, 1H), 8.80 – 8.78 (m, 1H), 8.75 – 8.69 (m, 2H), 7.99 (t, $J = 8.8$ Hz, 1H), 6.64 – 6.58 (m, 1H), 6.55 – 6.53 (m, 1H), 4.97 – 4.93 (m, 1H), 4.82 (d, $J = 2.0$ Hz, 2H), 4.29 – 4.24 (m, 1H), 2.90-2.82 (m, 2H), 2.72 – 2.65 (m, 2H), 2.29 (d, $J = 2.4$ Hz, 3H).

15

Example 55: Synthesis of (1*r*,3*r*)-3-((2,6-difluoropyridin-3-yl)oxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl

Step 55.1: Synthesis of *tert*-butyl ((1*r*,3*r*)-3-((2,6-difluoropyridin-3-yl)oxy)cyclobutyl)carbamate




20

The title compound was synthesized following the procedure as described in Step 1.2, using *tert*-butyl ((1*s*,3*s*)-3-hydroxycyclobutyl)carbamate (0.40 g, 2.14 mmol) and 2,6-difluoropyridin-3-ol [CAS No. 209328-85-8] (0.30 g, 2.35 mmol). Crude product was purified by flash chromatography (12 g SiliCycle column, 0 – 20% EtOAc in Hexane elution) to provide *tert*-butyl ((1*r*,3*r*)-3-((2,6-difluoropyridin-3-yl)oxy)cyclobutyl)carbamate (0.40 g, 60%). MS (ESI+) [Method 6A]: m/z 244.9 (M-*t*-Bu+H); Rt 1.58 min.

25

Step 55.2: Synthesis of (1*r*,3*r*)-3-((2,6-difluoropyridin-3-yl)oxy)cyclobutan-1-amine, HCl




A solution of *tert*-butyl ((1*r*,3*r*)-3-((2,6-difluoropyridin-3-yl)oxy)cyclobutyl)carbamate (0.40 g, 1.33 mmol) and HCl solution (4M in 1,4-dioxane) (10 mL) was stirred at rt for 16 h. Then the reaction

30


mixture was concentrated in *vacuo*. The residue was triturated with Et₂O, solid was filtered and dried to afford (1*r*,3*r*)-3-((2,6-difluoropyridin-3-yl)oxy)cyclobutan-1-amine, HCl (0.20 g, 63%). MS (ESI+) [Method 6A]: *m/z* 200.9 (M+H); Rt 4.84 min. ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.46 (brs, 3H), 7.70 – 7.61 (m, 1H), 7.14 – 7.10 (m, 1H), 5.15 – 5.07 (m, 1H), 3.89 – 3.80 (m, 1H), 2.69 – 2.60 (m, 2H), 2.50 – 2.41 (m, 2H).

Step 55.3: Synthesis of (1*r*,3*r*)-3-((2,6-difluoropyridin-3-yl)oxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl



A round bottom flask fitted with Dean-Stark apparatus was charged with (1*r*,3*r*)-3-((2,6-difluoropyridin-3-yl)oxy)cyclobutan-1-amine, HCl (0.20 g, 0.85 mmol), 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 0.15 g, 0.85 mmol), TEA (0.12 mL, 0.85 mmol) and benzene (50 mL), and then refluxed for 4 h. Reaction mixture was concentrated in *vacuo* to remove solvent, residue was dissolved in MeOH (10 mL), cooled to 0 °C, NaBH₄ (0.16 g, 4.23 mmol) was added portion wise and stirred at rt for 2 h. Then the reaction mixture was diluted with water and extracted with EtOAc twice. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The crude product was purified by prep-HPLC (Column: LUNA Phenomenex (250 mm x 21.2 mm), 5.0 μ; Mobile Phase: 0.1% HCO₂H in water and acetonitrile). The isolated product was stirred with HCl solution (4M in 1,4-dioxane) (5 mL) at rt for 1 h, and then concentrated in *vacuo*. The residue was triturated with Et₂O, solid was collected and dried in *vacuo* to afford (1*r*,3*r*)-3-((2,6-difluoropyridin-3-yl)oxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl (0.19 g, 56%). MS (ESI+) [Method 1A]: *m/z* 360.2 (M+H); Rt 0.13 min. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.90 (brs, 1H), 8.86 – 8.84 (m, 1H), 8.85 – 8.76 (m, 2H), 8.03 (t, *J* = 9.6 Hz, 1H), 7.62 – 7.56 (m, 1H), 6.91 (dd, *J* = 8.4, 2.8 Hz, 1H), 5.11 – 5.07 (m, 1H), 4.84 (d, *J* = 2.0 Hz, 2H), 4.33 – 4.28 (m, 1H), 2.96 – 2.88 (m, 2H), 2.78 – 2.70 (m, 2H).


Example 56: Synthesis of (1*r*,3*r*)-*N*-((6-fluoroisoquinolin-5-yl)methyl)-3-((2-(trifluoromethyl)pyridin-4-yl)oxy)cyclobutan-1-amine, HCl



- The title compound was synthesized following the procedure as described in Step 1.4, using (1*r*,3*r*)-3-((2-(trifluoromethyl)pyridin-4-yl)oxy)cyclobutan-1-amine, HCl (Step 16.2, 306 mg, 1.14 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 200 mg, 1.14 mmol). The crude product was purified by prep-HPLC (Column: WATERS X BRIDGE (150 mm x 21.2 mm), 5.0 μ ; Mobile Phase: 0.02% NH₄OH in water and acetonitrile). The isolated product was stirred with HCl solution (4M in 1,4-dioxane) (5 mL) at rt for 1 h, then concentrated in *vacuo*, and lyophilized to afford (1*r*,3*r*)-*N*-((6-fluoroisoquinolin-5-yl)methyl)-3-((2-(trifluoromethyl)pyridin-4-yl)oxy)cyclobutan-1-amine, HCl (120 mg, 24%). MS (ESI+) [Method 6A]: *m/z* 392.1 (M+H); Rt 1.25 min. ¹H NMR (400 MHz, CD₃OD) δ 9.92 (s, 1H), 8.89 (d, *J* = 6.8 Hz, 1H), 8.83 – 8.79 (m, 2H), 8.56 (d, *J* = 5.6 Hz, 1H), 8.05 (t, *J* = 9.2 Hz, 1H), 7.33 (d, *J* = 2.4 Hz, 1H), 7.16 – 7.14 (m, 1H), 5.27 – 5.23 (m, 1H), 4.86 (d, *J* = 1.5 Hz, 2H), 4.35 – 4.31 (m, 1H), 3.05 – 2.98 (m, 2H), 2.81 – 2.74 (m, 2H).


Example 57: Synthesis of (1*r*,3*r*)-3-((5,6-difluoropyridin-3-yl)oxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl

- 15 Step 57.1: Synthesis of 2,3-difluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine




- The sealed tube charged with 5-chloro-2,3-difluoropyridine [CAS No. 89402-43-7] (1.0 g, 6.69 mmol), bis(pinacolato)diboron (1.89 g, 8.03 mmol), KOAc (0.98 g, 10.03 mmol), tri-cyclohexyl phosphine (131 mg, 0.47 mmol) and 1,4-dioxane (15 mL) was purged with argon for 15 min. Then Pd₂(dba)₃ (123 mg, 0.34 mmol) was added and the reaction mixture was stirred at 85 °C for 16 h. Reaction mixture was cooled, filtered through celite bed and the bed was washed with EtOAc. The filtrate was washed with water 3x's, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 30% EtOAc in Hexane elution) to afford 2,3-difluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (1.29 g, 80%). ¹H NMR (300 MHz, CDCl₃) δ 8.31 (s, 1H), 7.88 (t, *J* = 9.9 Hz, 1H), 1.35 (s, 12H).

Step 57.2: Synthesis of 5,6-difluoropyridin-3-ol




- The title compound was prepared according to Step 51.3. The combined organic portion was further washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 20% EtOAc in Hexane elution) to afford 5,6-difluoropyridin-3-ol (415 mg, 64%). MS (ESI+) [Method 6A]: *m/z* 132.1 (M+H); Rt 0.31 min. ¹H NMR (300 MHz, CDCl₃) δ 7.58 (t, *J* = 2.4 Hz, 1H), 7.20 – 7.13 (m, 1H).

Step 57.3: Synthesis of *tert*-butyl ((1*r*,3*r*)-3-((5,6-difluoropyridin-3-yl)oxy)cyclobutyl)carbamate




The title compound was synthesized following the procedure as described in Step 1.2, using *tert*-butyl ((1*r*,3*s*)-3-hydroxycyclobutyl)carbamate (593 mg, 3.17 mmol) and 5,6-difluoropyridin-3-ol (415 mg, 3.17 mmol). Crude product was purified by flash chromatography (24 g SiliCycle column, 0 – 40% EtOAc in Hexane elution) to provide *tert*-butyl ((1*r*,3*r*)-3-((5,6-difluoropyridin-3-yl)oxy)cyclobutyl)carbamate (400 mg, 42%). MS (ESI+) [Method 6A]: *m/z* 245.1 (*M*-*t*-Bu+H); Rt 1.57 min. (600 MHz, CDCl₃) δ 7.44 (d, *J* = 1.8 Hz, 1H), 7.07 – 7.03 (m, 1H), 4.79 – 4.76 (m, 1H), 4.33 – 4.29 (m, 1H), 2.58 – 2.53 (m, 2H), 2.44 – 2.39 (m, 2H), 1.45 (s, 9H).

Step 57.4: Synthesis of (1*r*,3*r*)-3-((5,6-difluoropyridin-3-yl)oxy)cyclobutan-1-amine, HCl



The solution of *tert*-butyl ((1*r*,3*r*)-3-((5,6-difluoropyridin-3-yl)oxy)cyclobutyl)carbamate (200 mg, 0.67 mmol) and HCl solution (4M in 1,4-dioxane) (4 mL) was stirred at rt for 1 h. Then the reaction mixture was concentrated in *vacuo*. The residue was triturated with Et₂O, solid was filtered and dried to yield (1*r*,3*r*)-3-((5,6-difluoropyridin-3-yl)oxy)cyclobutan-1-amine, HCl (130 mg, 83%). MS (ESI+) [Method 1A]: *m/z* 201.1 (*M*+H); Rt 0.58 min. ¹H NMR (300 MHz, CDCl₃) δ 7.57 – 7.53 (m, 1H), 7.32 – 7.26 (m, 1H), 5.06 – 4.98 (m, 1H), 4.53 – 4.48 (m, 1H), 2.85 – 2.78 (m, 2H), 2.63 – 2.57 (m, 2H).

Step 57.5: Synthesis of (1*r*,3*r*)-3-((5,6-difluoropyridin-3-yl)oxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl




The title compound was synthesized following the procedure as described in Step 1.4, using (1*r*,3*r*)-3-((5,6-difluoropyridin-3-yl)oxy)cyclobutan-1-amine, HCl (130 mg, 0.55 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 87 mg, 0.49 mmol). The crude product was purified by prep-HPLC (Column: LUNA Phenomenex (250 mm x 21.2 mm), 5.0 μ; Mobile Phase: 0.02% NH₄OH in water and acetonitrile-MeOH (1:1)). The isolated product was stirred with HCl solution (4M in 1,4-dioxane) (2 mL) at rt for 2 h, then concentrated in *vacuo*. Residue was triturated with *n*-pentane. The solid was collected, dried and lyophilized to afford (1*r*,3*r*)-3-((5,6-difluoropyridin-3-yl)oxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl (50 mg, 25%). MS (ESI+) [Method 6A]: *m/z* 360.2 (*M*+H); Rt 1.24 min. ¹H NMR (400 MHz, CD₃OD) δ 9.83 (brs, 1H), 8.81 – 8.71 (m, 3H), 8.00 (t, *J* = 9.2 Hz, 1H), 7.61 – 7.60 (m, 1H), 7.50 – 7.45

(m, 1H), 5.10 – 5.04 (m, 1H), 4.84 (d, $J = 2.0$ Hz, 2H), 4.35 – 4.27 (m, 1H), 2.94 – 2.87 (m, 2H), 2.78 – 2.71 (m, 2H).


Example 58: Synthesis of ((1*r*,3*r*)-3-((2-fluoro-6-(trifluoromethyl)pyridin-3-yl)oxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl

5 Step 58.1: Synthesis of 2-fluoro-3-iodo-6-(trifluoromethyl)pyridine




To the solution of 2-fluoro-6-(trifluoromethyl)pyridine [CAS No. 94239-04-0] (0.5 g, 3.02 mmol), in anhydrous THF (10 mL), LDA (2M in THF) (2.2 mL, 4.40 mmol) was added dropwise at -65 °C and stirred for 10 min under N₂. Then I₂ (0.76 g, 3.02 mmol) dissolved in THF (2 mL) was added dropwise, temperature was raised slowly to rt and stirred for 2 h. The reaction was quenched with saturated NH₄Cl solution, then basified with 10% NaOH solution and extracted with EtOAc twice. Then the combined organic portion was washed with brine, dried over Na₂SO₄, filtered and concentrated in *vacuo* to afford crude 2-fluoro-3-iodo-6-(trifluoromethyl)pyridine (0.7 g, 80%). ¹H NMR (600 MHz, CDCl₃) δ 8.37 (t, $J = 7.8$ Hz, 1H), 7.35 (dd, $J = 7.8, 1.2$ Hz, 1H).

15 Step 58.2: Synthesis of 2-fluoro-6-(trifluoromethyl)pyridin-3-ol



The sealed tube charged with 2-fluoro-3-iodo-6-(trifluoromethyl)pyridine (0.5 g, 1.72 mmol), bis(pinacolato)diboron (0.65 g, 2.56 mmol), KOAc (0.49 g, 4.99 mmol) and 1,4-dioxane (5 mL) was purged with N₂ for 10 min. Then Pd(dppf)Cl₂.CH₂Cl₂ (0.13 g, 0.18 mmol) was added, vessel was closed and stirred at 80 °C. After 16 h, the reaction mixture was cooled, acetone (2 mL) and oxone (1.5 g, 2.44 mmol), dissolved in water (2 mL) were added, and stirred at rt for 1 h. Reaction mixture was then diluted with water and extracted with EtOAc 3x's. The combined filtrate was concentrated in *vacuo*. The residue was purified by flash chromatography (24 g SiliCycle column, 0 – 20% EtOAc in Hexane elution) to afford 2-fluoro-6-(trifluoromethyl)pyridin-3-ol (0.1 g, 28%). ¹H NMR (300 MHz, DMSO-d₆) δ 11.55 (brs, 1H), 7.69 (t, $J = 8.4$ Hz, 1H), 7.54 (t, $J = 9.9$ Hz, 1H).


25 Step 58.3: Synthesis of *tert*-butyl ((1*r*,3*r*)-3-((2-fluoro-6-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutyl)carbamate



The title compound was synthesized following the procedure as described in Step 1.2, using *tert*-butyl ((1*s*,3*s*)-3-hydroxycyclobutyl)carbamate (103 mg, 0.55 mmol) and 2-fluoro-6-(trifluoromethyl)pyridin-3-ol (100 mg, 0.55 mmol). Crude product was purified by flash chromatography (12 g SiliCycle column, 0 – 10% EtOAc in Hexane elution) to provide *tert*-butyl ((1*r*,3*r*)-3-((2-fluoro-6-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutyl)carbamate (150 mg, 85%). ¹H


NMR (300 MHz, CDCl₃) δ 7.48 (d, J = 7.8 Hz, 1H), 7.11 (t, J = 7.5 Hz, 1H), 4.93 – 4.87 (m, 1H), 4.32 – 4.27 (m, 1H), 2.66 – 2.59 (m, 2H), 2.54 – 2.48 (m, 2H), 1.45 (s, 9H).

Step 58.4: Synthesis of (1*r*,3*r*)-3-((2-fluoro-6-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutan-1-amine, HCl



5 The solution of *tert*-butyl ((1*r*,3*r*)-3-((2-fluoro-6-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutyl)carbamate (150 mg, 0.42 mmol) and HCl solution (4M in 1,4-dioxane) (4 mL) was stirred at rt for 1 h. Then the reaction mixture was concentrated in *vacuo*. The residue was triturated with Et₂O, solid was filtered and dried to afford (1*r*,3*r*)-3-((2-fluoro-6-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutan-1-amine, HCl (100 mg, 57%). ¹H NMR (300 MHz, CD₃OD) δ 7.67 (d, J = 8.4 Hz, 1H), 7.46 (t, J = 8.7 Hz, 1H), 5.13 – 5.09 (m, 1H), 4.06 – 4.00 (m, 1H), 2.73 – 2.68 (m, 4H).


Step 58.5: Synthesis of (1*r*,3*r*)-3-((2-fluoro-6-(trifluoromethyl)pyridin-3-yl)oxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl



15 The title compound was synthesized following the procedure as described in Step 1.4, using (1*r*,3*r*)-3-((2-fluoro-6-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutan-1-amine, HCl (50 mg, 0.17 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 25 mg, 0.15 mmol). The crude product was purified by prep-HPLC (Column: YMC-ACTUS TRIART C-18 (150 mm x 21.2 mm), 20 5.0 μ ; Mobile Phase: 0.01% NH₄OH in water and acetonitrile). The isolated product was stirred with HCl solution (4M in 1,4-dioxane) (1 mL) at rt for 1 h, then concentrated in *vacuo*. Residue was triturated with *n*-pentane. The solid was collected, dried and lyophilized to afford (1*r*,3*r*)-3-((2-fluoro-6-(trifluoromethyl)pyridin-3-yl)oxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl (12 mg, 16%). MS (ESI+) [Method 6A]: m/z 410.1 (M+H); Rt 1.28 min. ¹H NMR (400 MHz, CD₃OD) δ 9.86 (brs, 1H), 8.79 – 8.74 (m, 3H), 8.02 (t, J = 9.2 Hz, 1H), 7.70 (d, J = 8.4 Hz, 1H), 7.54 (t, J = 9.2 Hz, 1H), 5.24 – 4.99 (m, 1H), 4.85 (d, J = 2.0 Hz, 2H), 4.37 – 4.32 (m, 1H), 3.01 – 2.96 (m, 2H), 2.85 – 2.78 (m, 2H).


Example 59: Synthesis of 5-((1*r*,3*r*)-3-(((6-fluoroisoquinolin-5-yl)methyl)amino)cyclobutoxy)-2-(trifluoromethyl)benzonitrile, HCl

30 Step 59.1: Synthesis of *tert*-butyl ((1*r*,3*r*)-3-(3-cyano-4-(trifluoromethyl)phenoxy)cyclobutyl)carbamate




To the solution of *tert*-butyl ((1*r*,3*r*)-3-hydroxycyclobutyl)carbamate (150 mg, 0.80 mmol) in DMF (2 mL), NaH (60% on mineral oil) (48 mg, 2.00 mmol) was added at 0 °C, stirred for 5 min. Then and 5-fluoro-2-(trifluoromethyl)benzonitrile [CAS No. 240800-45-7] (182 mg, 0.96 mmol) was added at 0 °C and the reaction mixture was stirred at rt for 16 h under N₂. The reaction mixture was quenched with saturated NH₄Cl solution and stirred for 10 minutes. The solid separated was filtered, washed with water and dried in *vacuo* to afford crude *tert*-butyl ((1*r*,3*r*)-3-(3-cyano-4-(trifluoromethyl)phenoxy)cyclobutyl)carbamate (25 mg, 87%). MS (ESI+) [Method 6A]: *m/z* 357.2 (M+H); Rt 1.63 min. ¹H NMR (300 MHz, CDCl₃) δ 7.67 (d, *J* = 8.7 Hz, 1H), 7.16 – 7.14 (m, 1H), 7.04 (dd, *J* = 9.0, 1.8 Hz, 1H), 4.87 – 4.79 (m, 1H), 4.33 – 4.28 (m, 1H), 2.61 – 2.53 (m, 2H), 2.52 – 2.43 (m, 2H), 1.45 (s, 9H).

Step 59.2: Synthesis of 5-((1*r*,3*r*)-3-aminocyclobutoxy)-2-(trifluoromethyl)benzonitrile, HCl



A round bottom flask was charged with *tert*-butyl ((1*r*,3*r*)-3-(3-cyano-4-(trifluoromethyl)phenoxy)cyclobutyl)carbamate (250 mg, 0.70 mmol) and HCl solution (4M in 1,4-dioxane) (5 mL), and stirred at rt for 2 h. Then the reaction mixture was concentrated in *vacuo*. The residue was triturated with pentane, the solid appeared was filtered and dried to yield 5-((1*r*,3*r*)-3-aminocyclobutoxy)-2-(trifluoromethyl)benzonitrile, HCl (200 mg, 97%). MS (ESI+) [Method 6A]: *m/z* 256.9 (M+H); Rt 1.31 min.

Step 59.3: Synthesis of 5-((1*r*,3*r*)-3-((6-fluoroisoquinolin-5-yl)methyl)amino)cyclobutoxy)-2-(trifluoromethyl)benzonitrile, HCl




The title compound was synthesized following the procedure as described in Step 1.4, using 5-((1*r*,3*r*)-3-aminocyclobutoxy)-2-(trifluoromethyl)benzonitrile, HCl (100 mg, 0.34 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 54 mg, 0.31 mmol). The crude product was

purified by prep-HPLC (Column: XBRIDGE (150 mm x 19.0 mm), 5.0 μ ; Mobile Phase: 0.02% NH_4OH in water and acetonitrile). The isolated product was stirred with HCl solution (4M in 1,4-dioxane) (2 mL) at rt for 2 h, then concentrated in *vacuo*. Residue was triturated with *n*-pentane. The solid was collected, dried and lyophilized to afford 5-((1*r*,3*r*)-3-(((6-fluoroisoquinolin-5-yl)methyl)amino)cyclobutoxy)-2-(trifluoromethyl)benzonitrile, HCl (40 mg, 26%). MS (ESI+) [Method 6A]: m/z 416.1 (M+H); Rt 1.34 min. ^1H NMR (400 MHz, CD_3OD) δ 9.81 (brs, 1H), 8.85 – 8.78 (m, 3H), 8.04 (t, $J = 9.2$ Hz, 1H), 7.78 (d, $J = 8.7$ Hz, 1H), 7.51 – 7.50 (m, 1H), 7.33 – 7.30 (m, 1H), 5.22 – 5.17 (m, 1H), 4.87 (d, $J = 1.6$ Hz, 2H), 4.37 – 4.31 (m, 1H), 3.03 – 2.97 (m, 2H), 2.81 – 2.73 (m, 2H).


10 Example 60: Synthesis of ethyl 5-((1*r*,3*r*)-3-(((6-fluoroisoquinolin-5-yl)methyl)amino)cyclobutoxy)-2-(trifluoromethyl)benzoate

Step 60.1: Synthesis of ethyl 5-fluoro-2-(trifluoromethyl)benzoate




The stirred solution of 5-fluoro-2-(trifluoromethyl) benzoic acid [CAS No. 654-99-9] (3.0 g, 14.42 mmol) and SOCl_2 (3.5 g, 28.84 mmol) in EtOH (100 mL) was heated at 70 $^\circ\text{C}$ for 5h. Reaction mixture was concentrated, basified with saturated NaHCO_3 solution, and then extracted with EtOAc twice. Then the combined organic portion was washed with brine, dried over Na_2SO_4 , filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (40 g SiliCycle column, 15% EtOAc in Hexane elution) to afford ethyl 5-fluoro-2-(trifluoromethyl)benzoate (3.0 g, 88%). ^1H NMR (300 MHz, CDCl_3) δ 7.77 – 7.73 (m, 1H), 7.50 – 7.47 (m, 1H), 7.29 – 7.25 (m, 1H), 4.40 (q, $J = 7.2$ Hz, 2H), 1.39 (t, $J = 7.2$ Hz, 3H).

Step 60.2: Synthesis of ethyl 5-((1*r*,3*r*)-3-((tert-butoxycarbonyl)amino)cyclobutoxy)-2-(trifluoromethyl)benzoate




To the solution of *tert*-butyl ((1*r*,3*r*)-3-hydroxycyclobutyl)carbamate (1.18 g, 6.35 mmol) in anhydrous DMF (20 mL), NaH (60% on mineral oil) (0.26 g, 6.35 mmol) was added at 0 $^\circ\text{C}$ and stirred for 5 min. Then ethyl 5-fluoro-2-(trifluoromethyl)benzoate (1.5 g, 6.35 mmol) was added at 0 $^\circ\text{C}$ and stirred for 10 min under N_2 . Reaction mixture was poured in ice-water and extracted with EtOAc 3x's. The combined organic portion was washed with brine, dried over Na_2SO_4 , filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 25% EtOAc in Hexane elution) to afford ethyl 5-((1*r*,3*r*)-3-((tert-butoxycarbonyl)amino)cyclobutoxy)-2-(trifluoromethyl)benzoate (500 mg, 18%). ^1H NMR (400 MHz, CDCl_3) δ 7.62 (d, $J = 8.4$ Hz, 1H), 7.12 – 7.11 (m, 1H), 6.92 – 6.88 (m, 1H), 4.87 – 4.82 (m, 1H), 4.38 (q, $J = 7.2$ Hz, 2H), 4.33 – 4.27 (m, 1H), 2.58 – 2.52 (m, 2H), 2.47 – 2.39 (m, 2H), 1.45 (s, 9H), 1.38 (t, $J = 7.2$ Hz, 3H).

Step 60.3: Synthesis of ethyl 5-((1*r*,3*r*)-3-aminocyclobutoxy)-2-(trifluoromethyl)benzoate, HCl [C-07619-021]



A round bottom flask was charged with ethyl 5-((1*r*,3*r*)-3-((*tert*-butoxycarbonyl)amino)cyclobutoxy)-2-(trifluoromethyl)benzoate (500 mg, 1.24 mmol) and HCl solution (4M in 1,4-dioxane) (10 mL), and stirred at rt for 16 h. Then the reaction mixture was concentrated in *vacuo*. The residue was triturated with pentane, the solid appeared was filtered and dried to yield ethyl 5-((1*r*,3*r*)-3-aminocyclobutoxy)-2-(trifluoromethyl)benzoate, HCl (350 mg, 83%). MS (ESI+) [Method 1A]: *m/z* 304.6 (M+H); Rt 0.24 min. ¹H NMR (400 MHz, CD₃OD) δ 7.73 (d, *J* = 9.6 Hz, 1H), 7.18 – 7.17 (m, 1H), 7.08 (dd, *J* = 8.8, 2.0 Hz, 1H), 5.07 – 5.04 (m, 1H), 4.36 (q, *J* = 7.2 Hz, 2H), 4.03 – 3.97 (m, 1H), 2.70 – 2.62 (m, 4H), 1.36 (t, *J* = 7.2 Hz, 3H).


Step 60.4: Synthesis of ethyl 5-((1*r*,3*r*)-3-(((6-fluoroisoquinolin-5-yl)methyl)amino)cyclobutoxy)-2-(trifluoromethyl)benzoate [C-08247-017]




The round bottom flask fitted with Dean-Stark apparatus, was charged with ethyl 5-((1*r*,3*r*)-3-aminocyclobutoxy)-2-(trifluoromethyl)benzoate (150 mg, 0.44 mmol) and benzene (10 mL). Then 6-fluoroisoquinoline-5-carbaldehyde (77 mg, 0.44 mmol) and TEA (45 mg, 0.44 mmol) were added and then refluxed for 16 h. Reaction mixture was concentrated in *vacuo*, residue was dissolved in MeOH (5 mL), and Na(CN)BH₃ (55 mg, 0.88 mmol) was added at rt and stirred for 3 h. Reaction mixture was concentrated, residue was diluted with EtOAc and washed with saturated NaHCO₃ solution. The organic portion was dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The crude product was purified by prep-HPLC (Column: UNA Phenomenex (250 mm x 21.2 mm), 5.0 μ; Mobile Phase: 0.1% HCO₂H in water and acetonitrile) to afford ethyl 5-((1*r*,3*r*)-3-(((6-fluoroisoquinolin-5-yl)methyl)amino)cyclobutoxy)-2-(trifluoromethyl)benzoate (20 mg, 9%). MS (ESI+) [Method 5A]: *m/z* 463.2 (M+H); Rt 1.17 min. ¹H NMR (400 MHz, CD₃OD) δ 9.88 (brs, 1H), 8.83 – 8.74 (m, 3H), 8.03 (t, *J* = 8.4 Hz, 1H), 7.74 (d, *J* = 8.8 Hz, 1H), 7.21 – 7.20 (m, 1H), 7.13 – 7.99 (m, 1H), 5.16 – 5.12 (m, 1H), 4.84 (s, 2H), 4.37 (q, *J* = 7.2 Hz, 2H), 4.33 – 4.27 (m, 1H), 2.98 – 2.92 (m, 2H), 2.77 – 2.70 (m, 2H), 1.36 (t, *J* = 7.2 Hz, 3H).

Example 61: Synthesis of 2-((1*r*,3*r*)-3-(((6-fluoroisoquinolin-5-yl)methyl)amino)cyclobutoxy)-6-(trifluoromethyl)benzonitrile, HCl


Step 61.1: Synthesis of

tert-butyl ((1*r*,3*r*)-3-(2-cyano-3-(trifluoromethyl)phenoxy)cyclobutyl)carbamate

To the solution of *tert*-butyl ((1*r*,3*r*)-3-hydroxycyclobutyl)carbamate (800 mg, 4.27 mmol) in DMF (15 mL), NaH (60% on mineral oil) (154 mg, 6.41 mmol) was added at 0 °C, stirred for 1 h. Then
 5 2-fluoro-6-(trifluoromethyl)benzonitrile [CAS No. 133116-83-3] (1.2 g, 6.41 mmol) was added at 0 °C and reaction mixture was stirred at rt for 16 h under N₂. The reaction mixture was diluted with water, and extracted with EtOAc twice. The combined organic portion was washed with a brine solution, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 35% EtOAc in Hexane elution) to
 10 provide *tert*-butyl ((1*r*,3*r*)-3-(2-cyano-3-(trifluoromethyl)phenoxy)cyclobutyl)carbamate (485 mg, 31%). ¹H NMR (400 MHz, CDCl₃) δ 7.59 (t, *J* = 8.0 Hz, 1H), 7.33 (d, *J* = 8.0 Hz, 1H), 6.94 (dd, *J* = 8.8 Hz, 1H), 4.97 – 4.92 (m, 1H), 4.32 – 4.27 (m, 1H), 2.69 – 2.63 (m, 2H), 2.59 – 2.52 (m, 2H), 1.45 (s, 9H).

Step 61.2: Synthesis of 2-((1*r*,3*r*)-3-aminocyclobutoxy)-6-(trifluoromethyl)benzonitrile, HCl

15 A round bottom flask was charge with *tert*-butyl ((1*r*,3*r*)-3-(2-cyano-3-(trifluoromethyl)phenoxy)cyclobutyl)carbamate (250 mg, 0.70 mmol) and HCl solution (4M in 1,4-dioxane) (2.5 mL), and stirred at rt for 3 h. Then the reaction mixture was concentrated in *vacuo*. The residue was triturated with pentane, the solid appeared was filtered and dried to yield 2-
 20 ((1*r*,3*r*)-3-aminocyclobutoxy)-6-(trifluoromethyl)benzonitrile, HCl (175 mg, 85%). ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.27 (brs, 3H), 7.88 (t, *J* = 8.7 Hz, 1H), 7.57 (d, *J* = 8.1 Hz, 1H), 7.35 (d, *J* = 8.4 Hz, 1H), 5.25 – 5.19 (m, 1H), 3.92 – 3.86 (m, 1H), 2.73 – 2.65 (m, 2H), 2.59 – 2.52 (m, 2H).

Step 61.3: Synthesis of 2-((1*r*,3*r*)-3-((6-fluoroisoquinolin-5-yl)methyl)amino)cyclobutoxy)-6-(trifluoromethyl)benzonitrile, HCl

25 The title compound was synthesized following the procedure as described in Step 1.4, using 2-((1*r*,3*r*)-3-aminocyclobutoxy)-6-(trifluoromethyl)benzonitrile, HCl (175 mg, 0.6 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 95 mg, 0.54 mmol). The crude product was purified by flash chromatography (12 g SiliCycle column, 0 – 10% MeOH in CH₂Cl₂ elution),


followed by prep-HPLC (Column: LUNA Phenomenex (150 mm x 21.2 mm), 5.0 μ ; Mobile Phase: 0.1% HCO₂H in water and acetonitrile). The isolated product was stirred with HCl solution (4M in 1,4-dioxane) (2 mL) at rt for 2 h, then concentrated in *vacuo* and lyophilized to afford 2-((1*r*,3*r*)-3-(((6-fluoroisoquinolin-5-yl)methyl)amino)cyclobutoxy)-6-

- 5 (trifluoromethyl)benzonitrile, HCl (5 mg, 2%). MS (ESI+) [Method 6A]: *m/z* 416.2 (M+H); Rt 1.31 min. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.92 (brs, 2H), 8.70 (brs, 1H), 8.59 – 8.55 (m, 1H), 7.94 – 7.88 (m, 2H), 7.58 (d, *J* = 8.0 Hz, 1H), 7.38 (d, *J* = 8.8 Hz, 1H), 5.28 – 5.24 (m, 1H), 4.63 (s, 2H), 4.18 – 4.13 (m, 1H), 2.94 – 2.88 (m, 2H), 2.60 – 2.53 (m, 2H).

Example 62: Synthesis of (1*r*,3*r*)-3-((6-chloro-5-(trifluoromethyl)pyridin-3-yl)oxy)-*N*-((6-


- 10 **fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl**

Step 62.1: Synthesis of *tert*-butyl ((1*r*,3*r*)-3-((6-chloro-5-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutyl)carbamate




- A sealed tube was charged with 2-chloro-5-iodo-3-(trifluoromethyl)pyridine [CAS No. 887707-25-7] (1.0 g, 3.25 mmol), *tert*-butyl ((1*r*,3*r*)-3-hydroxycyclobutyl)carbamate (0.91 g, 4.88 mmol), Cs₂CO₃ (1.58 g, 4.88 mmol) and toluene (15 mL), and purged with N₂ for 10 min. Then CuI (31 mg, 0.16 mmol) and 3,4,7,8-tetramethyl-1,10-phenanthroline were added, purged with N₂, sealed tube was closed and stirred at 110 °C for 16 h. Reaction was cooled to rt, filtered through celite bed and the bed was washed with EtOAc. The filtrate was concentrated in *vacuo* and the residue was purified by flash chromatography (12 g SiliCycle column, 0 – 20% EtOAc in Hexane elution) to afford *tert*-butyl ((1*r*,3*r*)-3-((6-chloro-5-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutyl)carbamate (0.2 g, 17%). MS (ESI+) [Method 6A]: *m/z* 366.8 (M+H); Rt 1.63 min. ¹H NMR (300 MHz, CDCl₃) δ 8.08 (d, *J* = 3.0 Hz, 1H), 7.40 (d, *J* = 3.0 Hz, 1H), 4.88 – 4.81 (m, 1H), 4.35 – 4.28 (m, 1H), 2.62 – 2.53 (m, 2H), 2.51 – 2.42 (m, 2H), 1.45 (s, 9H).

- 25 Step 62.2: Synthesis of (1*r*,3*r*)-3-((6-chloro-5-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutan-1-amine, HCl



- A round bottom flask was charge with *tert*-butyl ((1*r*,3*r*)-3-((6-chloro-5-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutyl)carbamate (100 mg, 0.27 mmol) and HCl solution (4M in 1,4-dioxane) (4 mL), and stirred at rt for 4 h. Then the reaction mixture was concentrated in *vacuo* to yield (1*r*,3*r*)-3-((6-chloro-5-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutan-1-amine, HCl (70 mg, 85%). MS (ESI+) [Method 6A]: *m/z* 308.0 (M+MeCN+H); Rt 1.28 min.


Step 62.3: Synthesis of (1*r*,3*r*)-3-((6-chloro-5-(trifluoromethyl)pyridin-3-yl)oxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl




The title compound was synthesized following the procedure as described in Step 1.4, using (1*r*,3*r*)-3-((6-chloro-5-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutan-1-amine, HCl (70 mg, 0.23 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 37 mg, 0.21 mmol). The crude product was purified by prep-HPLC (Column: XBRIDGE C18 (150 mm x 19.0 mm), 5.0 μ ; Mobile Phase: 0.01% NH₄OH in water and acetonitrile-MeOH (1:1). The isolated product was stirred with HCl solution (4M in 1,4-dioxane) (1 mL) at rt for 2 h, then concentrated in *vacuo* and triturated with Et₂O. The solid was collected and dried to afford (1*r*,3*r*)-3-((6-chloro-5-(trifluoromethyl)pyridin-3-yl)oxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl (13 mg, 13%). MS (ESI+) [Method 6A]: *m/z* 426.0 (M+H); Rt 1.31 min. ¹H NMR (400 MHz, CD₃OD) δ 9.31 (s, 1H), 8.60 (d, *J* = 6.0 Hz, 1H), 8.30 – 8.26 (m, 1H), 8.20 (d, *J* = 2.8 Hz, 1H), 8.14 (d, *J* = 6.4 Hz, 1H), 7.66 – 7.59 (m, 2H), 5.07 – 5.01 (m, 1H), 4.43 (d, *J* = 2.0 Hz, 2H), 3.93 – 3.87 (m, 1H), 2.60 – 2.54 (m, 4H).

Example 63: Synthesis of *N*¹-(4-fluoro-3-(trifluoromethyl)phenyl)-*N*³-((6-fluoroisoquinolin-5-yl)methyl)cyclobutane-1,3-diamine

Step 63.1: Synthesis of *tert*-butyl (3-((4-fluoro-3-(trifluoromethyl)phenyl)amino)cyclobutyl)carbamate




To the stirred solution of *tert*-butyl (3-oxocyclobutyl)carbamate [CAS No. 154748-49-9] (0.5 g, 2.70 mmol) and 4-fluoro-3-(trifluoromethyl)aniline [CAS No. 2357-47-3] (1.4 g, 8.10 mmol) in MeOH (10 mL), AcOH (0.2 mL, 3.78 mmol) and NaCNBH₃ (0.25 g, 4.05 mmol) were added at rt. The reaction mixture was stirred at rt for 3 h. Reaction mixture was diluted with water and extracted with EtOAc twice. The combined organic portion was washed with brine solution, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (4 g SiliCycle column, 0 – 15% EtOAc in Hexane elution) to provide *tert*-butyl (3-((4-fluoro-3-(trifluoromethyl)phenyl)amino)cyclobutyl)carbamate (0.6 g, 64%) MS (ESI+) [Method 6A]: *m/z* 349.1 (M+H); Rt 1.63 min. ¹H NMR (300 MHz, CDCl₃) δ 6.99 (t, *J* = 9.3 Hz, 1H), 6.68 – 6.59 (m, 2H), 3.87 – 3.83 (m, 1H), 3.56 – 3.50 (m, 1H), 2.92 – 2.87 (m, 2H), 1.75 – 1.66 (m, 2H), 1.44 (s, 9H).

Step 63.2: Synthesis of *N*¹-(4-fluoro-3-(trifluoromethyl)phenyl)cyclobutane-1,3-diamine, HCl


A round bottom flask was charged with *tert*-butyl (3-((4-fluoro-3-(trifluoromethyl)phenyl)amino)cyclobutyl)carbamate (300 mg, 0.86 mmol) and HCl solution (4M in 1,4-dioxane) (2 mL), and stirred at rt for 4 h. Then the reaction mixture was concentrated in *vacuo* to yield *N*¹-(4-fluoro-3-(trifluoromethyl)phenyl)cyclobutane-1,3-diamine, HCl (240 mg, 97%). MS (ESI+) [Method 6A]: *m/z* 249.1 (M+H); Rt 1.30 min. ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.30 (brs, 1H), 7.26 – 7.18 (m, 1H), 6.79 – 6.70 (m, 2H), 3.64 – 3.59 (m, 1H), 3.45 – 3.39 (m, 1H), 2.73 – 2.64 (m, 2H), 2.00 – 1.90 (m, 2H).

10 Step 63.3: Synthesis of *N*¹-(4-fluoro-3-(trifluoromethyl)phenyl)-*N*³-((6-fluoroisoquinolin-5-yl)methyl)cyclobutane-1,3-diamine




The title compound was synthesized following the procedure as described in Step 1.4, using *N*¹-(4-fluoro-3-(trifluoromethyl)phenyl)cyclobutane-1,3-diamine, HCl (240 mg, 0.84 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 132 mg, 0.76 mmol) and AcOH (0.01 mL). Prep-HPLC of the crude (Column: LUNA Phenomenex (250 mm x 21.2 mm), 5.0 μ; Mobile Phase: 0.1% HCO₂H in water and acetonitrile) afforded two peaks of *N*¹-(4-fluoro-3-(trifluoromethyl)phenyl)-*N*³-((6-fluoroisoquinolin-5-yl)methyl)cyclobutane-1,3-diamine. Peak-1: (15 mg, 4%). MS (ESI+) [Method 6A]: *m/z* 408.2 (M+H); Rt 1.30 min. ¹H NMR (400 MHz, CD₃OD) δ 9.91 (s, 1H), 8.93 – 8.90 (m, 1H), 8.67 (d, *J* = 6.4 Hz, 1H), 8.53 (d, *J* = 6.8 Hz, 1H), 8.21 (d, *J* = 10.4 Hz, 1H), 7.17 (t, *J* = 9.6 Hz, 1H), 7.02 – 6.94 (m, 2H), 4.57 (s, 2H), 3.91 – 3.81 (m, 2H), 2.99 – 2.92 (m, 2H), 2.39 – 2.33 (m, 2H). Peak-2: (40 mg, 11%). MS (ESI+) [Method 6A]: *m/z* 408.1 (M+H); Rt 1.31 min. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.08 (brs, 2H, exchangeable with D₂O), 9.90 (s, 1H), 8.85 – 8.83 (m, 1H), 8.79 – 8.77 (m, 1H), 8.74 – 8.70 (m, 1H), 8.03 (t, *J* = 9.2 Hz, 1H), 7.22 (t, *J* = 9.6 Hz, 1H), 6.81 – 6.72 (m, 2H), 4.62 (s, 2H), 3.71 – 3.64 (m, 2H), 2.79 – 2.71 (m, 2H), 2.21 – 2.13 (m, 2H).

Example 64: Synthesis of (1*r*,3*r*)-3-((3-fluoro-4-(trifluoromethyl)benzyl)oxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl

Step 64.1: Synthesis of (3-fluoro-4-(trifluoromethyl)phenyl)methanol

To the solution of 3-fluoro-4-(trifluoromethyl)benzaldehyde [204339-72-0] (1.0 g, 5.21 mmol) in MeOH (10 mL), NaBH₄ (295 mg, 7.81 mmol) was added at 0 °C and stirred for 2 h. Then the reaction mixture was diluted with water and extracted with EtOAc 3x's. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo* to provide crude (3-fluoro-4-(trifluoromethyl)phenyl)methanol (1.2 g, 118%). ¹H NMR (300 MHz, CDCl₃) δ 7.58 (t, *J* = 7.5 Hz, 1H), 7.26 – 7.20 (m, 2H), 4.78 (s, 2H).


Step 64.2: Synthesis of 4-(bromomethyl)-2-fluoro-1-(trifluoromethyl)benzene



To the solution of (3-fluoro-4-(trifluoromethyl)phenyl)methanol (1.8 g, 9.27 mmol) in Et₂O (20 mL), PBr₃ (1M in CH₂Cl₂) (6.5 mL, 6.50 mmol) was added drop wise at 0 °C and then stirred at rt for 2 h. Then the reaction mixture was diluted with ice-water and extracted with EtOAc 3x's. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 10% EtOAc in Hexane elution) to provide 4-(bromomethyl)-2-fluoro-1-(trifluoromethyl)benzene (0.8 g, 33%). ¹H NMR (600 MHz, CDCl₃) δ 7.58 (t, *J* = 7.8 Hz, 1H), 7.27 – 7.24 (m, 2H), 4.45 (s, 2H).


Step 64.3: Synthesis of

tert-butyl ((1*r*,3*r*)-3-((3-fluoro-4-(trifluoromethyl)benzyl)oxy)cyclobutyl)carbamate




To the solution of *tert*-butyl ((1*r*,3*r*)-3-hydroxycyclobutyl)carbamate (200 mg, 1.07 mmol) in DMF (5 mL), NaH (60% on mineral oil) (39 mg, 0.44 mmol) was added at 0 °C, stirred for 30 min. Then 4-(bromomethyl)-2-fluoro-1-(trifluoromethyl)benzene (358 mg, 1.39 mmol) was added and the reaction mixture was stirred at rt for 16 h under N₂. The reaction mixture was diluted with ice-water, and extracted with EtOAc 3x's. The combined organic portion was washed with brine solution, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 15% EtOAc in Hexane elution) to provide *tert*-butyl ((1*r*,3*r*)-3-((3-fluoro-4-(trifluoromethyl)benzyl)oxy)cyclobutyl)carbamate (275 mg, 71%). ¹H NMR (400 MHz, DMSO-d₆) δ 7.77 (t, *J* = 8.0 Hz, 1H), 7.43 (d, *J* = 12.0 Hz, 1H), 7.37 (d, *J* = 8.0 Hz, 1H), 7.22 (d, *J* = 7.6 Hz, 1H), 4.46 (s, 2H), 4.14 – 4.10 (m, 1H), 4.03 – 3.98 (m, 1H), 2.25 – 2.19 (m, 2H), 2.14 – 2.07 (m, 2H), 1.37 (s, 9H).

Step 64.4: Synthesis of (1*r*,3*r*)-3-((3-fluoro-4-(trifluoromethyl)benzyl)oxy)cyclobutan-1-amine, HCl




A solution of *tert*-butyl ((1*r*,3*r*)-3-((3-fluoro-4-(trifluoromethyl)benzyl)oxy)cyclobutyl)carbamate (275 mg, 0.76 mmol) and HCl solution (4M in 1,4-dioxane) (3 mL), was stirred at rt for 3 h. Then the reaction mixture was concentrated in *vacuo* to yield crude (1*r*,3*r*)-3-((3-fluoro-4-(trifluoromethyl)benzyl)oxy)cyclobutan-1-amine, HCl (170 mg, 75%). ¹H NMR (300 MHz, DMSO-
 5 d₆) δ 8.15 (brs, 3H), 7.78 (t, *J* = 8.4 Hz, 1H), 7.45 (d, *J* = 8.7 Hz, 1H), 7.37 (d, *J* = 8.4 Hz, 1H), 4.49 (s, 2H), 4.33 – 4.28 (m, 1H), 3.77 – 3.73 (m, 1H), 2.33 (t, *J* = 6.6 Hz, 4H).

Step 64.5: Synthesis of (1*r*,3*r*)-3-((3-fluoro-4-(trifluoromethyl)benzyl)oxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl



The title compound was synthesized following the procedure as described in Step 25.6, using (1*r*,3*r*)-3-((3-fluoro-4-(trifluoromethyl)benzyl)oxy)cyclobutan-1-amine, HCl (100 mg, 0.33 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 53 mg, 0.30 mmol). Prep-HPLC (Column: LUNA Phenomenex (250 mm x 21.2 mm), 5.0 μ; Mobile Phase: 0.1% HCO₂H in water and acetonitrile-MeOH (1:1)) of the crude, followed by treatment with HCl solution (4M in 1,4-
 15 dioxane) afforded (1*r*,3*r*)-3-((3-fluoro-4-(trifluoromethyl)benzyl)oxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl (70 mg, 45%). MS (ESI+) [Method 4B]: *m/z* 423.2 (M+H); Rt 1.01 min. ¹H NMR (400 MHz, CD₃OD) δ 9.85 (s, 1H), 8.80 – 8.74 (m, 3H), 8.01 (t, *J* = 9.6 Hz, 1H), 7.69 (t, *J* = 8.0 Hz, 1H), 7.39 – 7.35 (m, 2H), 4.81 (d, *J* = 2.0 Hz, 2H), 4.59 (s, 2H), 4.42 – 4.38 (m, 1H), 4.25 – 4.20 (m, 1H), 2.64 (t, *J* = 7.2 Hz, 4H).

20 Example 65: Synthesis of *N*-((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)-2-(isoquinolin-5-yl)acetamide




To the stirred solution of 2-(isoquinolin-5-yl)acetic acid [CAS No. 395074-85-8] (300 mg, 1.60 mmol) in DMF (10 mL), HATU (913 mg, 2.40 mmol) was added. After 15 min, DIPEA (0.57 mL, 3.21 mmol) and (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl (Step
 25 1.3, 455 mg, 1.60 mmol) were added and stirred at rt for 16 h. Reaction mixture was diluted with water and extracted with EtOAc twice. The combined organic portion was washed with brine solution, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (4 g SiliCycle column, 3% MeOH in CHCl₃ elution) and the

isolated product was re-purified by prep-HPLC (Column: KINETEX EVO C18 (150 mm x 19.0 mm), 5.0 μ ; Mobile Phase: 0.02% NH₄OH in water and acetonitrile) to afford *N*-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)-2-(isoquinolin-5-yl)acetamide. MS (ESI+) [Method 4B]: *m/z* 419.4 (M+H); Rt 1.38 min. ¹H NMR (400 MHz, CD₃OD) δ 9.23 (s, 1H), 8.47 (d, *J* = 6.8 Hz, 1H), 8.04 (d, *J* = 8.4 Hz, 1H), 7.99 (d, *J* = 6.0 Hz, 1H), 7.74 (d, *J* = 6.4 Hz, 1H), 7.66 (dd, *J* = 8.0, 6.8 Hz, 1H), 7.23 (t, *J* = 9.6 Hz, 1H), 7.07 – 7.02 (m, 2H), 4.89 – 4.84 (m, 1H), 4.47 – 4.40 (m, 1H), 4.02 (s, 2H), 2.51 – 2.47 (m, 4H).

Example 66: Synthesis of *N*-(2-(6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)-2-


10 hydroxyethyl)methanesulfonamide

Step 66.1: Synthesis of 8-(((*tert*-butyldimethylsilyl)oxy)methyl)-5-(1,3-dioxolan-2-yl)-6-fluoroisoquinoline



To the stirred solution of 8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinoline-5-carbaldehyde (Step 6.9, 7.0 g, 21.91 mmol) and PTSA (0.83 g, 4.38 mmol) in EtOH-C₆H₆ (150 mL, 1:4 v/v), in a round bottom fitted with Dean – Stark apparatus, ethylene glycol (4.9 mL, 87.65 mmol) was added at rt. Then the reaction mixture was heated at 100 °C for 24 h. Reaction mixture was cooled to rt, quenched with saturated NaHCO₃ solution and extracted with EtOAc twice. The combined organic portion was washed with water, brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo* to yield the crude product. The crude was purified by flash chromatography (40 g SiliCycle column, 0 – 10% EtOAc in Hexane elution, followed by 0 – 10% MeOH in CH₂Cl₂ elution) to provide 8-(((*tert*-butyldimethylsilyl)oxy)methyl)-5-(1,3-dioxolan-2-yl)-6-fluoroisoquinoline (3.0 g, 37%). MS (ESI+) [Method 6A]: *m/z* 364.2 (M+H); Rt 1.66 min.


25 Step 66.2: Synthesis of (5-(1,3-dioxolan-2-yl)-6-fluoroisoquinolin-8-yl)methanol



To the solution of 8-(((*tert*-butyldimethylsilyl)oxy)methyl)-5-(1,3-dioxolan-2-yl)-6-fluoroisoquinoline (3.0 g, 8.25 mmol) in THF (50 mL), TBAF solution (1M in THF) (9.9 mL, 9.90 mmol) was added dropwise at 0 °C and stirred for 1 h. Reaction mixture was diluted with water and extracted with EtOAc twice. The combined organic portion was washed with brine solution,

dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was triturated with pentane and dried to provide (5-(1,3-dioxolan-2-yl)-6-fluoroisoquinolin-8-yl)methanol (2.0 g, 97%). MS (ESI+) [Method 1A]: m/z 250.3 (M+H); Rt 0.12 min.

Step 66.3: Synthesis of 5-(1,3-dioxolan-2-yl)-6-fluoroisoquinoline-8-carbaldehyde




5

To the stirred solution of (5-(1,3-dioxolan-2-yl)-6-fluoroisoquinolin-8-yl)methanol (2.0 g, 8.02 mmol) in CHCl₃ (40 mL), activated MnO₂ (6.97 g, 80.24 mmol) was added and heated at 70 °C for 2 h, under N₂. The reaction mixture was cooled to rt, filtered through celite bed and the bed was washed with chloroform. The combined filtrate was concentrated in *vacuo* to get crude compound. The crude was purified by flash chromatography (24 g SiliCycle column, 0 – 70% EtOAc in hexane elution) to provide 5-(1,3-dioxolan-2-yl)-6-fluoroisoquinoline-8-carbaldehyde (1.3 g, 65%). MS (ESI+) [Method 6A]: m/z 248.2 (M+H); Rt 1.29 min.

10


Step 66.4: Synthesis of 1-(5-(1,3-dioxolan-2-yl)-6-fluoroisoquinolin-8-yl)-2-nitroethan-1-ol



To the solution of 5-(1,3-dioxolan-2-yl)-6-fluoroisoquinoline-8-carbaldehyde (1.3 g, 5.26 mmol) in anhydrous THF (15 mL), MeNO₂ (0.56 mL, 10.51 mmol) and K₂CO₃ (0.14 g, 1.05 mmol) were added, and stirred at rt for 16 h under N₂. Reaction mixture was diluted with water and extracted with EtOAc twice. The combined organic portion was washed with brine solution, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo* to provide crude 1-(5-(1,3-dioxolan-2-yl)-6-fluoroisoquinolin-8-yl)-2-nitroethan-1-ol (1.2 g, 74%). MS (ESI+) [Method 1A]: m/z 309.1 (M+H); Rt 0.19 min.

20


Example 66.5: Synthesis of 8-(1-(((*tert*-butyldimethylsilyl)oxy)-2-nitroethyl)-5-(1,3-dioxolan-2-yl)-6-fluoroisoquinoline



To the stirred solution of 1-(5-(1,3-dioxolan-2-yl)-6-fluoroisoquinolin-8-yl)-2-nitroethan-1-ol (1.2 g, 3.89 mmol) and imidazole (1.32 g, 19.46 mmol) in DMF (15 mL), TBDMS-Cl (1.76 g, 11.67 mmol) was added portion wise at 0 °C. The reaction mixture was stirred at rt for 16 h under N₂. Then the reaction mixture was diluted with water and extracted with EtOAc twice. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 10% EtOAc in hexane elution) to afford 8-(1-((*tert*-butyldimethylsilyl)oxy)-2-nitroethyl)-5-(1,3-dioxolan-2-yl)-6-fluoroisoquinoline (1.1 g, 67%). MS (ESI+) [Method 1A]: m/z 423.4 (M+H); Rt 1.90 min.


Step 66.6: Synthesis of 2-(5-(1,3-dioxolan-2-yl)-6-fluoroisoquinolin-8-yl)-2-((*tert*-

10 butyldimethylsilyl)oxy)ethan-1-amine



To the stirred solution of 8-(1-((*tert*-butyldimethylsilyl)oxy)-2-nitroethyl)-5-(1,3-dioxolan-2-yl)-6-fluoroisoquinoline (1.1 g, 2.60 mmol) in MeOH – H₂O (90 mL, 8:1 v/v), NH₄Cl (2.08 g, 39.05 mmol) was added. The reaction mixture was cooled to 0 °C and Zn – dust (2.55 g, 39.05 mmol) was added portion wise. The reaction mixture was stirred at rt for 16 h. The reaction mixture was filtered through a celite bed, which was washed with MeOH. The combined filtrate was concentrated in *vacuo*. The residue was diluted with CH₂Cl₂, washed with saturated NaHCO₃ solution, brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo* to yield crude 2-(5-(1,3-dioxolan-2-yl)-6-fluoroisoquinolin-8-yl)-2-((*tert*-butyldimethylsilyl)oxy)ethan-1-amine (0.9 g, 88%). MS (ESI+) [Method 3A]: m/z 393.0 (M+H); Rt 1.31 min.

Step 66.7: Synthesis of N-(2-(5-(1,3-dioxolan-2-yl)-6-fluoroisoquinolin-8-yl)-2-((*tert*-




The stirred solution of 2-(5-(1,3-dioxolan-2-yl)-6-fluoroisoquinolin-8-yl)-2-((*tert*-butyldimethylsilyl)oxy)ethan-1-amine (0.22 g, 0.56 mmol) and TEA (0.31 mL, 2.24 mmol) in anhydrous CH₂Cl₂ (4 mL) was cooled to 0 °C. Then Ms₂O (0.19 g, 1.12 mmol) dissolved in CH₂Cl₂ (2 mL) was added dropwise and the reaction mixture was stirred at rt for 16 h under N₂. Reaction mixture was diluted with water and extracted with CH₂Cl₂ twice. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo* to yield the crude product. The crude was purified by flash chromatography (12 g

SiliCycle column, 0 – 5% MeOH in CH₂Cl₂ elution) to provide *N*-(2-(5-(1,3-dioxolan-2-yl)-6-fluoroisoquinolin-8-yl)-2-((*tert*-butyldimethylsilyl)oxy)ethyl)methanesulfonamide (0.15 g, 57%).


MS (ESI+) [Method 3A]: *m/z* 471.2 (M+H); Rt 1.78 min.

Step 66.8: Synthesis of *N*-(2-((*tert*-butyldimethylsilyl)oxy)-2-(6-fluoro-5-formylisoquinolin-8-yl)ethyl)methanesulfonamide



- To the solution of *N*-(2-(5-(1,3-dioxolan-2-yl)-6-fluoroisoquinolin-8-yl)-2-((*tert*-butyldimethylsilyl)oxy)ethyl)methanesulfonamide (150 mg, 0.32 mmol) in acetone (4 mL), PTSA (61 mg, 0.32 mmol) was added and stirred at rt. After 16 h, again PTSA (61 mg, 0.32 mmol) was added and stirred at rt for further 16 h. The reaction mixture was diluted with saturated NaHCO₃ solution and extracted with EtOAc twice. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo* to yield crude *N*-(2-((*tert*-butyldimethylsilyl)oxy)-2-(6-fluoro-5-formylisoquinolin-8-yl)ethyl)methanesulfonamide (0.1 g, 74%). MS (ESI+) [Method 3A]: *m/z* 427.3 (M+H); Rt 1.92 min.


- Step 66.9: Synthesis of *N*-(2-((*tert*-butyldimethylsilyl)oxy)-2-(6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethyl)methanesulfonamide



- The title compound was synthesized following the procedure as described in Step 1.4, using (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl (Step 1.3, 90 mg, 0.32 mmol) and *N*-(2-((*tert*-butyldimethylsilyl)oxy)-2-(6-fluoro-5-formylisoquinolin-8-yl)ethyl)methanesulfonamide (94 mg, 0.22 mmol). The crude product was obtained (200 mg, 96%). MS (ESI+) [Method 5A]: *m/z* 658.2 (M+H); Rt 1.22 min.

Example 66.10: Synthesis of *N*-(2-(6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)-2-


- hydroxyethyl)methanesulfonamide



To the solution of *N*-(2-((*tert*-butyldimethylsilyl)oxy)-2-(6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethyl)methanesulfonamide (200 mg, 0.30 mmol) in THF (5 mL), TBAF solution (1M in THF) (0.36 mL, 0.36 mmol) was added dropwise as 0 °C and stirred for 1 h. Reaction mixture was diluted with water and extracted with EtOAc twice. The combined organic portion was washed with a brine solution, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by prep-HPLC (Column: WATERS XBRIDGE (150 mm X 21.2 mm), 5.0 μ; Mobile Phase: 0.02% NH₄OH in in water and acetonitrile) to afford *N*-(2-(6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)-2-hydroxyethyl)methanesulfonamide (27 mg, 16%). MS (ESI+) [Method 1A]: *m/z* 546.2 (M+H); Rt 0.27 min. ¹H NMR (400 MHz, CD₃OD) δ 9.60 (s, 1H), 8.54 (d, *J* = 6.0 Hz, 1H), 8.13 (d, *J* = 6.0 Hz, 1H), 7.70 (d, *J* = 10.4 Hz, 1H), 7.24 – 7.19 (m, 1H), 7.06 – 7.00 (m, 2H), 5.67 – 5.64 (m, 1H), 4.85 – 4.82 (m, 2H), 4.89 (d, *J* = 1.6 Hz, 2H), 3.62 – 3.57 (m, 1H), 3.52 (dd, *J* = 14.0, 4.0 Hz, 1H), 2.93 (s, 3H), 2.36 (t, *J* = 6.0 Hz, 4H).

Example 67: Synthesis of *N*-(2-(6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)-2-hydroxyethyl)sulfuric diamide

Step 67.1: Synthesis of *tert*-butyl (*N*-(2-(5-(1,3-dioxolan-2-yl)-6-fluoroisoquinolin-8-yl)-2-((*tert*-butyldimethylsilyl)oxy)ethyl)sulfamoyl)carbamate




To the solution of chlorosulfonyl isocyanate (54 mg, 0.38 mmol) in anhydrous CH₂Cl₂ (3 mL), *t*-BuOH (0.4 mL, 0.38 mmol) was added dropwise at 0 °C and stirred for 20 min under argon atmosphere. This solution was added dropwise at 0 °C to a stirred solution of 2-(5-(1,3-dioxolan-2-yl)-6-fluoroisoquinolin-8-yl)-2-((*tert*-butyldimethylsilyl)oxy)ethan-1-amine (Step 66.6, 100 mg, 0.25 mmol) and DIPEA (0.22 mL, 1.27 mmol) in anhydrous CH₂Cl₂ (3 mL). Then the reaction mixture was allowed to stir at rt for 2 h. The reaction was diluted with water and extracted with

CH₂Cl₂ twice. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo* to yield the crude product. The crude was purified by flash chromatography (12 g SiliCycle column, 0 – 5% MeOH in CH₂Cl₂ elution) to provide crude *tert*-butyl (*N*-(2-(5-(1,3-dioxolan-2-yl)-6-fluoroisoquinolin-8-yl)-2-((*tert*-


- 5 butyldimethylsilyl)oxy)ethyl)sulfamoyl)carbamate (0.25 g, 172%). MS (ESI+) [Method 5A]: *m/z* 570.3 (M+H); Rt 1.65 min.

Step 67.2: Synthesis of *tert*-butyl (*N*-(2-((*tert*-butyldimethylsilyl)oxy)-2-(6-fluoro-5-formylisoquinolin-8-yl)ethyl)sulfamoyl)carbamate




- 10 The title compound was prepared according to Step 66.8, except that after 4 h a second lot of PTSA (84 mg, 0.44 mmol) was added and stirred at rt for further 12 h. *tert*-Butyl (*N*-(2-((*tert*-butyldimethylsilyl)oxy)-2-(6-fluoro-5-formylisoquinolin-8-yl)ethyl)sulfamoyl)carbamate was obtained as crude material (180 mg, 78%). MS (ESI+) [Method 3A]: *m/z* 528.0 (M+H); Rt 2.10 min.

- 15 Step 67.3: Synthesis of *tert*-butyl (*N*-(2-((*tert*-butyldimethylsilyl)oxy)-2-(6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethyl)sulfamoyl)carbamate



- The title compound was synthesized following the procedure as described in Step 1.4, using
 20 (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl (Step 1.3, 140 mg, 0.49 mmol) and *tert*-butyl (*N*-(2-((*tert*-butyldimethylsilyl)oxy)-2-(6-fluoro-5-formylisoquinolin-8-yl)ethyl)sulfamoyl)carbamate (180 mg, 0.34 mmol). The crude *tert*-butyl (*N*-(2-((*tert*-butyldimethylsilyl)oxy)-2-(6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethyl)sulfamoyl)carbamate
 25 was obtained (300 mg crude, 80%). MS (ESI+) [Method 6A]: *m/z* 659.1 (M-Boc+H); Rt 1.33 min.


Step 67.4: Synthesis of *N*-(2-((*tert*-butyldimethylsilyl)oxy)-2-(6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethyl) sulfuric diamide, HCl



- The solution of *tert*-butyl (*N*-(2-((*tert*-butyldimethylsilyl)oxy)-2-(6-fluoro-5-((((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethyl)sulfamoyl)carbamate (300 mg, 0.39 mmol) and HCl solution (4M in 1,4-dioxane) (4 mL) was stirred at rt for 4 h. Then
- 5 the reaction mixture was concentrated in *vacuo* to provide crude *N*-(2-((*tert*-butyldimethylsilyl)oxy)-2-(6-fluoro-5-((((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethyl) sulfuric diamide, HCl (250 mg crude, 91%). MS (ESI+) [Method 6A]: *m/z* 659.1 (M-H); Rt 1.34 min.

Step 67.5: Synthesis of *N*-(2-(6-fluoro-5-((((1*r*,3*r*)-3-(4-fluoro-3-


- 10 (trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)-2-hydroxyethyl) sulfuric diamide



- To the solution of *N*-(2-((*tert*-butyldimethylsilyl)oxy)-2-(6-fluoro-5-((((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethyl) sulfuric diamide, HCl
- 15 (250 mg, 0.36 mmol) in THF (5 mL), TBAF solution (1M in THF) (0.67 mL, 0.67 mmol) was added dropwise as 0 °C and stirred at rt for 2 h. Reaction mixture was diluted with water and extracted with EtOAc twice. The combined organic portion was washed with brine solution, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by prep-HPLC (Column: YMC –ACTUS TRIART (150 mm X 20.0 mm), 5.0 μ; Mobile Phase: 0.02%
- 20 NH₄OH in in water and acetonitrile) to afford *N*-(2-(6-fluoro-5-((((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)-2-hydroxyethyl) sulfuric diamide (3 mg, 1.5%). MS (ESI+) [Method 3A]: *m/z* 547.2 (M+H); Rt 0.98 min. ¹H NMR (400 MHz, CD₃OD) δ 9.63 (s, 1H), 8.54 (d, *J* = 6.4 Hz, 1H), 8.13 (d, *J* = 6.4 Hz, 1H), 7.70 (d, *J* = 10.8 Hz, 1H), 7.24 – 7.19 (m, 1H), 7.06 – 7.01 (m, 2H), 5.77 – 5.73 (m, 1H), 4.85 – 4.82 (m, 1H),
- 25 4.63 – 4.58 (m, 1H), 4.17 (d, *J* = 1.6 Hz, 2H), 3.62 – 3.57 (m, 1H), 3.50 (dd, *J* = 13.6, 3.2 Hz, 1H), 2.35 (t, *J* = 6.4 Hz, 4H).


Example 68: Synthesis of (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)-1-methylcyclobutan-1-amine and (1*s*,3*s*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)-1-methylcyclobutan-1-amine

5 Step 68.1: Synthesis of *tert*-butyl (3-hydroxy-1-methylcyclobutyl)carbamate




To the stirred solution of 3-amino-3-methylcyclobutan-1-ol, HCl [1403766-64-2] (200 mg, 1.45 mmol) and TEA (1.0 mL, 7.27 mmol) in anhydrous DMF (5 mL), (Boc)₂O (950 mg, 4.36 mmol) was added at 0 °C. Then the reaction was continued at rt for 16 h under N₂. Reaction mixture
 10 was diluted with water and extracted with EtOAc 3x's. The combined organic portion was washed with brine solution, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 20% EtOAc in Hexane elution) to provide *tert*-butyl (3-hydroxy-1-methylcyclobutyl)carbamate (230 mg, 78%). ¹H NMR (300 MHz, CDCl₃) δ 4.62 – 4.57 (m, 1H), 4.13 – 4.08 (m, 1H), 2.60 – 2.45
 15 (m, 4H), 1.44 (s, 9H), 1.31 (s, 3H).

Step 68.2: Synthesis of 3-((*tert*-butoxycarbonyl)amino)-3-methylcyclobutyl methanesulfonate



To the stirred solution of *tert*-butyl (3-hydroxy-1-methylcyclobutyl)carbamate (230 mg, 1.14 mmol) and TEA (0.5 mL, 1.49 mmol) in anhydrous CH₂Cl₂ (5 mL), MsCl (0.1 mL, 1.49 mmol)
 20 was added at 0 °C. Then the reaction mixture was stirred at rt for 2 h under N₂. Reaction mixture was diluted with water and extracted with CH₂Cl₂ 3x's. The combined organic portion was washed with brine solution, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 15% EtOAc in Hexane elution) to provide 3-((*tert*-butoxycarbonyl)amino)-3-methylcyclobutyl methanesulfonate
 25 (240 mg, 75%). ¹H NMR (300 MHz, CDCl₃) δ 4.91 – 4.83 (m, 1H), 2.99 (s, 3H), 2.74 – 2.68 (m, 2H), 2.60 – 2.54 (m, 2H), 1.44 (s, 9H), 1.38 (s, 3H).


Step 68.3: Synthesis of *tert*-butyl (3-(4-fluoro-3-(trifluoromethyl)phenoxy)-1-methylcyclobutyl)carbamate



30 To the stirred solution of 4-fluoro-3-(trifluoromethyl)phenol [CAS No. 61721-07-1] (185 g, 1.03 mmol) and 3-((*tert*-butoxycarbonyl)amino)-3-methylcyclobutyl methanesulfonate (240 mg, 0.86 mmol) in anhydrous DMF (5 mL), Cs₂CO₃ (840 mg, 2.58 mmol) was added at rt. The reaction

mixture was heated at 70 °C for 16 h under N₂. Reaction mixture was cooled to rt, diluted with EtOAc and washed with water, followed by brine. The organic portion was dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 25% EtOAc in Hexane elution) to provide *tert*-butyl (3-(4-fluoro-3-(trifluoromethyl)phenoxy)-1-methylcyclobutyl)carbamate (140 mg, 45%).¹H NMR (300 MHz, CDCl₃) δ 7.11 – 6.86 (m, 3H), 4.80 – 4.65 (m, 1H), 2.65 – 2.58 (m, 2H), 2.51 – 2.43 (m, 2H), 1.46 (s, 9H), 1.44 (s, 3H).

Step 68.4: Synthesis of 3-(4-fluoro-3-(trifluoromethyl)phenoxy)-1-methylcyclobutan-1-amine hydrochloride, HCl




10

The solution of *tert*-butyl (3-(4-fluoro-3-(trifluoromethyl)phenoxy)-1-methylcyclobutyl)carbamate (140 mg, 0.39 mmol) and HCl solution (4M in 1,4-dioxane) (1.0 mL) was stirred at rt for 4 h. The reaction mixture was concentrated in *vacuo* to provide 3-(4-fluoro-3-(trifluoromethyl)phenoxy)-1-methylcyclobutan-1-amine, HCl (80 mg, 69%). MS (ESI+) [Method 6A]: *m/z* 264.1 (M+H); Rt 1.30 min. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.33 (brs, 3H), 7.46 – 7.41 (m, 1H), 7.15 – 7.12 (m, 1H), 7.08 – 7.06 (m, 1H), 5.01 – 4.96 (m, 1H), 2.77 – 2.73 (m, 2H), 2.18 – 2.13 (m, 2H), 1.43 (s, 3H).

15

Step 68.5: Synthesis of (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)-1-methylcyclobutan-1-amine and (1*s*,3*s*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)-1-methylcyclobutan-1-amine

20



A round bottom flask fitted with Dean – Stark apparatus was charged with 3-(4-fluoro-3-(trifluoromethyl)phenoxy)-1-methylcyclobutan-1-amine hydrochloride, HCl (70 mg, 0.23 mmol), 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 36 mg, 0.21 mmol), TEA (0.05 mL, 0.23 mmol) and benzene (10 mL) and the reaction mixture heated at 100 °C for 16 h. Then the reaction mixture was concentrated in *vacuo*, the residue was dissolved in MeOH (5 mL), cooled to 0 °C, NaBH₄ (35 mg, 0.93 mmol) was added and stirred at rt for 3 h. Reaction mixture was diluted with water and extracted with EtOAc twice. The combined organic portion was washed with brine solution, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. Prep-HPLC purification of the crude (Column: X SELECT (250 mm x 19 mm), 5.0 μ ; Mobile Phase: 0.1% HCO₂H in water and acetonitrile; followed by GEMINI (150 mm x 21.2 mm), 5.0 μ ; Mobile


25

30

Phase: 0.02% NH₄OH in water and acetonitrile) afforded two peaks. Peak 1, (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)-1-methylcyclobutan-1-amine was obtained as off white solid (45 mg, 46%). MS (ESI+) [Method 6A]: *m/z* 423.1 (M+H); Rt 1.36 min. ¹H NMR (400 MHz, CD₃OD) δ 9.82 (s, 1H), 8.79 – 8.71 (m, 3H), 8.01 (t, *J* = 9.6 Hz, 1H), 7.30 (t, *J* = 9.2 Hz, 1H), 7.16 – 7.11 (m, 2H), 5.02 – 4.97 (m, 1H), 4.82 (s, 2H), 3.15 – 3.09 (m, 2H), 2.52 – 2.47 (m, 2H), 1.89 (s, 3H). Peak 2, (1*s*,3*s*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)-1-methylcyclobutan-1-amine (3 mg, 3%). MS (ESI+) [Method 6A]: *m/z* 423.15 (M+H); Rt 1.33 min. ¹H NMR (400 MHz, CD₃OD) δ 9.23 (s, 1H), 8.50 (d, *J* = 5.6 Hz, 1H), 8.15 – 8.12 (m, 1H), 8.09 – 8.07 (m, 1H), 7.52 (t, *J* = 9.6 Hz, 1H), 7.22 (t, *J* = 9.2 Hz, 1H), 7.12 – 7.06 (m, 2H), 5.02 – 4.97 (m, 1H), 4.82 (s, 2H), 3.15 – 3.09 (m, 2H), 2.51 – 2.47 (m, 2H), 1.89 (s, 3H).


Example 69: Synthesis of 2-(3-amino-6-fluoroisoquinolin-5-yl)-*N*-((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)acetamide

Step 69.1: Synthesis of ethyl 2-(3-(bis(*tert*-butoxycarbonyl)amino)-6-fluoroisoquinolin-5-yl)-2-oxoacetate



To the stirred solution of *tert*-butyl (tert-butoxycarbonyl)(6-fluoroisoquinolin-3-yl)carbamate (Step 14.3, 10.0 g, 27.59 mmol) in anhydrous THF (100 mL), LDA (2.0M in THF) (34.5 mL, 68.98 mmol) was added dropwise at -78°C under N₂. After stirring for 2.5 h, diethyl oxalate (12.1 g, 82.78 mmol) dissolved in anhydrous THF (50 mL) was added dropwise at -78°C, and the reaction mixture was stirred for 1 h under N₂. The reaction mixture was quenched with saturated NH₄Cl solution and extracted with EtOAc twice. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (80 g SiliCycle column, 0 – 20% EtOAc in hexane elution) to provide ethyl 2-(3-(bis(*tert*-butoxycarbonyl)amino)-6-fluoroisoquinolin-5-yl)-2-oxoacetate (7.0 g, 55%). MS (ESI+) [Method 5A]: *m/z* 363.1 (M-Boc+H); Rt 1.58 min. ¹H NMR (300 MHz, CDCl₃) δ 9.17 (s, 1H), 8.39 (s, 1H), 8.28 – 8.23 (m, 1H), 7.40 (t, *J* = 9.9 Hz, 1H), 4.46 (q, *J* = 7.2 Hz, 2H), 1.46 (s, 18H), 1.42 (t, *J* = 7.2 Hz, 3H).


Step 69.2: Synthesis of ethyl 2-(3-(bis(*tert*-butoxycarbonyl)amino)-6-fluoroisoquinolin-5-yl)-2-hydroxyacetate



To the stirred solution of ethyl 2-(3-(bis(*tert*-butoxycarbonyl)amino)-6-fluoroisoquinolin-5-yl)-2-oxoacetate (7.0 g, 15.13 mmol) in EtOH – H₂O mixture (124 mL, 55:7 v/v), AcOH (3.5 mL) and


NaCNBH₃ (1.14 g, 18.16 mmol) were added portion wise at rt. After stirring for 16 h, the reaction was quenched with saturated NaHCO₃ solution and extracted with EtOAc twice. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo* to provide crude ethyl 2-(3-(bis(*tert*-butoxycarbonyl)amino)-6-fluoroisoquinolin-5-yl)-2-hydroxyacetate (6.0 g, 85%). MS (ESI+) [Method 1A]: m/z 465.4 (M+H); Rt 1.67 min.

Step 69.3: Synthesis of ethyl 2-acetoxy-2-(3-(bis(*tert*-butoxycarbonyl)amino)-6-fluoroisoquinolin-5-yl)acetate




To the stirred solution of ethyl 2-(3-(bis(*tert*-butoxycarbonyl)amino)-6-fluoroisoquinolin-5-yl)-2-hydroxyacetate (6.0 g, 12.91 mmol) in anhydrous CH₂Cl₂ (80 mL), TEA (4.53 mL, 32.29 mmol) and DMAP (100 mg, 0.82 mmol) were added at rt. Then Ac₂O (1.7 mL, 18.08 mmol) was added drop wise at 0 °C and the reaction mixture was stirred at rt for 3 h under argon. The reaction mixture was diluted with water and extracted with CH₂Cl₂ twice. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo* to provide crude ethyl 2-acetoxy-2-(3-(bis(*tert*-butoxycarbonyl)amino)-6-fluoroisoquinolin-5-yl)acetate (7.0 g, 107%). MS (ESI+) [Method 1A]: m/z 507.2 (M+H); Rt 1.87 min.

Step 69.4: Synthesis of ethyl 2-(3-(bis(*tert*-butoxycarbonyl)amino)-6-fluoroisoquinolin-5-yl)acetate



The rock shaker vessel was charged with ethyl 2-acetoxy-2-(3-(bis(*tert*-butoxycarbonyl)amino)-6-fluoroisoquinolin-5-yl)acetate (7.0 g, 13.81 mmol) and EtOH (250 mL). Pd/C (10% w/w, 50% wet) (3.5 g) was added under argon and degassed. Then the reaction mixture agitated under H₂ (70 psi) at 60 °C for 16 h. Reaction mixture was filtered through celite bed, the bed was washed with EtOAc. The combined filtrate was concentrated in *vacuo* to afford ethyl 2-(3-(bis(*tert*-butoxycarbonyl)amino)-6-fluoroisoquinolin-5-yl)acetate (6.0 g, 97%). MS (ESI+) [Method 5A]: m/z 449.1 (M+H); Rt 2.37 min.

Step 69.5: Synthesis of 2-(3-(bis(*tert*-butoxycarbonyl)amino)-6-fluoroisoquinolin-5-yl)acetic acid




To the solution of ethyl 2-(3-(bis(*tert*-butoxycarbonyl)amino)-6-fluoroisoquinolin-5-yl)acetate (7.3 g, 16.27 mmol) in THF – MeOH – water (120 mL, 5:3:2 v/v/v), LiOH.H₂O (1.7 g, 40.69 mmol) was added at rt and stirred for 4 h. Then the solvent was evaporated, residue was diluted with

water and acidified with a citric acid solution. The solid appeared was filtered, washed with water and dried in *vacuo* to afford crude 2-(3-((*tert*-butoxycarbonyl)amino)-6-fluoroisoquinolin-5-yl)acetic acid (4.0 g, 76%). MS (ESI+) [Method 5A]: *m/z* 321.1 (M+H); Rt 1.33 min.


Step 69.6: Synthesis of *tert*-butyl (6-fluoro-5-(2-(((1*r*,3*r*)-3-(4-fluoro-3-

- 5 (trifluoromethyl)phenoxy)cyclobutyl)amino)-2-oxoethyl)isoquinolin-3-yl)carbamate



- To the stirred solution of 2-(3-((*tert*-butoxycarbonyl)amino)-6-fluoroisoquinolin-5-yl)acetic acid (2.0 g, 6.24 mmol) and (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl (Step 1.3, 1.78 g, 6.24 mmol) in DMF (30 mL), HATU (3.56 g, 9.37 mmol) was added. Then
 10 DIPEA (5.43 mL, 31.21 mmol) were added dropwise at 0 °C and the reaction mixture was stirred at rt for 2 h. The reaction mixture was diluted with cold water. The precipitated solid was filtered, washed with water and dried in *vacuo* to afford *tert*-butyl (6-fluoro-5-(2-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)-2-oxoethyl)isoquinolin-3-yl)carbamate (3.5 g crude, 101%). MS (ESI+) [Method 1A]: *m/z* 552.2 (M+H); Rt 1.89 min.


- 15 Step 69.7: Synthesis of 2-(3-amino-6-fluoroisoquinolin-5-yl)-*N*-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)acetamide



- The solution of *tert*-butyl (6-fluoro-5-(2-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)-2-oxoethyl)isoquinolin-3-yl)carbamate (3.5 g, 6.35
 20 mmol) in HCl (4M in 1,4-dioxane) (50 mL) was stirred at rt for 16 h. The reaction mixture was concentrated in *vacuo* and the residue was triturated with Et₂O. The crude product was purified by prep-HPLC (Column: X BRIDGE (150 mm x 21.2 mm), 5.0 μ; Mobile phase: 0.02% NH₄OH in water and acetonitrile). The isolated product was stirred with Et₂O (30 mL) for 30 min, solid was filtered and dried in *vacuo* to afford 2-(3-amino-6-fluoroisoquinolin-5-yl)-*N*-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)acetamide (1.41 g, 45%). MS (ESI+) [Method 1A]:
 25 *m/z* 452.2 (M+H); Rt 1.34 min. ¹H NMR (400 MHz, CD₃OD) δ 8.75 (s, 1H), 7.85 – 7.81 (m, 1H), 7.24 (t, *J* = 9.2 Hz, 1H), 7.09 – 7.02 (m, 3H), 6.82 (s, 1H), 4.88 – 4.83 (m, 1H), 4.48 – 4.44 (m, 1H), 3.87 (s, 2H), 2.51 (dd, *J* = 6.8, 5.6 Hz, 4H).


Example 70: Synthesis of *N*-(2-(6-fluoro-5-((((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)-2-hydroxyethyl)acetamide

Step 70.1: Synthesis of 1-(6-fluoroisoquinolin-8-yl)-2-nitroethan-1-ol




5 To the solution of 6-fluoroisoquinoline-8-carbaldehyde (Step 6.5, 4.0 g, 22.83 mmol) in anhydrous THF (40 mL), MeNO₂ (4.89 mL, 91.34 mmol) and K₂CO₃ (1.26 g, 9.13 mmol) were added, and stirred at rt for 16 h under N₂. Reaction mixture was diluted with water and extracted with EtOAc twice. The combined organic portion was washed with brine solution, dried over
10 anhydrous Na₂SO₄, filtered and concentrated in *vacuo* to provide crude 1-(6-fluoroisoquinolin-8-yl)-2-nitroethan-1-ol (5.0 g, 93%). MS (ESI+) [Method 1A]: m/z 237.3 (M+H); Rt 0.14 min.

Step 70.2: Synthesis of 8-(1-((*tert*-butyldimethylsilyl)oxy)-2-nitroethyl)-6-fluoroisoquinoline



To the stirred solution of 1-(6-fluoroisoquinolin-8-yl)-2-nitroethan-1-ol (5.0 g, 21.16 mmol) and
15 imidazole (7.2 g, 105.77 mmol) in DMF (50 mL), TBDMS-Cl (9.57 g, 63.50 mmol) was added portion wise at 0 °C. Then the reaction mixture was stirred at rt for 16 h. The reaction mixture was diluted with water and extracted with CH₂Cl₂ twice. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (40 g SiliCycle column, 0 – 15% EtOAc in Hexane
20 elution) to afford 8-(1-((*tert*-butyldimethylsilyl)oxy)-2-nitroethyl)-6-fluoroisoquinoline (5.0 g, 67%). MS (ESI+) [Method 5A]: m/z 351.2 (M+H); Rt 1.61 min.

Step 70.3: Synthesis of 2-((*tert*-butyldimethylsilyl)oxy)-2-(6-fluoroisoquinolin-8-yl)ethan-1-amine




To the stirred solution of 8-(1-((*tert*-butyldimethylsilyl)oxy)-2-nitroethyl)-6-fluoroisoquinoline (5.0
25 g, 14.26 mmol) in MeOH – H₂O (100 mL, 4:1 v/v), NH₄Cl (7.63 g, 142.64 mmol) was added. The reaction mixture was cooled to 0 °C and Zn – dust (9.32 g, 142.64 mmol) was added portion wise. The reaction mixture was stirred at rt for 16 h. The reaction mixture was filtered through celite bed, which was washed with MeOH. The combined filtrate was concentrated in *vacuo*. The residue was diluted with CH₂Cl₂, washed with saturated NaHCO₃ solution, brine, dried over
30 anhydrous Na₂SO₄, filtered and concentrated in *vacuo* to yield crude 2-((*tert*-

butyldimethylsilyl)oxy)-2-(6-fluoroisoquinolin-8-yl)ethan-1-amine (3.8 g, 83%). MS (ESI+)

[Method 5A]: m/z 321.2 (M+H); Rt 1.03 min.

Step 70.4: Synthesis of *N*-(2-((*tert*-butyldimethylsilyl)oxy)-2-(6-fluoroisoquinolin-8-yl)ethyl)acetamide




5

To the stirred solution of 2-((*tert*-butyldimethylsilyl)oxy)-2-(6-fluoroisoquinolin-8-yl)ethan-1-amine (300 mg, 0.94 mmol) in anhydrous CH_2Cl_2 (10 mL), TEA (0.52 mL, 3.74 mmol) and DMAP (23 mg, 0.19 mmol) were added at rt. Then Ac_2O (0.17 mL, 1.87 mmol) was added drop wise at 0 °C and the reaction mixture was stirred at rt for 16 h under N_2 . The reaction mixture was diluted with water and extracted with CH_2Cl_2 twice. The combined organic portion was washed with brine, dried over anhydrous Na_2SO_4 , filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 100% EtOAc in Hexane elution) to provide *N*-(2-((*tert*-butyldimethylsilyl)oxy)-2-(6-fluoroisoquinolin-8-yl)ethyl)acetamide (150 mg, 44%). MS (ESI+) [Method 5A]: m/z 363.2 (M+H); Rt 1.31 min.

10

15

Step 70.5: Synthesis of *N*-(2-((*tert*-butyldimethylsilyl)oxy)-2-(6-fluoro-5-formylisoquinolin-8-yl)ethyl)acetamide




To the stirred solution of *N*-(2-((*tert*-butyldimethylsilyl)oxy)-2-(6-fluoroisoquinolin-8-yl)ethyl)acetamide (150 mg, 0.41 mmol) in anhydrous THF (2 mL), LDA (2M in THF) (0.62 mL, 1.24 mmol) was added dropwise at -78 °C under N_2 atmosphere. After 2.5 h, ethyl formate (91 mg, 1.24 mmol) dissolved in THF (1 mL) was added dropwise at -78 °C, and stirred for further 1 h. The reaction was quenched with saturated NH_4Cl solution and extracted with EtOAc twice. The combined organic portion was washed with brine, dried over anhydrous Na_2SO_4 , filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 10% MeOH in CH_2Cl_2 elution) to provide *N*-(2-((*tert*-butyldimethylsilyl)oxy)-2-(6-fluoro-5-formylisoquinolin-8-yl)ethyl)acetamide (100 mg, 62%). MS (ESI+) [Method 5A]: m/z 391.2 (M+H); Rt 1.29 min.

20


25

Step 70.6: Synthesis of *N*-(2-((*tert*-butyldimethylsilyl)oxy)-2-(6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethyl)acetamide



The title compound was synthesized following the procedure as described in Step 1.4, using (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl (Step 1.3, 70 mg, 0.25 mmol) and *N*-(2-((*tert*-butyldimethylsilyl)oxy)-2-(6-fluoro-5-formylisoquinolin-8-yl)ethyl)acetamide
 5 (86 mg, 0.22 mmol). Purification of the crude by flash chromatography (4 g SiliCycle column, 0 – 5% MeOH in CHCl₃ elution) afforded *N*-(2-((*tert*-butyldimethylsilyl)oxy)-2-(6-fluoro-5-((((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethyl)acetamide (20 mg, 13%). MS (ESI+) [Method 1A]: *m/z* 624.1 (M+H); Rt 1.46 min.

Step 70.7: Synthesis of *N*-(2-(6-fluoro-5-((((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)-2-hydroxyethyl)acetamide, HCl
 10




To the solution of *N*-(2-((*tert*-butyldimethylsilyl)oxy)-2-(6-fluoro-5-((((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethyl)acetamide (20 mg, 0.03
 15 mmol) in THF (1 mL), TBAF solution (1M in THF) (0.04 mL, 0.04 mmol) was added dropwise as 0 °C and stirred for 2 h under argon. Reaction mixture was diluted with water and extracted with EtOAc twice. The combined organic portion was washed with brine solution, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by prep-HPLC (Column: LUNA Phenomenex (250 mm X 21.2 mm), 5.0 μ; Mobile Phase: 0.1% HCO₂H in in
 20 water and acetonitrile). To the isolated product, HCl solution (20% in 1,4-dioxane) (1 mL) was added, stirred at rt for 1 h, and then concentrated in *vacuo*. The residue was triturated with Et₂O, solid precipitated was filtered and dried to afford *N*-(2-(6-fluoro-5-((((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)-2-hydroxyethyl)acetamide, HCl (12 mg, 71%). MS (ESI+) [Method 1A]: *m/z* 510.2 (M+H); Rt 0.12 min. ¹H NMR (400 MHz, CD₃OD) δ 10.37 (s, 1H), 8.89 (d, *J* = 6.8 Hz, 1H), 8.81 (d, *J* = 7.2 Hz, 1H), 8.09 (d, *J* = 10.4 Hz,
 25

1H), 7.28 (t, $J = 9.6$ Hz, 1H), 7.15 – 7.09 (m, 2H), 5.69 – 5.66 (m, 1H), 5.09 – 5.04 (m, 1H), 4.82 (s, 2H), 4.31 – 4.25 (m, 1H), 3.73 (dd, $J = 14.0, 3.6$ Hz, 1H), 3.35 (dd, $J = 14.0, 7.6$ Hz, 1H), 2.96 – 2.89 (m, 2H), 2.73 – 2.67 (m, 2H), 1.95 (s, 3H).

Example 71: Synthesis of (1*r*,3*r*)-*N*-((6-fluoroisoquinolin-5-yl)methyl)-3-(3-


5 (trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl

Step 71.1: Synthesis of *tert*-butyl ((1*r*,3*r*)-3-(3-(trifluoromethyl)phenoxy)cyclobutyl)carbamate




To the solution of *tert*-butyl ((1*s*,3*s*)-3-hydroxycyclobutyl)carbamate (300 mg, 1.60 mmol), 3-(trifluoromethyl)phenol [CAS No. 98-17-9] (260 mg, 1.60 mmol) and diisopropyl azodicarboxylate (0.47 mL, 2.40 mmol) in THF (10 mL), PPh₃ (630 mg, 2.40 mmol) was added at rt. The reaction mixture was stirred at 50 °C for 16 h under N₂ atmosphere. Reaction mixture was diluted with water and extracted with EtOAc 3x's. The combined organic portion was washed with brine solution, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 20% EtOAc in Hexane elution) to provide *tert*-butyl ((1*r*,3*r*)-3-(3-(trifluoromethyl)phenoxy)cyclobutyl)carbamate (350 mg, 66%). ¹H NMR (300 MHz, CDCl₃) δ 7.37 (t, $J = 8.1$ Hz, 1H), 7.19 (d, $J = 8.1$ Hz, 1H), 6.98 (s, 1H), (d, $J = 8.1$ Hz, 1H), 6.94 (d, $J = 8.1$ Hz, 1H), 4.85 – 4.77 (m, 1H), 4.33 – 4.27 (m, 1H), 2.61 – 2.52 (m, 2H), 2.44 – 2.37 (m, 2H), 1.45 (s, 9H).

Step 71.2: Synthesis of (1*r*,3*r*)-3-(3-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl



The solution of *tert*-butyl ((1*r*,3*r*)-3-(3-(trifluoromethyl)phenoxy)cyclobutyl)carbamate (350 mg, 1.05 mmol) and HCl solution (4M in 1,4-dioxane) (5.0 mL) was stirred at rt for 16 h. The reaction mixture was concentrated in *vacuo* and the residue was triturated with pentane, the solid appeared was filtered and dried to yield (1*r*,3*r*)-3-(3-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl (270 g, 96%). MS (ESI+) [Method 6A]: m/z 231.90 (M+H); Rt 1.29 min.


Step 71.3: Synthesis of (1*r*,3*r*)-*N*-((6-fluoroisoquinolin-5-yl)methyl)-3-(3-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl




The title compound was synthesized following the procedure as described in Step 1.4, using (1*r*,3*r*)-3-(3-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl (60 mg, 0.22 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 36 mg, 0.20 mmol). The crude product was

purified by prep-HPLC (Column: WATERS X BRIDGE C18 (150 mm X 21.2 mm), 5.0 μ ; Mobile Phase: 0.02% NH₄OH in water and acetonitrile). To the isolated product, HCl solution (4M in 1,4-dioxane) (2 mL) was added, stirred at rt for 2 h, and then concentrated in *vacuo*. The residue was triturated with pentane and then lyophilized to provide (1*r*,3*r*)-*N*-((6-

- 5 fluoroisoquinolin-5-yl)methyl)-3-(3-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl (50 mg, 52%). MS (ESI+) [Method 6A]: *m/z* 391.2 (M+H); Rt 1.32 min. ¹H NMR (400 MHz, CD₃OD) δ 9.88 (s, 1H), 8.83 – 8.75 (m, 3H), 8.02 (t, *J* = 8.4 Hz, 1H), 7.50 (t, *J* = 6.8 Hz, 1H), 7.77 (d, *J* = 6.8 Hz, 1H), 7.12 – 7.09 (m, 2H), 5.11 – 5.07 (m, 1H), 4.84 (d, *J* = 2.0 Hz, 2H), 4.33 – 4.26 (m, 1H), 2.95 – 2.48 (m, 2H), 2.75 – 2.68 (m, 2H).
- 10 **Example 72: Synthesis of 2-(6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)-2-hydroxyacetic acid**
Step 72.1: Synthesis of 6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinoline-8-carbaldehyde




- 15 To the stirred solution of (6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)methanol (Step 6.11, 0.95 g, 2.17 mmol) in CHCl₃ (25 mL), activated MnO₂ (1.88 g, 21.66 mmol) was added at rt and heated at 70 °C for 2 h, under argon. The reaction mixture was cooled to rt, filtered through celite bed and the bed was washed with chloroform. The combined filtrate was concentrated in *vacuo* to
- 20 get crude compound. The crude was purified by flash chromatography (12 g SiliCycle column, 0 – 5% MeOH in CHCl₃ elution) to provide 6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinoline-8-carbaldehyde (0.5 g, 53%). MS (ESI+) [Method 6A]: *m/z* 437.1 (M+H); Rt 1.33 min.
- Step 72.2: Synthesis of 2-(6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)-2-hydroxyacetonitrile
- 25



To the solution of 6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinoline-8-carbaldehyde (250 mg, 0.57 mmol) in anhydrous CH₂Cl₂ (4 mL), Cu(OTf)₂ (10 mg, 0.03 mmol) was added at rt and stirred for 15 min. Then TMSCN (73 mg, 0.74 mmol) was added and the reaction mixture was stirred at rt for 16 h under argon. The reaction mixture was concentrated in *vacuo*. To the residue MeCN (1.0 mL) and 1M HCl (1.0 mL) were added at 0°C and stirred for 30 minutes. The solution was diluted with water and extracted with EtOAc 3x's. The combined organic portion was washed with brine solution, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo* to provide crude 2-(6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)-2-hydroxyacetonitrile (200 mg, 75%). MS (ESI+) [Method 6A]: *m/z* 464.2 (M+H); Rt 1.36 min.


Step 72.3: Synthesis of 2-(6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)-2-hydroxyacetic acid



To the stirred solution of 2-(6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)-2-hydroxyacetonitrile (200 mg, 0.43 mmol) in CH₂Cl₂ (1 mL), concentrated HCl (2.0 mL) was added at rt, and heated at 40 °C for 16 h. The reaction mixture was concentrated in *vacuo*, residue was dissolved in water and washed with Et₂O 3x's. Then the aqueous portion was concentrated. Prep-HPLC purification of the crude (Column: LUNA (250 mm x 21.2 mm), 5.0 μ; Mobile Phase: 0.1% HCO₂H in water and acetonitrile) afforded 2-(6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)-2-hydroxyacetic acid (10 mg, 4%). MS (ESI+) [Method 6A]: *m/z* 483.1 (M+H); Rt 1.34 min. ¹H NMR (600 MHz, CD₃OD) δ 9.84

(s, 1H), 9.73 (brs, 2H), 8.66 – 8.63 (m, 1H), 8.43 – 8.40 (m, 1H), 7.88 (d, $J = 8.4$ Hz, 1H), 7.47 (t, $J = 8.0$ Hz, 1H), 7.21 – 7.18 (m, 1H), 7.03 – 7.01 (m, 1H), 5.09 – 5.05 (m, 1H), 4.60 (s, 2H), 4.10 – 4.06 (m, 1H), 2.84 – 2.76 (m, 2H), 2.48 – 2.41 (m, 2H).


Example 73: Synthesis of 6-fluoro-5-((((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinoline 2-oxide



To the solution of (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine (Step 3.2, 60 mg, 0.15 mmol) in CH₂Cl₂ (4 mL), *m*-CPBA (50 mg, 0.29 mmol) was added and stirred at rt, for 16 h under argon. The reaction mixture was concentrated and the residue was dissolved in EtOAc, washed with saturated NaHCO₃ solution, followed by brine. Then the organic portion was dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The crude was purified by prep-HPLC (Column: GEMINI NX C18 (150 mm x 21.0 mm), 5.0 μ ; Mobile Phase: 0.02% NH₄OH in water and acetonitrile) to afford 6-fluoro-5-((((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinoline 2-oxide (30 mg, 48%). MS (ESI+) [Method 6A]: m/z 425.1 (M+H); Rt 1.45 min. ¹H NMR (400 MHz, CD₃OD) δ 9.21 (s, 1H), 8.47 (d, $J = 6.4$ Hz, 1H), 8.26 (d, $J = 5.6$ Hz, 1H), 8.14 (dd, $J = 8.4, 5.2$ Hz, 1H), 7.50 (t, $J = 9.6$ Hz, 1H), 7.23 (t, $J = 9.2$ Hz, 1H), 7.10 – 7.03 (m, 2H), 4.86 – 4.82 (m, 1H), 4.24 (s, 2H), 3.70 – 3.66 (m, 1H), 2.77 – 2.72 (m, 2H), 2.36 – 2.30 (m, 2H).

Example 74: Synthesis of 5-((((1*r*,3*r*)-3-((6-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutyl)amino)methyl)isoquinolin-3-amine


Step 74.1: Synthesis of *tert*-butyl (*tert*-butoxycarbonyl)(5-((((1*r*,3*r*)-3-((6-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutyl)amino)methyl)isoquinolin-3-yl)carbamate



The title compound was synthesized following the procedure as described in Step 25.6, using (1*r*,3*r*)-3-((6-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutan-1-amine, HCl (Step 2.2, 50 mg, 0.19 mmol) and *tert*-butyl (*tert*-butoxycarbonyl)(5-formylisoquinolin-3-yl)carbamate (Step 13.3, 70 mg, 0.19 mmol). The combined organic portion was washed with brine solution, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo* to afford crude *tert*-butyl (*tert*-butoxycarbonyl)(5-((((1*r*,3*r*)-3-((6-(trifluoromethyl)pyridin-3-

yl)oxy)cyclobutyl)amino)methyl)isoquinolin-3-yl)carbamate (70 mg, 64%). MS (ESI+) [Method 6A]: m/z 456.3 (M-Boc-*t*Bu+Na+H); Rt 1.38 min

Step 74.2: Synthesis of 5-((((1*r*,3*r*)-3-((6-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutyl)amino)methyl)isoquinolin-3-amine




5

Deprotection was carried out according to Step 13.5. The reaction mixture was stirred at rt for 4 h. Then the reaction mixture was concentrated in *vacuo* and purified by prep-HPLC (Column: KINETEX EVO C18 (150 mm x 21.0 mm), 5.0 μ ; Mobile Phase: 0.02% NH₄OH in water and acetonitrile) to provide 5-((((1*r*,3*r*)-3-((6-(trifluoromethyl)pyridin-3-

10 yl)oxy)cyclobutyl)amino)methyl)isoquinolin-3-amine (15 mg, 59%). MS (ESI+) [Method 6A]: m/z 389.2 (M+H); Rt 1.26 min. ¹H NMR (400 MHz, CD₃OD) δ 8.79 (d, J = 0.8 Hz, 1H), 8.28 (d, J = 2.8 Hz, 1H), 7.75 (dd, J = 10.4, 8.4 Hz, 2H), 7.75 (d, J = 6.0 Hz, 1H), 7.40 – 7.38 (m, 1H), 7.22 (dd, J = 8.4, 6.8 Hz, 1H), 7.01 (s, 1H), 5.03 – 4.99 (m, 1H), 4.03 (s, 2H), 3.70 – 3.66 (m, 1H), 2.45 (t, J = 5.6 Hz, 4H).


15 **Example 75: Synthesis of 6-fluoro-5-((1*r*,3*r*)-3-((6-fluoroisoquinolin-5-yl)methyl)amino)cyclobutoxy)picolinonitrile, HCl**

Step 75.1: Synthesis of 6-bromo-2-fluoropyridin-3-ol




The stirred solution of 2-fluoropyridin-3-ol [CAS No. 174669-74-0] (2.0 g, 17.56 mmol) in AcOH
20 (25 mL) was cooled to 0 °C; then Br₂ (2.82 g, 17.56 mmol) and NaOAc (1.59 g, 19.32 mmol) were added successively. The reaction mixture was stirred at rt for 1 h under argon. The reaction mixture was poured into ice water, neutralized with 2N NaOH solution, and extracted with EtOAc 3x's. The combined organic portion was washed with brine solution, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash chromatography
25 (12 g SiliCycle column, 0 – 30% EtOAc in Hexane elution) to provide 6-bromo-2-fluoropyridin-3-ol (3.4 g, 99%). ¹H NMR (300 MHz, CDCl₃) δ 7.31 – 7.27 (m, 2H).

Step 75.2: Synthesis of *tert*-butyl ((1*r*,3*r*)-3-((6-bromo-2-fluoropyridin-3-yl)oxy)cyclobutyl)carbamate




To the stirred solution of 6-bromo-2-fluoropyridin-3-ol (250 mg, 1.31 mmol) in anhydrous THF (5 mL), *tert*-butyl ((1*s*,3*s*)-3-hydroxycyclobutyl)carbamate (160 mg, 1.31 mmol) and TPP (340 mg, 1.96 mmol) were added at rt. The reaction mixture was cooled to 0 °C, DIAD (0.26 mL, 1.96 mmol) was added and then heated at 50 °C for 16h under argon. Reaction mixture was diluted with water and extracted with EtOAc 3x's. The combined organic portion was washed with brine solution, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 30% EtOAc in Hexane elution) to provide *tert*-butyl ((1*r*,3*r*)-3-((6-bromo-2-fluoropyridin-3-yl)oxy)cyclobutyl)carbamate (350 mg, 90%). MS (ESI+) [Method 6A]: *m/z* 304.5, 306.5 (M-*t*Bu+H); Rt 1.61 min. ¹H NMR (600 MHz, CDCl₃) δ 7.26 – 7.24 (m, 1H), 6.98 – 6.95 (m, 1H), 6.33 (brs, 1H), 4.81 – 4.77 (m, 1H), 4.32 – 4.27 (m, 1H), 2.62 – 2.56 (m, 2H), 2.48 – 2.42 (m, 2H), 1.45 (s, 9H).

Step 75.3: Synthesis of *tert*-butyl ((1*r*,3*r*)-3-((6-cyano-2-fluoropyridin-3-yl)oxy)cyclobutyl)carbamate




The stirred solution of *tert*-butyl ((1*r*,3*r*)-3-((6-bromo-2-fluoropyridin-3-yl)oxy)cyclobutyl)carbamate (250 mg, 0.69 mmol), Zn-dust (4 mg, 0.07 mmol), Zn(CN)₂ (40 mg, 0.34 mmol), dppf (7 mg, 0.01 mmol) and Pd₂(dba)₃ (12 mg, 0.001 mmol) in DMA (3 mL) was purged with argon for 15 min. The reaction mixture was heated at 100 °C for 5 h under argon. Reaction mixture was cooled rt, filtered through celite bed, then the bed was washed with EtOAc. The collected filtrate was washed with water 3x's, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 30% EtOAc in Hexane elution) to provide *tert*-butyl ((1*r*,3*r*)-3-((6-cyano-2-fluoropyridin-3-yl)oxy)cyclobutyl)carbamate (115 mg, 54%). ¹H NMR (400 MHz, CDCl₃) δ 7.54 (d, *J* = 8.4 Hz, 1H), 7.08 – 7.05 (m, 1H), 4.93 – 4.87 (m, 1H), 4.32 – 4.27 (m, 1H), 2.65 – 2.53 (m, 4H), 1.45 (s, 9H).

Step 75.4: Synthesis of 5-((1*r*,3*r*)-3-aminocyclobutoxy)-6-fluoropicolinonitrile, HCl



Deprotection was carried out according to Step 13.5. The reaction was stirred at rt for 2 h, then concentrated in *vacuo*. The residue was triturated with pentane, the solid appeared was filtered and dried to yield 5-((1*r*,3*r*)-3-aminocyclobutoxy)-6-fluoropicolinonitrile, HCl (60 mg, 69%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.23 (brs, 2H), 8.03 (d, *J* = 10.4 Hz, 1H), 7.57 (t, *J* = 9.6 Hz, 1H), 5.19 – 5.14 (m, 1H), 3.91 – 3.85 (m, 1H), 2.70 – 2.54 (m, 2H), 2.56 – 2.51 (m, 2H).


Step 75.5: Synthesis of 6-fluoro-5-((1*r*,3*r*)-3-(((6-fluoroisoquinolin-5-yl)methyl)amino)cyclobutoxy)picolinonitrile, HCl



The title compound was synthesized following the procedure as described in Step 1.4, using 5-((1*r*,3*r*)-3-aminocyclobutoxy)-6-fluoropicolinonitrile, HCl (60 mg, 0.25 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 39 mg, 0.22 mmol). The crude product was purified by prep-HPLC (Column: LUNA Phenomenex (250 mm X 21.2 mm), 5.0 μ ; Mobile Phase: 0.1% HCO₂H in water and acetonitrile). To the isolated product, HCl solution (4M in 1,4-dioxane) (2 mL) was added, stirred at rt for 2 h, and then concentrated in *vacuo*. The residue was triturated with *n*-pentane and then lyophilized to provide 6-fluoro-5-((1*r*,3*r*)-3-(((6-fluoroisoquinolin-5-yl)methyl)amino)cyclobutoxy)picolinonitrile, HCl (30 mg, 30%). MS (ESI+) [Method 6A]: *m/z* 367.2 (M+H); Rt 1.25 min. ¹H NMR (400 MHz, CD₃OD) δ 9.84 (s, 1H), 8.78 – 8.73 (m, 3H), 8.00 (t, *J* = 8.4 Hz, 1H), 7.77 (d, *J* = 8.0 Hz, 1H), 7.49 (t, *J* = 8.0 Hz, 1H), 5.23 – 5.17 (m, 1H), 4.83 (d, *J* = 1.6 Hz, 2H), 4.33 – 4.28 (m, 1H), 3.02 – 2.94 (m, 2H), 2.82 – 2.75 (m, 2H).


Example 76: Synthesis of (1*r*,3*r*)-*N*-((6-fluoroisoquinolin-5-yl)methyl)-3-(4-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl

15 Step 76.1: Synthesis of *tert*-butyl ((1*r*,3*r*)-3-(4-(trifluoromethyl)phenoxy)cyclobutyl)carbamate



The title compound was synthesized following the procedure as described in Step 1.2, using *tert*-butyl ((1*s*,3*s*)-3-hydroxycyclobutyl)carbamate (300 mg, 1.60 mmol) and 4-(trifluoromethyl)phenol [CAS No. 402-45-9] (260 mg, 1.60 mmol). The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 20% EtOAc in Hexane elution) to provide *tert*-butyl ((1*r*,3*r*)-3-(4-(trifluoromethyl)phenoxy)cyclobutyl)carbamate 380 mg, 71%). ¹H NMR (300 MHz, CDCl₃) δ 7.52 (d, *J* = 8.1 Hz, 2H), 6.82 (d, *J* = 8.1 Hz, 2H), 4.85 – 4.78 (m, 1H), 4.33 – 4.27 (m, 1H), 2.61 – 2.52 (m, 2H), 2.44 – 2.37 (m, 2H), 1.45 (s, 9H).


Step 76.2: Synthesis of (1*r*,3*r*)-3-(4-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl



25

Deprotection was carried out according to Step 13.5. The reaction mixture was concentrated in *vacuo* and the residue was triturated with *n*-pentane, the solid appeared was filtered and dried to yield (1*r*,3*r*)-3-(4-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl (300 g, 97%). MS (ESI+) [Method 6A]: *m/z* 231.9 (M+H); Rt 1.3 min.


Step 76.3: Synthesis of (1*r*,3*r*)-*N*-((6-fluoroisoquinolin-5-yl)methyl)-3-(4-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl [C-07664-106]



- 5 The title compound was synthesized following the procedure as described in Step 1.4, using (1*r*,3*r*)-3-(4-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl (60 mg, 0.22 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 36 mg, 0.20 mmol). The crude product was purified by prep-HPLC (Column: WATERS X BRIDGE C18 (150 mm X 21.2 mm), 5.0 μ ; Mobile Phase: 0.02% NH₄OH in water and acetonitrile). To the isolated product, HCl solution (4M in 1,4-dioxane) (2 mL) was added, stirred at rt for 2 h, and then concentrated in *vacuo*. The residue was trituated with *n*-pentane and then lyophilized to provide (1*r*,3*r*)-*N*-((6-fluoroisoquinolin-5-yl)methyl)-3-(4-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl (40 mg, 42%). MS (ESI+) [Method 6A]: *m/z* 391.2 (M+H); Rt 1.31 min. ¹H NMR (400 MHz, CD₃OD) δ 9.80 (s, 1H), 8.77 (d, *J* = 6.0 Hz, 1H), 8.72 – 8.68 (m, 2H), 7.98 (t, *J* = 8.4 Hz, 1H), 7.61 (d, *J* = 8.4 Hz, 2H), 6.99 (d, *J* = 8.8 Hz, 2H), 5.09 – 5.04 (m, 1H), 4.82 (d, *J* = 2.0 Hz, 2H), 4.30 – 4.25 (m, 1H), 2.91 – 2.84 (m, 2H), 2.75 – 2.68 (m, 2H).
- 10
- 15


Example 77: Synthesis of 2-(6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)butane-1,4-diol

Step 77.1: Synthesis of 2-(6-fluoroisoquinolin-8-yl)malononitrile




- 20 The suspension of NaH (60% on mineral oil) (4.25 g, 106.16 mmol) in anhydrous DME (350 mL) was cooled to 0 °C, malononitrile (8.78 g, 132.71 mmol) was added and stirred for 30 min at 0 °C under N₂. Then 8-bromo-6-fluoroisoquinoline (Step 6.4, 20.0 g, 88.47 mmol) dissolved in DME (50 mL) was added drop wise, followed by Pd(PPh₃)₄ (10.2 g, 8.85 mmol) and the reaction mixture
- 25 was stirred at 85 °C for 16 h under N₂. The reaction mixture was concentrated in *vacuo*, residue was washed with pentane, diluted with water and then neutralized with 3N HCl solution. The red solid precipitate was collected by filtration and dried to afford crude 2-(6-fluoroisoquinolin-8-yl)malononitrile (28.0 g, 150%). MS (ESI+) [Method 6A]: *m/z* 210.1 (M-H), 212.1 (M+1); Rt 1.37 min.

- 30 Step 77.2: Synthesis of dimethyl 2-(6-fluoroisoquinolin-8-yl)malonate




To the stirred solution of 2-(6-fluoroisoquinolin-8-yl)malononitrile (28.0 g, 132.58 mmol) in anhydrous MeOH (420 mL), SOCl_2 (280 mL) was added drop wise at 0 °C and stirred at rt for 16 h under N_2 . The reaction mixture concentrated in *vacuo*. The residue was basified with saturated NaHCO₃ solution, extracted with EtOAc 3x's. The combined organic layer was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The crude was purified by flash chromatography (80 g SiliCycle column, 0 – 30% EtOAc in Hexane elution) to provide dimethyl 2-(6-fluoroisoquinolin-8-yl)malonate (13.0 g, 41%). MS (ESI+) [Method 6A]: m/z 276.1 (M-H), 278.1 (M+1); Rt 1.36 min.

10 Step 77.3: Synthesis of methyl 2-(6-fluoroisoquinolin-8-yl)acetate



To the stirred solution of dimethyl 2-(6-fluoroisoquinolin-8-yl)malonate (6.0 g, 21.64 mmol) in DMSO – H₂O (66 mL, 10:1 v/v), LiCl (1.37 g, 32.46 mmol) was added at rt and then heated at 100 °C for 16 h. Reaction mixture was cooled to rt, diluted with water and extracted with EtOAc twice. The combined organic layer was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The crude was purified by flash chromatography (40 g SiliCycle column, 0 – 20% EtOAc in Hexane elution) to provide methyl 2-(6-fluoroisoquinolin-8-yl)acetate (2.5 g, 53%). MS (ESI+) [Method 6A]: m/z 220.1 (M+1); Rt 0.84 min. ¹H NMR (600 MHz, CDCl₃) δ 9.39 (s, 1H), 8.55 (d, J = 5.4 Hz, 1H), 7.63 (d, J = 6.0 Hz, 1H), 7.38 (d, J = 9.0 Hz, 1H), 7.30 (d, J = 8.4 Hz, 1H), 4.17 (s, 2H), 3.73 (s, 3H).


20 Step 77.4: Synthesis of 4-ethyl 1-methyl 2-(6-fluoroisoquinolin-8-yl)succinate



To the stirred solution of methyl 2-(6-fluoroisoquinolin-8-yl)acetate (2.40 g, 10.94 mmol) in anhydrous THF (25 mL), LiHMDS (1.0M in THF) (14.23 mL, 14.23 mmol) was added dropwise at -78°C and stirred for 1 h under N_2 . Then ethyl 2-bromoacetate (2.0 g, 12.04 mmol), dissolved in THF (10 mL), was added drop wise at -78°C and stirred for 2 h. Reaction was quenched with saturated NH₄Cl solution, and extracted with EtOAc twice. The combined organic layer was washed with brine dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The crude was purified by flash chromatography (24 g SiliCycle column, 0 – 20% EtOAc in Hexane elution)


- to provide 4-ethyl 1-methyl 2-(6-fluoroisoquinolin-8-yl)succinate (3.1 g, 93%). MS (ESI+) [Method 1A]: m/z 306.3 (M+1); Rt 0.31 min. ¹H NMR (300 MHz, CDCl₃) δ 9.56 (s, 1H), 8.55 (d, J = 5.4 Hz, 1H), 7.63 (d, J = 5.4 Hz, 1H), 7.37 (dd, J = 9.3, 2.1 Hz, 1H), 7.30 (dd, J = 9.9, 2.1 Hz, 1H), 5.04 (dd, J = 9.0, 5.1 Hz, 1H), 4.14 (q, J = 7.2 Hz, 2H), 3.70 (s, 3H), 3.37 (dd, J = 17.1, 9.9 Hz, 1H), 2.82 (dd, J = 17.1, 5.1 Hz, 1H), 1.21 (t, J = 7.2 Hz, 3H).

Step 77.5: Synthesis of 2-(6-fluoroisoquinolin-8-yl)butane-1,4-diol




- To the stirred solution of 4-ethyl 1-methyl 2-(6-fluoroisoquinolin-8-yl)succinate (250 mg, 0.82 mmol) in anhydrous THF (4 mL), LAH (62 mg, 1.64 mmol) was added portion wise at 0 °C. Reaction mixture was stirred at rt for 3 h under argon. The reaction was quenched with ice cold water and extracted with EtOAc. The combined organic layer was washed with brine dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The crude was purified by flash chromatography (24 g SiliCycle column, 0 – 25% EtOAc in Hexane elution) to provide 2-(6-fluoroisoquinolin-8-yl)butane-1,4-diol (80 mg, 41%). MS (ESI+) [Method 6A]: m/z 236.2 (M+1); Rt 0.16 min.

Step 77.6: Synthesis of 6-fluoro-8-(2,2,3,3,10,10,11,11-octamethyl-4,9-dioxa-3,10-disiladodecan-6-yl)isoquinoline




- To the stirred solution of 2-(6-fluoroisoquinolin-8-yl)butane-1,4-diol (80 mg, 0.34 mmol) and imidazole (162 mg, 2.38 mmol) in DMF (2 mL), TBDMS-Cl (256 mg, 1.70 mmol) was added portion wise at 0 °C. The reaction mixture was stirred at rt for 16 h under N₂. Then the reaction mixture was diluted with water and extracted with EtOAc twice. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 20% EtOAc in Hexane elution) to provide 6-fluoro-8-(2,2,3,3,10,10,11,11-octamethyl-4,9-dioxa-3,10-disiladodecan-6-yl)isoquinoline (130 mg, 83%). MS (ESI+) [Method 1A]: m/z 464.6 (M+H); Rt 2.52 min.

Step 77.7: Synthesis of 6-fluoro-8-(2,2,3,3,10,10,11,11-octamethyl-4,9-dioxa-3,10-disiladodecan-6-yl)isoquinoline-5-carbaldehyde




The title compound was prepared according to Step 6.8. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 10% EtOAc in Hexane elution) to provide 6-fluoro-8-(2,2,3,3,10,10,11,11-octamethyl-4,9-dioxo-3,10-disiladodecan-6-yl)isoquinoline-5-carbaldehyde (80 mg, 75%). MS (ESI+) [Method 5A]: m/z 493.5 (M+H); Rt 3.09 min.

Step 77.8: Synthesis of (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-*N*-((6-fluoro-8-(2,2,3,3,10,10,11,11-octamethyl-4,9-dioxo-3,10-disiladodecan-6-yl)isoquinolin-5-yl)methyl)cyclobutan-1-amine



The title compound was synthesized following the procedure as described in Step 1.4, using (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl (Step 1.3, 55 mg, 0.19 mmol) and 6-fluoro-8-(2,2,3,3,10,10,11,11-octamethyl-4,9-dioxo-3,10-disiladodecan-6-yl)isoquinoline-5-carbaldehyde (76 mg, 0.15 mmol). The crude product was purified by flash chromatography (4 g SiliCycle column, 0 – 10% MeOH in CHCl₃ elution) to provide (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-*N*-((6-fluoro-8-(2,2,3,3,10,10,11,11-octamethyl-4,9-dioxo-3,10-disiladodecan-6-yl)isoquinolin-5-yl)methyl)cyclobutan-1-amine (100 mg, 72%). MS (ESI+) [Method 5A]: m/z 725.4 (M+H); Rt 2.44 min.


Example 77.9: Synthesis of 2-(6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)butane-1,4-diol



Deprotection was carried out according to Step 7.6. The residue was purified by prep-HPLC (Column: X SELECT (250 mm X 21.2 mm), 5.0 μ ; Mobile Phase: 0.02% NH_4OH in water and acetonitrile) to afford 2-(6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)butane-1,4-diol (23 mg, 34%).
 MS (ESI+) [Method 1A]: m/z 497.2 ($M+H$); R_t 0.18 min. ^1H NMR (400 MHz, CD_3OD) δ 9.64 (s, 1H), 8.54 (d, $J = 6.0$ Hz, 1H), 8.13 (d, $J = 6.4$ Hz, 1H), 7.54 (d, $J = 8.4$ Hz, 1H), 7.24 (t, $J = 6.8$ Hz, 1H), 7.08 – 7.02 (m, 3H), 4.90 – 4.85 (m, 1H), 4.20 (s, 2H), 4.13 – 4.07 (m, 1H), 3.89 (d, $J = 6.0$ Hz, 2H), 3.64 – 3.57 (m, 2H), 3.48 – 3.42 (m, 1H), 2.39 – 2.35 (m, 4H), 2.26 – 2.18 (m, 1H), 2.03 – 1.97 (m, 1H).


Example 78: Synthesis of (1*r*,3*r*)-3-((3,4-difluorobenzyl)oxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine

Step 78.1: Synthesis of *tert*-butyl ((1*r*,3*r*)-3-((3,4-difluorobenzyl)oxy)cyclobutyl)carbamate



To the solution of *tert*-butyl ((1*r*,3*r*)-3-hydroxycyclobutyl)carbamate (200 mg, 1.07 mmol) in THF (3 mL), NaH (60% on mineral oil) (51 mg, 1.28 mmol) was added at 0 $^\circ\text{C}$, stirred for 15 min. Then 4-(bromomethyl)-1,2-difluorobenzene [CAS No. 85118-01-0] (243 mg, 1.18 mmol) was added dropwise and the reaction mixture was stirred at rt for 2 h under N_2 . The reaction mixture was diluted with ice-water, and stirred for 15 min. The white solid that precipitated was filtered and dried to provide *tert*-butyl ((1*r*,3*r*)-3-((3,4-difluorobenzyl)oxy)cyclobutyl)carbamate (240 mg, 72%).
 ^1H NMR (300 MHz, CDCl_3) δ 7.18 – 7.04 (m, 3H), 4.69 – 4.65 (m, 1H), 4.34 (s, 2H), 4.20 – 4.14 (m, 1H), 2.45 – 2.37 (m, 2H), 2.18 – 2.11 (m, 2H), 1.44 (s, 9H).


Step 78.2: Synthesis of (1*r*,3*r*)-3-((3,4-difluorobenzyl)oxy)cyclobutan-1-amine, HCl



A solution of *tert*-butyl ((1*r*,3*r*)-3-((3,4-difluorobenzyl)oxy)cyclobutyl)carbamate (240 mg, 0.77 mmol) and HCl solution (4M in 1,4-dioxane) (5 mL) was stirred at rt for 2 h. Then the reaction

mixture was concentrated in *vacuo* and the residue was triturated with Et₂O. The solid that precipitated was filtered and dried to yield crude (1*r*,3*r*)-3-((3,4-difluorobenzyl)oxy)cyclobutan-1-amine, HCl (210 mg, 109%). MS (ESI+) [Method 6A]: *m/z* 214.1 (M+H); Rt 1.25 min.

5 Step 78.3: Synthesis of (1*r*,3*r*)-3-((3,4-difluorobenzyl)oxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine



The title compound was synthesized following the procedure as described in Step 1.4, using (1*r*,3*r*)-3-((3,4-difluorobenzyl)oxy)cyclobutan-1-amine, HCl (100 mg, 0.40 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 63 mg, 0.36 mmol). The crude product was purified
10 by prep-HPLC (Column: LUNA Phenomenex (250 mm x 21.2 mm), 5.0 μ; Mobile Phase: 0.1% HCO₂H in water and acetonitrile-MeOH (1:1)) to afford (1*r*,3*r*)-3-((3,4-difluorobenzyl)oxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine (60 mg, 40%). MS (ESI+) [Method 6A]: *m/z* 373.1 (M+H); Rt 1.30 min. ¹H NMR (400 MHz, CD₃OD) δ 9.28 (brs, 1H), 8.57 (brs, 1H), 8.24 (dd, *J* = 8.8, 5.2 Hz, 1H), 8.10 (d, *J* = 6.0 Hz, 1H), 7.58 (t, *J* = 8.8 Hz, 1H), 7.27 – 7.18 (m, 2H), 7.13 –
15 7.19 (m, 1H), 4.39 (s, 2H), 4.36 (s, 2H), 4.26 – 4.01 (m, 1H), 3.77 – 3.72 (m, 1H), 2.38 – 2.32 (m, 2H), 2.30 – 2.24 (m, 2H).


Example 79: Synthesis of (1*r*,3*r*)-3-(3,4-dimethylphenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl

Step 79.1: Synthesis of *tert*-butyl ((1*r*,3*r*)-3-(3,4-dimethylphenoxy)cyclobutyl)carbamate



The title compound was synthesized following the procedure as described in Step 1.2, using *tert*-butyl ((1*s*,3*s*)-3-hydroxycyclobutyl)carbamate (200 mg, 1.07 mmol) and 3,4-dimethylphenol [CAS No. 95-65-8] (144 mg, 1.18 mmol). The crude was purified by flash chromatography (12 g SiliCycle column, 0 – 20% EtOAc in Hexane elution) to provide *tert*-butyl ((1*r*,3*r*)-3-(3,4-dimethylphenoxy)cyclobutyl)carbamate (270 mg, 87%). ¹H NMR (300 MHz, CDCl₃) δ 6.99 (t, *J* = 7.8 Hz, 1H), 6.65 – 6.48 (m, 2H), 5.27 – 5.22 (m, 1H), 4.77 – 4.73 (m, 1H), 2.59 – 2.50 (m, 2H),
25 2.38 – 2.31 (m, 2H), 2.21 (s, 3H), 2.18 (s, 3H), 1.45 (s, 9H).


Step 79.2: Synthesis of (1*r*,3*r*)-3-(3,4-dimethylphenoxy)cyclobutan-1-amine, HCl



The solution of *tert*-butyl ((1*r*,3*r*)-3-(3,4-dimethylphenoxy)cyclobutyl)carbamate (270 mg, 0.93 mmol) and HCl (4M in 1,4-dioxane) (3 mL) was stirred at rt for 16 h. Then the reaction mixture was concentrated in *vacuo*, the residue was triturated with Et₂O, the solid was filtered and dried to yield (1*r*,3*r*)-3-(3,4-dimethylphenoxy)cyclobutan-1-amine, HCl (80 mg, 38%). MS (ESI+)

5 [Method 6A]: *m/z* 192.2 (M+H); Rt 1.28 min.


Step 79.3: Synthesis of (1*r*,3*r*)-3-(3,4-dimethylphenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl



The title compound was synthesized following the procedure as described in Step 1.4, using (1*r*,3*r*)-3-(3,4-dimethylphenoxy)cyclobutan-1-amine, HCl (80 mg, 0.35 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 56 mg, 0.32 mmol). The crude product was purified by prep-HPLC (Column: LUNA C18 (250 mm x 21.0 mm), 5.0 μ ; Mobile Phase: 0.1% HCO₂H in water and acetonitrile). The isolated product was stirred with HCl solution (20% in 1,4-dioxane) (2 mL) at rt for 2 h, then concentrated in *vacuo* to afford (1*r*,3*r*)-3-(3,4-dimethylphenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl (30 mg, 22%). MS (ESI+) [Method 1A]: *m/z* 351.0 (M+H); Rt 0.18 min. ¹H NMR (400 MHz, CD₃OD) δ 9.87 (brs, 1H), 8.81 (brs, 1H), 8.78 – 8.74 (m, 2H), 8.02 (t, *J* = 9.2 Hz, 1H), 7.03 (d, *J* = 8.4 Hz, 1H), 6.64 (d, *J* = 2.4 Hz, 1H), 6.54 (dd, *J* = 8.0, 2.8 Hz, 1H), 4.97 – 4.93 (m, 1H), 4.83 (d, *J* = 1.6 Hz, 2H), 4.27 – 4.23 (m, 1H), 2.86 – 2.79 (m, 2H), 2.71 – 2.64 (m, 2H), 2.24 (s, 3H), 2.14 (s, 3H).


20 **Example 80: Synthesis of ethyl 4-((1*r*,3*r*)-3-((6-fluoroisoquinolin-5-yl)methyl)amino)cyclobutoxy)benzoate**

Step 80.1: Synthesis of ethyl 4-((1*r*,3*r*)-3-((*tert*-butoxycarbonyl)amino)cyclobutoxy)benzoate




The title compound was synthesized following the procedure as described in Step 1.2, using *tert*-butyl ((1*s*,3*s*)-3-hydroxycyclobutyl)carbamate (200 mg, 1.07 mmol) and ethyl 4-hydroxybenzoate [CAS No. 120-47-8] (195 g, 1.18 mmol). The crude product was purified by flash chromatography (12 g SiliCycle column, 0 – 40% EtOAc in Hexane elution) to provide ethyl 4-((1*r*,3*r*)-3-((*tert*-butoxycarbonyl)amino)cyclobutoxy)benzoate (250 mg, 70%). ¹H NMR (300 MHz, DMSO-*d*₆) δ 7.97 (d, *J* = 8.7 Hz, 2H), 6.77 (d, *J* = 9.3 Hz, 2H), 5.08 – 4.99 (m, 1H), 4.87 – 4.81 (m, 1H), 4.34 (q, *J* = 7.2 Hz, 2H), 2.61 – 2.53 (m, 2H), 2.45 – 2.38 (m, 2H), 1.45 (s, 9H), 1.37 (t, *J* = 7.2 Hz, 3H).

Step 80.2: Synthesis of ethyl 4-((1*r*,3*r*)-3-aminocyclobutoxy)benzoate, HCl



The solution of ethyl 4-((1*r*,3*r*)-3-((*tert*-butoxycarbonyl)amino)cyclobutoxy)benzoate (250 mg, 0.75 mmol) and HCl (4M in 1,4-dioxane) (3 mL) was stirred at rt for 2 h. Then the reaction mixture was concentrated in *vacuo*, and triturated with Et₂O to yield ethyl 4-((1*r*,3*r*)-3-aminocyclobutoxy)benzoate, HCl (110 mg, 54%). MS (ESI+) [Method 6A]: *m/z* 236.1 (M+H); Rt 1.28 min. ¹H NMR (400 MHz, CD₃OD) δ 7.98 (d, *J* = 8.8 Hz, 2H), 6.90 (d, *J* = 9.2 Hz, 2H), 5.06 – 5.00 (m, 1H), 4.34 (q, *J* = 7.2 Hz, 2H), 4.03 – 3.97 (m, 1H), 2.70 – 2.59 (m, 4H), 1.38 (t, *J* = 7.2 Hz, 3H).


Step 80.3: Synthesis of ethyl 4-((1*r*,3*r*)-3-((6-fluoroisoquinolin-5-yl)methyl)amino)cyclobutoxy)benzoate



The title compound was synthesized following the procedure as described in Step 1.4, using ethyl 4-((1*r*,3*r*)-3-aminocyclobutoxy)benzoate, HCl (80 mg, 0.30 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 46 mg, 0.27 mmol). Crude product was purified by prep-HPLC (Column: LUNA C18 (250 mm x 21.0 mm), 5.0 μ; Mobile Phase: 0.1% HCO₂H in water and acetonitrile) to provide ethyl 4-((1*r*,3*r*)-3-((6-fluoroisoquinolin-5-yl)methyl)amino)cyclobutoxy)benzoate (30 mg, 24%). MS (ESI+) [Method 6A]: *m/z* 395.1 (M+H); Rt 1.32 min. ¹H NMR (400 MHz, CD₃OD) δ 9.26 (s, 1H), 8.54 (d, *J* = 6.0 Hz, 1H), 8.18 (dd, *J* = 9.2, 5.6 Hz, 1H), 8.13 (d, *J* = 6.4 Hz, 1H), 7.95 (dd, *J* = 7.2, 2.0 Hz, 2H), 7.54 (t, *J* = 9.2 Hz, 1H), 6.86 (dd, *J* = 7.2, 2.0 Hz, 2H), 4.93 – 4.89 (m, 1H), 4.33 (q, *J* = 7.2 Hz, 2H), 4.22 (d, *J* = 1.6 Hz, 2H), 3.65 – 3.60 (m, 1H), 2.39 (dd, *J* = 6.4, 5.6 Hz, 4H), 1.38 (t, *J* = 7.2 Hz, 3H).

Example 81: Synthesis of 5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)-*N,N*-dimethylisoquinolin-6-amine, HCl

Step 81.1: Synthesis of 6-(dimethylamino)isoquinoline-5-carbaldehyde




To the solution of 6-fluoroisoquinoline [CAS No. 1075-11-2] (0.5 g, 3.40 mmol) in anhydrous THF (10 mL), LDA (2M in THF) (4.25 mL, 8.49 mmol) was added dropwise at -78 °C and stirred for 2.5

h under N₂ atmosphere. Then anhydrous DMF (0.78 mL, 10.19 mmol) was added dropwise at -78 °C, stirred for 30 min and temperature was raised to 0 °C slowly over a period of 1 h while stirring. The reaction was quenched with saturated NH₄Cl solution and extracted with EtOAc twice. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄,
 5 filtered and concentrated in *vacuo* to yield the crude product. The crude was purified by flash chromatography (12 g SiliCycle column, 0 – 20% EtOAc in Hexane elution) to elute 6-fluoroisoquinoline-5-carbaldehyde (pale brown solid, 30 mg, 5%), followed by 6-(dimethylamino)isoquinoline-5-carbaldehyde (pale brown gummy liquid, 70 mg, 10%). Peak 1: 6-fluoroisoquinoline-5-carbaldehyde: MS (ESI+) [Method 6A]: m/z 175.8 (M+H); Rt 0.84 min. Peak
 10 2: 6-(dimethylamino)isoquinoline-5-carbaldehyde: MS (ESI+) [Method 6A]: m/z 200.9 (M+H); Rt 0.44 min. ¹H NMR (300 MHz, CDCl₃) δ 10.30 (s, 1H), 9.01 (s, 1H), 8.76 (d, *J* = 6.6 Hz, 1H), 8.52 (d, *J* = 6.3 Hz, 1H), 7.93 (d, *J* = 9.6 Hz, 1H), 7.35 (d, *J* = 9.3 Hz, 1H), 3.24 (s, 6H).

Step 81.2: Synthesis of


5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)-*N,N*-
 15 dimethylisoquinolin-6-amine, HCl



The title compound was synthesized following the procedure as described in Step 1.4, using (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl (Step 1.3, 80 mg, 0.28 mmol) and 6-(dimethylamino)isoquinoline-5-carbaldehyde (50 mg, 0.25 mmol). The crude product
 20 was purified by prep-HPLC (Column: KINETEX (150 mm x 21.2 mm), 5.0 μ; Mobile Phase: 0.02% NH₄OH in water and acetonitrile). The isolated product was stirred with HCl solution (4M in 1,4-dioxane) (2 mL) at rt for 2 h, then concentrated in *vacuo*. The residue was triturated with Et₂O, filtered and dried to afford 5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)-*N,N*-dimethylisoquinolin-6-amine, HCl (20
 25 mg, 15%). MS (ESI+) [Method 6A]: m/z 434.4 (M+H); Rt 1.31 min. ¹H NMR (400 MHz, CD₃OD) δ 9.48 (s, 1H), 8.51 (d, *J* = 7.2 Hz, 1H), 8.44 (d, *J* = 5.2 Hz, 1H), 8.41 (s, 1H), 7.96 (d, *J* = 9.2 Hz, 1H), 7.29 (t, *J* = 9.2 Hz, 1H), 7.13 – 7.07 (m, 2H), 4.99 – 4.96 (m, 1H), 4.83 (s, 2H), 4.16 – 4.10 (m, 1H), 3.15 (s, 6H), 2.83 – 2.76 (m, 2H), 2.65 – 2.59 (m, 2H).


Example 82: Synthesis of (1*r*,3*r*)-3-(3,5-difluorophenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl
 30

Step 82.1: Synthesis of *tert*-butyl ((1*r*,3*r*)-3-(3,5-difluorophenoxy)cyclobutyl)carbamate



The title compound was synthesized following the procedure as described in Step 1.2, using *tert*-butyl ((1*r*,3*s*)-3-hydroxycyclobutyl)carbamate (150 mg, 0.80 mmol) and 3,5-difluorophenol [CAS No. 2713-34-0] (100 mg, 0.80 mmol). Crude product was purified by flash chromatography (8 g SiliCycle column, 0 – 10% EtOAc in Hexane elution) to provide *tert*-butyl ((1*r*,3*r*)-3-(3,5-difluorophenoxy)cyclobutyl)carbamate (120 mg, 50%). ¹H NMR (300 MHz, CDCl₃) δ 6.42 – 6.38 (m, 1H), 6.28 (dd, *J* = 9.0, 2.4 Hz, 2H), 4.73 – 4.69 (m, 1H), 4.32 – 4.26 (m, 1H), 2.58 – 2.51 (m, 2H), 2.41 – 2.34 (m, 2H), 1.45 (s, 9H).

Step 82.2: Synthesis of (1*r*,3*r*)-3-(3,5-difluorophenoxy)cyclobutan-1-amine, HCl




10

A round bottom flask was charge with *tert*-butyl ((1*r*,3*r*)-3-(3,5-difluorophenoxy)cyclobutyl)carbamate (120 mg, 0.40 mmol) and HCl solution (4M in 1,4-dioxane) (2 mL), and stirred at rt for 1 h. Then the reaction mixture was concentrated in *vacuo*. The residue was triturated with Et₂O, solid was filtered and dried to yield (1*r*,3*r*)-3-(3,5-difluorophenoxy)cyclobutan-1-amine, HCl (90 mg, 84%). ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.19 (brs, 3H), 6.86 – 6.79 (m, 1H), 6.59 (dd, *J* = 9.3, 2.4 Hz, 2H), 5.01 – 4.96 (m, 1H), 3.86 – 3.81 (m, 1H), 2.64 – 2.57 (m, 2H), 2.49 – 2.37 (m, 2H).

15

Step 82.3: Synthesis of (1*r*,3*r*)-3-(3,5-difluorophenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl



20


The title compound was synthesized following the procedure as described in Step 1.4, using (1*r*,3*r*)-3-(3,5-difluorophenoxy)cyclobutan-1-amine, HCl (70 mg, 0.29 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 46 mg, 0.26 mmol). The crude product was purified by prep-HPLC (Column: XBRIDGE C18 (150 mm X 19 mm), 5.0 μ; Mobile Phase: 0.1% HCO₂H in water and acetonitrile). To the isolated product, HCl solution (4M in 1,4-dioxane) (1 mL) was added, stirred at rt for 1 h, and then concentrated in *vacuo*. The residue was triturated with pentane and then lyophilized to provide (1*r*,3*r*)-3-(3,5-difluorophenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl (7 mg, 6%). MS (ESI+) [Method 6A]: *m/z* 359.1 (M+H); Rt 1.29 min. ¹H NMR (400 MHz, CD₃OD) δ 9.83 (s, 1H), 8.80 – 8.78 (m, 1H), 8.76 – 8.72 (m, 2H), 8.01

25

(t, $J = 8.8$ Hz, 1H), 6.61 – 6.56 (m, 1H), 6.52 – 6.49 (m, 2H), 5.03 – 4.99 (m, 1H), 4.83 (d, $J = 2.0$ Hz, 2H), 4.31 – 4.26 (m, 1H), 2.92 – 2.85 (m, 2H), 2.75 – 2.68 (m, 2H).


Example 83: Synthesis of (1*r*,3*r*)-*N*-((6-fluoroisoquinolin-5-yl)methyl)-3-(4-(pentafluoro- λ^6 -sulfaneyl)phenoxy)cyclobutan-1-amine, HCl

- 5 Step 83.1: Synthesis of *tert*-butyl ((1*r*,3*r*)-3-(4-(pentafluoro- λ^6 -sulfaneyl)phenoxy)cyclobutyl)carbamate




- The title compound was synthesized following the procedure as described in Step 1.2, using *tert*-butyl ((1*s*,3*s*)-3-hydroxycyclobutyl)carbamate (120 mg, 0.64 mmol) and 4-(pentafluorosulfaneyl)phenol [CAS No. 774-94-7] (150 mg, 0.68 mmol). Crude product was purified by flash chromatography (8 g SiliCycle column, 0 – 10% EtOAc in Hexane elution) to provide *tert*-butyl ((1*r*,3*r*)-3-(4-(pentafluoro- λ^6 -sulfaneyl)phenoxy)cyclobutyl)carbamate as a yellowish gummy oil (150 mg, 67%). ¹H NMR (600 MHz, CDCl₃) δ 7.65 (d, $J = 8.4$ Hz, 2H), 6.77 (d, $J = 8.4$ Hz, 2H), 4.82 – 4.78 (m, 1H), 4.33 – 4.28 (m, 1H), 2.58 – 2.53 (m, 2H), 2.43 – 2.38 (m, 2H), 1.45 (s, 9H).

Step 83.2: Synthesis of (1*r*,3*r*)-3-(4-(pentafluoro- λ^6 -sulfaneyl)phenoxy)cyclobutan-1-amine, HCl



- A round bottom flask was charge with *tert*-butyl ((1*r*,3*r*)-3-(4-(pentafluoro- λ^6 -sulfaneyl)phenoxy)cyclobutyl)carbamate (150 mg, 0.39 mmol) and HCl solution (4M in 1,4-dioxane) (2 mL), and stirred at rt for 1 h. Then the reaction mixture was concentrated in *vacuo*. The residue was triturated with Et₂O, solid was filtered and dried to yield (1*r*,3*r*)-3-(4-(pentafluoro- λ^6 -sulfaneyl)phenoxy)cyclobutan-1-amine, HCl (110 mg, 96%). ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.20 (brs, 3H), 7.84 (d, $J = 9.3$ Hz, 2H), 6.97 (d, $J = 9.0$ Hz, 2H), 5.08 – 5.03 (m, 1H), 3.88 – 3.82 (m, 1H), 2.65 – 2.57 (m, 2H), 2.49 – 2.43 (m, 2H).

- 25 Step 83.3: Synthesis of (1*r*,3*r*)-*N*-((6-fluoroisoquinolin-5-yl)methyl)-3-(4-(pentafluoro- λ^6 -sulfaneyl)phenoxy)cyclobutan-1-amine, HCl




- The title compound was synthesized following the procedure as described in step 1.4, using (1*r*,3*r*)-3-(4-(pentafluoro- λ^6 -sulfaneyl)phenoxy)cyclobutan-1-amine, HCl (70 mg, 0.21 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 32 mg, 0.18 mmol). The crude product was purified by prep-HPLC (Column: GEMINI-NX (150 mm X 21.2 mm), 5.0 μ ; Mobile Phase: 0.02% NH₄OH in water and acetonitrile). To the isolated product, HCl solution (4M in 1,4-dioxane) (1 mL)

was added, stirred at rt for 1 h, and then concentrated in *vacuo*. The residue was triturated with pentane and then lyophilized to provide (1*r*,3*r*)-*N*-((6-fluoroisoquinolin-5-yl)methyl)-3-(4-(pentafluoro- λ^6 -sulfaneyl)phenoxy)cyclobutan-1-amine, HCl (30 mg, 28%). MS (ESI+) [Method 6A]: *m/z* 449.1 (M+H); Rt 1.34 min. ¹H NMR (400 MHz, CD₃OD) δ 9.78 (s, 1H), 8.77 (d, *J* = 6.8 Hz, 1H), 8.73 – 8.66 (m, 2H), 7.97 (t, *J* = 8.8 Hz, 1H), 7.78 (d, *J* = 9.6 Hz, 2H), 6.98 (d, *J* = 8.8 Hz, 2H), 5.11 – 5.06 (m, 1H), 4.82 (d, *J* = 1.6 Hz, 2H), 4.33 – 4.25 (m, 1H), 2.93 – 2.86 (m, 2H), 2.76 – 2.69 (m, 2H).


Example 84: Synthesis of (1*r*,3*r*)-3-(3,5-dimethylphenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl

10 Step 84.1: Synthesis of *tert*-butyl ((1*r*,3*r*)-3-(3,5-dimethylphenoxy)cyclobutyl)carbamate




The title compound was synthesized following the procedure as described in Step 1.2, using *tert*-butyl ((1*s*,3*s*)-3-hydroxycyclobutyl)carbamate (150 mg, 0.80 mmol) and 3,5-dimethylphenol [CAS No. 108-68-9] (108 mg, 0.88 mmol). Crude product was purified by flash chromatography (12 g SiliCycle column, 0 – 10% EtOAc in Hexane elution) to provide *tert*-butyl ((1*r*,3*r*)-3-(3,5-dimethylphenoxy)cyclobutyl)carbamate (140 mg, 60%). ¹H NMR (400 MHz, CDCl₃) δ 6.59 (s, 1H), 6.46 (s, 1H), 6.39 (s, 1H), 4.77 – 4.72 (m, 1H), 4.39 – 4.33 (m, 1H), 2.57 – 2.51 (m, 2H), 2.38 – 2.31 (m, 2H), 2.27 (s, 6H), 1.45 (s, 9H).

Step 84.2: Synthesis of (1*r*,3*r*)-3-(3,5-dimethylphenoxy)cyclobutan-1-amine, HCl



20 A round bottom flask was charged with *tert*-butyl ((1*r*,3*r*)-3-(3,5-dimethylphenoxy)cyclobutyl)carbamate (140 mg, 0.48 mmol) and HCl solution (4M in 1,4-dioxane) (3 mL), and stirred at rt for 16 h. Then the reaction mixture was concentrated in *vacuo*. The residue was triturated with Et₂O, solid was filtered and dried to yield (1*r*,3*r*)-3-(3,5-dimethylphenoxy)cyclobutan-1-amine, HCl (72 mg, 66%). ¹H NMR (600 MHz, CDCl₃) δ 8.65 (brs, 3H), 6.57 (s, 1H), 6.38 (s, 2H), 5.03 – 5.00 (m, 1H), 4.09 – 4.04 (m, 1H), 2.87 – 2.82 (m, 2H), 2.67 – 2.62 (m, 2H), 2.24 (s, 6H).

Step 84.3: Synthesis of (1*r*,3*r*)-3-(3,5-dimethylphenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl




The title compound was synthesized following the procedure as described in Step 1.4, using (1*r*,3*r*)-3-(3,5-dimethylphenoxy)cyclobutan-1-amine, HCl (75 mg, 0.31 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 49 mg, 0.28 mmol). The crude product was purified by prep-HPLC (Column: LUNA C18 (250 mm X 21.2 mm), 5.0 μ ; Mobile Phase: 0.1% HCO₂H in water and acetonitrile). To the isolated product, HCl solution (4M in 1,4-dioxane) (1 mL) was added, stirred at rt for 1 h, and then concentrated to provide (1*r*,3*r*)-3-(3,5-dimethylphenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl (25 mg, 23%). MS (ESI+) [Method 1A]: *m/z* 351.1 (M+H); Rt 0.21 min. ¹H NMR (400 MHz, CD₃OD) δ 9.74 (s, 1H), 8.77 (d, *J* = 6.0 Hz, 1H), 8.79 – 8.75 (m, 1H), 8.59 (d, *J* = 6.8 Hz, 1H), 7.95 (t, *J* = 9.2 Hz, 1H), 6.34 (s, 1H), 6.45 (s, 2H), 4.97 – 4.93 (m, 1H), 4.81 (d, *J* = 2.0 Hz, 2H), 4.27 – 4.23 (m, 1H), 2.82 – 2.77 (m, 2H), 2.71 – 2.66 (m, 2H), 2.27 (s, 6H).

Example 85: Synthesis of (1*r*,3*r*)-3-(4-cyclopropylphenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl


Step 85.1: Synthesis of *tert*-butyl ((1*r*,3*r*)-3-(4-cyclopropylphenoxy)cyclobutyl)carbamate

15




The title compound was synthesized following the procedure as described in Step 1.2, using *tert*-butyl ((1*s*,3*s*)-3-hydroxycyclobutyl)carbamate (300 mg, 1.60 mmol) 4-cyclopropylphenol [CAS No. 10292-61-2] (200 mg, 1.49 mmol). Crude product was purified by flash chromatography (12 g SiliCycle column, 0 – 10% EtOAc in Hexane elution) to provide *tert*-butyl ((1*r*,3*r*)-3-(4-cyclopropylphenoxy)cyclobutyl)carbamate (80 mg, 17%). ¹H NMR (400 MHz, CDCl₃) δ 6.97 (d, *J* = 9.0 Hz, 2H), 6.67 (d, *J* = 9.0 Hz, 2H), 4.76 – 4.71 (m, 1H), 4.28 – 4.22 (m, 1H), 2.57 – 2.49 (m, 2H), 2.37 – 2.31 (m, 2H), 1.85 – 1.82 (m, 1H), 1.45 (s, 9H), 0.90 – 0.86 (m, 2H), 0.61 – 0.58 (m, 2H).

25



A round bottom flask was charged with *tert*-butyl ((1*r*,3*r*)-3-(4-cyclopropylphenoxy)cyclobutyl)carbamate (80 mg, 0.34 mmol) and HCl solution (4M in 1,4-dioxane) (2 mL), and stirred at rt for 1 h. Then the reaction mixture was concentrated in *vacuo*. The residue was triturated with Et₂O, solid was filtered and dried to yield (1*r*,3*r*)-3-(4-cyclopropylphenoxy)cyclobutan-1-amine, HCl (60 mg, 96%). ¹H NMR (400 MHz, CDCl₃) δ 8.28 (brs, 3H), 6.99 (d, *J* = 8.4 Hz, 2H), 6.68 (d, *J* = 8.4 Hz, 2H), 4.97 – 4.93 (m, 1H), 3.82 – 3.77 (m, 1H), 2.59 – 2.50 (m, 2H), 2.41 – 2.35 (m, 2H), 1.87 – 1.80 (m, 1H), 0.88 – 0.85 (m, 2H), 0.57 – 0.55 (m, 2H).

Step 85.3: Synthesis of (1*r*,3*r*)-3-(4-cyclopropylphenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl




The title compound was synthesized following the procedure as described in Step 1.4, using (1*r*,3*r*)-3-(4-cyclopropylphenoxy)cyclobutan-1-amine, HCl (60 mg, 0.25 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 39 mg, 0.22 mmol). The crude product was purified by prep-HPLC (Column: GEMINI-NX (150 mm X 21.2 mm), 5.0 μ ; Mobile Phase: 0.02% NH₄OH in water and acetonitrile). To the isolated product, HCl solution (4M in 1,4-dioxane) (1 mL) was added, stirred at rt for 1 h, concentrated and then lyophilized to provide (1*r*,3*r*)-3-(4-cyclopropylphenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl (12 mg, 15%). MS (ESI+) [Method 1A]: *m/z* 363.2 (M+H); Rt 1.31 min. ¹H NMR (400 MHz, CD₃OD) δ 9.88 (brs, 1H), 8.77 – 8.74 (m, 3H), 8.01 (t, *J* = 9.2 Hz, 1H), 7.01 (d, *J* = 8.4 Hz, 2H), 6.72 (d, *J* = 8.4 Hz, 2H), 4.97 – 4.93 (m, 1H), 4.83 (s, 2H), 4.27 – 4.23 (m, 1H), 2.86 – 2.79 (m, 2H), 2.70 – 2.64 (m, 2H), 1.89 – 1.82 (m, 1H), 0.92 – 0.88 (m, 2H), 0.60 – 0.56 (m, 2H).

Example 86: Synthesis of 4-((1*r*,3*r*)-3-(((6-fluoroisoquinolin-5-yl)methyl)amino)cyclobutoxy)-2-(trifluoromethyl)benzonitrile, HCl

Step 86.1: Synthesis of

tert-butyl ((1*r*,3*r*)-3-(4-cyano-3-(trifluoromethyl)phenoxy)cyclobutyl)carbamate




20

To the stirred solution of tert-butyl ((1*r*,3*r*)-3-hydroxycyclobutyl)carbamate (200 mg, 1.07 mmol) in anhydrous DMF (2 mL), NaH (60% on oil) (39 mg, 1.60 mmol) was added at 0 °C, followed by 4-fluoro-2-(trifluoromethyl)benzonitrile [CAS No. 194853-86-6] (303 mg, 1.60 mmol). The reaction mixture was stirred at rt for 16 h under N₂. The reaction was quenched with water and extracted with EtOAc twice. The combined organic portion was washed with brine solution, dried over anhydrous Na₂SO₄, filtered and concentrated in vacuo. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 20% EtOAc in Hexane elution) to afford tert-butyl ((1*r*,3*r*)-3-(4-cyano-3-(trifluoromethyl)phenoxy)cyclobutyl)carbamate as white solid (413 mg, 108%). ¹H NMR (300 MHz, CDCl₃) δ 7.73 (d, *J* = 8.1 Hz, 1H), 7.15 (d, *J* = 3.0 Hz, 1H), 6.96 (dd, *J* = 9.0, 2.4 Hz, 1H), 4.89 – 4.85 (m, 1H), 4.33 – 4.28 (m, 1H), 2.62 – 2.54 (m, 2H), 2.53 – 2.45 (m, 2H), 1.45 (s, 9H).


30

Step 86.2: Synthesis of 4-((1*r*,3*r*)-3-(4-cyano-3-(trifluoromethyl)phenoxy)cyclobutoxy)-2-(trifluoromethyl)benzonitrile, HCl [C-07711-069]




The solution of *tert*-butyl ((1*r*,3*r*)-3-(4-cyano-3-(trifluoromethyl)phenoxy)cyclobutyl)carbamate (413 mg, 1.16 mmol) and HCl (4M in 1,4-dioxane) (5 mL) was stirred at rt for 16 h. Then the reaction mixture was concentrated in *vacuo*. The residue was triturated with Et₂O, solid was filtered and dried to yield 4-((1*r*,3*r*)-3-(4-cyano-3-(trifluoromethyl)phenoxy)cyclobutoxy)-2-(trifluoromethyl)benzonitrile, HCl as white solid (330 mg, 97%). MS (ESI+) [Method 6A]: *m/z* 257.1 (M+H); Rt 1.27 min.

Step 86.3: Synthesis of 4-((1*r*,3*r*)-3-(((6-fluoroisoquinolin-5-yl)methyl)amino)cyclobutoxy)-2-(trifluoromethyl)benzonitrile, HCl



The title compound was synthesized following the procedure as described in Step 25.6, using 4-((1*r*,3*r*)-3-(4-cyano-3-(trifluoromethyl)phenoxy)cyclobutoxy)-2-(trifluoromethyl)benzonitrile, HCl (70 mg, 0.24 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 39 mg, 0.22 mmol). The crude product was purified by prep-HPLC (Column: ZORBAX C18 (150 mm X 21.2 mm), 5.0 μ; Mobile Phase: 10 mM NH₄OAc in water and acetonitrile). To the isolated product, HCl solution (4M in 1,4-dioxane) (1 mL) was added, stirred at rt for 1 h, concentrated to provide 4-((1*r*,3*r*)-3-(((6-fluoroisoquinolin-5-yl)methyl)amino)cyclobutoxy)-2-(trifluoromethyl)benzonitrile, HCl (38 mg, 35%). MS (ESI+) [Method 6A]: *m/z* 416.2 (M+H); Rt 1.31 min. ¹H NMR (400 MHz, CD₃OD) δ 9.80 (brs, 1H), 8.79 (d, *J* = 6.8 Hz, 1H), 8.75 – 8.68 (m, 2H), 8.01 – 7.96 (m, 2H), 7.37 (s, 1H), 7.25 (d, *J* = 8.0 Hz, 1H), 5.21 – 5.17 (m, 1H), 4.84 (s, 2H), 4.34 – 4.30 (m, 1H), 2.97 – 2.92 (m, 2H), 2.81 – 2.75 (m, 2H).


Example 87: Synthesis of (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-*N*-(quinazolin-8-ylmethyl)cyclobutan-1-amine, HCl



- The title compound was synthesized following the procedure as described in Step 1.4, using (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl (Step 1.3, 60 mg, 0.21 mmol) and quinazoline-8-carbaldehyde [CAS No. 1823899-37-1] (39 mg, 0.22 mmol). The crude product was purified by prep-HPLC (Column: Gemini-NX (150 mm X 21.2 mm), 5.0 μ ; Mobile Phase: 0.01% NH₄OH in water and acetonitrile). To the isolated product, HCl solution (20% in 1,4-dioxane) (0.5 mL) was added, stirred at rt for 1 h. The solution was concentrated, residue was triturated with Et₂O, the solid was collected and dried to provide (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-*N*-(quinazolin-8-ylmethyl)cyclobutan-1-amine, HCl (28 mg, 31%). MS (ESI+) [Method 6A]: *m/z* 392.3 (M+H); Rt 1.33 min. ¹H NMR (400 MHz, CD₃OD) δ 9.54 (s, 1H), 9.32 (s, 1H), 8.08 (dd, *J* = 8.0, 1.6 Hz, 1H), 8.04 (d, *J* = 6.8 Hz, 1H), 7.56 (dd, *J* = 8.0, 7.2 Hz, 1H), 7.24 (t, *J* = 9.6 Hz, 1H), 7.08 – 7.03 (m, 2H), 4.89 – 4.85 (m, 1H), 4.32 (s, 2H), 3.64 – 3.59 (m, 1H), 2.39 – 2.34 (m, 4H).


Example 88: Synthesis of (1*r*,3*r*)-3-(3-cyclopropylphenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl

- 15 Step 88.1: Synthesis of (3-bromophenoxy)(*tert*-butyl)dimethylsilane



- To the stirred solution of 3-bromophenol [CAS No. 591-20-8] (1.0 g, 5.82 mmol) in CH₂Cl₂ (20 mL), imidazole (1.2 g, 17.44 mmol) was added at rt and stirred for 15 min. Reaction mixture was cooled to 0 °C, TBDMS-Cl (2.0 g, 14.53 mmol) was added and stirred at rt for 16 h under N₂. Reaction mixture was diluted with water and extracted with ethyl acetate 3x's. The combined organic portion was washed with brine solution, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 20% EtOAc in Hexane elution) to afford (3-bromophenoxy)(*tert*-butyl)dimethylsilane (1.6 g, 96%). ¹H NMR (300 MHz, CD₃OD) δ 7.18 – 7.08 (m, 2H), 6.99 (s, 1H), 6.83 – 6.80 (m, 1H), 0.99 (s, 9H), 0.21 (s, 6H).


Step 88.2: Synthesis of *tert*-butyl(3-cyclopropylphenoxy)dimethylsilane



- The stirred solution of (3-bromophenoxy)(*tert*-butyl)dimethylsilane (1.6 g, 5.59 mmol), cyclopropyl boronic acid (0.96 g, 11.18 mmol) and K₃PO₄ (2.4 g, 11.18 mmol) in toluene (20 mL) was purged with N₂ for 10 min. Then Pd(OAc)₂ (120 mg, 0.56 mmol) and tricyclohexylphosphine (156 mg, 0.56 mmol) were added, and the reaction mixture was heated at 120 °C for 16 h under N₂. The reaction mixture was cooled to rt, filtered through a celite bed and the bed was thoroughly washed with EtOAc. The combined filtrate was concentrated in *vacuo* to afford crude *tert*-butyl(3-cyclopropylphenoxy)dimethylsilane (1.2 g, 86%). ¹H NMR (400 MHz, CD₃OD) δ 7.10 (t, *J* = 8.0


Hz, 1H), 6.69 (d, $J = 7.2$ Hz, 1H), 6.63 – 6.60 (m, 1H), 6.54 (t, $J = 2.0$ Hz, 1H), 1.88 – 1.83 (m, 1H), 1.01 (s, 9H), 0.98 – 0.93 (m, 2H), 0.66 – 0.62 (m, 2H), 0.20 (s, 6H).

Step 88.3: Synthesis of 3-cyclopropylphenol




- 5 To the solution of *tert*-butyl(3-cyclopropylphenoxy)dimethylsilane (1.2 g, 4.84 mmol), in THF (8 mL), TBAF (1M in THF) (4.8 mL, 4.84 mmol) was added drop wise at 0 °C and the stirred at rt for 1 h. Reaction was quenched with saturated NH₄Cl solution and extracted with EtOAc 3x's. The combined organic portion was washed with brine solution and dried over anhydrous Na₂SO₄, filtered and then concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 20% EtOAc in Hexane elution) to afford 3-cyclopropylphenol (0.6 g, 92%).
- 10 ¹H NMR (300 MHz, CD₃OD) δ 7.01 (t, $J = 8.1$ Hz, 1H), 6.55 – 6.47 (m, 2H), 6.47 – 6.46 (m, 1H), 1.83 – 1.77 (m, 1H), 0.92 – 0.88 (m, 2H), 0.64 – 0.58 (m, 2H).

Step 88.4: Synthesis of *tert*-butyl ((1*r*,3*r*)-3-(3-cyclopropylphenoxy)cyclobutyl)carbamate




- 15 The title compound was synthesized following the procedure as described in Step 1.2, using *tert*-butyl ((1*s*,3*s*)-3-hydroxycyclobutyl)carbamate (500 mg, 2.67 mmol) 3-cyclopropylphenol (360 mg, 2.67 mmol). Crude product was purified by flash chromatography (12 g SiliCycle column, 0 – 35% EtOAc in Hexane elution) to provide *tert*-butyl ((1*r*,3*r*)-3-(3-cyclopropylphenoxy)cyclobutyl)carbamate (200 mg, 25%). ¹H NMR (300 MHz, CDCl₃) δ 7.02 – 6.99 (m, 1H), 6.54 – 6.47 (m, 3H), 4.88 – 4.84 (m, 1H), 4.20 – 4.15 (m, 1H), 2.43 – 2.35 (m, 4H), 1.44 (s, 9H), 1.83 – 1.77 (m, 1H), 0.93 – 0.88 (m, 2H), 0.64 – 0.60 (m, 2H).
- 20

Step 88.5: Synthesis of (1*r*,3*r*)-3-(3-cyclopropylphenoxy)cyclobutan-1-amine, HCl



- The solution of *tert*-butyl ((1*r*,3*r*)-3-(3-cyclopropylphenoxy)cyclobutyl)carbamate (200 mg, 0.66 mmol) and HCl (4M in 1,4-dioxane) (3 mL) was stirred at rt for 2 h. Then the reaction mixture was concentrated in *vacuo*. The residue was triturated with Et₂O, solid was filtered and dried to yield (1*r*,3*r*)-3-(3-cyclopropylphenoxy)cyclobutan-1-amine, HCl (70 mg, 44%). ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.32 (brs, 3H), 7.14 (t, $J = 8.1$ Hz, 1H), 6.66 (d, $J = 8.1$ Hz, 1H), 6.54 (d, $J = 8.1$ Hz, 1H), 6.49 (s, 1H), 5.01 – 4.96 (m, 1H), 3.82 – 3.78 (m, 1H), 2.62 – 2.51 (m, 2H), 2.44 – 2.36 (m, 2H), 1.90 – 1.84 (m, 1H), 0.94 – 0.91 (m, 2H), 0.66 – 0.63 (m, 2H).
- 25
- 30

Step 88.6: Synthesis of (1*r*,3*r*)-3-(3-cyclopropylphenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl




The title compound was synthesized following the procedure as described in Step 1.4, using (1*r*,3*r*)-3-(3-cyclopropylphenoxy)cyclobutan-1-amine, HCl (60 mg, 0.25 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 40 mg, 0.23 mmol). The crude product was purified by prep-HPLC (Column: KINETEX EVO C18 (150 mm X 21.2 mm), 5.0 μ ; Mobile Phase: 0.02% NH₄OH in water and acetonitrile). To the isolated product, HCl solution (20% in 1,4-dioxane) (2 mL) was added, stirred at rt for 1 h. The solution was concentrated, the residue was triturated with Et₂O, the solid was collected and dried to provide (1*r*,3*r*)-3-(3-cyclopropylphenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl (30 mg, 33%). MS (ESI+) [Method 6A]: *m/z* 363.2 (M+H); Rt 1.30 min. ¹H NMR (400 MHz, CD₃OD) δ 9.87 (s, 1H), 8.79 – 8.74 (m, 3H), 8.02 (t, *J* = 9.6 Hz, 1H), 7.14 (t, *J* = 8.0 Hz, 1H), 6.68 (d, *J* = 7.6 Hz, 1H), 6.60 – 6.57 (m, 1H), 6.55 – 6.54 (m, 1H), 5.00 – 4.96 (m, 1H), 4.83 (d, *J* = 2.0 Hz, 2H), 4.28 – 4.24 (m, 1H), 2.88 – 2.81 (m, 2H), 2.71 – 2.64 (m, 2H), 1.90 – 1.85 (m, 1H), 0.98 – 0.94 (m, 2H), 0.67 – 0.63 (m, 2H).

Example 89: Synthesis of (6-fluoro-5-(((1*s*,3*s*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)methanol, HCl


Step 89.1: Synthesis of

tert-butyl ((1*s*,3*s*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)carbamate




The title compound was synthesized following the procedure as described in Step 1.2, using *tert*-butyl ((1*r*,3*r*)-3-hydroxycyclobutyl)carbamate [CAS No. 389890-42-0] (0.5 g, 2.67 mmol) and 4-fluoro-3-(trifluoromethyl)phenol [CAS No. 61721-07-1] (0.52 g, 2.94 mmol). The reaction mixture was concentrated and the residue was purified by flash chromatography (12 g SiliCycle column, 0 – 10% EtOAc in Hexane elution) to provide *tert*-butyl ((1*s*,3*s*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)carbamate as pale yellow gummy mass (0.6 g, 64%). ¹H NMR (300 MHz, CDCl₃) δ 7.09 (t, *J* = 9.3 Hz, 1H), 6.99 – 6.96 (m, 1H), 6.94 – 6.89 (m, 1H), 4.74 – 4.69 (m, 1H), 3.93 – 3.87 (m, 1H), 2.99 – 2.92 (m, 2H), 2.05 – 1.96 (m, 2H), 1.44 (s, 9H).

Step 89.2: Synthesis of (1*s*,3*s*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl




A round bottom flask was charge with *tert*-butyl ((1*s*,3*s*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)carbamate (0.6 g, 1.72 mmol) and HCl solution (4M in 1,4-dioxane) (10 mL), and stirred at rt for 16 h. Then the reaction mixture was concentrated in *vacuo*. The residue was triturated with pentane, the solid appeared was filtered and dried to yield (1*s*,3*s*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl as pale yellow solid (0.45 g, 92%). LCMS [Method 4A]: *m/z* 250.0 [M+H]⁺; Rt 0.98 min. ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.35 (brs, 3H), 7.46 (t, *J* = 9.0 Hz, 1H), 7.25 – 7.20 (m, 1H), 7.16 – 7.13 (m, 1H), 4.62 – 4.56 (m, 1H), 3.42 – 3.37 (m, 1H), 2.88 – 2.79 (m, 2H), 2.28 – 2.18 (m, 2H).

Step 89.3: Synthesis of (1*s*,3*s*)-*N*-((8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinolin-5-yl)methyl)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine



The title compound was synthesized following the procedure as described in Step 1.4, using (1*s*,3*s*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl (150 mg, 0.53 mmol) and 8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinoline-5-carbaldehyde (150 mg, 0.47 mmol). The crude product was purified by flash chromatography (12 g SiliCycle column, 0 – 5% MeOH in CHCl₃ elution) to provide (1*s*,3*s*)-*N*-((8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinolin-5-yl)methyl)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine as yellowish gummy mass (200 mg, 69%). MS (ESI+) [Method 6A]: *m/z* 553.3 (M+H); Rt 1.42 min.

Step 89.4: Synthesis of (6-fluoro-5-(((1*s*,3*s*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)methanol, HCl




Deprotection was carried out according to Step 8.5. The residue was purified by prep-HPLC (Column: KINETEX EVO (150 mm x 21.2 mm), 5.0 μ ; Mobile Phase: 0.02% NH₄OH in water and acetonitrile). To the isolated product, HCl solution (20% in 1,4-dioxane) (4 mL) was added and stirred at rt for 1 h, concentrated in *vacuo*, triturated with Et₂O-Pentane, collected solid was dried to provide (6-fluoro-5-(((1*s*,3*s*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)methanol, HCl as white solid (50 mg, 29%). MS (ESI+) [Method 4A]: *m/z* 439.2 (M+H); Rt 1.46 min. ¹H NMR (400 MHz, CD₃OD) δ 9.95 (s, 1H), 8.84 (d, *J* = 6.8 Hz, 1H), 8.79 (d, *J* = 7.2 Hz, 1H), 8.03 (d, *J* = 10.4 Hz, 1H), 7.27

(t, $J = 9.2$ Hz, 1H), 7.17 – 7.11 (m, 2H), 5.31 (d, $J = 0.4$ Hz, 2H), 4.82 (d, $J = 1.6$ Hz, 2H), 4.73 – 4.68 (m, 1H), 3.89 – 3.83 (m, 1H), 3.15 – 3.10 (m, 2H), 2.49 – 2.43 (m, 2H).


Example 90: Synthesis of (6-fluoro-5-(((1*r*,3*r*)-3-((2-(trifluoromethyl)pyridin-4-yl)oxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)methanol

- 5 Step 90.1: Synthesis of (1*r*,3*r*)-N-((8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinolin-5-yl)methyl)-3-((2-(trifluoromethyl)pyridin-4-yl)oxy)cyclobutan-1-amine



The title compound was synthesized following the procedure as described in Step 1.4, using (1*r*,3*r*)-3-((2-(trifluoromethyl)pyridin-4-yl)oxy)cyclobutan-1-amine, HCl (Step 16.2, 150 mg, 0.56 mmol) and 8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinoline-5-carbaldehyde (Step 6.8, 140 mg, 0.45 mmol). The crude product was purified by flash chromatography (12 g SiliCycle column, 0 – 5% MeOH in CHCl₃ elution) to provide (1*r*,3*r*)-N-((8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinolin-5-yl)methyl)-3-((2-(trifluoromethyl)pyridin-4-yl)oxy)cyclobutan-1-amine (120 mg, 40%). MS (ESI+) [Method 6A]: m/z 536.23 (M+H); Rt 1.38 min.

Step 90.2: Synthesis of (6-fluoro-5-(((1*r*,3*r*)-3-((2-(trifluoromethyl)pyridin-4-yl)oxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)methanol, HCl




Deprotection was carried out according to Step 8.5. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 5% MeOH in CH₂Cl₂ elution), and then re-purified by prep-HPLC (Column: XBRIDGE (150 mm X 21.2 mm), 5.0 μ ; Mobile Phase: 0.02% NH₄OH in water and acetonitrile). To the isolated product, HCl solution (20% in 1,4-dioxane) (0.5 mL) was added, and stirred at rt for 1 h; then concentrated. The residue was triturated with Et₂O, solid was collected and dried to afford (6-fluoro-5-(((1*r*,3*r*)-3-((2-(trifluoromethyl)pyridin-4-yl)oxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)methanol, HCl (32 mg, 31%). MS (ESI+) [Method

6A]: m/z 422.1 (M+H); Rt 1.24 min. ^1H NMR (400 MHz, CD_3OD) δ 9.98 (s, 1H), 8.88 (d, $J = 7.2$ Hz, 1H), 8.81 (d, $J = 7.2$ Hz, 1H), 8.56 (d, $J = 5.6$ Hz, 1H), 8.06 (d, $J = 10.4$ Hz, 1H), 7.33 (d, $J = 2.4$ Hz, 1H), 7.15 (dd, $J = 6.0, 2.8$ Hz, 1H), 5.32 (s, 2H), 5.27 – 5.21 (m, 1H), 4.83 (s, 2H), 4.34 – 4.29 (m, 1H), 3.03 – 2.96 (m, 2H), 2.81 – 2.74 (m, 2H).


5 Example 91: Synthesis of (1*r*,3*r*)-3-(3-(difluoromethyl)-4-fluorophenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl

Step 91.1: Synthesis of 4-fluoro-3-formylphenyl benzoate




- To the solution of 2-fluoro-5-hydroxy benzaldehyde [CAS No. 103438-84-2] (750 mg, 5.35 mmol),
 10 TEA (1.62 g, 16.05 mmol) and DMAP (65 mg, 0.54 mmol) in anhydrous THF (50 mL), PhCOCl (1.0 g, 5.89 mmol) was added at rt and stirred for 16 h under N_2 . Then the reaction mixture was diluted with EtOAc and washed with water, aqueous 1M HCl solution and saturated NHCO_3 solution successively. The organic portion was collected, dried over anhydrous MgSO_4 , filtered and then concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 5% EtOAc in Hexane elution) to afford 4-fluoro-3-formylphenyl benzoate (1.0 g, 77%).
 15 ^1H NMR (600 MHz, CDCl_3) δ 10.37 (s, 1H), 8.19 (d, $J = 7.2$ Hz, 2H), 7.72 (dd, $J = 6.0, 3.0$ Hz, 1H), 7.67 (t, $J = 7.8$ Hz, 1H), 7.53 (t, $J = 8.4$ Hz, 2H), 7.49 – 7.47 (m, 1H), 7.26 (t, $J = 7.8$ Hz, 1H).

Step 91.2: Synthesis of 3-(difluoromethyl)-4-fluorophenyl benzoate




- 20 To the solution of 4-fluoro-3-formylphenyl benzoate (400 mg, 1.63 mmol) in anhydrous CH_2Cl_2 (50 mL), DAST (530 mg, 3.27 mmol) was added at 0 °C and stirred at rt for 16 h under N_2 . Then the reaction was quenched with saturated NaHCO_3 solution and extracted with EtOAc 3x's. The combined organic portion was washed with brine solution and dried over anhydrous Na_2SO_4 , filtered and then concentrated in *vacuo*. The residue was purified by flash chromatography (12 g
 25 SiliCycle column, 0 – 5% EtOAc in Hexane elution) to afford 3-(difluoromethyl)-4-fluorophenyl benzoate (300 mg, 69%). MS (ESI+) [Method 6A]: m/z 265.0 (M-H); Rt 1.61 min. ^1H NMR (600 MHz, CDCl_3) δ 8.20 (d, $J = 7.8$ Hz, 2H), 7.67 (d, $J = 7.8$ Hz, 1H), 7.53 (t, $J = 8.4$ Hz, 2H), 7.47 – 7.45 (m, 1H), 7.35 – 7.33 (m, 1H), 7.21 (t, $J = 9.0$ Hz, 1H), 6.91 (t, $J = 54.6$ Hz, 1H).

Step 91.3: Synthesis of 3-(difluoromethyl)-4-fluorophenol




To the solution of 3-(difluoromethyl)-4-fluorophenyl benzoate (300 mg, 1.12 mmol) in THF - MeOH (12 mL, 5:1 v/v), 3N NaOH solution (1.12 mL, 3.36 mmol) was added at rt and stirred for 6 h. Reaction mixture was concentrated to dryness, the residue was diluted with water and acidified with 2N HCl solution, and then extracted with EtOAc twice. The combined organic portion was washed with saturated NaHCO₃ solution and dried over anhydrous Na₂SO₄, filtered and then concentrated in *vacuo* to afford crude 3-(difluoromethyl)-4-fluorophenol (150 mg, 82%). ¹H NMR (400 MHz, CDCl₃) δ 7.04 – 6.99 (m, 2H), 6.92 – 6.88 (m, 1H), 6.83 (t, *J* = 55.6 Hz, 1H).

Step 91.4: Synthesis of *tert*-butyl ((1*r*,3*r*)-3-(3-(difluoromethyl)-4-fluorophenoxy)cyclobutyl)carbamate




To the solution of *tert*-butyl ((1*s*,3*s*)-3-hydroxycyclobutyl)carbamate (172 mg, 0.92 mmol) in THF (0.5 M), 3-(difluoromethyl)-4-fluorophenol (150 mg, 0.92 mmol), PPh₃ (1.5 eq) and diisopropyl azodicarboxylate (1.5 eq) were added at rt. The reaction mixture was stirred at 50 – 60 °C for 16 h under N₂ atmosphere. Reaction mixture was diluted with water and extracted with EtOAc 3x's. The combined organic portion was washed with brine solution, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. Crude was purified by flash chromatography (8 g SiliCycle column, 0 – 8% EtOAc in Hexane elution) to provide *tert*-butyl ((1*r*,3*r*)-3-(3-(difluoromethyl)-4-fluorophenoxy)cyclobutyl)carbamate (100 mg, 33%). ¹H NMR (400 MHz, CDCl₃) δ 7.03 (t, *J* = 9.2 Hz, 1H), 6.93 – 6.90 (m, 1H), 6.87 – 6.83 (m, 1H), 6.85 (t, *J* = 55.2 Hz, 1H), 4.79 – 4.73 (m, 1H), 4.32 – 4.27 (m, 1H), 2.58 – 2.51 (m, 2H), 2.41 – 2.35 (m, 2H), 1.45 (s, 9H).

Step 91.5: Synthesis of (1*r*,3*r*)-3-(3-(difluoromethyl)-4-fluorophenoxy)cyclobutan-1-amine, HCl



To the solution of *tert*-butyl ((1*r*,3*r*)-3-(3-(difluoromethyl)-4-fluorophenoxy)cyclobutyl)carbamate (100 mg, 0.30 mmol) in 1,4-dioxane (2 mL), 4M HCl solution (in 1,4-dioxane) (0.75 mL) was stirred at rt for 16 h. Then the reaction mixture was concentrated in *vacuo*. The residue was triturated with Et₂O, solid was filtered and dried to yield (1*r*,3*r*)-3-(3-(difluoromethyl)-4-fluorophenoxy)cyclobutan-1-amine, HCl (80 mg, 100%). MS (ESI+) [Method 6A]: *m/z* 232.1 (M+H); Rt 1.27 min. ¹H NMR (300 MHz, DMSO-*d*₆) δ 7.18 (t, *J* = 8.0 Hz, 1H), 7.01 – 6.98 (m, 2H), 6.96 (t, *J* = 55.6 Hz, 1H), 4.98 – 4.92 (m, 1H), 4.01 – 3.97 (m, 1H), 2.66 – 2.61 (m, 4H).


Step 91.6: Synthesis of (1*r*,3*r*)-3-(3-(difluoromethyl)-4-fluorophenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl



- 5 The title compound was synthesized following the procedure as described in Step 1.4, using (1*r*,3*r*)-3-(3-(difluoromethyl)-4-fluorophenoxy)cyclobutan-1-amine, HCl (80 mg, 0.30 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 53 mg, 0.30 mmol). The crude product was purified by prep-HPLC (Column: LUNA (250 mm X 21.2 mm), 5.0 μ ; Mobile Phase: 0.1% HCO₂H in water and acetonitrile). To the isolated product, HCl solution (20% in 1,4-dioxane) (2 mL) was added, stirred at rt for 1 h. The solution was concentrated, residue was triturated with Et₂O, the solid was collected and dried to provide (1*r*,3*r*)-3-(3-(difluoromethyl)-4-fluorophenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl (40 mg, 33%). MS (ESI+) [Method 1A]: *m/z* 391.0 (M+H); Rt 0.18 min. ¹H NMR (400 MHz, CD₃OD) δ 9.82 (s, 1H), 8.78 – 8.72 (m, 3H), 7.99 (t, *J* = 9.2 Hz, 1H), 7.18 (t, *J* = 10.0 Hz, 1H), 7.03 – 7.00 (m, 2H), 6.95 (t, *J* = 54.8 Hz, 1H), 5.03 – 4.99 (m, 1H), 4.82 (d, *J* = 2.0 Hz, 2H), 4.31 – 4.24 (m, 1H), 2.90 – 2.85 (m, 2H), 2.73 – 2.66 (m, 2H).

Example 92: Synthesis of (1*r*,3*r*)-*N*-((6-fluoroisoquinolin-5-yl)methyl)-3-((6-methoxy-5-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutan-1-amine, HCl


- Step 92.1: Synthesis of tert-butyl ((1*r*,3*r*)-3-((6-chloro-5-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutyl)carbamate



- A sealed tube was charged with 2-chloro-5-iodo-3-(trifluoromethyl)pyridine [CAS No. 887707-25-7] (1.0 g, 3.25 mmol), *tert*-butyl ((1*r*,3*r*)-3-hydroxycyclobutyl)carbamate (0.91 g, 4.88 mmol), Cs₂CO₃ (1.58 g, 4.88 mmol) and toluene (15 mL), and purged with N₂ for 10 min. Then CuI (31 mg, 0.16 mmol) and 3,4,7,8-tetramethyl-1,10-phenanthroline were added, purged with N₂, sealed tube was closed and stirred at 110 °C for 16 h. Reaction was cooled to rt, filtered through celite bed and the bed was washed with EtOAc. The filtrate was concentrated in *vacuo* and the residue was purified by flash chromatography (12 g SiliCycle column, 0 – 20% EtOAc in Hexane elution) to afford *tert*-butyl ((1*r*,3*r*)-3-((6-chloro-5-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutyl)carbamate as white liquid (0.2 g, 17%). MS (ESI+) [Method 6A]: *m/z* 366.8 (M+H); Rt 1.63 min. ¹H NMR (300


MHz, CDCl₃) δ 8.08 (d, J = 3.0 Hz, 1H), 7.40 (d, J = 3.0 Hz, 1H), 4.88 – 4.81 (m, 1H), 4.35 – 4.28 (m, 1H), 2.62 – 2.53 (m, 2H), 2.51 – 2.42 (m, 2H), 1.45 (s, 9H).

Step 92.2: Synthesis of (1*r*,3*r*)-3-((6-methoxy-5-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutan-1-amine




To the stirred solution of *tert*-butyl ((1*r*,3*r*)-3-((6-chloro-5-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutyl)carbamate (80 mg, 0.22 mmol) in anhydrous MeOH (5 mL), NaOMe (59 mg, 1.09 mmol) was added and heated at 70 °C for 16 h. The reaction mixture was concentrated in *vacuo*. Then the residue was diluted water and extracted 3x with EtOAc. The combined organic portion was washed with brine solution and dried over anhydrous Na₂SO₄, filtered and then concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 10% MeOH in CH₂Cl₂ elution) to afford (1*r*,3*r*)-3-((6-methoxy-5-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutan-1-amine (50 mg, 88%). MS (ESI+) [Method 6A]: m/z 263.1 (M+H); Rt 1.33 min.

Step 92.3: Synthesis of (1*r*,3*r*)-*N*-((6-fluoroisoquinolin-5-yl)methyl)-3-((6-methoxy-5-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutan-1-amine, HCl




The solution of (1*r*,3*r*)-3-((6-methoxy-5-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutan-1-amine (50 mg, 0.19 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (step 3.1, 30 mg, 0.17 mmol), catalytic AcOH was added, and stirred at rt for 16 h under argon. Then the reaction mixture was cooled to 0 °C, NaBH₄ (14 mg, 0.38 mmol) was added and stirred at rt for 2 h. Reaction mixture was diluted with water and extracted with EtOAc twice. The combined organic portion was washed with brine solution, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by prep-HPLC (Column: LUNA, (250 mm x 21.2 mm), 5.0 μ ; Mobile Phase: 0.1% HCO₂H in water and acetonitrile). To the isolated product HCl solution (20% in 1,4-dioxane) (0.5 mL) was added, stirred for 1 h and then concentrated. The residue was triturated with Et₂O, solid was collected and dried to afford (1*r*,3*r*)-*N*-((6-fluoroisoquinolin-5-yl)methyl)-3-((6-methoxy-5-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutan-1-amine, HCl (16 mg, 19%). MS (ESI+) [Method 6A]: m/z 422.2 (M+H); Rt 1.31 min. ¹H NMR (400 MHz, CD₃OD) δ 9.78 (s, 1H), 8.80 (s, 2H), 8.78 (dd, J = 9.2, 5.2 Hz, 1H), 8.03 (t, J = 9.2 Hz, 1H), 7.98 – 7.97 (m, 1H), 7.57 (d, J = 2.4 Hz, 1H), 5.03 – 4.99 (m, 1H), 4.85 (d, J = 2.0 Hz, 2H), 4.33 – 4.27 (m, 1H), 3.98 (s, 3H), 2.92 – 2.87 (m, 2H), 2.77 – 2.71 (m, 2H).


Example 93: Synthesis of (1*r*,3*r*)-3-(3-fluoro-4-(trifluoromethoxy)phenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl

Step 93.1: Synthesis of*tert*-butyl ((1*r*,3*r*)-3-(3-fluoro-4-(trifluoromethoxy)phenoxy)cyclobutyl)carbamate

To the solution of *tert*-butyl ((1*s*,3*s*)-3-hydroxycyclobutyl)carbamate (100 mg, 0.53 mmol) in THF (0.5 M), 3-fluoro-4-(trifluoromethoxy)phenol [CAS No. 177596-38-2] (100 mg, 0.53 mmol), PPh₃ (1.5 eq) and diisopropyl azodicarboxylate (1.5 eq) were added at rt. The reaction mixture was stirred at 50 – 60 °C for 16 h under N₂ atmosphere. Reaction mixture was diluted with water and extracted with EtOAc (3x's). The combined organic portion was washed with brine solution, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The crude product was purified by flash chromatography (12 g SiliCycle column, 0 – 20% EtOAc in Hexane elution) to provide *tert*-butyl ((1*r*,3*r*)-3-(3-fluoro-4-(trifluoromethoxy)phenoxy)cyclobutyl)carbamate (100 mg, 51%). ¹H NMR (300 MHz, CDCl₃) δ 7.15 (t, *J* = 8.7 Hz, 1H), 7.69 (dd, *J* = 11.1, 3.0 Hz, 1H), 6.62 – 6.58 (m, 1H), 4.77 – 4.69 (m, 1H), 4.33 – 4.27 (m, 1H), 2.60 – 2.51 (m, 2H), 2.43 – 2.35 (m, 2H), 1.45 (s, 9H).

15 Step 93.2: Synthesis of (1*r*,3*r*)-3-(3-fluoro-4-(trifluoromethoxy)phenoxy)cyclobutan-1-amine, HCl


A round bottom flask was charged with *tert*-butyl ((1*r*,3*r*)-3-(3-fluoro-4-(trifluoromethoxy)phenoxy)cyclobutyl)carbamate (100 mg, 0.27 mmol) and HCl solution (4M in 1,4-dioxane) (2 mL); and the solution was stirred rt for 4 h. Then the reaction mixture was concentrated in *vacuo*. The residue was triturated with Et₂O, solid was filtered and dried to yield (1*r*,3*r*)-3-(3-fluoro-4-(trifluoromethoxy)phenoxy)cyclobutan-1-amine, HCl (70 mg, 85%). MS (ESI+) [Method 6A]: *m/z* 265.9 (M+H); Rt 1.35 min. ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.12 (brs, 3H), 7.51 (t, *J* = 9.0 Hz, 1H), 7.00 (dd, *J* = 12.0, 3.0 Hz, 1H), 6.78 – 6.73 (m, 1H), 5.00 – 4.95 (m, 1H), 3.89 – 3.82 (m, 1H), 2.64 – 2.44 (m, 4H).

25 Step 93.3: Synthesis of (1*r*,3*r*)-3-(3-fluoro-4-(trifluoromethoxy)phenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl

The title compound was synthesized following the procedure as described in Step 1.4, using (1*r*,3*r*)-3-(3-fluoro-4-(trifluoromethoxy)phenoxy)cyclobutan-1-amine, HCl (70 mg, 0.23 mmol) and

6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 36 mg, 0.21 mmol). The crude product was purified by prep-HPLC (Column: WATERS X BRIDGE (150 mm X 21.2 mm), 5.0 μ ; Mobile Phase: 0.02% NH₄OH in water and acetonitrile). To the isolated product, HCl solution (4M in 1,4-dioxane) (1 mL) was added, stirred at rt for 1 h. The solution was concentrated, residue was triturated with Et₂O, the solid was collected and dried to provide (1*r*,3*r*)-3-(3-fluoro-4-(trifluoromethoxy)phenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl (8 mg, 8%). MS (ESI+) [Method 6A]: *m/z* 425.1 (M+H); Rt 1.36 min. ¹H NMR (600 MHz, CD₃OD) δ 9.58 (s, 1H), 8.71 (d, *J* = 6.0 Hz, 1H), 8.56 (dd, *J* = 9.6, 5.4 Hz, 1H), 8.39 (d, *J* = 6.6 Hz, 1H), 7.83 (t, *J* = 9.6 Hz, 1H), 7.35 (t, *J* = 9.0 Hz, 1H), 6.84 (dd, *J* = 12.0, 2.4 Hz, 1H), 6.72 (dq, *J* = 9.0, 1.2 Hz, 1H), 4.99 – 4.95 (m, 1H), 4.76 (s, 2H), 4.28 – 4.24 (m, 1H), 2.85 – 2.80 (m, 2H), 2.72 – 2.67 (m, 2H).


Example 94: Synthesis of (1*r*,3*r*)-*N*-((6-fluoroisoquinolin-5-yl)methyl)-3-((6-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutan-1-amine, HCl



The title compound was synthesized following the procedure as described in Step 1.4, using (1*r*,3*r*)-3-((6-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutan-1-amine, HCl (Step 2.2, 300 mg, 1.12 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 230 mg, 1.31 mmol). The crude product was purified by prep-HPLC (Column: GEMINI-NX (150 mm X 21.2 mm), 5.0 μ ; Mobile Phase: 0.02% NH₄OH in water and acetonitrile). To the isolated product, HCl solution (4M in 1,4-dioxane) (1 mL) was added, stirred at rt for 1 h. The solution was concentrated, and then lyophilized to provide (1*r*,3*r*)-*N*-((6-fluoroisoquinolin-5-yl)methyl)-3-((6-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutan-1-amine, HCl (180 mg, 17%). MS (ESI+) [Method 6A]: *m/z* 392.2 (M+H); Rt 1.27 min. ¹H NMR (600 MHz, CD₃OD) δ 9.88 (s, 1H), 8.83 – 8.75 (m, 3H), 8.33 (d, *J* = 2.8 Hz, 1H), 8.03 (t, *J* = 9.6 Hz, 1H), 7.77 (d, *J* = 9.2 Hz, 1H), 7.45 (dd, *J* = 9.2, 2.8 Hz, 1H), 5.20 – 5.16 (m, 1H), 4.84 (d, *J* = 2.0 Hz, 2H), 4.34 – 4.29 (m, 1H), 2.98 – 2.93 (m, 2H), 2.80 – 2.73 (m, 2H).

Example 95: Synthesis of (1*r*,3*r*)-*N*-((6-fluoroisoquinolin-5-yl)methyl)-3-((5-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutan-1-amine, HCl


Step 95.1: Synthesis of 3-(benzyloxy)-5-(trifluoromethyl)pyridine



The stirred solution of benzyl alcohol (2.0 g, 18.49 mmol) and 3-chloro-5-(trifluoromethyl)pyridine [CAS No. 85148-26-1] (3.69 g, 20.34 mmol) in DMF (40 mL) was cooled to 0 °C. Then NaH (60% on mineral oil) (0.96 g, 24.04 mmol) was added portion wise and the reaction mixture was heated at 40 °C for 2 h under argon atmosphere. The reaction was quenched with saturated NH₄Cl


solution and extracted with EtOAc twice. The combined organic layer was washed with water, then with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 30% EtOAc in Hexane elution) to afford 3-(benzyloxy)-5-(trifluoromethyl)pyridine (1.3 g, 28%). MS (ESI+) [Method 1A]: m/z 254.2 (M+H); Rt 2.56 min. ¹H NMR (300 MHz, CDCl₃) δ 8.59 – 8.51 (m, 1H), 7.46 – 7.28 (m, 7H), 4.53 (s, 2H).

Step 95.2: Synthesis of 5-(trifluoromethyl)pyridin-3-ol




To the stirred solution of 3-(benzyloxy)-5-(trifluoromethyl)pyridine (900 mg, 3.55 mmol) in EtOH (12 mL), Pd/C (10% w/w) (150 mg) was added under N₂. The flask was connected with H₂ balloon and the reaction mixture was stirred at rt for 2 h under H₂ atmosphere. The reaction mixture was filtered through celite bed, and the bed was thoroughly washed with EtOAc. The combined filtrate was concentrated in *vacuo* to provide crude 5-(trifluoromethyl)pyridin-3-ol (400 mg, 69%). MS (ESI+) [Method 6A]: m/z 163.9 (M+H); Rt 1.37 min.

Step 95.3: Synthesis of *tert*-butyl ((1*r*,3*r*)-3-((5-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutyl)carbamate




To the solution of *tert*-butyl ((1*s*,3*s*)-3-hydroxycyclobutyl)carbamate (300 mg, 1.60 mmol) in THF (0.5 M), 5-(trifluoromethyl)pyridin-3-ol (261 mg, 1.60 mmol), PPh₃ (1.5 eq) and diisopropyl azodicarboxylate (1.5 eq) were added at rt. The reaction mixture was stirred at 50 – 60 °C for 16 h under N₂ atmosphere. Reaction mixture was diluted with water and extracted with EtOAc (3x's). The combined organic portion was washed with brine solution, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The crude product was purified by flash chromatography (12 g SiliCycle column, 0 – 20% EtOAc in Hexane elution) to provide *tert*-butyl ((1*r*,3*r*)-3-((5-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutyl)carbamate (300 mg, 56%). MS (ESI+) [Method 6A]: m/z 332.9 (M+H); Rt 1.57 min.

Step 95.4: Synthesis of (1*r*,3*r*)-3-((5-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutan-1-amine, HCl



A round bottom flask was charged with *tert*-butyl ((1*r*,3*r*)-3-((5-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutyl)carbamate (100 mg, 0.30 mmol) and HCl solution (4M in 1,4-dioxane) (5 mL) and the solution was stirred rt for 16 h. Then the reaction mixture was concentrated in *vacuo*. The residue was triturated with *n*-pentane, solid was filtered and dried to yield (1*r*,3*r*)-3-((5-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutan-1-amine, HCl (80 mg, 99%). MS (ESI+) [Method 6A]: m/z 232.9 (M+H); Rt 1.22 min.


Step 95.5: Synthesis of (1*r*,3*r*)-*N*-((6-fluoroisoquinolin-5-yl)methyl)-3-((5-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutan-1-amine, HCl



The title compound was synthesized following the procedure as described in Step 1.4, using (1*r*,3*r*)-3-((5-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutan-1-amine, HCl (80 mg, 0.3 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 47 mg, 0.27 mmol). The crude product was purified by prep-HPLC (Column: YMC – ACUTUS – TRIART C18 (150 mm X 21.2 mm), 5.0 μ ; Mobile Phase: 0.02% NH₄OH in water and acetonitrile). To the isolated product, HCl solution (4M in 1,4-dioxane) (2 mL) was added, stirred at rt for 2 h. The solution was concentrated, residue was triturated with *n*-pentane, the solid was collected, dried and lyophilized to provide (1*r*,3*r*)-*N*-((6-fluoroisoquinolin-5-yl)methyl)-3-((5-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutan-1-amine, HCl (40 mg, 31%). MS (ESI+) [Method 6A]: *m/z* 392.1 (M+H); Rt 1.29 min. ¹H NMR (600 MHz, CD₃OD) δ 9.93 (s, 1H), 8.89 – 8.80 (m, 3H), 8.61 (s, 1H), 8.54 (s, 1H), 8.07 (t, *J* = 9.6 Hz, 1H), 7.71 (s, 1H), 5.26 – 5.22 (m, 1H), 4.67 (s, 2H), 4.38 – 4.32 (m, 1H), 4.36 (p, *J* = 8.0 Hz, 1H), 3.02 – 2.96 (m, 2H), 2.83 – 2.76 (m, 2H).


Example 96: Synthesis of (1*r*,3*r*)-3-(benzo[d]thiazol-2-yloxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl

Step 96.1: Synthesis of *tert*-butyl ((1*r*,3*r*)-3-(benzo[d]thiazol-2-yloxy)cyclobutyl)carbamate




To the solution of *tert*-butyl ((1*s*,3*s*)-3-hydroxycyclobutyl)carbamate (200 mg, 1.07 mmol) in THF (0.5 M), benzo[d]thiazol-2-ol [CAS No. 934-34-9] (160 mg, 1.07 mmol), PPh₃ (1.5 eq) and diisopropyl azodicarboxylate (1.5 eq) were added at rt. The reaction mixture was stirred at 50 – 60 °C for 16 h under N₂ atmosphere. Reaction mixture was diluted with water and extracted with EtOAc 3x's. The combined organic portion was washed with brine solution, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The crude product was purified by flash chromatography (12 g SiliCycle column, 0 – 25% EtOAc in Hexane elution) to provide *tert*-butyl ((1*r*,3*r*)-3-(benzo[d]thiazol-2-yloxy)cyclobutyl)carbamate (200 mg, 58%). MS (ESI+) [Method 6A]: *m/z* 321.1 (M+H); Rt 1.61 min. ¹H NMR (300 MHz, CDCl₃) δ 7.65 (t, *J* = 8.1 Hz, 2H), 7.35 (dt, *J* = 6.9, 1.2 Hz, 1H), 7.25 – 7.19 (m, 1H), 5.51 – 5.45 (m, 1H), 4.37 – 4.31 (m, 1H), 2.73 – 2.63 (m, 2H), 2.52 – 2.43 (m, 2H), 1.45 (s, 9H).

Step 96.2: Synthesis of (1*r*,3*r*)-3-(benzo[d]thiazol-2-yloxy)cyclobutan-1-amine, HCl



A round bottom flask was charged with *tert*-butyl ((1*r*,3*r*)-3-(benzo[d]thiazol-2-yloxy)cyclobutyl)carbamate (200 mg, 0.62 mmol) and HCl solution (4M in 1,4-dioxane) (10 mL) and the solution was stirred rt for 16 h. Then the reaction mixture was concentrated in *vacuo* to yield (1*r*,3*r*)-3-(benzo[d]thiazol-2-yloxy)cyclobutan-1-amine, HCl (130 mg, 81%). MS (ESI+) [Method 6A]: *m/z* 220.9 (M+H); Rt 1.28 min. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.41 (brs, 3H), 7.90 (d, *J* = 7.6 Hz, 1H), 7.67 (d, *J* = 7.6 Hz, 1H), 7.40 (t, *J* = 8.4 Hz, 1H), 7.31 (t, *J* = 8.4 Hz, 1H), 5.63 – 5.58 (m, 1H), 3.91 – 3.86 (m, 1H), 2.70 – 2.62 (m, 4H).


Step 96.3: Synthesis of (1*r*,3*r*)-3-(benzo[d]thiazol-2-yloxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl



The title compound was synthesized following the procedure as described in Step 1.4, using (1*r*,3*r*)-3-(benzo[d]thiazol-2-yloxy)cyclobutan-1-amine, HCl (70 mg, 0.27 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 43 mg, 0.25 mmol). The crude product was purified by prep-HPLC (Column: YMC – ACUTUS – TRIART C18 (150 mm X 21.2 mm), 5.0 μ; Mobile Phase: 0.02% NH₄OH in water and acetonitrile). To the isolated product, HCl solution (20% in 1,4-dioxane) (0.5 mL) was added, stirred at rt for 1 h. The solution was concentrated, residue was triturated with Et₂O, the solid was collected, dried in *vacuo* to provide (1*r*,3*r*)-3-(benzo[d]thiazol-2-yloxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl (26 mg, 25%). MS (ESI+) [Method 6A]: *m/z* 380.1 (M+H); Rt 1.29 min. ¹H NMR (600 MHz, CD₃OD) δ 9.26 (s, 1H), 8.55 (d, *J* = 6.4 Hz, 1H), 8.19 – 8.14 (m, 2H), 7.74 (d, *J* = 8.0 Hz, 1H), 6.62 (d, *J* = 8.0 Hz, 1H), 7.55 (t, *J* = 9.6 Hz, 1H), 7.38 (t, *J* = 8.0 Hz, 1H), 7.26 (t, *J* = 7.2 Hz, 1H), 5.47 – 5.43 (m, 1H), 4.22 (d, *J* = 1.6 Hz, 2H), 3.70 – 3.64 (m, 1H), 2.53 – 2.44 (m, 4H).

Example 97: Synthesis of (1*r*,3*r*)-*N*-((6-ethylisoquinolin-5-yl)methyl)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl

Step 97.1: Synthesis of 6-vinylisoquinoline




The stirred solution of 6-bromoisoquinoline [CAS No. 34784-05-9] (2.0 g, 9.70 mmol), tributyl(vinyl)stannane (3.5 g, 11.01 mmol) in 1,4-dioxane (20 mL) was degassed with N₂ for 10 min. Then Pd(PPh₃)₄ (0.8 g, 0.69 mmol) was added, degassed, reaction vessel was closed and

heated at 100°C for 16 h. Reaction mixture was cooled to rt, diluted with water and extracted with EtOAc 3x's. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The crude product was purified by flash chromatography (24 g SiliCycle column, 0 – 30% EtOAc in Hexane elution) to provide 6-vinylisoquinoline (1.5 g, 99%).


- 5 MS (ESI+) [Method 6A]: m/z 155.8 (M+H); Rt 1.12 min.

Step 97.2: Synthesis of 6-ethylisoquinoline




- A round bottom flask charged with 6-vinylisoquinoline (500 mg, 3.22 mmol) and EtOAc (5 mL). The solution was purged with N₂ for 10 min. Then Pd/C (10% w/w) (50 mg) was added, H₂ balloon was connected and the reaction mixture was stirred at rt for 1 h. Reaction mixture was filtered through celite bed, the bed was washed with EtOAc. The combined filtrate was concentrated in *vacuo* to afford crude 6-ethylisoquinoline (500 mg, 99%). ¹H NMR (600 MHz, CdCl₂) δ 9.19 (s, 1H), 8.48 (d, J = 6.0 Hz, 1H), 7.88 (d, J = 8.4 Hz, 1H), 7.60 – 7.58 (m, 2H), 7.47 (d, J = 8.4 Hz, 1H), 2.85 (q, J = 7.8 Hz, 2H), 1.34 (t, J = 7.8 Hz, 3H).

- 15 Step 97.3: Synthesis of 5-bromo-6-ethylisoquinoline



- A round bottom flask charged with 6-ethylisoquinoline (460 mg, 2.93 mmol) and AlCl₃ (780 mg, 5.85 mmol) was heated to 75 °C. Then Br₂ (0.1 mL, 5.85 mmol) was added drop wise over a period of 10 min and the resulting mixture was stirred at 75 °C for 2 h. The nearly black reaction mixture was poured into vigorously stirred ice – water. The cold mixture was treated with NH₄OH solution and extracted with EtOAc twice. The combined organic layer was washed with brine solution, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (8 g SiliCycle column, 0 – 30% EtOAc in Hexane elution) to provide 5-bromo-6-ethylisoquinoline (180 mg, 26%). MS (ESI+) [Method 6A]: m/z 235.9, 237.90 (M+H); Rt 1.48 min.


Step 97.4: Synthesis of 6-ethyl-5-vinylisoquinoline



- The stirred solution of 5-bromo-6-ethylisoquinoline (180 mg, 0.76 mmol), potassium trifluoro(vinyl)borate (204 mg, 1.52 mmol) and TEA (0.21 mL, 1.52 mmol) in IPA (5 mL) was degassed with argon for 5 min. Then Pd(dppf)Cl₂.CH₂Cl₂ (100 mg, 0.13 mmol) was added, degassed and heated at 90°C for 16 h under argon atmosphere. Reaction mixture was cooled to rt, filtered through celite bed and the bed was thoroughly washed with EtOAc. The combined filtrate was concentrated in *vacuo* and the residue was purified by flash chromatography (4 g

SiliCycle column, 0 – 30% EtOAc in Hexane elution) to provide 6-ethyl-5-vinylisoquinoline (120 mg, 86%). MS (ESI+) [Method 6A]: m/z 184.0 (M+H); Rt 1.31 min.


Step 97.5: Synthesis of 6-ethylisoquinoline-5-carbaldehyde



- 5 To the solution of 6-ethyl-5-vinylisoquinoline (120 mg, 0.65 mmol) in *t*-BuOH – 1,4-dioxane (8 mL, 1:3 v/v), OsO₄ (5 mg, 0.02 mmol) was added at rt and stirred for 15 min. Then NaIO₄ (700 mg, 3.27 mmol) dissolved in water (2 mL) was added drop wise at rt and stirred for 16 h. Reaction mixture was diluted with water and extracted with EtOAc 3x's. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo* to yield the
- 10 crude product. The crude was purified by flash chromatography (12 g SiliCycle column, 0 – 35% EtOAc in Hexane elution) to provide 6-ethylisoquinoline-5-carbaldehyde (120 mg, 59%). MS (ESI+) [Method 6A]: m/z 186.0 (M+H); Rt 1.24 min

Step 97.6: Synthesis of (1*r*,3*r*)-*N*-((6-ethylisoquinolin-5-yl)methyl)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl

15




- The title compound was synthesized following the procedure as described in Step 1.4, using (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl (Step 1.3, 100 mg, 0.35 mmol) and 6-ethylisoquinoline-5-carbaldehyde (58 mg, 0.32 mmol). The crude product was
- 20 purified by prep-HPLC (Column: GEMINI – NX (150 mm X 21.2 mm), 5.0 μ ; Mobile Phase: 0.02% NH₄OH in water and acetonitrile). To the isolated product, HCl solution (20% in 1,4-dioxane) (2 mL) was added, stirred at rt for 2 h. The solution was concentrated and the residue was triturated with *n*-Pentane, the solid was collected, and dried in *vacuo* to provide (1*r*,3*r*)-*N*-((6-ethylisoquinolin-5-yl)methyl)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl (70
- 25 mg, 44%). MS (ESI+) [Method 6A]: m/z 419.2 (M+H); Rt 1.34 min. ¹H NMR (400 MHz, CD₃OD) δ 9.83 (s, 1H), 8.77 (dd, J = 17.4, 6.4 Hz, 2H), 8.61 (d, J = 8.8 Hz, 1H), 8.13 (d, J = 8.4 Hz, 1H), 7.32 (t, J = 9.6 Hz, 1H), 7.19 – 7.13 (m, 2H), 5.11 – 5.06 (m, 1H), 4.86 (s, 2H), 4.46 – 4.40 (m, 1H), 3.20 (q, J = 7.2 Hz, 2H), 3.00 – 2.93 (m, 2H), 2.79 – 2.73 (m, 2H), 1.43 (t, J = 7.2 Hz, 3H).

Example 98: Synthesis of (1*r*,3*r*)-*N*-((3-chloroisoquinolin-5-yl)methyl)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl


30

Step 98.1: Synthesis of 5-bromo-3-chloroisoquinoline



The stirred solution of 3-chloroisoquinoline [CAS No. 19493-45-9] (1.0 g, 6.11 mmol) in H₂SO₄ (10.0 mL) was cooled to 0 °C. Then NBS (1.6 g, 9.17 mmol) was added portion wise and stirred for 4 h. The reaction was poured into ice – water, basified with aqueous NH₄OH solution and then
 5 extracted with EtOAc twice. The combined organic layer was washed with brine solution, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 10% EtOAc in Hexane elution) to provide 5-bromo-3-chloroisoquinoline (1.0 g, 67%). MS (ESI+) [Method 1A]: m/z 244.0 (M+H); Rt 1.88 min.


Step 98.2: Synthesis of 3-chloro-5-vinylisoquinoline



10


The title compound was prepared according to Step 97.4. The reaction mixture was heated at 90°C for 3 h under N₂. Reaction mixture was cooled to rt, diluted with water and extracted with EtOAc 3x's. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo* to yield the crude product. The crude was purified by flash
 15 chromatography (12 g SiliCycle column, 0 – 30% EtOAc in Hexane elution) to provide 3-chloro-5-vinylisoquinoline (233 mg, 60%). MS (ESI+) [Method 1A]: m/z 190.0 (M+H); Rt 1.83 min.

Step 98.3: Synthesis of 3-chloroisoquinoline-5-carbaldehyde



To the solution of 3-chloro-5-vinylisoquinoline (233 mg, 1.23 mmol) in *t*-BuOH – 1,4-dioxane (8
 20 mL, 3:5 v/v), OsO₄ (10 mg, 0.04 mmol) was added at rt and stirred for 15 min. Then NaIO₄ (1.3 g, 6.14 mmol) dissolved in water (3 mL) was added drop wise at rt and stirred for 16 h. Reaction mixture was diluted with water and extracted with EtOAc 3x's. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo* to yield the crude product. The crude was purified by flash chromatography (12 g SiliCycle column, 0 – 30%
 25 EtOAc in Hexane elution) to provide 3-chloroisoquinoline-5-carbaldehyde (97 mg, 41%). MS (ESI+) [Method 6A]: m/z 191.8 (M+H); Rt 1.46 min


Step 98.4: Synthesis of (1*r*,3*r*)-*N*-((3-chloroisoquinolin-5-yl)methyl)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl



The title compound was synthesized following the procedure as described in Step 1.4, using (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl (Step 1.3, 80 mg, 0.28 mmol) and 3-chloroisoquinoline-5-carbaldehyde (42 mg, 0.25 mmol). The crude product was purified by prep-HPLC (Column: KINETEX EVO C18 (150 mm X 21.2 mm), 5.0 μ ; Mobile Phase: 0.02% NH_4OH in water and acetonitrile). To the isolated product, HCl solution (20% in 1,4-dioxane) (0.5 mL) was added, stirred at rt for 1 h. Then the solution was concentrated, residue was triturated with Et_2O , the solid was collected, dried in *vacuo* to provide (1*r*,3*r*)-*N*-((3-chloroisoquinolin-5-yl)methyl)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl (37 mg, 29%). MS (ESI+) [Method 6A]: m/z 424.8 ($\text{M}+\text{H}$); R_t 1.36 min. ^1H NMR (400 MHz, CD_3OD) δ 9.23 (s, 1H), 8.27 (d, $J = 21.4$ Hz, 1H), 8.23 (s, 1H), 8.03 (d, $J = 7.6$ Hz, 1H), 7.79 (dd, $J = 8.0, 6.0$ Hz, 1H), 7.28 (t, $J = 9.2$ Hz, 1H), 7.14 – 7.07 (m, 2H), 5.02 – 4.96 (m, 1H), 4.68 (s, 2H), 4.25 – 4.20 (m, 1H), 2.85 – 2.79 (m, 2H), 2.70 – 2.63 (m, 2H).


Example 99: Synthesis of (1*r*,3*r*)-3-((4-fluoro-3-(trifluoromethyl)phenyl)thio)-*N*-(isoquinolin-5-ylmethyl)cyclobutan-1-amine, HCl

Step 99.1: Synthesis of (1*s*,3*s*)-3-((*tert*-butoxycarbonyl)amino)cyclobutyl methanesulfonate



To the stirred solution of *tert*-butyl ((1*s*,3*s*)-3-hydroxycyclobutyl)carbamate (1.0 g, 5.34 mmol) in CH_2Cl_2 (10 mL), TEA (2.2 mL, 16.02 mmol) was added drop wise at rt. The reaction mixture was cooled to -10°C , then MsCl (0.54 mL, 6.94 mmol) was added drop wise and stirred at rt for 1 h under N_2 . Reaction mixture was diluted with water and extracted with CH_2Cl_2 thrice. The combined organic portion was washed with brine solution, dried over anhydrous Na_2SO_4 , filtered and concentrated in *vacuo* to provide crude (1*s*,3*s*)-3-((*tert*-butoxycarbonyl)amino)cyclobutyl methanesulfonate (1.4 g, 99%). ^1H NMR (300 MHz, CDCl_3) δ 4.73 – 4.69 (m, 1H), 3.84 – 3.78 (m, 1H), 2.98 (s, 3H), 2.95 – 2.86 (m, 2H), 2.24 – 2.12 (m, 2H), 1.43 (s, 9H).

Step 99.2: Synthesis of *S*-((1*r*,3*r*)-3-((*tert*-butoxycarbonyl)amino)cyclobutyl) ethanethioate



A sealed tube was charged with (1*s*,3*s*)-3-((*tert*-butoxycarbonyl)amino)cyclobutyl methanesulfonate (700 mg, 2.64 mmol) and DMF (15 mL). Then potassium ethanethioate (603

mg, 5.28 mmol) was added and the reaction mixture was degassed with argon. The vessel was closed and stirred at 90 °C for 18 h. Reaction mixture was cooled to rt, diluted with water and extracted with EtOAc twice. The combined organic portion was washed with brine solution, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 20% EtOAc in Hexane elution) to provide *S*-((1*r*,3*r*)-3-((*tert*-butoxycarbonyl)amino)cyclobutyl) ethanethioate (470 mg, 73%). ¹H NMR (300 MHz, CDCl₃) δ 4.78 (brs, 1H), 4.31 (brs, 1H), 3.94 – 3.90 (m, 1H), 2.48 – 2.32 (m, 4H), 2.30 (s, 3H), 1.43 (s, 9H).

Step 99.3: Synthesis of *tert*-butyl ((1*r*,3*r*)-3-mercaptocyclobutyl)carbamate




To the stirred solution of *S*-((1*r*,3*r*)-3-((*tert*-butoxycarbonyl)amino)cyclobutyl) ethanethioate (470 mg, 1.92 mmol) in THF – MeOH (9 mL, 2:2 v/v), 1N NaOH solution (11.5 mL, 11.49 mmol) was added. The reaction mixture was stirred at rt for 20 min, then diluted with water and extracted with EtOAc twice. The combined organic portion was washed with brine solution, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo* to provide crude *tert*-butyl ((1*r*,3*r*)-3-mercaptocyclobutyl)carbamate (350 mg, 90%). ¹H NMR (300 MHz, CDCl₃) δ 4.70 (brs, 1H), 4.43 (brs, 1H), 3.54 – 3.47 (m, 1H), 2.42 – 2.27 (m, 4H), 1.43 (s, 9H).

Step 99.4: Synthesis of *tert*-butyl ((1*r*,3*r*)-3-((4-fluoro-3-(trifluoromethyl)phenyl)thio)cyclobutyl)carbamate



The stirred solution of *tert*-butyl ((1*r*,3*r*)-3-mercaptocyclobutyl)carbamate (330 mg, 1.62 mmol), 4-bromo-1-fluoro-2-(trifluoromethyl)benzene [CAS No. 393-37-3] (0.3 mL, 2.44 mmol) and DIPEA (0.6 mL, 0.19 mmol) in 1,4-dioxane was degassed with argon. Then Xantphos (94 mg, 0.16 mmol) and Pd₂(dba)₃ (75 mg, 0.08 mmol) were added, and the reaction mixture was heated at 110 °C for 18 h under argon. The reaction mixture was concentrated in *vacuo* and the residue was purified by flash chromatography (12 g SiliCycle column, 0 – 20% EtOAc in Hexane elution) to provide *tert*-butyl ((1*r*,3*r*)-3-((4-fluoro-3-(trifluoromethyl)phenyl)thio)cyclobutyl)carbamate (750 mg, 120%). ¹H NMR (600 MHz, CDCl₃) δ 7.45 – 7.43 (m, 1H), 7.40 – 7.38 (m, 1H), 7.12 (t, *J* = 9.6 Hz, 1H), 4.76 (brs, 1H), 4.42 (brs, 1H), 3.80 – 3.76 (m, 1H), 2.42 – 2.33 (m, 4H), 1.43 (s, 9H).


30 Step 99.5: Synthesis of (1*r*,3*r*)-3-((4-fluoro-3-(trifluoromethyl)phenyl)thio)cyclobutan-1-amine, HCl



A round bottom flask was charged with *tert*-butyl ((1*r*,3*r*)-3-((4-fluoro-3-(trifluoromethyl)phenyl)thio)cyclobutyl)carbamate (710 mg, 1.94 mmol) and HCl solution (20% in


1,4-dioxane) (10 mL); and the solution was stirred rt for 16 h. Then the reaction mixture was concentrated in *vacuo* to afford (1*r*,3*r*)-3-((4-fluoro-3-(trifluoromethyl)phenyl)thio)cyclobutan-1-amine, HCl (410 mg, 80%). MS (ESI+) [Method 6A]: *m/z* 266.0 (M+H); Rt 1.31 min.

Step 99.6: Synthesis of (1*r*,3*r*)-3-((4-fluoro-3-(trifluoromethyl)phenyl)thio)-*N*-(isoquinolin-5-ylmethyl)cyclobutan-1-amine, HCl



The title compound was synthesized following the procedure as described in Step 25.6, using (1*r*,3*r*)-3-((4-fluoro-3-(trifluoromethyl)phenyl)thio)cyclobutan-1-amine, HCl (80 mg, 0.27 mmol) and isoquinoline-5-carbaldehyde [CAS No. 80278-67-7] (38 mg, 0.24 mmol). The crude product was purified by prep-HPLC (Column: GEMINI-NX (150 mm X 21.2 mm), 5.0 μ ; Mobile Phase: 0.02% NH₄OH in water and acetonitrile). The isolated product was stirred with HCl solution (20% in 1,4-dioxane), then concentrated and dried to afford (1*r*,3*r*)-3-((4-fluoro-3-(trifluoromethyl)phenyl)thio)-*N*-(isoquinolin-5-ylmethyl)cyclobutan-1-amine, HCl (45 mg, 38%). MS (ESI+) [Method 1A]: *m/z* 406.8 (M+H); Rt 0.22 min. ¹H NMR (400 MHz, CD₃OD) δ 9.86 (s, 1H), 8.75 – 8.72 (m, 2H), 8.61 (d, *J* = 8.8 Hz, 1H), 8.41 (d, *J* = 7.2 Hz, 1H), 8.12 (dd, *J* = 8.0, 7.2 Hz, 1H), 7.35 – 7.61 (m, 2H), 7.36 (t, *J* = 8.8 Hz, 1H), 4.80 (s, 2H), 4.33 – 4.28 (m, 1H), 4.19 – 4.13 (m, 1H), 2.98 – 2.90 (m, 2H), 2.52 – 2.46 (m, 2H).

Example 100: Synthesis of (1*r*,3*r*)-3-((4-fluoro-3-(trifluoromethyl)phenyl)thio)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl




The title compound was synthesized following the procedure as described in Step 25.6, using (1*r*,3*r*)-3-((4-fluoro-3-(trifluoromethyl)phenyl)thio)cyclobutan-1-amine, HCl (Step 99.5, 80 mg, 0.27 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 42 mg, 0.24 mmol). The crude product was purified by prep-HPLC (Column: GEMINI-NX (150 mm X 21.2 mm), 5.0 μ ; Mobile Phase: 0.02% NH₄OH in water and acetonitrile). The isolated product was stirred with HCl solution (20% in 1,4-dioxane), then concentrated and dried to afford (1*r*,3*r*)-3-((4-fluoro-3-(trifluoromethyl)phenyl)thio)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine, HCl (16 mg, 14%). MS (ESI+) [Method 1A]: *m/z* 425.2 (M+H); Rt 0.29 min. ¹H NMR (400 MHz, CD₃OD) δ 9.89

(s, 1H), 8.82 – 8.76 (m, 3H), 8.02 (t, $J = 9.6$ Hz, 1H), 7.67 – 7.61 (m, 2H), 7.35 (t, $J = 9.6$ Hz, 1H), 4.80 (s, 2H), 4.33 – 4.28 (m, 1H), 4.19 – 4.13 (m, 1H), 2.98 – 2.91 (m, 2H), 2.54 – 2.48 (m, 2H).

Example 101: Synthesis of (1*r*,3*r*)-3-(4-(difluoromethyl)-3-fluorophenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine


5 Step 101.1: Synthesis of 4-(difluoromethyl)-3-fluorophenol



To the solution of 2-fluoro-4-hydroxybenzaldehyde [CAS No. 348-27-6] (500 mg, 3.57 mmol) in CH_2Cl_2 (5 mL), bis(2-methoxyethyl)aminosulfur trifluoride (50% in THF) (4.8 mL, 10.71 mmol) was added drop wise for 5 min at 0 °C and the reaction mixture was stirred at rt for 60 h under argon.


- 10 The reaction was quenched with saturated aqueous NaHCO_3 solution and extracted with CH_2Cl_2 3x's. The combined organic portion was washed with brine solution, dried over anhydrous Na_2SO_4 , filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 – 7% EtOAc in Hexane elution) to provide 4-(difluoromethyl)-3-fluorophenol (200 mg, 35%). MS (ESI+) [Method 6A]: m/z 160.9 (M-H); Rt 1.44 min.

15 Step 101.2: Synthesis of (1*s*,3*s*)-3-aminocyclobutan-1-ol, HCl




The solution of *tert*-butyl ((1*s*,3*s*)-3-hydroxycyclobutyl)carbamate [CAS No. 389890-43-1] (300 mg, 1.60 mmol) and HCl (20% solution in 1,4-dioxane) (3 mL) was stirred at rt for 16 h. Then the reaction mixture was concentrated in *vacuo*. The residue was triturated with Et_2O , the brick red solid was collected and dried to yield (1*s*,3*s*)-3-aminocyclobutan-1-ol, HCl (160 mg, 81%). ^1H NMR (400 MHz, DMSO-d_6) δ 8.21 (brs, 3H), 3.90 – 3.84 (m, 1H), 3.15 – 3.09 (m, 1H), 2.51 – 2.46 (m, 2H), 1.96 – 1.90 (m, 2H).

Step 101.3: Synthesis of (1*s*,3*s*)-3-(((6-fluoroisoquinolin-5-yl)methyl)amino)cyclobutan-1-ol



- 25 The title compound was synthesized using (1*s*,3*s*)-3-aminocyclobutan-1-ol, HCl (80 mg, 0.65 mmol) and 6-fluoroisoquinoline-5-carbaldehyde (Step 3.1, 102 mg, 1.17 mmol), following the procedure as described in step 1.4. The crude product was purified by flash chromatography (4 g SiliCycle column, 0 – 8% MeOH in CH_2Cl_2 elution) to provide (1*s*,3*s*)-3-(((6-fluoroisoquinolin-5-yl)methyl)amino)cyclobutan-1-ol (70 mg, 44%). MS (ESI+) [Method 6A]: m/z 247.0 (M+H); Rt 0.13 min.
- 30


Step 101.4: Synthesis of (1*r*,3*r*)-3-(4-(difluoromethyl)-3-fluorophenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine



To the solution (1*s*,3*s*)-3-(((6-fluoroisoquinolin-5-yl)methyl)amino)cyclobutan-1-ol (50 mg, 0.31 mmol) in THF (0.5 M), 4-(difluoromethyl)-3-fluorophenol (70 mg, 0.31 mmol), PPh₃ (1.5 eq) and diisopropyl azodicarboxylate (1.5 eq) were added at rt. The reaction mixture was stirred at 50 – 60 °C for 16 h under N₂ atmosphere. Reaction mixture was diluted with water and extracted with EtOAc (3x's). The combined organic portion was washed with brine solution, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The crude product was purified by flash chromatography (4 g SiliCycle column, 0 – 8% MeOH in CH₂Cl₂ elution). The isolated compound (90 mg) was re-purified by prep-HPLC (Column: XBRIDGE (150 mm X 21.2 mm), 5.0 μ; Mobile Phase: 0.02% NH₄OH in water and acetonitrile) to afford (1*r*,3*r*)-3-(4-(difluoromethyl)-3-fluorophenoxy)-*N*-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine (4 mg, 3%). MS (ESI+) [Method 6A]: *m/z* 391.1 (M+H); Rt 1.31 min. ¹H NMR (400 MHz, CD₃OD) δ 9.26 (s, 1H), 8.54 (d, *J* = 6.0 Hz, 1H), 8.20 – 8.16 (m, 1H), 8.13 (d, *J* = 6.4 Hz, 1H), 7.55 (t, *J* = 8.8 Hz, 1H), 7.48 (t, *J* = 8.8 Hz, 1H), 6.88 (t, *J* = 55.2 Hz, 1H), 6.74 – 6.72 (m, 1H), 6.66 (d, *J* = 12.4 Hz, 1H), 4.91 – 4.86 (m, 1H), 4.22 (d, *J* = 2.0 Hz, 2H), 3.65 – 3.59 (m, 1H), 2.40 – 2.36 (m, 4H).

Example 102: Synthesis of (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-*N*-((7-fluoroquinazolin-8-yl)methyl)cyclobutan-1-amine


Step 102.1: Synthesis of (Z)-*N*-(3-fluoro-2-methylphenyl)-2-(hydroxyimino)acetamide



In a 1000 mL four necked RB flask fitted with reflux condenser, thermometer pocket and nitrogen inlet, hydroxyl amine hydrochloride (36 g, 0.52 mol) and anhydrous Na₂SO₄ (137 g) was added to a boiling solution of 3-fluoro-2-methylaniline [443-86-7] (20g, 0.160 mol), 1 N HCl (145 mL), and H₂O (450 mL). A boiling solution of chloral hydrate (31.7g, 0.194mol) in H₂O was added. The resulting reaction mixture was boiled at 80 °C for 4 h and the reaction progress was monitored by TLC and LC-MS. After completion, the reaction mixture was cooled to rt and extracted with Diethyl ether (3 x 200 mL). The combined organic layers were dried over anhydrous Na₂SO₄ and filtered. The filtrate was evaporated under reduced pressure to provide (Z)-*N*-(3-fluoro-2-methylphenyl)-


2-(hydroxyimino)acetamide (27.0 g) as a white yellow solid. MS (ESI-) [Method 7A]: m/z 195 (M-H); Rt 1.82 min. ¹H NMR NMR-400-c (400 MHz, DMSO-*d*₆): δ 12.26 (s, 1H), 9.73 (s, 1H), 7.70 (s, 1H), 7.33 (d, *J* = 8.0 Hz, 1H), 7.24 (q, *J* = 7.6 Hz, 1H), 7.06 (t, *J* = 8.9 Hz, 1H), 2.11 (d, *J* = 2.1 Hz, 3H).

5 Step 102.2: Synthesis 6-fluoro-7-methylindoline-2,3-dione




In a 500 mL four necked RB flask fitted with reflux condenser, thermometer pocket and nitrogen inlet, (*Z*)-*N*-(3-fluoro-2-methylphenyl)-2-(hydroxyimino)acetamide (27 g, 0.137 mol) was added portion-wise to a stirred solution of conc. H₂SO₄ (140 mL) at 80 °C for 2 h. After completion, the
 10 reaction mixture was cooled to rt and poured over crushed ice. The resulting solid was collected by filtration and dried in a rotating flask under vacuum at 50 °C to provide 6-fluoro-7-methylindoline-2,3-dione (16.0 g,) as brown solid. MS (ESI-) [Method 7A]: m/z 178 (M-H)⁺; Rt 1.81 min. ¹H NMR NMR-400-c (400 MHz, DMSO-*d*₆): δ 11.32 (s, 1H), 7.46 (dd, *J* = 8.3, 5.5 Hz, 1H), 6.87 (dd, *J* = 10.3, 8.3 Hz, 1H), 2.12 (d, *J* = 1.8 Hz, 3H).

15 Step 102.3: Synthesis of 7-fluoro-8-methyl-2H-benzo[d][1,3]oxazine-2,4(1H)-dione




In a 500 mL four necked RB flask fitted with reflux condenser, thermometer pocket and nitrogen inlet, Hydrogen peroxide (13 mL) was added drop-wise to a stirred solution of 6-fluoro-7-methylindoline-2,3-dione (16 g, 0.089 mol) and sulfuric acid (0.5 mL) in acetic acid (150 mL) at
 20 70 °C for 4 h. Progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was cooled to rt, diluted with water (100 mL) and extracted the reaction mixture with ethyl acetate (3 x 100 mL). The combined organic layers were dried over anhydrous Na₂SO₄ and filtered. The filtrate was concentrated under reduced pressure to provide 7-fluoro-8-methyl-2H-benzo[d][1,3]oxazine-2,4(1H)-dione (16.0 g) as a black brown solid. MS (ESI-)
 25 [Method 7A]: m/z 194 (M-H)⁺; Rt 1.80 min.

Step 102.4: Synthesis of 2-amino-4-fluoro-3-methylbenzamide




In a 250 mL single neck RB flask, ammonia (35 mL) was added to a stirred solution of 7-fluoro-8-methyl-2*H*-benzo[*d*][1,3]oxazine-2,4(1*H*)-dione (16 g, 0.082 mol) in water (70 mL). The reaction mixture was stirred at rt for 72 h, progress of reaction was monitored by TLC. After completion of reaction, the reaction mixture was diluted with water (100 mL) and extracted with ethyl acetate (3 x 100 mL). The combined organic layers were dried over anhydrous Na₂SO₄ and filtered. The filtrate was concentrated under reduced pressure to provide 2-amino-4-fluoro-3-methylbenzamide (7.5 g) as a brown solid. MS (ESI+) [Method 7A]: *m/z* 169 (M+H)⁺; Rt 1.73 min. ¹H NMR NMR-400-c (400 MHz, DMSO-*d*₆): δ 7.75 (s, 1H), 7.49 (dd, *J* = 8.9, 6.5 Hz, 1H), 7.11 (s, 1H), 6.81 (s, 2H), 6.33 (t, *J* = 9.0 Hz, 1H), 2.08 – 1.88 (m, 3H).

10 Step 102.5: Synthesis of 7-fluoro-8-methylquinazolin-4(3*H*)-one



p-Toluenesulfonic acid monohydrate (0.85 g, 0.004 mol) was added portions to a stirred mixture of 2-amino-4-fluoro-3-methylbenzamide (7.5 g, 0.045 mol) in triethyl orthoformate (26 mL). The resulting reaction mixture was refluxed for 1 h. Progress of reaction was monitored by TLC. After completion of the reaction the solvent was evaporated on the rotovap and the crude material was purified by flash column chromatography using 0-40% EtOAc in *n*-hexane to provide 7-fluoro-8-methylquinazolin-4(3*H*)-one (5.6 g) as a white solid. MS (ESI+) [Method 7A]: *m/z* 179 (M+H)⁺; Rt 1.75 min. ¹H NMR NMR-400-c (400 MHz, DMSO-*d*₆): 12.36 (s, 1H), 9.17 (d, *J* = 3.5 Hz, 1H), 8.10 (t, 1H), 7.34 (t, *J* = 9.1 Hz, 1H), 2.50 (s, 3H).


20 Step 102.6: Synthesis of 4-chloro-7-fluoro-8-methylquinazoline



In a 100 mL three necked RB flask fitted with thermometer pocket, reflux condenser, DIPEA (21 mL, 0.123 mol) was added drop-wise to a stirred solution of 7-fluoro-8-methylquinazolin-4(3*H*)-one (5.5 g, 0.031 mol), POCl₃ (5.7 mL, 0.0061 mol) in toluene (55 mL) at 0 °C. The resulting reaction mixture was stirred at 100 °C for 12 h. Progress of the reaction was monitored by TLC. The reaction mixture was cooled to rt and poured over a mixture of ice and water. Extracted the reaction mixture with EtOAc (3 x 70 mL). The combined organic layers were dried over anhydrous Na₂SO₄ and filtered. Evaporated the filtrate under reduced pressure and the crude product was purified by flash column chromatography using 0-15% EtOAc in *n*-hexane to provide 4-chloro-7-fluoro-8-methylquinazoline (2.7 g) as an off-white solid. MS (ESI+) [Method 7A]: *m/z* 196.6 (M)⁺;


Rt 2.18 min. ¹H NMR NMR-400-c (400 MHz, DMSO-*d*₆): δ 8.22 (s, 1H), 8.02 (t, J = 8.8, 6.3 Hz, 1H), 7.36 (t, J = 9.1 Hz, 1H), 2.42 (s, J = 2.4 Hz, 3H).

Step 102.7: Synthesis of 7-fluoro-8-methylquinazoline




- 5 In a 30 mL sealed tube, Pd(dppf)Cl₂ (0.19 g, 0.00026 mol) and TMEDA (2.1 mL g, 0.0138 mol) were added to a stirred solution of 4-chloro-7-fluoro-8-methylquinazoline (1.6 g, 0.0081 mol) in THF (20 mL) and degassed and placed under argon. Sodium borohydride (0.52 g, 0.0138 mol) was then added and the resulting reaction mixture was stirred at rt for 4 h. Progress of reaction was monitored by TLC. After completion, the reaction mixture was diluted with water (70 mL),
 10 and extracted with EtOAc (3 x 50 mL). The combined organic layers were dried over anhydrous Na₂SO₄ and filtered. Evaporated filtrate under reduced pressure to get crude product which was purified by flash column chromatography by using 0-20% EtOAc in *n*-hexane to provide 7-fluoro-8-methylquinazoline (0.80 g) as an off-white solid. MS (ESI+) [Method 7A]: m/z 163.2 (M+H); Rt 1.85 min. ¹H NMR NMR-400-c (400 MHz, DMSO-*d*₆): δ 9.59 (s, 1H), 9.34 (s, 1H), 8.12 (dd, J =
 15 9.0, 6.2 Hz, 1H), 7.68 (t, J = 9.3 Hz, 1H), 2.58 (d, J = 2.4 Hz, 3H).

Step 102.8: Synthesis of 8-(bromomethyl)-7-fluoroquinazoline



- In a 25 mL three necked RB flask, fitted with reflux condenser, thermometer pocket and nitrogen
 20 inlet, *N*-Bromosuccinimide (0.82 g, 0.0046 mol) and benzoyl peroxide (0.074 g, 0.0003 mol) were added to a stirred solution of 7-fluoro-8-methylquinazoline (0.5 g, 0.0030 mol) in CCl₄ (6 mL). The resulting reaction mixture was stirred 76 °C for 4 h. Progress of reaction was monitored by TLC. Upon completion of the reaction, the reaction mixture was cooled to rt and diluted with CCl₄ (30 mL). Filtered the reaction mixture and the filtrate was evaporated on a rotovap to provide 8-
 25 (bromomethyl)-7-fluoroquinazoline (0.67 g) as a pale yellow solid. MS (ESI+) [Method 7B]: m/z 241 (M+2H)⁺; Rt 1.57 min.


Step 102.9: Synthesis of (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-N-((7-fluoroquinazolin-8-yl)methyl)cyclobutan-1-amine



To (1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine, HCl salt (0.252 g, 0.883 mmol) was added dioxane (6 mL) and DMF (1 mL) and 5 eq of TEA. The mixture was stirred and then sonicated for 5 minutes and then concentrated to a clear solution (DMF remaining). Then added Dioxane (6 mL) and TEA (0.308 mL, 2.208 mmol). 8-(bromomethyl)-7-fluoroquinazoline (0.212 g, 0.883 mmol) was then added in dioxane (3.00 mL) and the light yellow cloudy reaction was stirred at room temperature for 2h. Then added another 1 mL of DMF and 2.5 eq of TEA and continued stirring. After an additional 30 minutes, the reaction was diluted with EtOAc (50 mL) and water and extracted. This was done 3x's. The combined organics were washed with water (50 mL), dried over sodium sulfate and concentrated to an oil that was purified by flash column chromatography (0-10% MeOH:DCM) to obtain an oil that was then purified via basic HPLC (50-70%-Acetonitrile (ACN/H₂O + 5mM NH₄OH) at 30ml/min) Column: XBridge C18 OBD 19 x 150 mm) to obtain a semi-solid that was dissolved in dioxane and treated with 4 N HCl in dioxane (0.5mL) at 0 °C and then stirred at room temperature for 2 hours. The white mixture reaction was concentrated, dissolved in 4:1 ACN:Water and placed on the lyophilizer to provide (1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-N-((7-fluoroquinazolin-8-yl)methyl)cyclobutan-1-amine as an HCl salt (0.030 g, 7.24%). MS (ESI+) [Method 7C]: m/z 410.3 (M+H); Rt 1.52 min. ¹H NMR (NMR-400-b) (400 MHz, DMSO-*d*₆): δ 9.73 (s, 1H), 9.67 (d, J = 6.0 Hz, 1H), 9.48 (s, 1H), 8.44 (dd, J = 9.1, 6.0 Hz, 1H), 7.86 (t, J = 9.3 Hz, 1H), 7.47 (t, J = 9.7 Hz, 1H), 7.19 (dt, J = 9.1, 3.6 Hz, 1H), 7.12 (dd, J = 5.8, 3.1 Hz, 1H), 5.06 (tt, J = 7.2, 3.7 Hz, 1H), 4.67 – 4.55 (m, 2H), 4.01 (tt, J = 8.2, 5.7 Hz, 1H), 2.87 – 2.74 (m, 2H), 2.48 – 2.42 (m, 2H).

Example 103: Synthesis of *N*-((1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)-2-(6-fluoro-8-(hydroxymethyl)isoquinolin-5-yl)acetamide


Step 103.1: Synthesis of ethyl 2-(8-(((tert-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinolin-5-yl)-2-oxoacetate



To the stirred solution of 8-(((tert-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinoline (Step 6.7, 6.0 g, 20.58 mmol) in dry THF (90 mL), LDA (2M in THF) (20.5 mL, 41.17 mmol) was added dropwise at -78 °C and stirred for 2.5 h, under N₂. Then diethyl oxalate (8.3 mL, 61.76 mmol) dissolved in dry THF (30 mL) was added dropwise at -78 °C and stirred for further 1 h. The reaction mixture was quenched with saturated NH₄Cl solution and extracted with EtOAc twice. The combined


organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The crude was purified by flash chromatography (24 g SiliCycle column, 0 - 15% EtOAc in Hexane elution) to provide ethyl 2-(8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinolin-5-yl)-2-oxoacetate (6.0 g). MS (ESI+) [Method 5A]: *m/z* 390.1 (M-H); Rt 1.73 min.

5 Step 103.2: Synthesis of ethyl 2-(8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinolin-5-yl)-2-hydroxyacetate




To the solution of ethyl 2-(8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinolin-5-yl)-2-oxoacetate (1.8 g, 4.59 mmol) in EtOH – AcOH – H₂O (45 mL, 40:1:4 v/v/v), NaCNBH₃ (0.35 g, 5.52 mmol) was added at rt and stirred for 16 h under argon. The reaction was quenched with saturated NaHCO₃ solution and extracted with EtOAc twice. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The crude product was purified by flash chromatography (24 g SiliCycle column, 0 - 20% EtOAc in Hexane elution) to provide ethyl 2-(8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinolin-5-yl)-2-hydroxyacetate (1.4 g). MS (ESI+) [Method 1A]: *m/z* 394.2 (M+H); Rt 1.72 min.

15 Step 103.3: Synthesis of ethyl 2-acetoxy-2-(8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinolin-5-yl)acetate



To the solution of ethyl 2-(8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinolin-5-yl)-2-hydroxyacetate (2.5 g, 6.35 mmol) in CH₂Cl₂ (20 mL), TEA (4.4 mL, 31.76 mmol) and DMAP (100 mg) were added at rt. Then Ac₂O (1.2 mL, 12.71 mmol) was added dropwise at 0 °C and the reaction mixture was stirred at rt for 2 h. The reaction mixture was diluted with water and extracted with CH₂Cl₂ twice. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The crude product was purified by flash chromatography (24 g SiliCycle column, 0 - 20% EtOAc in Hexane elution) to provide ethyl 2-acetoxy-2-(8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinolin-5-yl)acetate as (2.6 g). MS (ESI+) [Method 1A]: *m/z* 436.2 (M+H); Rt 2.02 min.

25 Step 103.4: Synthesis of ethyl 2-(8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinolin-5-yl)acetate




To the solution of ethyl 2-acetoxy-2-(8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinolin-5-yl)acetate (2.6 g, 5.97 mmol), HMPA (8.3 mL, 47.75 mmol) and MeOH (0.23 g, 7.16 mmol), SmI_2 (0.1M in THF) (179 mL, 17.91 mmol) was added dropwise and stirred at rt for 16 h, under argon.

- 5 The reaction was quenched with saturated K_2CO_3 solution, and extracted with EtOAc twice. The combined organic portion was washed with brine, dried over anhydrous Na_2SO_4 , filtered and concentrated in *vacuo* to provide crude ethyl 2-(8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinolin-5-yl)acetate (2.6 g). MS (ESI+) [Method 6A]: m/z 378.4 (M+H); Rt 1.68 min.


Step 103.5: Synthesis of methyl 2-(8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinolin-5-yl)acetate

10



The crude ethyl 2-(8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinolin-5-yl)acetate (2.6 g, 5.97 mmol) was dissolved in MeOH (20 mL). Then K_2CO_3 (412 mg, 2.94 mmol) was added and stirred at rt for 1 h. The reaction mixture was diluted with water and extracted with EtOAc twice. The combined organic portion was washed with brine, dried over anhydrous Na_2SO_4 , filtered and concentrated in *vacuo*. The residue was purified by flash chromatography (12 g SiliCycle column, 0 - 30% EtOAc in Hexane elution) to provide methyl 2-(8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinolin-5-yl)acetate (1.3 g). MS (ESI+) [Method 6A]: m/z 364.1 (M+H); Rt 1.62 min.

20 Step 103.6: Synthesis of 2-(8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinolin-5-yl)acetic acid




To the solution of methyl 2-(8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinolin-5-yl)acetate (1.3 g, 3.58 mmol) in THF – MeOH – H_2O (20 mL, 7:2:1 v/v/v), $\text{LiOH}\cdot\text{H}_2\text{O}$ (0.3 g, 7.15 mmol) was added and the reaction mixture was stirred at rt for 2 h. The reaction mixture was concentrated under reduced pressure, residue was acidified with citric acid solution and the solid

25

formed was filtered and dried in *vacuo* to afford 2-(8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinolin-5-yl)acetic acid (1.17 g). MS (ESI+) [Method 5A]: *m/z* 350.2 (M+H); *Rt* 1.40 min.

Step 103.7: Synthesis of 2-(8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinolin-5-yl)-N-((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)acetamide

5




To the stirred solution of 2-(8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinolin-5-yl)acetic acid (1.17 g, 3.35 mmol) in DMF (20 mL), (1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine (1.14 g, 4.02 mmol) and HATU (1.9 g, 5.02 mmol) were added. Then DIPEA (2.9 mL, 16.74 mmol) was added drop wise at 0 °C and the reaction mixture was stirred at rt for 3 h. The reaction mixture was diluted with water and extracted with EtOAc 3x's. The combined organic portion was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo* to provide crude 2-(8-(((*tert*-butyldimethylsilyl)oxy)methyl)-6-fluoroisoquinolin-5-yl)-N-((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)acetamide (2.0 g). MS (ESI+) [Method 6A]: *m/z* 581.3 (M+H); *Rt* 1.71 min.

10

15

Step 103.8: Synthesis of N-((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)-2-(6-fluoro-8-(hydroxymethyl)isoquinolin-5-yl)acetamide




Deprotection was carried out according to Step 8.5. The residue was purified by prep-HPLC (Column: EPIC C18 (150 mm X 21.2 mm), 5.0 μ; Mobile Phase: 0.02% NH₄OH in water and acetonitrile) to afford N-((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)-2-(6-fluoro-8-(hydroxymethyl)isoquinolin-5-yl)acetamide as white solid (1.0 g, 52%). MS (ESI+) [Method 1A]: *m/z* 467.2 (M+H); *Rt* 0.68 min. ¹H NMR (400 MHz, CD₃OD) δ 9.45 (s, 1H), 8.50 (d, *J* = 6.0 Hz, 1H), 7.94 (d, *J* = 6.0 Hz, 1H), 7.56 (d, *J* = 10.4 Hz, 1H), 7.22 (t, *J* = 9.6 Hz, 1H), 7.07 – 7.03 (m, 2H), 5.18 (s, 2H), 4.89 – 4.86 (m, 1H), 4.46 – 4.41 (m, 1H), 4.03 (s, 2H), 2.50 (dd, *J* = 7.2, 6.4 Hz, 4H).

20


25

The following compounds were made in an analogous manner to the examples described herein.


Example 104: 2-amino-1-(6-fluoro-5-(((1*r*,3*r*)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethan-1-ol



- 5 Example 105: (1*r*,3*r*)-3-((2,4-difluorobenzyl)oxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine




Example 106: (1*r*,3*r*)-N-((6-fluoroisoquinolin-5-yl)methyl)-3-((2-methyl-6-(trifluoromethyl)pyridin-4-yl)oxy)cyclobutan-1-amine




10


Example 107: (1*r*,3*r*)-N-((6-fluoroisoquinolin-5-yl)methyl)-3-((4-(trifluoromethyl)thiazol-2-yl)oxy)cyclobutan-1-amine




Example 108: 5-(((1r,3r)-3-(((6-fluoroisoquinolin-5-yl)methyl)amino)cyclobutoxy)pyrimidine-2-carbonitrile




Example 109: 5-((((1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-1-amine




Example 110: (1r,3r)-3-((6-(difluoromethyl)pyridin-3-yl)oxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine



10 Example 111: (1r,3r)-3-((2-(difluoromethyl)pyridin-4-yl)oxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine



Example 112: (1r,3r)-N-(isoquinolin-5-ylmethyl)-3-((6-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutan-1-amine



15

Biological data**Determination of TRPV1 inhibition**

Chinese Hamster Ovary (CHO) cells transfected to express human TrpV1 receptor (which are herein referred to as CHO-huTrpV1 cells), were grown in F-12 Ham's Nutrient Mixture media (HyClone SH30026.01) supplemented with 10% Fetal Bovine Serum (Invitrogen #26140-079), 1% Antibiotic/antimycotic (Invitrogen #15240-062) and 500 ug/mL geneticin (ThermoFisher scientific #1031035). Cells were grown in T-75 flasks at 37°C incubator with 5% CO₂. The cells were passaged twice a week at a ratio of 1:10 to 1:20 to maintain steady growth. For experimentation, cells were harvested at approximately 80% confluency and plated onto 384 well black cell culture plates (cat#781091, Greiner Bio-One Inc.) at 15,000 cells per well in 20 µl media and grown overnight.

FLIPR Calcium Assay to detect Calcium influx in CHO-hu TrpV1 cells

The loading dye was prepared following instruction of Calcium 6 assay kit (Molecular Probes, #R8190): 10ml buffer from bottle B was added to 1 vial of bottle A (adapted to room temperature from -20°C) and mixed well, then 2.5 mM of fresh prepared probenecid, was added and mixed well. 20 µl/ well of loading dye was added on top of the cells, and incubated at 37°C for 1 hour 30 min.

Assay buffer preparation: 1x HBSS, 2mM HEPES, 0.1% BSA plus 2.5mM freshly prepared probenecid (Invitrogen, #P36400). 25 µl/ well assay buffer in 384 well clear plate (cat# 782281, Greiner Bio-one) was dispensed with buffer distributor (Multidrop ComB1 from Thermo Scientific). The compounds were in 384 Echo plate (cat# LPL0200, Labcyte) and the starting concentration of compound was 10 mM, then 1 to 3 serial dilution in 100% DMSO, 8 µl/ well). 125 nl compounds was transferred to the 384 well plate containing 25 µl/ well buffer with Echo® 555 Liquid Handler (Labcyte), such that the compound concentration was 5 fold of final concentration. The plate was shook slowly at 40 rpm/ min for 10 min to mix. 10 µl of 5 fold compound in the buffer was transferred to the cell plate (containing 20 µl cells and 20 µl dye) using Vertical Pipetting Station 384ST (Agilent Technologies). Six fold of final concentration of NADA(N-arachidonyl dopamine, cat# A8848, Sigma) in the assay buffer was prepared and 30 µl/ well was distributed in 384 well clear plate.

After compounds were added to the cell plate with loading dye, within 10-15 minutes, cell plate and plate containing NADA was placed into the FLIPR (Fluorescent Imaging Plate Reader) instrument (Tetra System, Molecular device). The TRPV1 receptor was stimulated by application of 10 µl per well of NADA. For testing the effect of compounds for possible antagonism, 2.5 µM NADA was used at the EC80 concentration.

For determination of antagonist IC₅₀ values (concentration of antagonist that inhibits response to NADA by 50%), at least 10 antagonist concentration were measured in triplicate. The response in the presence of the antagonist was calculated as a percentage of the control response to NADA and was plotted against the concentration of the antagonist. The IC₅₀ was estimated by non-

linear regression analysis to sigmoidal-logistic curves by HELIOS (PROD 2) system. These values were averaged (means and standard error of the mean) for at least three independent experiments. The IC₅₀ values are shown in Table 1 below.

Table 1: Antagonist effect of compounds of the disclosure against human TRPV1

Example No.	IC ₅₀ (μM)	peak 1	
1	0.0208	21	0.0113
2	0.711	peak 2	
3	0.00344	22	0.436
4	0.0268	23	0.232
5	0.259	24	0.906
6	0.00725	25	0.100
7 peak 1	0.00062	26	0.108
7 peak 2	0.0063	27	0.0230
7 racemic	0.0104	28	0.280
8	0.165	29	0.0623
9 peak 1	0.00009	30	0.186
9 peak 2	0.0137	31	0.264
9 racemic	0.00058	32	0.102
10	0.166	33	0.0154
11	0.395	34	0.0836
12	0.0578	35	0.128
13	0.0637	36	0.0989
14	0.00404	37	0.0813
15	0.0510	38	0.0514
16	0.0310	39	0.0108
17	0.130	40	0.124
18	0.00163	41	0.0900
19	0.0162	42	0.173
20	0.0872	43	0.528
21	0.00442	44	0.0326

45	0.0188
46	0.0402
47	0.0238
48	0.0345
49	0.0163
50	0.0806
51	0.117
52	0.0271
53	0.0769
54	0.0595
55	0.352
56	0.119
57	0.656
58	0.0829
59	0.0758
60	0.320
61	0.194
62	0.336
63	0.0986
64	0.163
65	0.00098
66	1.11
67	0.00377
68 <i>cis</i>	0.333
68 <i>trans</i>	0.0129
69	0.00015
70	0.402
71	0.0316

72	0.0521
73	0.193
74	0.995
75	0.269
76	0.0277
77	0.691
78	0.770
79	0.147
80	0.980
81	0.255
82	0.169
83	0.207
84	0.722
85	0.155
86	0.0693
87	0.321
88	0.0952
89	0.440
90	0.874
91	0.0399
92	0.580
93	0.0826
94	0.193
95	0.323
96	0.747
97	0.280
98	0.418
99	0.362

100	0.0740
101	0.0147
102	0.0603
103	0.00044
104	2.15
105	1.28
106	1.65

107	1.91
108	2.51
109	1.46
110	1.38
111	1.65
112	2.69

The compounds of the disclosure inhibit NADA-mediated cellular TRPV1 activity with IC_{50} down to sub-nanomolar level. As such, the compounds of the disclosure may be useful in treating the diseases and/or disorders described herein, *e.g.*, a disease/disorder mediated by TRPV1.

5

All publications and patent documents cited herein are incorporated herein by reference as if each such publication or document was specifically and individually indicated to be incorporated herein by reference. The present invention and its embodiments have been described in detail. However, the scope of the present invention is not intended to be limited to the particular


10 embodiments of any process, manufacture, composition of matter, compounds, means, methods, and/or steps described in the specification. Various modifications, substitutions, and variations can be made to the disclosed material without departing from the spirit and/or essential characteristics of the present invention. Accordingly, one of ordinary skill in the art will readily appreciate from the invention that later modifications, substitutions, and/or variations performing

15 substantially the same function or achieving substantially the same result as embodiments described herein may be utilized according to such related embodiments of the present invention. Thus, the following claims are intended to encompass within their scope modifications, substitutions, and variations to processes, manufactures, compositions of matter, compounds, means, methods, and/or steps disclosed herein. The claims should not be read as limited to the

20 described order or elements unless stated to that effect. It should be understood that various changes in form and detail may be made without departing from the scope of the appended claims.

Claims

1. A compound of Formula (I) or a pharmaceutically acceptable salt thereof,



- 5 wherein:
- W is C(=O) or absent;
- X is N or N oxide;
- Y is N or CH;
- Z is NH, O or S;
- 10 A is CH₂ or absent;
- L is selected from 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from N, O, and S, C₆-C₁₀aryl, and 6- to 10-membered partially saturated heterocyclyl having 1-3 heteroatoms independently selected from N, O, and S;
- R^A is at each occurrence independently selected from halo, -CN, C₁-C₆haloalkyl, C₁-C₆alkyl, SF₅, C₃-C₆cycloalkyl, C₁-C₆alkoxyl, C₁-C₆haloalkoxyl, 4- to 6-membered heterocyclyl having 1-2 heteroatoms independently selected from N, O, and S, -(CH₂)_p-NR³R⁴ and -C(=O)-O-(C₁-C₆alkyl),
- wherein the C₃-C₆cycloalkyl and 4- to 6-membered heterocyclyl are each independently substituted with 0-4 R^{A1};
- 20 R^{A1} is at each occurrence independently selected from halo and C₁-C₆haloalkyl;
- R¹ is at each occurrence independently selected from hydroxyl, C₁-C₆alkyl, C₁-C₆alkoxyl, halo, C₁-C₆haloalkyl and NR³R⁴,
- wherein the C₁-C₆alkyl and C₁-C₆haloalkyl are each independently substituted with 0-4 R^{1a};
- 25 R^{1a} is at each occurrence independently selected from hydroxyl, NR³R⁴ and -C(=O)-OH;
- R² is selected from hydrogen and C₁-C₆alkyl;
- R³ is at each occurrence independently selected from hydrogen and C₁-C₆alkyl;
- R⁴ is at each occurrence independently selected from -SO₂R⁵, hydrogen, -C(=O)-(C₁-C₆alkyl) and C₁-C₆alkyl;
- 30 R⁵ is at each occurrence independently selected from NH₂ and C₁-C₆alkyl;

n is 0, 1, 2, 3 or 4;
 m is 0, 1, 2, 3, 4 or 5;
 p is 0, 1 or 2.

- 5 2. The compound of claim 1 or a pharmaceutically acceptable salt thereof,
 wherein
 W is C(=O) or absent;
 X is N or N oxide;
 Y is CH;
 10 Z is NH, O or S;
 A is CH₂ or absent;
 L is selected from 5- to 10-membered heteroaryl having 1-3 heteroatoms independently
 selected from N, O, and S, C₆-C₁₀aryl and 6- to 10-membered partially saturated heterocyclyl
 having 1-3 heteroatoms independently selected from N, O, and S;
 15 R^A is at each occurrence independently selected from halo, -CN, C₁-C₆haloalkyl, C₁-
 C₆alkyl, SF₅, C₃-C₆cycloalkyl, C₁-C₆alkoxyl, C₁-C₆haloalkoxyl, 4- to 6-membered heterocyclyl
 having 1-2 heteroatoms independently selected from N, O, and S and -(CH₂)_p-NR³R⁴,
 wherein the C₃-C₆cycloalkyl and 4- to 6-membered heterocyclyl are each independently
 substituted with 0-4 R^{A1};
 20 R^{A1} is at each occurrence independently selected from halo and C₁-C₆haloalkyl;
 R¹ is at each occurrence independently selected from C₁-C₆alkyl, halo, C₁-C₆haloalkyl
 and NR³R⁴,
 wherein the C₁-C₆alkyl and C₁-C₆haloalkyl are each independently substituted with 0-4
 R^{1a};
 25 R^{1a} is at each occurrence independently selected from hydroxyl, NR³R⁴ and -C(=O)-OH;
 R² is selected from hydrogen and C₁-C₆alkyl;
 R³ is at each occurrence independently selected from hydrogen and C₁-C₆alkyl;
 R⁴ is at each occurrence independently selected from -SO₂R⁵, hydrogen, -C(=O)-(C₁-
 C₆alkyl) and C₁-C₆alkyl;
 30 R⁵ is at each occurrence independently selected from NH₂ and C₁-C₆alkyl;
 n is 0, 1, 2, 3, 4;
 m is 0, 1, 2, 3, 4 or 5;
 p is 0, 1 or 2.
- 35 3. The compound of claim 1 or 2 or a pharmaceutically acceptable salt thereof,
 wherein
 W is C(=O) or absent;
 X is N or N oxide;

Y is CH;

Z is NH, O or S;

A is CH₂ or absent;

L is selected from 5- to 10-membered heteroaryl having 1-3 heteroatoms independently
5 selected from N, O, and S, C₆-C₁₀aryl and 6- to 10-membered partially saturated heterocycl
having 1-3 heteroatoms independently selected from N, O, and S;

R^A is at each occurrence independently selected from halo, -CN, C₁-C₆haloalkyl, C₁-
C₆alkyl, C₃-C₆cycloalkyl, C₁-C₆alkoxyl, C₁-C₆haloalkoxyl, 4- to 6-membered heterocycl having 1-
2 heteroatoms independently selected from N, O, and S and -(CH₂)_p-NR³R⁴,

10 wherein the C₃-C₆cycloalkyl and 4- to 6-membered heteocycl are each independently
substituted with 0-4 R^{A1};

R^{A1} is at each occurrence independently selected from halo and C₁-C₆haloalkyl;

R¹ is at each occurrence independently selected from C₁-C₆alkyl, halo, C₁-C₆haloalkyl
and NH₂,

15 wherein the C₁-C₆alkyl and C₁-C₆haloalkyl are each independently substituted with 0-4
R^{1a};

R^{1a} is at each occurrence independently selected from hydroxyl, NR³R⁴ and -C(=O)-OH;

R² is selected from hydrogen and C₁-C₃alkyl;

R³ is at each occurrence independently selected from hydrogen and C₁-C₆alkyl;

20 R⁴ is at each occurrence independently selected from -SO₂R⁵, hydrogen, -C(=O)-(C₁-
C₆alkyl) and C₁-C₆alkyl;

R⁵ is at each occurrence independently selected from NH₂ and C₁-C₆alkyl;

n is 0, 1, 2 or 3;

m is 0, 1, 2, 3 or 4;

25 p is 0, 1 or 2.

4. The compound of any of the preceding claims or a pharmaceutically acceptable salt
thereof,

wherein

30 W is absent;

X is N;

Y is CH;

Z is NH, O or S;

A is absent;

35 L is selected from 5- to 10-membered heteroaryl having 1-3 heteroatoms independently
selected from N, O, and S, C₆-C₁₀aryl, and 6- to 10-membered partially saturated heterocycl
having 1-3 heteroatoms independently selected from N, O, and S;

R^A is at each occurrence independently selected from halo, $-\text{CN}$, $\text{C}_1\text{-C}_6\text{haloalkyl}$, $\text{C}_1\text{-C}_6\text{alkyl}$, $\text{C}_3\text{-C}_6\text{cycloalkyl}$, $\text{C}_1\text{-C}_6\text{haloalkoxyl}$, 4- to 6-membered heterocyclyl having 1-2 heteroatoms independently selected from N, O, and S and $-(\text{CH}_2)_p\text{-NR}^3\text{R}^4$,

wherein the $\text{C}_3\text{-C}_6\text{cycloalkyl}$ and 4- to 6-membered heterocyclyl are each independently substituted with 0-4 R^{A1} ;

R^{A1} is at each occurrence independently selected from halo and $\text{C}_1\text{-C}_6\text{haloalkyl}$;

R^1 is at each occurrence independently selected from $\text{C}_1\text{-C}_6\text{alkyl}$, halo, $\text{C}_1\text{-C}_6\text{haloalkyl}$, wherein the $\text{C}_1\text{-C}_6\text{alkyl}$ and $\text{C}_1\text{-C}_6\text{haloalkyl}$ are each independently substituted with 0-4 R^{1a} ;

R^{1a} is at each occurrence independently selected from hydroxyl, NR^3R^4 and $-\text{C}(=\text{O})\text{-OH}$;

R^2 is selected from hydrogen and $\text{C}_1\text{-C}_3\text{alkyl}$;

R^3 is at each occurrence independently selected from hydrogen and $\text{C}_1\text{-C}_6\text{alkyl}$;

R^4 is at each occurrence independently selected from $-\text{SO}_2\text{R}^5$, hydrogen, $-\text{C}(=\text{O})\text{-(C}_1\text{-C}_6\text{alkyl)}$ and $\text{C}_1\text{-C}_6\text{alkyl}$;

R^5 is at each occurrence independently selected from NH_2 and $\text{C}_1\text{-C}_6\text{alkyl}$;

n is 0, 1, 2 or 3;

m is 0, 1, 2, 3 or 4;

p is 0, 1 or 2.

5. The compound of any of the preceding claims or a pharmaceutically acceptable salt thereof,

wherein R^A is selected from fluoro, chloro, $-\text{CN}$, $\text{C}_1\text{-C}_6\text{fluoroalkyl}$ (e.g., $\text{C}_1\text{-C}_3\text{fluoroalkyl}$), $\text{C}_1\text{-C}_6\text{alkyl}$, $\text{C}_3\text{-C}_6\text{cycloalkyl}$, $\text{C}_1\text{-C}_6\text{fluoroalkoxyl}$ and 4-membered heterocyclyl having 1 oxygen atom,

wherein the $\text{C}_3\text{-C}_6\text{cycloalkyl}$ and the 4-membered oxygen containing heterocyclyl are each independently substituted with 0-3 R^{A1} , and wherein

R^{A1} is at each occurrence independently selected from halo and $\text{C}_1\text{-C}_6\text{haloalkyl}$.

6. The compound of any of the preceding claims or a pharmaceutically acceptable salt thereof,

wherein R^A is selected from fluoro, $-\text{CN}$, $-\text{CF}_3$, $-\text{CHF}_2$, $-\text{CHFCH}_2\text{F}$, $-\text{CH}_2\text{F}$, $\text{C}_1\text{-C}_4\text{alkyl}$, $\text{C}_3\text{-C}_6\text{cycloalkyl}$, $-\text{OCF}_3$, $-\text{OCHF}_2$, $-\text{OCH}_2\text{F}$, $-\text{OCHFCH}_2\text{F}$ and 4-membered heterocyclyl having 1 oxygen atom

wherein the $\text{C}_3\text{-C}_6\text{cycloalkyl}$ and the 4-membered O containing heterocyclyl are each independently substituted with 0-2 R^{A1} , and wherein


R^{A1} is at each occurrence independently selected from fluoro and $\text{C}_1\text{-C}_6\text{fluoroalkyl}$.

7. The compound of any of the preceding claims or a pharmaceutically acceptable salt thereof,

wherein R^A is selected from fluoro, $-\text{CN}$, $-\text{CF}_3$, $-\text{CHF}_2$, $-\text{CHFCH}_2\text{F}$ and $-\text{CH}_2\text{F}$.

8. The compound of any of the preceding claims or a pharmaceutically acceptable salt thereof,


wherein L is selected from $\text{C}_6\text{-C}_{10}$ aryl, 6- to 10-membered partially saturated heterocyclyl having 1-3 heteroatoms independently selected from N, O, and S, and 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from N, O, and S selected from



wherein the $\text{C}_6\text{-C}_{10}$ aryl, 6- to 10-membered partially saturated heterocyclyl and 5- to 10-membered heteroaryl are each independently substituted with 0-4 R^A , and wherein R^A is defined according to any of the preceding claims.

9. The compound of any of the preceding claims or a pharmaceutically acceptable salt thereof,

wherein L is selected from $\text{C}_6\text{-C}_{10}$ aryl, 6- to 10-membered partially saturated heterocyclyl having 1-3 heteroatoms independently selected from N, O, and S, and 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from N, O, and S selected from



wherein the $\text{C}_6\text{-C}_{10}$ aryl and 6- to 10-membered partially saturated heterocyclyl are each independently substituted with 0-2 R^A ,


and wherein R^A is defined according to any of the preceding claims.

25

10. The compound of any of the preceding claims or a pharmaceutically acceptable salt thereof,

wherein L is selected from $\text{C}_6\text{-C}_{10}$ aryl, 6- to 10-membered partially saturated heterocyclyl having 1-3 heteroatoms independently selected from N, O, and S, and 5- to 10-membered

30 heteroaryl having 1-3 heteroatoms independently selected from N, O, and S selected from




wherein the C₆-C₁₀aryl and 6- to 10-membered partially saturated heterocyclyl are each independently substituted with 0-2 R^A, and wherein R^A is defined according to any of the preceding claims.

11. The compound of any of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein L is selected from 6- to 10-membered partially saturated heterocyclyl having 1-3 heteroatoms independently selected from N, O, and S, 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from N, O, and S, and C₆-C₁₀aryl selected from phenyl and naphthyl,

wherein the 6- to 10-membered partially saturated heterocyclyl, 5- to 10-membered heteroaryl, phenyl and naphthyl are each independently substituted with 0-4 R^A, and wherein R^A is defined according to any of the preceding claims.

15

12. The compound of any of claims 1 to 7, 11, or a pharmaceutically acceptable salt thereof, wherein L is selected from 6- to 10-membered partially saturated heterocyclyl having 1-3 heteroatoms independently selected from N, O, and S, 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from N, O, and S, and C₆-C₁₀aryl selected from




wherein the 6- to 10-membered partially saturated heterocyclyl and 5- to 10-membered heteroaryl are each independently substituted with 0-3 R^A, and wherein R^A is defined according to any of the preceding claims.

25



13. The compound of any of claims 1 to 7, 11, 12, or a pharmaceutically acceptable salt thereof,

wherein L is selected from 6- to 10-membered partially saturated heterocyclyl having 1-3 heteroatoms independently selected from N, O, and S, 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from N, O, and S, and C₆-C₁₀aryl selected from





wherein the 6- to 10-membered partially saturated heterocyclyl and 5- to 10-membered heteroaryl are each independently substituted with 0-3 R^A, and wherein R^A is defined according to any of the preceding claims.



14. The compound of any of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein L is selected from 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from N, O, and S, C₆-C₁₀aryl and 6- to 10-membered partially saturated heterocycl

selected from  and , wherein the 5- to 10-membered heteroaryl, C₆-C₁₀aryl and 6- to 10-membered partially saturated heterocycl are each independently substituted with 0-4 R^A, and wherein R^A is defined according to any of the preceding claims.

15. The compound of any of claims 1 to 7, 14, or a pharmaceutically acceptable salt thereof, wherein L is selected from 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from N, O, and S, C₆-C₁₀aryl and 6- to 10-membered partially saturated heterocycl

selected from  and , wherein the 5- to 10-membered heteroaryl and C₆-C₁₀aryl are each independently substituted with 0-4 R^A, and wherein R^A is defined according to any of the preceding claims.

16. The compound of any of claims 1 to 7, 14, 15, or a pharmaceutically acceptable salt thereof, wherein L is selected from 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from N, O, and S, C₆-C₁₀aryl and 6- to 10-membered partially saturated

heterocycl selected from  and , wherein the 5- to 10-membered heteroaryl and C₆-C₁₀aryl are each independently substituted with 0-4 R^A, and wherein R^A is defined according to any of the preceding claims.

17. The compound of any of the preceding claims or a pharmaceutically acceptable salt thereof,

wherein R¹ is at each occurrence independently selected from C₁-C₆alkyl, halo, C₁-C₆haloalkyl and NH₂,
wherein the C₁-C₆alkyl and C₁-C₆haloalkyl are each independently substituted with 0-4 R^{1a},
wherein R^{1a} is at each occurrence independently selected from hydroxyl and NR³R⁴.

18. The compound of any of the preceding claims or a pharmaceutically acceptable salt thereof,

wherein R¹ is at each occurrence independently selected from C₁-C₆alkyl, fluoro, NH₂, -N(C₁-C₆alkyl)₂ and chloro,

wherein the C₁-C₆alkyl is at each occurrence independently substituted with 0-4 hydroxyl.

19. The compound of any of the preceding claims or a pharmaceutically acceptable salt thereof,

5 wherein R¹ is at each occurrence independently selected from C₁-C₆alkyl and fluoro, wherein the C₁-C₆alkyl is each occurrence independently substituted with 0-4 hydroxyl.

20. The compound of any of the preceding claims or a pharmaceutically acceptable salt thereof,

10 wherein n is 1, 2 or 3.

21. The compound of any of the preceding claims or a pharmaceutically acceptable salt thereof,

wherein m is 1, 2 or 3.

15

22. The compound of any of the preceding claims or a pharmaceutically acceptable salt thereof,

wherein R² is hydrogen.

20 23. The compound of any of the preceding claims or a pharmaceutically acceptable salt thereof,

wherein Y is CH.

24. The compound of any of the preceding claims or a pharmaceutically acceptable salt thereof,

25

wherein W is absent.

25. The compound of any of the preceding claims or a pharmaceutically acceptable salt thereof,

30

wherein Z is O.

26. The compound of any of the preceding claims or a pharmaceutically acceptable salt thereof,

wherein

35

W is absent;

X is N;

Y is CH;

Z is O;

A is absent;

L is C₆-C₁₀aryl;

R^A is at each occurrence independently selected from halo, -CN, C₁-C₆haloalkyl, C₁-C₆alkyl;

R¹ is at each occurrence independently selected from C₁-C₆alkyl, halo and C₁-C₆haloalkyl,

5 wherein the C₁-C₆alkyl and C₁-C₆haloalkyl are each independently substituted with 0-4 R^{1a};

R^{1a} is at each occurrence independently selected from hydroxyl and NR³R⁴;

R² is selected from hydrogen and C₁-C₃alkyl;

R³ is at each occurrence independently selected from hydrogen and C₁-C₆alkyl;

R⁴ is at each occurrence independently selected from -SO₂R⁵, hydrogen and C₁-C₆alkyl;

10 R⁵ is at each occurrence independently selected from NH₂ and C₁-C₆alkyl;

n is 1, 2 or 3;

m is 0, 1, 2 or 3.

27. The compound of any of the preceding claims or a pharmaceutically acceptable salt

15 thereof,

wherein

W is absent;

X is N;

Y is CH;

20 Z is O;

A is absent;

L is C₆-C₁₀aryl;

R^A is at each occurrence independently selected from halo (e.g., fluoro), C₁-C₆haloalkyl (e.g., C₁-C₆fluoroalkyl) and C₁-C₆alkyl;

25 R¹ is at each occurrence independently selected from C₁-C₆alkyl and halo (e.g., fluoro),

wherein the C₁-C₆alkyl is substituted with 0-4 hydroxyl;

R² is hydrogen;


n is 1, 2 or 3;

m is 1, 2 or 3.

30


28. The compound of any of the preceding claims or a pharmaceutically acceptable salt

thereof, wherein R¹ is at each occurrence independently selected from




35 29. The compound of any of the preceding claims or a pharmaceutically acceptable salt

thereof, wherein R¹ is at each occurrence independently selected from




30. The compound of any of the preceding claims or a pharmaceutically acceptable salt thereof, wherein R¹ is at each occurrence independently selected from



wherein R^{1b} is hydrogen or C₁-C₅alkyl,

wherein the C₁-C₅alkyl is substituted with 0-3 hydroxyl.


31. The compound of any of the preceding claims or a pharmaceutically acceptable salt thereof, of Formula (Ia)



wherein W, L, R¹, R², R^A, n and m are defined according to any of the preceding claims.


15

32. The compound of any of the preceding claims or a pharmaceutically acceptable salt thereof, of Formula (Ib)



wherein W, L, R¹, R², R^A, n and m are defined according to any of the preceding claims.


33. The compound of any of the preceding claims or a pharmaceutically acceptable salt thereof, of Formula (lc)



5

wherein L, R¹, R², R^A, n and m are defined according to any of the preceding claims.

34. The compound of any of the preceding claims or a pharmaceutically acceptable salt thereof, of Formula (ld)




10

wherein L, R¹, R², R^A, n and m are defined according to any of the preceding claims.


35. The compound of any of the preceding claims or a pharmaceutically acceptable salt thereof, of Formula (le)

15



wherein L, R¹, R², R^A and m are defined according to any of the preceding claims.

36. The compound of any of the preceding claims or a pharmaceutically acceptable salt thereof, of Formula (If)





















5









wherein L, R¹, R², R^A and m are defined according to any of the preceding claims.









37. The compound of claim 1 or a pharmaceutically acceptable salt thereof, selected from:









1-(6-fluoro-5-(((1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)propane-1,3-diol	(S)-1-(6-fluoro-5-(((1r,3S)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethane-1,2-diol
(1r,3r)-N-((6-fluoroisoquinolin-5-yl)methyl)-3-(3-(pentafluoro-λ⁶-sulfaneyl)phenoxy)cyclobutan-1-amine	(1r,3r)-N-((6-fluoroisoquinolin-5-yl)methyl)-3-(3-(trifluoromethoxy)phenoxy)cyclobutan-1-amine











 (1r,3r)-3-(4-(2,2-difluorocyclopropyl)phenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine	 (1r,3r)-3-((3-fluoro-4-(trifluoromethyl)benzyl)oxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine
 (1r,3r)-N1-(4-fluoro-3-(trifluoromethyl)phenyl)-N3-((6-fluoroisoquinolin-5-yl)methyl)cyclobutane-1,3-diamine	 2-(6-fluoro-5-(((1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethan-1-ol
 (1r,3r)-3-(3,4-difluorophenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine	 (5-(((1r,3r)-3-(3,5-difluoro-4-methoxyphenoxy)cyclobutyl)amino)methyl)-6-fluoroisoquinolin-8-yl)methanol
 N-(2-(6-fluoro-5-(((1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)-2-hydroxyethyl sulfonic diamide	 (1r,3r)-3-((4-fluoro-3-(trifluoromethyl)phenyl)thio)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine











 1-(6-fluoro-5-(((1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)propane-1,3-diol	 (1r,3r)-3-(4-(difluoromethoxy)phenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine
 (1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-N-((7-fluoroquinazolin-8-yl)methyl)cyclobutan-1-amine	 ethyl 4-(((1r,3r)-3-((6-fluoroisoquinolin-5-yl)methyl)amino)cyclobutoxy)benzoate
 (1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-N-(quinazolin-8-ylmethyl)cyclobutan-1-amine	 (1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-N-((6-methylisoquinolin-5-yl)methyl)cyclobutan-1-amine
 (1s,3s)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)-1-methylcyclobutan-1-amine	 (R)-1-(6-fluoro-5-(((1r,3R)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethane-1,2-diol
 (1r,3r)-N-((6-fluoroisoquinolin-5-yl)methyl)-3-(3-(trifluoromethyl)phenoxy)cyclobutan-1-amine	 (1r,3r)-N-((6-fluoroisoquinolin-5-yl)methyl)-3-(3-(trifluoromethyl)phenoxy)cyclobutan-1-amine











(1 <i>r</i> ,3 <i>r</i>)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)-1-methylcyclobutan-1-amine	
 2-(3-amino-6-fluoroisoquinolin-5-yl)-N-(((1<i>r</i>,3<i>r</i>)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)acetamide	 5-((((1<i>r</i>,3<i>r</i>)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-amine
 (<i>S</i>)-1-(3-amino-6-fluoro-5-((((1<i>r</i>,3<i>S</i>)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethane-1,2-diol	 (1<i>r</i>,3<i>r</i>)-3-((2,6-difluoropyridin-3-yl)oxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine
 N-(((1<i>r</i>,3<i>r</i>)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)-2-(6-fluoro-8-(hydroxymethyl)isoquinolin-5-yl)acetamide	 5-((((1<i>r</i>,3<i>r</i>)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)methanol
 (3-amino-6-fluoro-5-((((1<i>r</i>,3<i>r</i>)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)methanol	 (1<i>r</i>,3<i>r</i>)-N-((6-fluoroisoquinolin-5-yl)methyl)-3-(4-(pentafluoro-λ⁶-sulfanyl)phenoxy)cyclobutan-1-amine









 (1r,3r)-N-((6-fluoroisoquinolin-5-yl)methyl)-3-(naphthalen-2-yloxy)cyclobutan-1-amine	 (1r,3r)-3-(4-(difluoromethyl)-3-fluorophenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine
 (3-amino-6-fluoro-5-(((1r,3r)-3-((2-(trifluoromethyl)pyridin-4-yl)oxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)methanol	 ethyl 5-((1r,3r)-3-(((6-fluoroisoquinolin-5-yl)methyl)amino)cyclobutoxy)-2-(trifluoromethyl)benzoate
 (1r,3r)-3-(3-fluoro-4-(trifluoromethoxy)phenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine	 6-fluoro-5-(((1r,3r)-3-((2-(trifluoromethyl)pyridin-4-yl)oxy)cyclobutyl)amino)methyl)isoquinolin-3-amine
 4-(((1r,3r)-3-(((6-fluoroisoquinolin-5-yl)methyl)amino)cyclobutoxy)-2-(trifluoromethyl)benzonitrile	 (1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-N-((8-methylisoquinolin-5-yl)methyl)cyclobutan-1-amine









 (1r,3r)-3-(4-(difluoromethoxy)-3-fluorophenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine	 (R)-1-(3-amino-6-fluoro-5-(((1r,3R)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethane-1,2-diol
 (1r,3r)-3-(3,5-dimethylphenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine	 (5-(((1r,3r)-3-(4-(tert-butyl)-3,5-difluorophenoxy)cyclobutyl)amino)methyl)-6-fluoroisoquinolin-8-yl)methanol
 6-fluoro-5-(((1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-3-amine	 ethyl 3-(((1r,3r)-3-((6-fluoroisoquinolin-5-yl)methyl)amino)cyclobutoxy)benzoate
 N-(2-(6-fluoro-5-(((1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)-2-hydroxyethyl)methanesulfonamide	 2-(6-fluoro-5-(((1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)butane-1,4-diol









 3-fluoro-6-(((1r,3r)-3-(((6-fluoroisoquinolin-5-yl)methyl)amino)cyclobutoxy)-2-(trifluoromethyl)aniline	 5-((((1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-3-amine
 (1r,3r)-3-(benzo[d]thiazol-2-yloxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine	 (1r,3r)-3-(3-(difluoromethoxy)phenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine
 5-((((1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)-N,N-dimethylisoquinolin-6-amine	 (1r,3r)-N-((6-methylisoquinolin-5-yl)methyl)-3-((6-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutan-1-amine
 (1r,3r)-3-((4-fluoro-3-(trifluoromethyl)phenyl)thio)-N-(isoquinolin-5-ylmethyl)cyclobutan-1-amine	 (1r,3r)-N-((6-fluoroisoquinolin-5-yl)methyl)-3-((2,2,3,3-tetrafluoro-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)oxy)cyclobutan-1-amine
 5-((((1r,3r)-3-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)methyl)amino)methyl)isoquinolin-3-amine	 6-fluoro-5-((((1r,3r)-3-((6-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutyl)amino)methyl)isoquinolin-3-amine










yl)oxy)cyclobutyl)amino)methyl)-6-fluoroisoquinolin-8-yl)methanol	
 6-fluoro-5-(((1r,3r)-3-(((6-fluoroisoquinolin-5-yl)methyl)amino)cyclobutoxy)picolinonitrile	 (1r,3r)-N-((6-fluoroisoquinolin-5-yl)methyl)-3-((6-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutan-1-amine
 (1r,3r)-3-(3-(3,5-difluoro-4-methylphenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine	 (5-(((1r,3r)-3-(3-(3,5-difluoro-4-methylphenoxy)cyclobutyl)amino)methyl)-6-fluoroisoquinolin-8-yl)methanol
 (1r,3r)-3-(3-(3,5-difluorophenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine	 (1r,3r)-3-((6-chloro-5-(trifluoromethyl)pyridin-3-yl)oxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine
 (1r,3r)-3-(3-(cyclopropylphenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine	 2-(6-fluoro-5-(((1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)-2-hydroxyacetic acid
 (1r,3r)-3-((2-fluoro-6-(trifluoromethyl)pyridin-3-yl)oxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine	 1-(6-fluoro-5-(((1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethan-1-ol

 (1r,3r)-N-((6-fluoroisoquinolin-5-yl)methyl)-3-(3-(2-(trifluoromethyl)oxetan-2-yl)phenoxy)cyclobutan-1-amine	 (3-amino-5-(((1r,3r)-3-(2,4-difluorophenoxy)cyclobutyl)amino)methyl)-6-fluoroisoquinolin-8-yl)methanol
 (1r,3r)-3-(3,5-difluoro-4-methoxyphenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine	 (1r,3r)-N-((6-fluoroisoquinolin-5-yl)methyl)-3-((6-methoxy-5-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutan-1-amine
 (1r,3r)-3-(2,3-difluorophenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine	 (1r,3r)-3-(4-fluoro-3-(trifluoromethoxy)phenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine
 (1r,3r)-N-((3-chloroisoquinolin-5-yl)methyl)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine	 (1r,3r)-3-((3,4-difluorobenzyl)oxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine
 (1r,3r)-3-(2,4-difluorophenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine	 (1r,3r)-3-(2,4-difluorophenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine

	1-(6-fluoro-5-((((1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethane-1,2-diol
 (6-fluoro-5-((((1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)methanol	 (1r,3r)-3-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)oxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine
 (1r,3r)-N-((6-fluoroisoquinolin-5-yl)methyl)-3-((5-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutan-1-amine	 (1r,3r)-3-(3-(difluoromethoxy)-4-fluorophenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine
 (1r,3r)-3-(4-cyclopropylphenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine	 (1r,3r)-3-(3,4-difluoro-5-methylphenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine
 6-fluoro-5-((((1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinoline 2-oxide	 (1r,3r)-N-((6-ethylisoquinolin-5-yl)methyl)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutan-1-amine

 (1r,3r)-3-(3-(1,2-difluoroethyl)-4-fluorophenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine	 (1r,3r)-N-((6-fluoroisoquinolin-5-yl)methyl)-3-(4-(trifluoromethoxy)phenoxy)cyclobutan-1-amine
 (1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-N-(isoquinolin-5-ylmethyl)cyclobutan-1-amine	 (1r,3r)-3-(3,4-dimethylphenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine
 N-(2-(6-fluoro-5-(((1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)-2-hydroxyethyl)acetamide	 (1r,3r)-3-(4-fluoro-3-isopropylphenoxy)-N-(isoquinolin-5-ylmethyl)cyclobutan-1-amine
 (1r,3r)-3-(3-chloro-4-fluorophenoxy)-N-(isoquinolin-5-ylmethyl)cyclobutan-1-amine	 3,3,3-trifluoro-1-(6-fluoro-5-(((1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)propan-1-ol

 5-((((1r,3r)-3-(2,4-difluorophenoxy)cyclobutyl)amino)methyl)-6-fluoroisoquinolin-3-amine	 1-(6-fluoro-5-((((1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)propane-1,3-diol
 5-((((1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-ol	 (1r,3r)-3-((5,6-difluoropyridin-3-yl)oxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine
 (1r,3r)-N-((6-fluoroisoquinolin-5-yl)methyl)-3-((7-fluoronaphthalen-2-yl)oxy)cyclobutan-1-amine	 (1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine
 5-((1r,3r)-3-((6-fluoroisoquinolin-5-yl)methyl)amino)cyclobutoxy)-2-(trifluoromethyl)benzonitrile	 N-((1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)-2-(isoquinolin-5-yl)acetamide

 (1r,3r)-3-(3-(difluoromethyl)-4-fluorophenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine	 (1r,3r)-N-((6-fluoroisoquinolin-5-yl)methyl)-3-(4-(trifluoromethyl)phenoxy)cyclobutan-1-amine
 2-(((1r,3r)-3-((6-fluoroisoquinolin-5-yl)methyl)amino)cyclobutoxy)-6-(trifluoromethyl)benzonitrile	 (1r,3r)-N-((6-fluoroisoquinolin-5-yl)methyl)-3-((2-(trifluoromethyl)pyridin-4-yl)oxy)cyclobutan-1-amine
 5-((((1r,3r)-3-((2-(trifluoromethyl)pyridin-3-yl)oxy)cyclobutyl)amino)methyl)isoquinolin-3-amine	 (6-fluoro-5-((((1r,3r)-3-((2-(trifluoromethyl)pyridin-4-yl)oxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)methanol
 6-fluoro-5-((((1r,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-amine	 (6-fluoro-5-((((1s,3s)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)methanol
 (1r,3r)-3-(4-fluoro-3-(fluoromethyl)phenoxy)-N-((6-fluoroisoquinolin-5-yl)methyl)cyclobutan-1-amine	

38. A pharmaceutical composition comprising a therapeutically effective amount of a compound of any one of claims 1 to 37, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
- 5 39. A method of treating or preventing a disease or disorder mediated by TRPV1 in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1 to 37, or a pharmaceutically acceptable salt thereof.
- 10 40. A method of treating an ocular disease or disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1 to 37, or a pharmaceutically acceptable salt thereof, wherein the ocular disease or disorder is mediated by TRPV1.
- 15 41. A method of treating an ocular surface disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1 to 37, or a pharmaceutically acceptable salt thereof.
42. The method of claim 41, wherein the ocular surface disorder is selected from chronic
 20 ocular surface pain (COSP), dry eye disease, Sjogren's Syndrome, conjunctivitis (including keratoconjunctivitis, vernal keratoconjunctivitis, allergic conjunctivitis), Map-Dot-Fingerprint Dystrophy, acanthamoeba, fibromyalgia, Meibomian gland dysfunction, thyroid eye disease, rosacea, ptosis, keratoconus, ocular pain syndrome, Steven-Johnson's syndrome, corneal epitheliopathies, corneal neuropathies (including LASIK induced corneal neuropathies), corneal
 25 dystrophies (including recurrent corneal dystrophies), epithelial basement membrane dystrophy, corneal erosions or abrasions (including recurrent corneal erosions or abrasions), ocular surface diseases, blepharitis, graft vs host disease, meibomitis, glaucoma, conjunctivochalasis, keratopathies (including herpetic keratopathy, filamentary keratopathy, band or bullous keratopathy, exposure keratopathy), keratitis (including herpes simplex virus keratitis), iritis,
 30 episcleritis, corneal surgery, multiple sclerosis, trichiasis, pterygium, neuralgia, xerophthalmia, and patients recovering from neurotrophic keratitis.
43. The method of claim 42, wherein the ocular surface disorder is dry eye disease.
- 35 44. A method of treating ocular surface pain (e.g., corneal induced pain) in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1 to 37, or a pharmaceutically acceptable salt thereof.
45. The method of claim 44, wherein the ocular surface pain is episodic, i.e., acute.
- 40

46. The method of claim 44, wherein the ocular surface pain is chronic.

47. The method according to any of claims 44 to 46, wherein the ocular surface pain is associated with one or more of dry eye disease, Sjogren's Syndrome, conjunctivitis (including
5 keratoconjunctivitis, vernal keratoconjunctivitis, allergic conjunctivitis), Map-Dot-Fingerprint Dystrophy, acanthamoeba, fibromyalgia, Meibomian gland dysfunction, thyroid eye disease, rosacea, ptosis, keratoconus, ocular pain syndrome, Steven-Johnson's syndrome, corneal epitheliopathies, corneal neuropathies (including LASIK induced corneal neuropathies), corneal dystrophies (including recurrent corneal dystrophies), epithelial basement membrane dystrophy,
10 corneal erosions or abrasions (including recurrent corneal erosions or abrasions), ocular surface diseases, blepharitis, graft vs host disease, meibomitis, glaucoma, conjunctivochalasis, keratopathis (including herpetic keratopathy, filamentary keratopathy, band or bullous keratopathy, exposure keratopathy), keratitis (including herpes simplex virus keratitis), iritis, episclentis, corneal surgery, multiple sclerosis, trichiasis, pterygium, neuralgia, xerophthalmia,
15 or patients recovering from neurotrophic keratitis.

48. The method according to any of claims 44 to 47, wherein the ocular surface pain is associated with dry eye disease or Sjogren's Syndrome.

20 49. A method of treating ocular hyperemia in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1 to 37, or a pharmaceutically acceptable salt thereof.

50. The method of claim 49, wherein wherein the ocular hyperemia is associated with one or
25 more of dry eye disease, Sjogren's Syndrome, conjunctivitis (including keratoconjunctivitis, vernal keratoconjunctivitis, allergic conjunctivitis), Map-Dot-Fingerprint Dystrophy, acanthamoeba, fibromyalgia, Meibomian gland dysfunction, thyroid eye disease, rosacea, ptosis, keratoconus, ocular pain syndrome, Steven-Johnson's syndrome, corneal epitheliopathies, corneal neuropathies (including LASIK induced corneal neuropathies), corneal dystrophies (including recurrent corneal dystrophies), epithelial basement membrane dystrophy, corneal erosions or abrasions (including recurrent corneal erosions or abrasions), ocular surface diseases, blepharitis, graft vs host disease, meibomitis, glaucoma, conjunctivochalasis, keratopathis (including herpetic keratopathy, filamentary keratopathy, band or bullous keratopathy, exposure keratopathy), keratitis (including herpes simplex virus keratitis), iritis, episclentis, corneal
30 surgery, multiple sclerosis, trichiasis, pterygium, neuralgia, xerophthalmia, or patients recovering from neurotrophic keratitis. In particular embodiments, the ocular hyperemia is associated with dry eye disease. In some embodiments of the methods described herein, the ocular hyperemia persists for at least three months after photorefractive keratectomy (PRK) surgery or laser-assisted in situ keratomileusis (LASIK) surgery.

51. A compound of any of claims 1 to 37 or a pharmaceutically acceptable salt thereof, for use in the treatment of ocular surface pain (e.g., corneal induced pain).
52. The compound for use according to claim 51, or a pharmaceutically acceptable salt thereof, wherein the ocular surface pain is episodic, i.e., acute.
53. The compound for use according to claim 51, or a pharmaceutically acceptable salt thereof, wherein the ocular surface pain is chronic.
54. The compound for use according to any of claims 51 to 53, or a pharmaceutically acceptable salt thereof, wherein the ocular surface pain is associated with one or more of dry eye disease, Sjogren's Syndrome, conjunctivitis (including keratoconjunctivitis, vernal keratoconjunctivitis, allergic conjunctivitis), Map-Dot-Fingerprint Dystrophy, acanthamoeba, fibromyalgia, Meibomian gland dysfunction, thyroid eye disease, rosacea, ptosis, keratoconus, ocular pain syndrome, Steven-Johnson's syndrome, corneal epitheliopathies, corneal neuropathies (including LASIK induced corneal neuropathies), corneal dystrophies (including recurrent corneal dystrophies), epithelial basement membrane dystrophy, corneal erosions or abrasions (including recurrent corneal erosions or abrasions), ocular surface diseases, blepharitis, graft vs host disease, meibomitis, glaucoma, conjunctivochalasis, keratopathy (including herpetic keratopathy, filamentary keratopathy, band or bullous keratopathy, exposure keratopathy), keratitis (including herpes simplex virus keratitis), iritis, episcleritis, corneal surgery, multiple sclerosis, trichiasis, pterygium, neuralgia, xerophthalmia, or patients recovering from neurotrophic keratitis.
55. The compound for use according to any of claims 51 to 54, or a pharmaceutically acceptable salt thereof, wherein the ocular surface pain is associated with dry eye disease or Sjogren's Syndrome.
56. A compound of any of claims 1 to 37 or a pharmaceutically acceptable salt thereof, for use in the treatment of ocular hyperemia.
57. The compound for use according to claim 56, or a pharmaceutically acceptable salt thereof, wherein the ocular hyperemia is associated with one or more of dry eye disease, Sjogren's Syndrome, conjunctivitis (including keratoconjunctivitis, vernal keratoconjunctivitis, allergic conjunctivitis), Map-Dot-Fingerprint Dystrophy, acanthamoeba, fibromyalgia, Meibomian gland dysfunction, thyroid eye disease, rosacea, ptosis, keratoconus, ocular pain syndrome, Steven-Johnson's syndrome, corneal epitheliopathies, corneal neuropathies (including LASIK induced corneal neuropathies), corneal dystrophies (including recurrent corneal dystrophies),

epithelial basement membrane dystrophy, corneal erosions or abrasions (including recurrent corneal erosions or abrasions), ocular surface diseases, blepharitis, graft vs host disease, meibomitis, glaucoma, conjunctivochalasis, keratopathis (including herpetic keratopathy, filamentary keratopathy, band or bullous keratopathy, exposure keratopathy), keratitis (including
5 herpes simplex virus keratitis), iritis, episcleritis, corneal surgery, multiple sclerosis, trichiasis, pterygium, neuralgia, xerophthalmia, or patients recovering from neurotrophic keratitis. In particular embodiments, the ocular hyperemia is associated with dry eye disease. In some embodiments of the methods described herein, the ocular hyperemia persists for at least three months after photorefractive keratectomy (PRK) surgery or laser-assisted in situ keratomileusis
10 (LASIK) surgery.

58. A compound of any of claims 1 to 37 or a pharmaceutically acceptable salt thereof, for use in the treatment of an ocular surface disorder.

59. The compound for use according to claim 58, or a pharmaceutically acceptable salt thereof, wherein the ocular surface disorder is selected from chronic ocular surface pain (COSP), dry eye disease, Sjogren's Syndrome, conjunctivitis (including keratoconjunctivitis, vernal keratoconjunctivitis, allergic conjunctivitis), Map-Dot-Fingerprint Dystrophy, acanthamoeba, fibromyalgia, Meibomian gland dysfunction, thyroid eye disease, rosacea,
20 ptosis, keratoconus, ocular pain syndrome, Steven-Johnson's syndrome, corneal epitheliopathies, corneal neuropathies (including LASIK induced corneal neuropathies), corneal dystrophies (including recurrent corneal dystrophies), epithelial basement membrane dystrophy, corneal erosions or abrasions (including recurrent corneal erosions or abrasions), ocular surface diseases, blepharitis, graft vs host disease, meibomitis, glaucoma, conjunctivochalasis, keratopathis (including herpetic keratopathy, filamentary keratopathy, band or bullous
25 keratopathy, exposure keratopathy), keratitis (including herpes simplex virus keratitis), iritis, episcleritis, corneal surgery, multiple sclerosis, trichiasis, pterygium, neuralgia, xerophthalmia, or patients recovering from neurotrophic keratitis. In some embodiments, the subject suffers from ocular pain persisting for at least three months after photorefractive keratectomy (PRK)
30 surgery and laser-assisted in situ keratomileusis (LASIK) surgery.

60. Use of a compound of any one of claims 1 to 37, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating an ocular disease or disorder that is mediated by TRPV1.

35

61. Use according to claim 60, wherein the ocular disease or disorder is selected from ocular surface disorder, ocular surface pain (e.g., corneal induced pain) and ocular hyperemia.

62. Use according to claim 61, wherein the ocular surface disorder is selected from chronic ocular surface pain (COSP), dry eye disease, Sjogren's Syndrome, conjunctivitis (including keratoconjunctivitis, vernal keratoconjunctivitis, allergic conjunctivitis), Map-Dot-Fingerprint Dystrophy, acanthamoeba, fibromyalgia, Meibomian gland dysfunction, thyroid eye disease,
- 5 rosacea, ptosis, keratoconus, ocular pain syndrome, Steven-Johnson's syndrome, corneal epitheliopathies, corneal neuropathies (including LASIK induced corneal neuropathies), corneal dystrophies (including recurrent corneal dystrophies), epithelial basement membrane dystrophy, corneal erosions or abrasions (including recurrent corneal erosions or abrasions), ocular surface diseases, blepharitis, graft vs host disease, meibomitis, glaucoma, conjunctivochalasis,
- 10 keratopathis (including herpetic keratopathy, filamentary keratopathy, band or bullous keratopathy, exposure keratopathy), keratitis (including herpes simplex virus keratitis), iritis, episclentis, corneal surgery, multiple sclerosis, trichiasis, pterygium, neuralgia, xerophthalmia, and patients recovering from neurotrophic keratitis.
- 15 63. Use according to claim 61 or 62, wherein the ocular surface disorder is dry eye disease.
64. Use according to claim 61, wherein ocular surface pain is pain is episodic, i.e., acute.
65. Use according to claim 61, wherein ocular surface pain is pain is chronic.
- 20 66. Use according to any of claims 61, 64 or 65, wherein the ocular surface pain is associated with one or more of dry eye disease, Sjogren's Syndrome, conjunctivitis (including keratoconjunctivitis, vernal keratoconjunctivitis, allergic conjunctivitis), Map-Dot-Fingerprint Dystrophy, acanthamoeba, fibromyalgia, Meibomian gland dysfunction, thyroid eye disease,
- 25 rosacea, ptosis, keratoconus, ocular pain syndrome, Steven-Johnson's syndrome, corneal epitheliopathies, corneal neuropathies (including LASIK induced corneal neuropathies), corneal dystrophies (including recurrent corneal dystrophies), epithelial basement membrane dystrophy, corneal erosions or abrasions (including recurrent corneal erosions or abrasions), ocular surface diseases, blepharitis, graft vs host disease, meibomitis, glaucoma, conjunctivochalasis,
- 30 keratopathis (including herpetic keratopathy, filamentary keratopathy, band or bullous keratopathy, exposure keratopathy), keratitis (including herpes simplex virus keratitis), iritis, episclentis, corneal surgery, multiple sclerosis, trichiasis, pterygium, neuralgia, xerophthalmia, or patients recovering from neurotrophic keratitis.
- 35 67. Use according to any of claims 61, 64 to 66, wherein the ocular surface pain is associated with dry eye disease or Sjogren's Syndrome.
68. Use according to claim 61, wherein wherein the ocular hyperemia is associated with one or more of dry eye disease, Sjogren's Syndrome, conjunctivitis (including keratoconjunctivitis,

vernal keratoconjunctivitis, allergic conjunctivitis), Map-Dot-Fingerprint Dystrophy,
 acanthamoeba, fibromyalgia, Meibomian gland dysfunction, thyroid eye disease, rosacea,
 ptosis, keratoconus, ocular pain syndrome, Steven-Johnson's syndrome, corneal
 epitheliopathies, corneal neuropathies (including LASIK induced corneal neuropathies), corneal
 5 dystrophies (including recurrent corneal dystrophies), epithelial basement membrane dystrophy,
 corneal erosions or abrasions (including recurrent corneal erosions or abrasions), ocular
 surface diseases, blepharitis, graft vs host disease, meibomitis, glaucoma, conjunctivochalasis,
 keratopathis (including herpetic keratopathy, filamentary keratopathy, band or bullous
 keratopathy, exposure keratopathy), keratitis (including herpes simplex virus keratitis), iritis,
 10 episcleritis, corneal surgery, multiple sclerosis, trichiasis, pterygium, neuralgia, xerophthalmia,
 or patients recovering from neurotrophic keratitis. In particular embodiments, the ocular
 hyperemia is associated with dry eye disease. In some embodiments of the methods described
 herein, the ocular hyperemia persists for at least three months after photorefractive keratectomy
 (PRK) surgery or laser-assisted in situ keratomileusis (LASIK) surgery.

15

69. Use of a compound of any of claims 1 to 37 or a pharmaceutically acceptable salt thereof, in the treatment of an ocular disease or disorder that is mediated by TRPV1.

70. Use according to claim 69, wherein the ocular disease or disorder is selected from
 20 ocular surface disorder, ocular surface pain (e.g., corneal induced pain) and ocular hyperemia.

71. Use according to claim 70, wherein the ocular surface disorder is selected from chronic
 ocular surface pain (COSP), dry eye disease, Sjogren's Syndrome, conjunctivitis (including
 keratoconjunctivitis, vernal keratoconjunctivitis, allergic conjunctivitis), Map-Dot-Fingerprint
 25 Dystrophy, acanthamoeba, fibromyalgia, Meibomian gland dysfunction, thyroid eye disease,
 rosacea, ptosis, keratoconus, ocular pain syndrome, Steven-Johnson's syndrome, corneal
 epitheliopathies, corneal neuropathies (including LASIK induced corneal neuropathies), corneal
 dystrophies (including recurrent corneal dystrophies), epithelial basement membrane dystrophy,
 corneal erosions or abrasions (including recurrent corneal erosions or abrasions), ocular
 30 surface diseases, blepharitis, graft vs host disease, meibomitis, glaucoma, conjunctivochalasis,
 keratopathis (including herpetic keratopathy, filamentary keratopathy, band or bullous
 keratopathy, exposure keratopathy), keratitis (including herpes simplex virus keratitis), iritis,
 episcleritis, corneal surgery, multiple sclerosis, trichiasis, pterygium, neuralgia, xerophthalmia
 and patients recovering from neurotrophic keratitis.

35

72. Use according to claim 70 or 71, wherein the ocular surface disorder is dry eye disease.

73. Use according to claim 70, wherein ocular surface pain is pain is episodic, i.e., acute.

74. Use according to claim 70, wherein ocular surface pain is chronic.
75. Use according to any of claims 70, 73 or 74, wherein the ocular surface pain is associated with one or more of dry eye disease, Sjogren's Syndrome, conjunctivitis (including
5 keratoconjunctivitis, vernal keratoconjunctivitis, allergic conjunctivitis), Map-Dot-Fingerprint Dystrophy, acanthamoeba, fibromyalgia, Meibomian gland dysfunction, thyroid eye disease, rosacea, ptosis, keratoconus, ocular pain syndrome, Steven-Johnson's syndrome, corneal epitheliopathies, corneal neuropathies (including LASIK induced corneal neuropathies), corneal dystrophies (including recurrent corneal dystrophies), epithelial basement membrane dystrophy,
10 corneal erosions or abrasions (including recurrent corneal erosions or abrasions), ocular surface diseases, blepharitis, graft vs host disease, meibomitis, glaucoma, conjunctivochalasis, keratopathis (including herpetic keratopathy, filamentary keratopathy, band or bullous keratopathy, exposure keratopathy), keratitis (including herpes simplex virus keratitis), iritis, episcleritis, corneal surgery, multiple sclerosis, trichiasis, pterygium, neuralgia, xerophthalmia,
15 or patients recovering from neurotrophic keratitis.
76. Use according to any of claims 70, 73 to 75, wherein the ocular surface pain is associated with dry eye disease or Sjogren's Syndrome.
- 20 77. Use according to claim 70, wherein wherein the ocular hyperemia is associated with one or more of dry eye disease, Sjogren's Syndrome, conjunctivitis (including keratoconjunctivitis, vernal keratoconjunctivitis, allergic conjunctivitis), Map-Dot-Fingerprint Dystrophy, acanthamoeba, fibromyalgia, Meibomian gland dysfunction, thyroid eye disease, rosacea, ptosis, keratoconus, ocular pain syndrome, Steven-Johnson's syndrome, corneal
25 epitheliopathies, corneal neuropathies (including LASIK induced corneal neuropathies), corneal dystrophies (including recurrent corneal dystrophies), epithelial basement membrane dystrophy, corneal erosions or abrasions (including recurrent corneal erosions or abrasions), ocular surface diseases, blepharitis, graft vs host disease, meibomitis, glaucoma, conjunctivochalasis, keratopathis (including herpetic keratopathy, filamentary keratopathy, band or bullous
30 keratopathy, exposure keratopathy), keratitis (including herpes simplex virus keratitis), iritis, episcleritis, corneal surgery, multiple sclerosis, trichiasis, pterygium, neuralgia, xerophthalmia, or patients recovering from neurotrophic keratitis. In particular embodiments, the ocular hyperemia is associated with dry eye disease. In some embodiments of the methods described herein, the ocular hyperemia persists for at least three months after photorefractive keratectomy
35 (PRK) surgery or laser-assisted in situ keratomileusis (LASIK) surgery.
78. A pharmaceutical combination comprising a compound of any of claims 1 to 37, or a pharmaceutically acceptable salt thereof, and one or more additional therapeutic agent(s).